
<html lang="en"     class="pb-page"  data-request-id="d575c5d8-3e7f-42bb-9c8d-ff9218be5fff"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;article:article:10.1021/acs.jmedchem.1c00117;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion" /></meta><meta name="dc.Creator" content="Xiaojun  Zhang" /></meta><meta name="dc.Creator" content="Yitian  Wu" /></meta><meta name="dc.Creator" content="Qi  Zeng" /></meta><meta name="dc.Creator" content="Tianxin  Xie" /></meta><meta name="dc.Creator" content="Shulin  Yao" /></meta><meta name="dc.Creator" content="Jinming  Zhang" /></meta><meta name="dc.Creator" content="Mengchao  Cui" /></meta><meta name="dc.Description" content="The prostate-specific membrane antigen (PSMA) is considered to be an excellent theranostic target of prostate cancer (PCa). In this study, three 18F-labeled PSMA tracers with a more lipophilic quin..." /></meta><meta name="Description" content="The prostate-specific membrane antigen (PSMA) is considered to be an excellent theranostic target of prostate cancer (PCa). In this study, three 18F-labeled PSMA tracers with a more lipophilic quin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 30, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00117" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00117" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00117" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00117" /></link>
        
    
    

<title>Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00117" /></meta><meta property="og:title" content="Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0014.jpeg" /></meta><meta property="og:description" content="The prostate-specific membrane antigen (PSMA) is considered to be an excellent theranostic target of prostate cancer (PCa). In this study, three 18F-labeled PSMA tracers with a more lipophilic quinoline functional spacer were designed, synthesized, and evaluated based on the Glu-Ureido-Lys binding motif. The effect of structure-related lipophilic difference on distribution and excretion of these tracers in vitro and in vivo (cells, rodent, primate, and human) was investigated by comparing with [18F]DCFPyL. There is no significant correlation between the renal elimination and the lipophilicity of the tracers in all species. However, the higher the lipophilicity of tracer, the higher the radioactivity accumulation in the liver of primate and human, and the less radioactivity is to excrete to the bladder with urine. The screened tracer [18F]8c, with a Ki value of 4.58 nM, displayed notable low bladder retention and demonstrated good imaging properties in patients with PCa." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00117"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00117">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00117&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00117&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00117&amp;href=/doi/10.1021/acs.jmedchem.1c00117" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 4179-4195</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00079" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00123" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiaojun Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaojun Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China</div><div class="loa-info-affiliations-info">Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaojun++Zhang">Xiaojun Zhang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yitian Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yitian Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yitian++Wu">Yitian Wu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Qi Zeng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qi Zeng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qi++Zeng">Qi Zeng</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Tianxin Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tianxin Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tianxin++Xie">Tianxin Xie</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Shulin Yao</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shulin Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e59c848a968d90898c8bd6d5d4a5d4d3d6cb868a88"><span class="__cf_email__" data-cfemail="a9d0c8c6dac1dcc5c0c79a9998e9989f9a87cac6c4">[emailÂ protected]</span></a>, Tel: +86-13301072900.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shulin++Yao">Shulin Yao</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jinming Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinming Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing 100853, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#661c0e0708010c0b555657265750554805090b"><span class="__cf_email__" data-cfemail="23594b424d44494e101312631215100d404c4e">[emailÂ protected]</span></a>, Tel: +86-13801210291.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinming++Zhang">Jinming Zhang</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Mengchao Cui</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mengchao Cui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China</div><div class="loa-info-affiliations-info">Center for Advanced Materials Research, Advanced Institute of Natural Sciences, Beijing Normal University at Zhuhai, Zhuhai 519087, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#3f5c525c7f5d514a115a5b4a115c51"><span class="__cf_email__" data-cfemail="9efdf3fddefcf0ebb0fbfaebb0fdf0">[emailÂ protected]</span></a>, Tel: +86-13811995064.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mengchao++Cui">Mengchao Cui</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3488-7864" title="Orcid link">http://orcid.org/0000-0002-3488-7864</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00117&amp;href=/doi/10.1021%2Facs.jmedchem.1c00117" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 4179â4195</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 30, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 January 2021</li><li><span class="item_label"><b>Published</b> online</span>30 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00117" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00117</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4179%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaojun%2BZhang%252C%2BYitian%2BWu%252C%2BQi%2BZeng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.1c00117%26title%3DSynthesis%252C%2BPreclinical%2BEvaluation%252C%2Band%2BFirst-in-Human%2BPET%2BStudy%2Bof%2BQuinoline-Containing%2BPSMA%2BTracers%2Bwith%2BDecreased%2BRenal%2BExcretion%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4195%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00117"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">772</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00117" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaojun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yitian&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Qi&quot;,&quot;last_name&quot;:&quot;Zeng&quot;},{&quot;first_name&quot;:&quot;Tianxin&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Shulin&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Jinming&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Mengchao&quot;,&quot;last_name&quot;:&quot;Cui&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4179-4195&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00117&quot;},&quot;abstract&quot;:&quot;The prostate-specific membrane antigen (PSMA) is considered to be an excellent theranostic target of prostate cancer (PCa). In this study, three 18F-labeled PSMA tracers with a more lipophilic quinoline functional spacer were designed, synthesized, and evaluated based on the Glu-Ureido-Lys binding motif. The effect of structure-related lipophilic difference on distribution and excretion of these tracers in vitro and in vivo (cells, rodent, primate, and human) was investigated by comparing with [18F]DCFPyL. There is no significant correlation between the renal elimination and the lipophilicity of the tracers in all species. However, the higher the lipophilicity of tracer, the higher the radioactivity accumulation in the liver of primate and human, and the less radioactivity is to excrete to the bladder with urine. The screened tracer [18F]8c, with a Ki value of 4.58 nM, displayed notable low bladder retention and demonstrated good imaging properties in patients with PCa.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00117&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00117" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00117&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00117" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00117&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00117" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00117&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00117&amp;href=/doi/10.1021/acs.jmedchem.1c00117" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00117" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00117" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (11 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00117%26sid%3Dliteratum%253Aachs%26pmid%3D33783213%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DSynthesis%252C%2BPreclinical%2BEvaluation%252C%2Band%2BFirst-in-Human%2BPET%2BStudy%2Bof%2BQuinoline-Containing%2BPSMA%2BTracers%2Bwith%2BDecreased%2BRenal%2BExcretion%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D4179%26epage%3D4195%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291716" title="Excretion">Excretion</a>,</li><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=290795" title="Quinolines">Quinolines</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The prostate-specific membrane antigen (PSMA) is considered to be an excellent theranostic target of prostate cancer (PCa). In this study, three <sup>18</sup>F-labeled PSMA tracers with a more lipophilic quinoline functional spacer were designed, synthesized, and evaluated based on the Glu-Ureido-Lys binding motif. The effect of structure-related lipophilic difference on distribution and excretion of these tracers in vitro and in vivo (cells, rodent, primate, and human) was investigated by comparing with [<sup>18</sup>F]DCFPyL. There is no significant correlation between the renal elimination and the lipophilicity of the tracers in all species. However, the higher the lipophilicity of tracer, the higher the radioactivity accumulation in the liver of primate and human, and the less radioactivity is to excrete to the bladder with urine. The screened tracer [<sup>18</sup>F]<b>8c</b>, with a <i>K</i><sub>i</sub> value of 4.58 nM, displayed notable low bladder retention and demonstrated good imaging properties in patients with PCa.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and it is also an important cause of cancer-related deaths among men.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> According to the stages of PCa, different treatments (surgery, radiation therapy, hormonal therapy, chemotherapy, immunotherapy) will be applied to effectively prolong the survival of patients.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Proper patient management options and prognostic judgment depend on the accurate staging and restaging of PCa. Tests that examine the serum testosterone and prostate-specific antigen (PSA) are convenient and effective but often affected by uncertain factors.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> In addition, various imaging strategies have been introduced for the examination of PCa, such as contrast-enhanced computed tomography (CT),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> transrectal ultrasound (TRUS),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> multiparametric magnetic resonance imaging (MRI),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> single photon emission computed tomography (SPECT) bone scan,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and positron emission tomography (PET).<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11â14)</a> Among these imaging modalities, PET is considered to be the most promising detection method. Especially in the past decade, prostate-specific membrane antigen (PSMA, also named glutamate carboxypeptidase II, GCP II), which is highly expressed on the cell membrane of PCa cells (1000-fold than normal prostate cells),<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> has attracted much attention as an excellent theranostic target of PCa.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Various small-molecule-based PSMA inhibitors with high binding affinity to PSMA (with <i>K</i><sub>i</sub> value of pM to nM) were labeled by radionuclides and have been successfully used in PCa imaging and treatment.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21">(17â21)</a> Based on the Glu-Ureido-Lys pharmacophore, plenty of diagnostic and therapeutic tracers, such as [<sup>68</sup>Ga]PSMA-11,<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> [<sup>18</sup>F]DCFPyL ([<sup>18</sup>F]PyL),<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> [<sup>18</sup>F]PSMA-1007,<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> and [<sup>68</sup>Ga/<sup>177</sup>Lu]PSMA-617,<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> consisting of the PSMA binding motif, functional spacers, and the radiolabeled motifs, were investigated in humans. Due to the facile preparation method and very positive imaging results in phase II/III trials,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> the application of [<sup>68</sup>Ga]PSMA-11 spread worldwide rapidly, and more recently, it was approved by the United States Food and Drug Administration (FDA) as the first tracer for PET imaging of PSMA in PCa patients. However, there are still some drawbacks that limit its clinical application, for example, the unsuitable inherent characteristics of the <sup>68</sup>Ga nuclide including short half-life (<i>t</i><sub>1/2</sub> = 68 min) and higher positron energy, making it inconvenient to transport and causing low spatial resolution, and smaller production capacity due to the capacity limitation of <sup>68</sup>Ge/<sup>68</sup>Ga generator.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> On the contrary, the <sup>18</sup>F-labeled PSMA tracers may avoid the above drawbacks. As the most widely used PSMA imaging agents, [<sup>18</sup>F]PyL with primary renal excretion and [<sup>18</sup>F]PSMA-1007 with predominant hepatobiliary excretion show excellent sensitivity and specificity for detecting primary disease in lymph node and metastases.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Most notably, [<sup>18</sup>F]PSMA-1007 exhibits minimal urinary retention and bladder uptake, which might be useful in the visualization of lesions adjacent to the urinary tract and bladder.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Another tracer, [<sup>18</sup>F]rhPSMA-7, also displayed low bladder excretion in humans.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> However, the correlation between the in vivo predominant excretion pathways and the physicochemical properties of these PSMA tracers is still not fully elucidated.</div><div class="NLM_p">From the structureâproperty relationship results of these Glu-Ureido-Lys-based PSMA inhibitors, the functional spacers play an important role in their PSMA inhibition potency, tumor cell internalization rate, as well as in vivo pharmacokinetics.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> In addition, spacer modification or optimization is relatively simple, and there are many alternative strategies available. In this study, we adopted a simple strategy by replacing the [<sup>18</sup>F]fluoropyridyl group in [<sup>18</sup>F]PyL with [<sup>18</sup>F]fluoroquinolinyl to increase the lipophilicity (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Three <sup>18</sup>F-labeled positional isomers of quinoline-based PSMA tracers were designed and synthesized. Their properties were characterized and evaluated in different species, including rodent, primate, and human. A direct comparison of these tracers with [<sup>18</sup>F]PyL was also performed to explore the lipophilicity and structure-related effects on their in vivo properties.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of reported tracers for the detection of PCa and the newly designed quinoline-based PSMA tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">All reagents and solvents used in chemical synthesis were commercially available. The tri-<i>tert</i>-butyl protected PSMA binding motif H-Lys-O<i>t</i>Bu-ureido-Glu(O<i>t</i>Bu)<sub>2</sub> was synthesized according to previously reported methods. The detailed synthesis route is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The <i>N</i>-oxide quinolines (<b>2a</b>, <b>2b</b>, <b>2c</b>) were prepared in high yields by <i>m</i>-CPBA oxidation of quinolone carboxylic acid ethyl esters followed by hydrolysis of the ethyl group. Then the carboxylic acid group was transformed to a 2,3,5,6-tetrafluorophenyl active ester to give compounds <b>3a</b>, <b>3b</b>, and <b>3c</b>. 2-Quinolyltrimethylammonium salts (compounds <b>4a</b>, <b>4b</b>, and <b>4c</b>) were obtained by regioselective conversion of quinoline <i>N</i>-oxides under mild conditions with trimethylamine and trifluoroacetic anhydride and subsequently reacted with the free amino group of H-Lys-O<i>t</i>Bu-ureido-Glu(O<i>t</i>Bu)<sub>2</sub> to give compounds <b>5a</b>, <b>5b</b>, and <b>5c</b> in yields of 77â95%, followed by TFA deprotection to give the precursors <b>7a</b>, <b>7b</b>, and <b>7c</b> for <sup>18</sup>F-labeling. The fluorinated reference compounds <b>8a</b>, <b>8b</b>, and <b>8c</b> were prepared by aromatic nucleophilic fluorination of the 2-quinolyltrimethylammonium salts followed by TFA deprotection.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinoline-Based PSMA Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, RT; (b) NaOH, THF, EtOH, RT; (c) 2,3,5,6-tetrafluorophenol, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT; (d) NMe<sub>3</sub> (2M in THF), TFAA, CH<sub>2</sub>Cl<sub>2</sub>, RT; (e) H-Lys-O<i>t</i>Bu-ureido-Glu(O<i>t</i>Bu)<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N,RT; (f) TBAF (1M in THF), MeCN, 60 Â°C; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, RT; (h) [<sup>18</sup>F]Bu<sub>4</sub>NF/Bu<sub>4</sub>NHCO<sub>3</sub>, DMF, 50 Â°C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Radiochemical Synthesis and Quality Control</h3><div class="NLM_p">To achieve the radiolabeled tracers of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b>, 2-quinolyltrimethylammonium salts as precursors were treated with [<sup>18</sup>F]Bu<sub>4</sub>NF/Bu<sub>4</sub>NHCO<sub>3</sub> in DMF at 50 Â°C for 5 min, followed by semipreparative HPLC purification (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Figure S2</a>). [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b> were reproducibly and consistently generated in a nondecay-corrected radiochemical yield (RCY) of 23â48% with radiochemical purity (RCP) of more than 98% and molar activity (MA) of 251 Â± 27, 298 Â± 156, and 245 Â± 44 GBq/Î¼mol, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Figures S4âS6</a>). The total synthesis time of the three probes was <30 min. By contrast, synthesis of [<sup>18</sup>F]PyL by a one-pot two steps approach was applied in our experiment.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Analytical Data of Prepared Radiotracers</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="Â±" /></col><col align="char" char="." /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tracer</th><th class="colsep0 rowsep0" align="center" char="Â±">RCY (%,Â isolated)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">RCP<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center" char="Â±">MA (GBq/Î¼mol)</th><th class="colsep0 rowsep0" align="center" char="Â±">Log <i>D</i><sub>pHÂ 7.4</sub> (<i>n</i> = 3)</th><th class="colsep0 rowsep0" align="center" char="Â±"><i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>r</sub> in MeCN (min)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>r</sub> in EtOH (min)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0" align="char" char="Â±">23.4Â Â±Â 6.2</td><td class="colsep0 rowsep0" align="char" char=".">>98</td><td class="colsep0 rowsep0" align="char" char="Â±">251Â Â±Â 27</td><td class="colsep0 rowsep0" align="char" char="Â±">â3.02Â Â±Â 0.09</td><td class="colsep0 rowsep0" align="char" char="Â±">25.48Â Â±Â 5.32</td><td class="colsep0 rowsep0" align="char" char=".">7.55</td><td class="colsep0 rowsep0" align="char" char=".">5.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0" align="char" char="Â±">48.9Â Â±Â 12.6</td><td class="colsep0 rowsep0" align="char" char=".">>98</td><td class="colsep0 rowsep0" align="char" char="Â±">298Â Â±Â 156</td><td class="colsep0 rowsep0" align="char" char="Â±">â2.54Â Â±Â 0.29</td><td class="colsep0 rowsep0" align="char" char="Â±">4.78Â Â±Â 0.03</td><td class="colsep0 rowsep0" align="char" char=".">9.33</td><td class="colsep0 rowsep0" align="char" char=".">9.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0" align="char" char="Â±">32.6Â Â±Â 5.5</td><td class="colsep0 rowsep0" align="char" char=".">>98</td><td class="colsep0 rowsep0" align="char" char="Â±">245Â Â±Â 44</td><td class="colsep0 rowsep0" align="char" char="Â±">â2.67Â Â±Â 0.20</td><td class="colsep0 rowsep0" align="char" char="Â±">4.58Â Â±Â 0.40</td><td class="colsep0 rowsep0" align="char" char=".">10.13</td><td class="colsep0 rowsep0" align="char" char=".">7.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0" align="char" char="Â±">20.1Â Â±Â 2.9</td><td class="colsep0 rowsep0" align="char" char=".">>98</td><td class="colsep0 rowsep0" align="char" char="Â±">73Â Â±Â 36</td><td class="colsep0 rowsep0" align="char" char="Â±">â3.26Â Â±Â 0.10</td><td class="colsep0 rowsep0" align="char" char="Â±">6.11Â Â±Â 0.45</td><td class="colsep0 rowsep0" align="char" char=".">4.21</td><td class="colsep0 rowsep0" align="char" char=".">4.04</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The nondecay-corrected isolated radiochemical yields are expressed as means Â± SD (<i>n</i> = 3, 7, 4, and 6) for [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL, respectively. Same repetitions for RCP and MA measurements.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">RCP was detected by radio-HPLC.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Retention time of radiotracers on analytical HPLC using 20% acetonitrile and 80% water (containing 0.1% TFA) as mobile phase at a flow rate of 1 mL/min.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Retention time of radiotracers on analytical HPLC using 25% ethanol and 75% water (containing 0.2% H<sub>3</sub>PO<sub>4</sub>) as mobile phase at a flow rate of 1 mL/min.</p></div></div></div><div class="NLM_p last">QC procedures for [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b> are based on the current requirements for radiopharmaceuticals referred to by the Chinese Pharmacopoeia 2020.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Detailed data of QC procedures are provided in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Table S1</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Figure S3</a>). Each of the three radiotracers met all of the established QC criteria, such as RCP > 95%, residual TBA < 0.26 mg/mL, endotoxin <15 EU/mL, and sterile.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Binding Affinity Determination</h3><div class="NLM_p last">The inhibition constants (<i>K</i><sub>i</sub>) of [<sup>19</sup>F]<b>8a</b>, [<sup>19</sup>F]<b>8b</b>, [<sup>19</sup>F]<b>8c</b>, and [<sup>19</sup>F]PyL to PSMA were evaluated by a fluorescence-based Amplex Red glutamic acid assay. All compounds displayed high inhibition potencies for PSMA. Compounds <b>8b</b> and <b>8c</b> with PSMA binding motifs at 6 and 7 positions of the quinoline ring demonstrated similar <i>K</i><sub>i</sub> values of 4.78 Â± 0.03 nM and 4.58 Â± 0.40 nM, respectively. However, compound <b>8a</b> with PSMA binding motif at the 5 position displayed a lower binding affinity (<i>K</i><sub>i</sub> = 25.48 Â± 5.32 nM). As a control, the <i>K</i><sub>i</sub> value of [<sup>19</sup>F]PyL was 6.11 Â± 0.45 nM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Lipophilicity</h3><div class="NLM_p">The lipophilicity of these radiotracers was determined by a shake-flask method. The log <i>D</i><sub>pHÂ 7.4</sub> values of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL were determined to be â3.02 Â± 0.09, â2.54 Â± 0.29, â2.67 Â± 0.20, and â3.26 Â± 0.10, respectively. The log <i>D</i><sub>pHÂ 7.4</sub> value of [<sup>18</sup>F]<b>8a</b> was slightly lower than that of [<sup>18</sup>F]PyL but significantly lower than [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> (<i>p</i> < 0.05). In addition, the lipophilicity of these radiotracers was compared by their retention time on a reverse HPLC column. When the same mobile phase of 25/75 ethanol/water containing 0.2% H<sub>3</sub>PO<sub>4</sub> at 1 mL/min was used, the retention times of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL were 5.58, 9.55, 7.24, and 4.04 min, respectively. However, when 20/80 acetonitrile/water containing 0.1% TFA was used as the mobile phase at 1 mL/min, the retention times of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL were 7.55, 9.33, 10.24, and 4.21 min, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Integration diagram of analytical HPLC radioactive traces of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL using two different mobile phases. (A) Mobile phase of 25/75 ethanol/water containing 0.2% H<sub>3</sub>PO<sub>4</sub> at 1 mL/min. (B) Mobile phase of 20/80 acetonitrile/water containing 0.1% TFA at 1 mL/min.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Cellular Uptake Assay</h3><div class="NLM_p">As a human prostate carcinoma epithelial cell line with a high expression of PSMA, the LNCaP cells were used to evaluate the binding specificity of these radiotracers to PSMA. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, after 1 h incubation, [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL showed uptakes in the LNCaP cells of 0.85 Â± 0.11, 1.61 Â± 0.29, 1.71 Â± 0.24, and 1.24 Â± 0.12 IA%/10<sup>5</sup>, respectively. For the blockade group, 2 Î¼mol/well of 2-(phosphonomethyl)pentanedioic acid (2-PMPA, a potent and selective inhibitor of glutamate carboxypeptidase II) displayed moderate to significant inhibition of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL in the LNCaP cells after 1 h incubation. The uptake values were 0.08 Â± 0.02, 0.11 Â± 0.02, 0.14 Â± 0.04, and 0.05 Â± 0.02 IA%/10<sup>5</sup>, with inhibition ratio of 91%, 93%, 92%, and 96%, respectively. As a negative control, the uptakes of four tracers in PC-3 cells were lower than 0.02 IA%/10<sup>5</sup> after 1 h incubation.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell uptake of the radio tracers in LNCaP and PC-3 cell line; blocked with 2 Î¼mol/well of 2-PMPA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Ex Vivo Biodistribution Study in Normal Mice</h3><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Table S2</a>, the three radiotracers could be quickly washed out from the blood after intravenous injection with residual radioactivity <1%ID/g at 60 min. In the heart, lungs, and pancreas, they displayed similar trends in uptake and clearance. Similar to the other reported Glu-Ureido-Lys-based PSMA imaging agents, [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b> were mainly excreted through the mouse urinary system. Due to the relatively high expression of PSMA and the faster concentration rate than the excretion rate, the radioactivity in the kidney showed a rapid increase with time (Kidney<sub>60Â min</sub>/Kidney<sub>2Â min</sub> > 3 for the three probes), which reached 254.91 Â± 16.49, 167.45 Â± 9.66, and 219.45 Â± 38.26% ID/g at 60 min, respectively. In addition, significant hepatic uptake of the three tracers was observed. However, only a small amount of radiotracers were excreted into the small intestine at 1 h. Finally, none of the three probes could enter the brain through the bloodâbrain barrier (with brain uptake of 0.47 Â± 0.06, 0.47 Â± 0.07, and 0.34 Â± 0.05 at 60 min, respectively), and the low bone uptake values at all-time points after injection confirmed their stability against radio-defluorination in vivo.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Uptake values for ex vivo tissues of [<sup>18</sup>F]<b>8a</b> (A), [<sup>18</sup>F]<b>8b</b> (B), and [<sup>18</sup>F]<b>8c</b> (C) in normal male ICR mice (6â7 weeks, 20 Â± 2 g, male, <i>n</i> = 5). Error bars indicate SD values.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> micro-PET Studies of Tumor-Bearing Mice</h3><div class="NLM_p">The maximum intensity projection (MIP) images of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL in tumor-bearing mice (22Rv1 and PC-3) using micro-PET are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, with detailed statistical data provided in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Table S3</a>. At 1 h postinjection, the mean of standardized uptake value based on body weight (SUV<sub>mean</sub>) of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL in the 22Rv1 tumor was 1.12 Â± 0.12, 3.53 Â± 0.68, 3.54 Â± 0.89, and 1.59 Â± 0.59, providing a tumor-to-muscle ratio of 8.0, 20.7, 19.6, and 13.3, respectively. The concentration of all probes in the 22Rv1 tumor increased over time, while the uptake in muscle decreased, providing the SUV<sub>mean</sub> of 1.42 Â± 0.24, 4.16 Â± 1.32, 4.94 Â± 1.22, and 2.03 Â± 0.86 at 2 h postinjection, with a tumor-to-muscle ratio of 10.1, 34.6, 30.8, and 29.0, respectively. Although the 22Rv1 tumor uptake value of [<sup>18</sup>F]PyL was lower than that of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> at 2 h postinjection, hydrophilic [<sup>18</sup>F]PyL has the fastest clearance from muscle and displayed a most rapid raise of the tumor-to-muscle ratio from 13.3 to 29.0, which is comparable with that of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b>. As a excretory and PSMA-expressing organ, the kidneys showed a high accumulation of all tracers and could be inhibited by 2-PMPA. The liver exhibited a similar uptake with or without co-injection of 2-PMPA. As expected, low uptakes of all tracers in PC-3 tumors were observed. In addition, as shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Table S3</a>, for the [<sup>18</sup>F]PyL, a large amount of radioactivity was excreted into the bladder via the kidneys (SUV<sub>mean</sub> = 13.28 Â± 5.79) at 1 h postinjection. Relatively, for the [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b>, significantly lower uptakes of 3.66 Â± 0.42, 2.63 Â± 0.62, and 2.54 Â± 0.61 were observed. At 2 h postinjection, all tracers showed a mounting uptake in the bladder, while [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> presented the minimum increase.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Uptake values of tumors for [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyLat 1 h postinjection in tumor-bearing mice (BALB/c nude mice, aged 9â11 weeks with the 22Rv1 tumors reached diameter of 0.6â1.0 cm, <i>n</i> = 4; BALB/c nude mice aged 11â13 weeks with the PC-3 tumors reached diameter of 1.0â1.5 cm, <i>n</i> = 4) based on the micro-PET studies. For all tracers, uptake in 22Rv1 tumors was significantly blocked by 2-PMPA. PC-3 tumors showed a significantly lower uptake than 22Rv1 tumors. Error bars indicate SD values. Significant differences between [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL presented at top of bars: *<i>P</i> < 0.05, NS = not significant, and SUV<sub>mean</sub> = mean of the standardized uptake value based on body weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MIP images of 22Rv1 tumor-bearing mice injected [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL without (top row) or with (second row) 2-PMPA (2 mg/kg) inhibition and PC-3 tumor-bearing mice (bottom row) at 1 h postinjection. The 22Rv1 tumors are under the left shoulders (white solid arrow), whereas the PC-3 tumors are under the bilateral shoulders (yellow solid arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Dynamic PET Studies in Monkeys</h3><div class="NLM_p">The sequential PET MIP images of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b> and [<sup>18</sup>F]PyL from one monkey are shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. The corresponding time-activity curves (TACs) of major organs are available in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. Comparison of the dynamic TACs of different tracers in selected organs is presented in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>. During the perfusion phase (0â4 min), all tracers rapidly distributed to the main tissues of the male monkey as the heart, liver, kidneys, salivary glands, spleen, and vascular system. Among these organs or tissues, the heart, lungs, muscle, bone, salivary glands, brain, normal prostate, and testis showed low initial uptakes and rapid clearance rates. These tracers displayed a continuous increase in radioactivity over time in the liver and spleen of monkeys, with the order of uptake values as [<sup>18</sup>F]<b>8b</b> > [<sup>18</sup>F]<b>8c</b> > [<sup>18</sup>F]<b>8a</b> > [<sup>18</sup>F]PyL, which were consistent with the order of the tracersâ lipophilicity. Through the MIP diagrams shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and TAC of bladder shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, it can be intuitively observed that [<sup>18</sup>F]PyL was excreted into the bladder very quickly and the bladder was clearly outlined in the 9â13 min image. Meanwhile, a small amount of the bladder uptake was observed for [<sup>18</sup>F]<b>8a</b>, while barely visible bladders could be observed for [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> at this duration. Until in the 18â22 min image, [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> slightly concentrated in the bladder. In addition, all tracers showed little radio-defluorination, as the accumulation of radioactivity in the bone stayed low during the whole PET study, suggesting the stability of these tracers in primates.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Selected sequential PET MIP images from the same monkey injected with [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL. Four 1 min/bed positions covered from the vertex to midthighs of monkeys were acquired for each PET scan. A total of 14 sequences were collected from the injection of tracers to the end of scanning (1 h).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Timeâactivity curves of the selected monkey tissues after injection of [<sup>18</sup>F]PyL (A), [<sup>18</sup>F]<b>8a</b> (B), [<sup>18</sup>F]<b>8b</b> (C), and [<sup>18</sup>F]<b>8c</b> (D). Values are expressed as SUV<sub>mean</sub> Â± SD, <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Direct comparison of timeâactivity curves of liver (A), kidneys (B), bladder (C), salivary glands (D), and spleen (E) in monkeys after injection of tracers. Upake values of liver, kidneys, salivary glands, and spleen are expressed as SUV<sub>mean</sub> Â± SD. Uptake values of bladder are expressed as MBq<sub>mean</sub> Â± SD; uptake (MBq) = average concentration (Bq/mL) Ã bladder volume (mL) Ã 10<sup>â6</sup>, <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Preliminary Clinical Study in Humans</h3><div class="NLM_p">The preliminary human study was approved by the Ethics Committee of Chinese PLA General Hospital. Participant recruitment and the clinical trial were conducted from November, 2019 to November, 2020. After obtaining written informed consent, six patients who had PSMA-avid lesions corresponding to the pathology proven of PCa were enrolled in this study and were divided into two cohorts. For cohort A, two patients underwent both [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]PyL injections for direct comparison (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Only [<sup>18</sup>F]<b>8b</b> examination was acquired for the other patient (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Figure S7</a>). For cohort B, one patient was injected with [<sup>18</sup>F]<b>8c</b> and [<sup>18</sup>F]PyL (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), and the other two patients underwent only [<sup>18</sup>F]<b>8c</b> injections (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Figure S8</a>).</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Comparison of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]PyL in a 64-year-old patient with a rising PSA level of 0.933 ng/mL. Both tracers revealed the lesion (red arrow) of the right prostate gland. (A) MIP image injected with [<sup>18</sup>F]<b>8b</b>. (B) MIP image of the patient injected with [<sup>18</sup>F]PyL. (C) Image of low-dose CT. (D) Fused axial PET/CT image of the patient injected with [<sup>18</sup>F]<b>8b</b>. (E) Fused axial PET/CT image of the patient injected with [<sup>18</sup>F]PyL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Comparison of [<sup>18</sup>F]<b>8c</b> and [<sup>18</sup>F]PyL in a 73-year-old patient with a Gleason pattern of 4 + 5 and a PSA level of 61.6 ng/mL. MIP image of the patient injected with [<sup>18</sup>F]<b>8c</b> (A) and [<sup>18</sup>F]PyL (B). Image of low-dose CT (C and F). Fused axial PET/CT image of the patient injected with [<sup>18</sup>F]<b>8c</b>, which clearly depicts the diffuse prostatic carcinoma in situ and the lymph node (red arrow) adjacent to the pelvic wall (D) and the lymph node (blue arrow) adjacent external iliac vessels (G). Fused axial PET/CT image of the patient injected with [<sup>18</sup>F]PyL (E and H).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">No adverse effects were observed for all patients up to 24 h after the application of these radiotracers. All PSMA lesions found by [<sup>18</sup>F]<b>8b</b> or [<sup>18</sup>F]<b>8c</b> were also detected by [<sup>18</sup>F]PyL. The detailed data of comparison are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. For cohort A, local tumor uptakes of [<sup>18</sup>F]<b>8b</b> were slightly lower than that of [<sup>18</sup>F]PyL. For patient 4 in cohort B, local tumor uptakes of [<sup>18</sup>F]<b>8c</b> were slightly higher than that of [<sup>18</sup>F]PyL, whereas the uptake of the lymph node metastases was lower than [<sup>18</sup>F]PyL.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Individual Patient Characteristics and Tumor Uptake Values<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">patients</th><th class="colsep0 rowsep0" align="center" char=".">age (y)</th><th class="colsep0 rowsep0" align="center" char=".">tPSA<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (ng/mL)</th><th class="colsep0 rowsep0" align="center">Gleason score</th><th class="colsep0 rowsep0" align="center">local tumor (SUV<sub>max</sub>)</th><th class="colsep0 rowsep0" align="center">lymph node metastases (SUV<sub>max</sub>)</th><th class="colsep0 rowsep0" align="center">bone metastases (SUV<sub>max</sub>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">1</td><td class="colsep0 rowsep0" rowspan="2" align="char" valign="middle" char=".">64</td><td class="colsep0 rowsep0" rowspan="2" align="char" valign="middle" char=".">0.93</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">4Â +Â 5</td><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8b</b>: 18.24</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">none</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">none</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]PyL: 21.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">2</td><td class="colsep0 rowsep0" rowspan="2" align="char" valign="middle" char=".">59</td><td class="colsep0 rowsep0" rowspan="2" align="char" valign="middle" char=".">0.08</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">4Â +Â 3</td><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8b</b>: 17.81</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">none</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">none</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]PyL: 23.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="char" char=".">8.90</td><td class="colsep0 rowsep0" align="left">4Â +Â 4</td><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8b</b>: 13.68</td><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8b</b>: 4.91</td><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8b</b>: 19.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">4</td><td class="colsep0 rowsep0" rowspan="2" align="char" valign="middle" char=".">73</td><td class="colsep0 rowsep0" rowspan="2" align="char" valign="middle" char=".">61.60</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">4Â +Â 5</td><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8c</b>: 33.41</td><td class="colsep0 rowsep0" align="left">(1) [<sup>18</sup>F]<b>8c</b>: 23.5; [<sup>18</sup>F]PyL: 25.18</td><td class="colsep0 rowsep0" rowspan="2" align="left" valign="middle">none</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]PyL: 30.30</td><td class="colsep0 rowsep0" align="left">(2) [<sup>18</sup>F]<b>8c</b>: 8.19; [<sup>18</sup>F]PyL: 12.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">9.94</td><td class="colsep0 rowsep0" align="left">4Â +Â 3</td><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8c</b>: 8.49</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">none</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">4.53</td><td class="colsep0 rowsep0" align="left">4Â +Â 3</td><td class="colsep0 rowsep0" align="left">[<sup>18</sup>F]<b>8c</b>: 10.83</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">none</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Patients 1 and 2 underwent [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]PyL examinations. Patient 3 underwent [<sup>18</sup>F]<b>8b</b> examination. Patient 4 underwent [<sup>18</sup>F]<b>8c</b> and[<sup>18</sup>F]PyL examinations. Patients 5 and 6 underwent [<sup>18</sup>F]<b>8c</b> examination.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">tPSA: total PSA in serum.</p></div></div></div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>, [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> displayed a different distribution in normal organs compared to [<sup>18</sup>F]PyL, but similar to [<sup>18</sup>F]PSMA-1007.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Uptake in the spleen, lungs, bone, muscle and salivary glands did not demonstrate a statistical difference between [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b> and [<sup>18</sup>F]PyL. In addition, similar to the results of the above monkey studies, [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> were prone to excrete via the liver. Uptake in the liver for [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> was significantly higher than [<sup>18</sup>F]PyL (mean SUV<sub>max</sub> of 19.59, 14.56, and 7.14 for [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL, respectively). However, [<sup>18</sup>F]PyL showed a significantly higher uptake of 65.91 in the kidneys (mean SUV<sub>max</sub> of 48.50 and 24.33 for [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b>, respectively). Especially in the bladder, the mean SUV<sub>max</sub> for [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL was 13.55, 3.46 and 40.61, respectively ([<sup>18</sup>F]<b>8b</b> vs [<sup>18</sup>F]PyL, <i>P</i> =  0.012; [<sup>18</sup>F]<b>8c</b> vs [<sup>18</sup>F]PyL, <i>P</i> =  0.004). A lower urinary excretion of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b>, especially [<sup>18</sup>F]<b>8c</b>, provided a better ability to differentiate pelvic microcarcinoma from the bladder, compared to [<sup>18</sup>F]PyL (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Comparison of mean SUV<sub>max</sub> of [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL for normal organs in patients at 1 h postinjection (<i>n</i> = 3). Significant differences between [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL presented at the top of bars: *<i>P</i> < 0.05; SUV<sub>max</sub> = maximum of the standardized uptake value based on body weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83838" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83838" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Recently, a new drug application for [<sup>18</sup>F]PyL was submitted to the U.S. FDA by Lantheus Holdings, Inc., based on its positive results from the Phase 3 trial which focused on the evaluation of the diagnostic performance and clinical impact of [<sup>18</sup>F]PyL on patients with biochemical recurrence of PCa.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> As one of the most popular PSMA-targeted PET imaging agents around the world, [<sup>18</sup>F]PyL shows the potential for high sensitivity and specificity in detecting PCa with favorable distribution in humans, such as high accumulation of metastases or local tumor and fast clearance from the blood pool. However, as a renally excreted PSMA ligand, [<sup>18</sup>F]PyL exhibits fast renal excretion and thus appears high accumulation in the ureters and the bladder, which makes it difficult to find lesions in the pelvic cavity. Subsequently, another <sup>18</sup>F-labeled PSMA tracer, [<sup>18</sup>F]PSMA-1007 with higher lipophilicity (log <i>D</i><sub>pHÂ 7.4</sub> = â1.6),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> was originally designed to mimic the in vivo distribution of [<sup>177</sup>Lu]PSMA-617 via a similar structure. Compared with [<sup>18</sup>F]PyL in rodents, [<sup>18</sup>F]PSMA-1007 shows quite comparable liver uptake and significantly slower blood clearance and higher accumulation in nontarget tissues. These differences may be explained by the presence of two acidic Glu residues leading to stronger electrostatic interactions of [<sup>18</sup>F]PSMA-1007 with Lys- and Arg-rich proteins like serum albumin.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> However, [<sup>18</sup>F]PSMA-1007 shows predominant hepatic uptake and rarely eliminates through the kidneys in humans.<a onclick="showRef(event, 'ref32 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref32 ref44 ref45">(32,44,45)</a> A reported intraindividual comparison of [<sup>18</sup>F]PSMA-1007 with renally excreted PSMA agents ([<sup>18</sup>F]PyL, [<sup>68</sup>Ga]PSMA-11, and [<sup>18</sup>F]JK-PSMA-7) concluded that [<sup>18</sup>F]PSMA-1007 may increase confidence in interpreting small locoregional lesions adjacent to the urinary tract.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Although a series of optimized functional spacers between the PSMA binding motif and radiolabeled motifs were investigated to improve the tumor uptake and reduce the uptake in normal organs, there are still many problems to be solved. First, an optimized spacer usually has a complicated structure to enhance the PSMA affinity and tumor cell internalization rate, but the influence of spacer-structure-related distribution in vivo is very complicated and cannot be predicted. Furthermore, the huge differences between species make it difficult to infer the distribution and excretion pathway of a new tracer in humans through animal experiments. Third, the main excretion of the Glu-Ureido-Lys-based probe through the kidneys or liver is still unclear. In this study, to investigate the relationship between the lipophilicity of the tracers and the dominant excretory organ in different species, we discarded the complex functional spacer in [<sup>18</sup>F]PSMA-1007 to eliminate its influence on drug interaction in vivo. A very simple strategy was adopted to replace the pyridine ring in [<sup>18</sup>F]PyL with a more lipophilic quinoline ring, thereby obtaining a set of quinoline-based PSMA tracers. Their in vivo and in vitro characteristics were fully investigated, including comparisons between different species, especially the first human studies. More importantly, in all these studies, [<sup>18</sup>F]PyL was selected for direct comparison. In general, 2-trialkylammonium salts of electron-deficient N-heteroarenes have been shown to be effective precursors for the synthesis of 2-fluoro-<i>N</i>-hetreoarenes. Recently, Xiong et al. developed a new and effective method to prepare 2-trialkylammonium salts from <i>N</i>-heteroarene <i>N</i>-oxides under mild conditions,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> which expands the application potential of 2-fluoro-<i>N</i>-heteroarenes in PET tracers. According to this new method, three 2-quinolyltrimethylammonium precursors (<b>7a</b>, <b>7b</b>, and <b>7c</b>) with different positions (5, 6, or 7) of the carboxylic group in the quinoline ring were synthesized from their <i>N</i>-oxides. The final tracers [<sup>18</sup>F]<b>8a</b>,[<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b> were easily obtained by a one-step nucleophilic substitution<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> with good radiochemical yield (nondecay-corrected) under a mild heating condition (50 Â°C) and lower precursor consumption (0.3â0.5 mg), which could inhibit the formation of byproducts and save the cost of synthesis. Manual radiolabeling results indicated that the radiochemical conversion rates were similar whether kryptofix 222/K<sub>2</sub>CO<sub>3</sub> or TBAB was used as phase-transfer catalyst (PTC). In addition, to further reduce the preparation time and facilitate the final formulation for clinical use, ethanol aqueous solution containing 0.2% of H<sub>3</sub>PO<sub>4</sub> was used as the semiprepared HPLC mobile phase to avoid the later solid-phase extraction steps.<a onclick="showRef(event, 'ref43 ref47'); return false;" href="javascript:void(0);" class="ref ref43 ref47">(43,47)</a> Under optimized conditions, the final products [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b> were obtained with high molar activity and high radiochemical yield, and they all meet the established QC standards, which is very favorable for clinical translational studies.</div><div class="NLM_p">In general, the affinity of small-molecular inhibitors to PSMA mainly depends on the Glu-Ureido-Lys motif binding to the Zn<sup>2+</sup> active site and the S1â² glutamate recognition pocket as well as the hydrophobic interaction of lipophilic aryl functional spacers to the S1 accessory hydrophobic pocket or the arene-binding site (ABS, an entrance lid part of PSMA).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> With the Glu-Ureido-Lys binding motif unchanged, increasing the lipophilicity by altering the aryl scaffolds and the position of functional groups of tracer could increase its binding affinity to PSMA. Therefore, in this study, the pyridine group of [<sup>18</sup>F]PyL was replaced by a more lipophilic quinoline group to increase the binding affinity. As expected, these quinoline-based PSMA tracers exhibited higher lipophilicity compared to [<sup>18</sup>F]PyL, and the position of the Glu-Ureido-Lys substituents on the quinoline ring will also affect their lipophilicity. The retention time of these tracers on the C18 reverse column also supports this conclusion well (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, the difference in retention time of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> between ethanol and acetonitrile may be due to their different solubility.</div><div class="NLM_p">However, the introduction of a more lipophilic quinoline ring does not specifically increase their binding affinity to PSMA, which explained that ligand <b>8a</b> with a higher lipophilic exhibited a lower affinity compared with PyL. The position (5, 6, or 7) of the Glu-Ureido-Lys binding motif on the quinoline ring has a significant influence on their PSMA inhibition potency. Compounds <b>8b</b> and <b>8c</b> displayed similar <i>K</i><sub>i</sub> values, which were slightly higher than that of PyL. However, compound <b>8a</b> with PSMA binding motif at 5 position displayed 4 times lower affinity than that of PyL. The possible explanation is that the entrance funnel of PSMA is not very flexible, and the orientation of the functional spacer in compound <b>8a</b> reduced the hydrophobic interaction between the quinoline ring and the S1 pocket.</div><div class="NLM_p">Generally, the lipophilicity of radiotracers will largely determine their distribution in different tissues and organs, and this distribution may vary greatly between different species. In the rodent, the ex vivo biodistribution and Î¼PET studies showed that the kidney uptake increased continuously within 2 h for the quinoline-based tracers, along with the liver uptake slightly increased ([<sup>18</sup>F]<b>8a</b> and [<sup>18</sup>F]<b>8c</b>) or retention ([<sup>18</sup>F]<b>8b</b>). Conversely, the relative hydrophilic [<sup>18</sup>F]PyL cleaned up fast from the blood and excreted rapidly from the kidneys to bladder. The MIP images clearly illustrate a larger bladder uptake of [<sup>18</sup>F]PyL than that of [<sup>18</sup>F]<b>8a</b>,[<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b> in both 22Rv1 and PC-3 tumor bearing mice (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In the blocking studies, the high tumor and kidney uptakes of these tracers were significantly inhibited by 2-PMPA, and the radioactivity was most excreted from the kidneys to the bladder in 1 h. The radioactive retention of the kidney is not only related to its expression of PSMA but also comes from its function as a excretory organ. Faster kidney excretion of [<sup>18</sup>F]PyL than that of [<sup>18</sup>F]<b>8a</b> indicated that the excretion of the kidney is more related to the lipophilicity than to the affinity of the probe to PSMA. Besides, 2-PMPA did not inhibit the hepatobiliary excretory pathway in the rodent. The 22Rv1 tumor uptakes of these tracers coincided with their <i>K</i><sub>i</sub> values and increased gradually with the time. The tumor-to-muscle ratios of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> were higher than that of [<sup>18</sup>F]PyL at 1 h, but ratio values between them tended to be similar at 2 h due to the slower muscle clearance rate of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b>, which indicated that the optimal PET acquisition time for [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> was 1 h.</div><div class="NLM_p">Because Cynomolgus monkeys as nonhuman primates are phylogenetically closer to humans, it is generally believed that the pharmacokinetic characteristics of tracers in monkeys are closer to those in humans. We performed the sequential PET scanning of these tracers in healthy monkeys. Across the board, the distribution of the four tracers in the main organs of monkeys was similar at 1 h (54â58 min) postinjection, which was mainly concentrated in the liver, kidneys, spleen, and bladder. Slight uptakes were seen in the salivary glands, heart (macrovascular), and bone. Among these organs, the liver and spleen displayed a sustained increase in radioactivity uptake within 1 h. Furthermore, the level of uptake by the liver and spleen was consistent with the lipophilicity of the tracers ([<sup>18</sup>F]<b>8b</b> > [<sup>18</sup>F]<b>8c</b> > [<sup>18</sup>F]<b>8a</b> > [<sup>18</sup>F]PyL, [<sup>18</sup>F]<b>8b</b> vs [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b> vs [<sup>18</sup>F]PyL, [<sup>18</sup>F]<b>8c</b> vs [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8c</b> vs [<sup>18</sup>F]PyL, [<sup>18</sup>F]<b>8a</b> vs [<sup>18</sup>F]PyL, <i>P</i> < 0.05 at 1 h). It can be seen from the MIP images (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) that although the liver acts as a excretory organ, the gastrointestinal tract was hardly visible in monkeys at 1 h, which revealed the retention of tracers in the liver of monkeys. As an important excretory and endocrine organ, the kidneys extract the tracers from the blood and synchronously excrete them to the bladder with urine. Tracers that are more lipophilic tend to excrete more slowly into the bladder in monkeys, which is similar to rodents. The uptake in the kidneys was in a dynamic balance, which related to the lipophilicity of the tracer, the affinity to PSMA, and the physical condition of the monkeys (water intake or not before injection of the tracer). In addition, the nonspecific uptake in the salivary glands was not related to the lipophilicity or <i>K</i><sub>i</sub> value of the tracers.</div><div class="NLM_p">Owing to the relatively low affinity of [<sup>18</sup>F]<b>8a</b> to PSMA and high uptake in the monkey bladder, [<sup>18</sup>F]<b>8a</b> was excluded from further human study. [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> demonstrated similar biodistribution in humans, such as the concentration of radioactivity in the liver, spleen, kidneys, vessels, and salivary glands. Similar to monkeys, the uptake of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> in the liver was significantly higher than [<sup>18</sup>F]PyL, which also corresponds to their lipophilicity. Different from the excretory characteristics in monkeys, these tracers were partly excreted into the intestine through the liver. As the most available PSMA imaging agents currently, [<sup>18</sup>F]PyL was mainly excreted through the urologic system, thus leading to a high accumulation in the kidneys and bladder. In contrast to [<sup>18</sup>F]PyL, [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> were excreted primarily through the hepatobiliary system, thus the uptake in the kidneys and bladder were significantly lower. It is worth mentioning that compared with [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b> displayed minimal uptake in the bladder (SUV<sub>max</sub> = 3.46) without the urinary tractâs signal, which may benefit to differentiate the small PSMA-positive lesions close to the urinary tract or bladder. However, there is still a small amount of [<sup>18</sup>F]<b>8b</b> excreted into the bladder with urine, leading to a high background signal in the urinary tract (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Figure S7</a>), indicating an inadequacy for clinical application. We assume that the difference between the excretion of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> in the urinary system is due to their different interaction with kidneys. Individual comparison of the patients demonstrated comparable tumor-targeting properties of these tracers. Compared with other imaging methods (enhanced CT, MRI) and other PET radiotracers ([<sup>11</sup>C]Choline, [<sup>18</sup>F]FDG, [<sup>18</sup>F]FACBC), PET/CT based on PSMA-targeted tracers with the Glu-Ureido-Lys ligand provides superior detection rates and accuracy in patients with early biochemical recurrence after a radical prostatectomy, especially among patients with low PSA values (PSA < 2 ng/mL).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Among the patients recruited in our study, only two patients had PSA < 2 ng/mL (patients 1 and 2) and [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]PyL detected tumors in the same location. In addition, a high off-targeted accumulation of [<sup>18</sup>F]PSMA-1007 and, consequently, a higher incidence of pitfalls in [<sup>18</sup>F]PSMA-1007 PET<a onclick="showRef(event, 'ref44 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref44 ref51 ref52">(44,51,52)</a> may attribute to the presence of two additional acidic Glu residues. [<sup>18</sup>F]<b>8c</b>, without unnecessary amino acid residues, may offer a lower false positive of [<sup>18</sup>F]<b>8c</b> PET than that of [<sup>18</sup>F]PSMA-1007 PET, and is comparable to [<sup>18</sup>F]PyL PET. Large comparison trials need to be conducted to further evaluate tracer-specific characteristics and pooled detection rates of [<sup>18</sup>F]<b>8c</b> versus [<sup>18</sup>F]PyL.</div><div class="NLM_p">The relationship between the lipophilicity and the PSMA-binding affinity of tracers and their biodistribution in different spices is shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Whether in cells or tumor-bearing mice, the affinity of tracers to PSMA was positively correlated with their PSMA targeting ability, while the relationship between the tumor uptake and <i>K</i><sub>i</sub> value of tracer in humans needs more comparative study. It should be noticed that there is no obvious correlation between the liver uptake and the lipophilicity of the tracers in mice. However, in primates and humans, the liver uptake raises along with the increase of tracerâs lipophilicity, which means that the liver uptake of mice cannot predict the distribution of the tracer in the human liver, but the lipophilicity can. A variety of factors affect the renal uptake of PSMA tracers, such as physiological conditions, the expression level of PSMA, renal accumulation and excretion kinetics, and the inherent properties of tracers. It is hard to regulate the uptake in the kidneys. The good thing is that the renal uptake has little effect on the diagnosis of PCa. However, it is very important to determine whether the radioactivity will be discharged into the bladder with urine during the image acquisition. In this study, the increase in the lipophilicity of these quinoline-based PSMA tracers will definitely slow down the excretion of radioactivity from the kidneys to the bladder in different species. Note that low urine excretion of radioactivity may increase the total effective dose. On the premise of comparable diagnostic accuracy, the radiation dose for the body may be decreased by reducing the injection dose or prolonging PET acquisition time.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Sorting of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL under Different Parameters<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">ICR mice<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="rowsep1 colsep0" colspan="3" align="center">22Rv1-bearing mice PET</th><th class="rowsep1 colsep0" colspan="2" align="center">monkey PET</th><th class="rowsep1 colsep0" colspan="2" align="center">human PET</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">rank</th><th class="colsep0 rowsep0" align="center">lipophilicity<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">affinity<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cell uptake<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">liver</th><th class="colsep0 rowsep0" align="center">kidney</th><th class="colsep0 rowsep0" align="center">liver</th><th class="colsep0 rowsep0" align="center">kidney</th><th class="colsep0 rowsep0" align="center">tumor</th><th class="colsep0 rowsep0" align="center">liver</th><th class="colsep0 rowsep0" align="center">kidney</th><th class="colsep0 rowsep0" align="center">liver</th><th class="colsep0 rowsep0" align="center">kidney</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">2</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">3</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8c</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">4</td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">â</td><td class="colsep0 rowsep0">â</td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8a</b></td><td class="colsep0 rowsep0">[<sup>18</sup>F]PyL</td><td class="colsep0 rowsep0">[<sup>18</sup>F]<b>8b</b></td><td class="colsep0 rowsep0">â</td><td class="colsep0 rowsep0">â</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The order of grades is determined by the mean of the values. Comparisons between data are not all of statistically significant.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Log <i>D</i><sub>pHÂ 7.4</sub>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Data from <i>K</i><sub>i</sub> value.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Data from in vitro cell uptake assay.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Data of uptakes in liver, kidneys, and tumor in different species collected from ex vivo or in vivo studies at 1 h.</p></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52148" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52148" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, a simple strategy was used by replacing the [<sup>18</sup>F]fluoropyridyl with [<sup>18</sup>F]fluoroquinolinyl based on the widely used [<sup>18</sup>F]PyL. The effect of the increased lipophilicity and various PSMA affinity of three quinoline-based positional isomers on the distribution in different species was studied. No correlation between the renal radioactive uptake level and the lipophilicity of the tracers in all species was found, and the results of animal experiments (rodent or primate) could not be used as a reference for human kidney uptake. However, the liver uptake raises along with the increase of tracerâs lipophilicity in primates and humans, but not in rodents. In addition, increased lipophilicity prevents the excretion of radioactivity to the bladder, indicating that when improving the pharmacokinetics of the established tracer, the liver uptake level and urinary excretion rate can be modified by slightly changing the lipophilicity of the tracer. Finally, a promising PSMA-targeting tracer [<sup>18</sup>F]<b>8c</b> with notably low bladder retention, which is comparable to [<sup>18</sup>F]PSMA-1007, was screened out. Future larger cohort studies are needed to explore the pooled detection rate of [<sup>18</sup>F]<b>8c</b> in patients with biochemically recurrent PCa.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General</h3><div class="NLM_p last">All reagents and solvents used in chemical synthesis were commercially available. [<sup>18</sup>F]Fluoride was generated by the <sup>18</sup>O(p,n)<sup>18</sup>F reaction with an cyclotron (HM-20, Sumitomo, Japan). Thin-layer chromatography (TLC) was used to monitor reactions with silica gel 60 F<sub>254</sub> plates (Merck, Germany). Flash chromatography purification system was used to purify compounds with Silica HPLC column (Bonna-Agela Technologies, China). A Bruker Avance III NMR spectrometer was used to record <sup>1</sup>H and <sup>13</sup>C NMR spectra (400 or 600 MHz for <sup>1</sup>H, 100 or 150 MHz for <sup>13</sup>C) in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, or CD<sub>3</sub>OD with tetramethylsilane as an internal standard at room temperature. Coupling constants (<i>J</i>) are described in Hertz (Hz), and chemical shifts (Î´) are reported in parts per million (ppm). High-resolution mass spectra were record on a Q Exactive (ESI) detector (Thermo Scientific, USA). PET-MF-2 V-IT-I synthesis module equipped with a Alltech 626 pump and a UVSI 200 detector at 254 nm (PET Beijing Science and Technology, China) was used for automated radioactive labeling. HPLC analyses of the radiotracer were acquired on a 1260 Infinity II LC System (Agilent, USA) equipped with a Bioscan Flow Count Î³-radiation scintillation detector using a Phenomenex Gemini C18 column (110 Ã, 150 Ã 4.6 mm, 5 Î¼m). All key-targeted compounds were confirmed with purity <95% by HPLC.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 1-Oxy-quinoline-5-carboxylic Acid Ethyl Ester (<b>1a</b>)</h3><div class="NLM_p last">To a solution of quinoline-5-carboxylic acid ethyl ester (1.64 g, 8.16 mmol) in DCM (50 mL), 3-chloroperoxybenzoic acid (2.12 g, 12.28 mmol) was added. The reaction mixture was stirred at room temperature for 2 h and then was concentrated to dryness and purified by column chromatography (SiO<sub>2</sub>) to afford the desired product as a white solid (2.15 g, 94%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) Î´ 9.38 (d, <i>J</i> = 8.8 Hz, 1H), 8.96 (dd, <i>J</i> = 4.2, 1.7 Hz, 1H), 8.33 (d, <i>J</i> = 8.4 Hz, 1H), 8.31 (dd, <i>J</i> = 7.3, 1.2 Hz, 1H), 7.76 (dd, <i>J</i> = 8.4, 7.3 Hz, 1H), 7.54 (dd, <i>J</i> = 8.7, 4.2 Hz, 1H), 4.48 (q, <i>J</i> = 7.2 Hz, 2H), 1.47 (t, <i>J</i> = 7.1 Hz, 3H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 218.0811 [M + H]<sup>+</sup> (calcd for C<sub>12</sub>H<sub>12</sub>NO<sub>3</sub><sup>+</sup>: 218.0812).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 1-Oxy-quinoline-5-carboxylic Acid (<b>2a</b>)</h3><div class="NLM_p last">1-Oxy-quinoline-5-carboxylic acid ethyl ester (1.68 g, 7.74 mmol) was dissolved in a mixture of THF (50 mL), anqueous NaOH (30.75 mmol, 15 mL, 2 M), and MeOH (5 mL). The mixture was stirred for 10 h at room temperature, concentrated to remove organic solvents, and diluted with 20 mL of water. The aqueoues phase was washed by EtOAc (2 Ã 25 mL) and then acidified with 1 M HCl to pH 2â4, and the reforming solid was isolated by filtration, washed with water, and dried to afford the desired product as a gray white powder (1.46 g, 100%). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 13.63 (s, 1H), 8.82 (d, <i>J</i> = 8.7 Hz, 1H), 8.77 (d, <i>J</i> = 9.0 Hz, 1H), 8.67 (dd, <i>J</i> = 6.1, 0.8 Hz, 1H), 8.34 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 7.89 (dd, <i>J</i> = 8.8, 7.3 Hz, 1H), 7.59 (dd, <i>J</i> = 9.0, 6.1 Hz, 1H). HRMS (ESI<sup>â</sup>) <i>m</i>/<i>z</i> 188.0348 [M â H]<sup>â</sup> (calcd for C<sub>10</sub>H<sub>6</sub>NO<sub>3</sub><sup>â</sup>: 188.0353).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 1-Oxy-quinoline-5-carboxylic Acid 2,3,5,6-Tetrafluoro-phenyl Ester (<b>3a</b>)</h3><div class="NLM_p last">A solution of 1-oxy-quinoline-5-carboxylic acid (1.51 g, 8 mmol), 2,3,5,6-tetrafluorophenol (1.59 g, 9.5 mmol), and <i>N</i>,<i>N</i>â²-dicyclohexylcarbodiimide (DCC) (1.96 g, 9.5 mmol) in DCM (50 mL) was stirred for 12 h at room temperature. The solvent was concentrated after filtration of dicyclohexylurea. The residue was purified by column chromatography (SiO<sub>2</sub>) to afford the desired product as a white solid (2.07 g, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 9.19 (d, <i>J</i> = 9.1 Hz, 1H), 8.99 (d, <i>J</i> = 8.3 Hz, 1H), 8.73 (d, <i>J</i> = 7.3 Hz, 2H), 7.99â7.92 (m, 1H), 7.58â7.51 (m, 1H), 7.16â7.08 (m, 1H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 338.0431 [M + H]<sup>+</sup> (calcd for C<sub>16</sub>H<sub>8</sub>F<sub>4</sub>NO<sub>3</sub><sup>+</sup>: 338.0435).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> [5-(2,3,5,6-Tetrafluoro-phenoxycarbonyl)-quinolin-2-yl]-trimethylammonium Trifluoroacetate Salt (<b>4a</b>)</h3><div class="NLM_p last">To a stirred solution of 1-oxy-quinoline-5-carboxylic acid 2,3,5,6-tetrafluoro-phenyl ester (0.98 g, 2.9 mmol) and NMe<sub>3</sub> (2 M in THF, 8.7 mL, 6.0 equiv) in DCM (30 mL) was carefully added trifluoroacetic anhydride (3.0 equiv). The mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated and dissolved in a minimal amount of ethyl acetate, and ether was added while sonicating. The crude salts were isolated by filtration and washed with Et<sub>2</sub>O and dried to give yellow solid as mixtures with excess of Me<sub>3</sub>NÂ·TFA. The yield was corrected to 31% (0.49 g) by <sup>1</sup>H NMR spectrum). <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 9.54 (d, <i>J</i> = 9.4 Hz, 1H), 8.85 (dd, <i>J</i> = 7.2, 1.1 Hz, 1H), 8.57 (d, <i>J</i> = 8.5 Hz, 1H), 8.51 (d, <i>J</i> = 9.4 Hz, 1H), 8.21 (dd, <i>J</i> = 8.2, 7.6 Hz, 1H), 8.09 (tt, <i>J</i> = 10.8, 7.4 Hz, 1H), 3.74 (s, 9H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 379.1061 [M]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>15</sub>F<sub>4</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup>: 379.1064).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (5-{5-[3-(1,3-Bis-<i>tert</i>-butoxycarbonyl-propyl)-ureido]-5-<i>tert</i>-butoxycarbonyl-pentylcarbamoyl}-quinolin-2-yl)-trimethylammonium Trifluoroacetate Salt (<b>5a</b>)</h3><div class="NLM_p last">[5-(2,3,5,6-Tetrafluoro-phenoxycarbonyl)-quinolin-2-yl]-trimethylammonium trifluoroacetate salt (0.49 g, 1 mmol) and 2-[3-(5-amino-1-<i>tert</i>-butoxycarbonyl-pentyl)-ureido]-pentanedioic acid di-<i>tert</i>-butyl ester (0.49 g, 1 mmol) were dissolved in 8 mL of DCM. TEA (0.2 mL, 2 mmol) was added, and the mixture was stirred at room temperature for 2 h. The organic solvent was removed under reduced pressure. The mixture was dissolved in a minimal amount of acetonitrile, and ether (50 mL) was added while stirring. The mixture was kept at room temperature for 10 min, and the semisolid was formed and stuck to the wall of the flask. The liquor was removed, and the semisolid was dried under vacuum to give white solid (0.62 g, 77%). <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 9.08 (d, <i>J</i> = 9.3 Hz, 1H), 8.79 (t, <i>J</i> = 5.5 Hz, 1H), 8.30 (d, <i>J</i> = 9.3 Hz, 1H), 8.20 (d, <i>J</i> = 8.4 Hz, 1H), 7.99 (dd, <i>J</i> = 8.4, 7.2 Hz, 1H), 7.95â7.92 (m, 1H), 6.35â6.29 (m, 2H), 4.08â3.96 (m, 2H), 3.70 (s, 9H), 3.33 (d, <i>J</i> = 7.0 Hz, 2H), 2.30â2.16 (m, 2H), 1.91â1.83 (m, 1H), 1.74â1.52 (m, 6H), 1.39 (s, 27H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 700.4269 [M]<sup>+</sup> (calcd for C<sub>37</sub>H<sub>58</sub>N<sub>5</sub>O<sub>8</sub><sup>+</sup>: 700.4280).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 2-(3-{1-<i>tert</i>-Butoxycarbonyl-5-[(2-fluoro-quinoline-5-carbonyl)-amino]-pentyl}-ureido)-pentanedioic Acid Di-<i>tert</i>-butyl Ester (<b>6a</b>)</h3><div class="NLM_p last">(5-{5-[3-(1,3-Bis-<i>tert</i>-butoxycarbonyl-propyl)-ureido]-5-<i>tert</i>-butoxycarbonyl-pentylcarbamoyl}-quinolin-2-yl)-trimethylammonium trifluoroacetate salt (0.64 g, 0.78 mmol) was dissolved in 5 mL of anhydrous acetonitrile. Tetrabutylammonium fluoride (1 mL, 1 M in THF) was added, and the solution was stirring at 60 Â°C for 3 h. The solvent was removed under vacuum. The residue was purified by column chromatography (SiO<sub>2</sub>) to afford the desired product as foamy solid (0.23 g, 45%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) Î´ 8.95 (t, <i>J</i> = 8.6 Hz, 1H), 8.02 (dd, <i>J</i> = 5.6, 4.0 Hz, 1H), 7.72 (s, 1H), 7.71 (d, <i>J</i> = 2.2 Hz, 1H), 7.16 (dd, <i>J</i> = 9.1, 2.6 Hz, 1H), 6.77 (s, 1H), 5.40â5.15 (m, 2H), 4.34 (dd, <i>J</i> = 8.3, 4.2 Hz, 1H), 4.08 (dd, <i>J</i> = 7.7, 5.1 Hz, 1H), 3.52 (dd, <i>J</i> = 12.2, 6.2 Hz, 2H), 2.29â2.17 (m, 2H), 1.89â1.82 (m, 1H), 1.81â1.61 (m, 7H), 1.46 (s, 9H), 1.43 (s, 9H), 1.39 (s, 9H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 661.3601 [M + H]<sup>+</sup> (calcd for C<sub>34</sub>H<sub>50</sub>FN<sub>4</sub>O<sub>8</sub><sup>+</sup>: 661.3607).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (5-{5-Carboxy-5-[3-(1,3-dicarboxy-propyl)-ureido]-pentylcarbamoyl}-quinolin-2-yl)-trimethylammonium Trifluoroacetate Salt (<b>7a</b>)</h3><div class="NLM_p last">To a solution of Boc-protected compound <b>5</b> (400 mg, 0.49 mmol) in 5 mL of DCM was added 5 mL of TFA. The mixture was stirred for 1 h at room temperature, then concentrated, and dissolved in a minimal amount of ethanol, and ether was added while sonicating. The crude salts were isolated by centrifugation and washed with petroleum ether several times and finally dried to give a gray solid (0.17 g, 54%). The product <b>7a</b> was purified by a Semi-Prep RP-HPLC using a mobile phase of 10/90 acetonitrile/water containing 0.1% TFA at 4 mL/min (retention time of 10.9 min and recovery rate of 80%). <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 9.04 (d, <i>J</i> = 9.3 Hz, 1H), 8.80 (t, <i>J</i> = 5.4 Hz, 1H), 8.33â8.28 (m, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 1H), 7.99 (t, <i>J</i> = 7.8 Hz, 1H), 7.92 (d, <i>J</i> = 7.1 Hz, 1H), 6.44 (d, <i>J</i> = 8.1 Hz, 1H), 6.32 (d, <i>J</i> = 6.8 Hz, 1H), 4.11â3.99 (m, 2H), 3.71 (s, 9H), 3.34 (dd, <i>J</i> = 12.6, 6.4 Hz, 2H), 2.30â2.14 (m, 2H), 1.81â1.65 (m, 3H), 1.65â1.49 (m, 3H), 1.41 (dd, <i>J</i> = 15.0, 7.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 174.53, 174.14, 173.69, 166.65, 157.30, 155.45, 144.55, 140.04, 134.59, 130.98, 130.62, 127.93, 125.25, 113.15, 54.41, 52.30, 51.65, 31.83, 29.88, 28.62, 27.54, 22.68, 20.74. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 532.2411 [M]<sup>+</sup> (calcd for C<sub>25</sub>H<sub>34</sub>N<sub>5</sub>O<sub>8</sub><sup>+</sup>: 532.2402).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 2-(3-{1-Carboxy-5-[(2-fluoro-quinoline-5-carbonyl)-amino]-pentyl}-ureido)-pentanedioic Acid (<b>8a</b>)</h3><div class="NLM_p last">The same procedures described above to prepare compound <b>7</b> was used, and the product was obtained as a white solid (0.14 g, 86%). The product <b>8a</b> was further purified by a Semi-Prep RP-HPLC using a mobile phase of 20/80 acetonitrile/water containing 0.1% TFA at 4 mL/min (retention time of 14.7 min and recovery rate of 81%). <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 12.39 (s, 1H), 8.82 (t, <i>J</i> = 8.6 Hz, 1H), 8.67 (d, <i>J</i> = 4.8 Hz, 1H), 7.97 (d, <i>J</i> = 8.3 Hz, 1H), 7.84 (t, <i>J</i> = 7.7 Hz, 1H), 7.73 (d, <i>J</i> = 7.0 Hz, 1H), 7.42 (d, <i>J</i> = 8.6 Hz, 1H), 6.34 (s, 2H), 4.16â4.04 (m, 2H), 3.39â3.28 (m, 2H), 2.32â2.18 (m, 2H), 1.98â1.87 (m, 1H), 1.72 (d, <i>J</i> = 4.7 Hz, 2H), 1.59 (dd, <i>J</i> = 13.8, 6.9 Hz, 3H), 1.45â1.36 (m, 2H). <sup>13</sup>C NMR (151 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 174.69, 174.26, 167.70, 162.00, 160.40, 157.83, 145.83 (d, <i>J</i> = 17.3 Hz), 141.56 (d, <i>J</i> = 9.9 Hz), 135.53, 130.63, 129.87, 125.99, 124.53, 111.35 (d, <i>J</i> = 42.1 Hz), 52.85, 52.19, 32.36, 30.44, 29.22, 28.11, 23.20, 21.28. <sup>19</sup>F NMR (565 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ â61.83 (d, <i>J</i> = 11.9 Hz), â74.86. HRMS (ESI<sup>â</sup>) <i>m</i>/<i>z</i> 491.1582 [M â H]<sup>â</sup> (calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>4</sub>O<sub>8</sub><sup>â</sup>: 491.1584).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 1-Oxy-quinoline-6-carboxylic Acid Ethyl Ester (<b>1b</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>1a</b> was used, and compound <b>1b</b> was obtained in yield of 73%. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 8.78 (d, <i>J</i> = 1.8 Hz, 1H), 8.70 (dd, <i>J</i> = 6.1, 0.9 Hz, 1H), 8.63 (d, <i>J</i> = 9.1 Hz, 1H), 8.25 (dd, <i>J</i> = 9.1, 1.9 Hz, 1H), 8.16 (d, <i>J</i> = 8.6 Hz, 1H), 7.58 (dd, <i>J</i> = 8.5, 6.1 Hz, 1H), 4.41 (q, <i>J</i> = 7.1 Hz, 2H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 218.0812 [M + H]<sup>+</sup> (calcd for C<sub>12</sub>H<sub>12</sub>NO<sub>3</sub><sup>+</sup>: 218.0812).</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 1-Oxy-quinoline-6-carboxylic Acid (<b>2b</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>2a</b> was used, and compound <b>2b</b> was obtained in yield of 100%. <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 13.48 (s, 1H), 8.74 (d, <i>J</i> = 1.4 Hz, 1H), 8.68 (d, <i>J</i> = 5.8 Hz, 1H), 8.60 (d, <i>J</i> = 9.0 Hz, 1H), 8.24 (dd, <i>J</i> = 9.1, 1.7 Hz, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.56 (dd, <i>J</i> = 8.4, 6.1 Hz, 1H). HRMS (ESI<sup>â</sup>) <i>m</i>/<i>z</i> 188.0347 [M â H]<sup>â</sup> (calcd for C<sub>10</sub>H<sub>6</sub>NO<sub>3</sub><sup>â</sup>: 188.0342).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 1-Oxy-quinoline-6-carboxylic Acid 2,3,5,6-Tetrafluoro-phenyl Ester (<b>3b</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>3a</b> was used, and compound <b>3b</b> was obtained in yield of 76%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) Î´ 9.00â8.83 (m, 3H), 8.55 (d, <i>J</i> = 5.8 Hz, 1H), 8.12 (dd, <i>J</i> = 8.3, 3.7 Hz, 1H), 7.57 (s, 1H), 7.14â7.09 (m, 1H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 338.0432 [M + H]<sup>+</sup> (calcd for C<sub>16</sub>H<sub>8</sub>F<sub>4</sub>NO<sub>3</sub><sup>+</sup>: 338.0435).</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> [6-(2,3,5,6-Tetrafluoro-phenoxycarbonyl)-quinolin-2-yl]-trimethylammonium Trifluoroacetate Salt (<b>4b</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>4a</b> was used, and compound <b>4b</b> (a mixture with Me<sub>3</sub>NÂ·TFA) was obtained in corrected yield of 62% according to <sup>1</sup>H NMR. <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 9.23 (d, <i>J</i> = 2.0 Hz, 1H), 9.19 (d, <i>J</i> = 8.9 Hz, 1H), 8.57 (dd, <i>J</i> = 8.9, 2.0 Hz, 1H), 8.45 (d, <i>J</i> = 9.1 Hz, 1H), 8.35 (d, <i>J</i> = 8.8 Hz, 1H), 8.09 (tt, <i>J</i> = 10.9, 7.5 Hz, 1H), 3.74 (s, 9H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 379.1061 [M]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>15</sub>F<sub>4</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup>: 379.1064).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (6-{5-[3-(1,3-Bis-<i>tert</i>-butoxycarbonyl-propyl)-ureido]-5-<i>tert</i>-butoxycarbonyl-pentylcarbamoyl}-quinolin-2-yl)-trimethylammonium Trifluoroacetate Salt (<b>5b</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>5a</b> was used, and compound <b>5b</b> was obtained in yield of 95%. <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 8.96 (d, <i>J</i> = 8.9 Hz, 1H), 8.85 (t, <i>J</i> = 5.5 Hz, 1H), 8.67 (d, <i>J</i> = 1.9 Hz, 1H), 8.35 (dd, <i>J</i> = 8.8, 1.9 Hz, 1H), 8.31 (d, <i>J</i> = 9.0 Hz, 1H), 8.18 (d, <i>J</i> = 8.8 Hz, 1H), 6.32â6.28 (m, 2H), 4.06â3.96 (m, 2H), 3.70 (s, 9H), 3.09 (s, 3H), 2.28â2.16 (m, 2H), 1.89â1.84 (m, 1H), 1.69â1.54 (m, 6H), 1.39â1.37 (m, 27H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 700.4271 [M]<sup>+</sup> (calcd for C<sub>37</sub>H<sub>58</sub>N<sub>5</sub>O<sub>8</sub><sup>+</sup>: 700.4280).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-(3-{1-<i>tert</i>-Butoxycarbonyl-5-[(2-fluoro-quinoline-6-carbonyl)-amino]-pentyl}-ureido)-pentanedioic Acid Di-<i>tert</i>-butyl Ester (<b>6b</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>6a</b> was used, and compound <b>6b</b> was obtained in yield of 75%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) Î´ 8.46 (s, 1H), 8.40 (t, <i>J</i> = 8.3 Hz, 1H), 8.18 (d, <i>J</i> = 8.7 Hz, 1H), 7.99 (d, <i>J</i> = 8.7 Hz, 1H), 7.15 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 6.97 (s, 1H), 5.30 (s, 2H), 4.32 (dd, <i>J</i> = 9.5, 5.5 Hz, 1H), 4.20 (dd, <i>J</i> = 7.6, 5.2 Hz, 1H), 3.53â3.50 (m, 2H), 2.35â2.24 (m, 2H), 1.90â1.82 (m, 2H), 1.77â1.68 (m, 6H), 1.46 (s, 9H), 1.44 (s, 9H), 1.39â1.38 (s, 9H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 661.3601 [M + H]<sup>+</sup> (calcd for C<sub>34</sub>H<sub>50</sub>FN<sub>4</sub>O<sub>8</sub><sup>+</sup>: 661.3607).</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (6-{5-Carboxy-5-[3-(1,3-dicarboxy-propyl)-ureido]-pentylcarbamoyl}-quinolin-2-yl)-trimethylammonium Trifluoroacetate Salt (<b>7b</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>7a</b> was used, and compound <b>7b</b> was obtained in yield of 80% (before RP-HPLC purfication). The recovery rate of RP-HPLC purfication was 62%, and retention time was 13.5 min. <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 12.99 (s, 1H), 8.97 (d, <i>J</i> = 9.1 Hz, 1H), 8.89â8.85 (m, 1H), 8.68 (s, 1H), 8.33 (dd, <i>J</i> = 18.9, 8.9 Hz, 2H), 8.17 (d, <i>J</i> = 8.8 Hz, 1H), 6.39 (d, <i>J</i> = 7.8 Hz, 1H), 6.29 (s, 1H), 4.10â4.00 (m, 2H), 3.71 (s, 9H), 3.32 (d, <i>J</i> = 6.1 Hz, 2H), 2.29â2.17 (m, 2H), 1.77 (dd, <i>J</i> = 14.4, 7.3 Hz, 2H), 1.73â1.65 (m, 1H), 1.63â1.51 (m, 3H), 1.43â1.33 (m, 2H). <sup>13</sup>C NMR (151 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 174.53, 174.12, 173.74, 165.12, 157.26, 156.36, 145.30, 143.03, 134.59, 129.97, 128.68, 127.59, 127.23, 113.24, 54.44, 52.30, 51.77, 31.84, 30.13, 28.66, 27.72, 22.71, 20.71. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 532.2411 [M]<sup>+</sup> (calcd for C<sub>25</sub>H<sub>34</sub>N<sub>5</sub>O<sub>8</sub><sup>+</sup>: 532.2402).</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-(3-{1-Carboxy-5-[(2-fluoro-quinoline-6-carbonyl)-amino]-pentyl}-ureido)-pentanedioic Acid (<b>8b</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>8a</b> was used, and compound <b>8b</b> was obtained in yield of 84% (before RP-HPLC purfication). The recovery rate of RP-HPLC purfication was 79%, and retention time was 19.1 min. <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO)z Î´ 12.41 (s, 2H), 8.75â8.64 (m, 2H), 8.55 (s, 1H), 8.21 (d, <i>J</i> = 8.6 Hz, 1H), 7.94 (d, <i>J</i> = 8.6 Hz, 1H), 7.44 (d, <i>J</i> = 8.1 Hz, 1H), 6.32 (t, <i>J</i> = 8.0 Hz, 2H), 4.09 (d, <i>J</i> = 6.0 Hz, 2H), 3.31 (d, <i>J</i> = 6.0 Hz, 2H), 2.32â2.17 (m, 2H), 1.98â1.87 (m, 1H), 1.71 (dd, <i>J</i> = 13.3, 5.6 Hz, 2H), 1.57 (d, <i>J</i> = 6.2 Hz, 3H), 1.42â1.32 (m, 2H). <sup>13</sup>C NMR (151 MHz, CD<sub>3</sub>OD) Î´ 175.77, 175.20, 174.75, 168.60, 159.52, 147.51, 144.51, 133.23, 129.50, 128.16, 127.08, 111.36 (d, <i>J</i> = 45.5 Hz, 1H), 53.35, 52.87, 40.32, 32.61, 30.45, 29.35, 28.26, 23.45. <sup>19</sup>F NMR (565 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ â60.05 (d, <i>J</i> = 11.7 Hz), â74.50. HRMS (ESI<sup>â</sup>) <i>m</i>/<i>z</i> 491.1585 [M â H]<sup>â</sup> (calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>4</sub>O<sub>8</sub><sup>â</sup>: 491.1584).</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 1-Oxy-quinoline-7-carboxylic Acid Ethyl Ester (<b>1c</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>1a</b> was used, and compound <b>1c</b> was obtained in yield of 75%. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 9.08 (s, 1H), 8.67 (d, <i>J</i> = 6.0 Hz, 1H), 8.18 (dt, <i>J</i> = 8.6, 4.9 Hz, 2H), 8.01 (d, <i>J</i> = 8.5 Hz, 1H), 7.61 (dd, <i>J</i> = 8.4, 6.1 Hz, 1H), 4.42 (q, <i>J</i> = 7.1 Hz, 2H), 1.39 (t, <i>J</i> = 7.1 Hz, 3H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 218.0812 [M + H]<sup>+</sup> (calcd for C<sub>12</sub>H<sub>12</sub>NO<sub>3</sub><sup>+</sup>: 218.0812).</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1-Oxy-quinoline-7-carboxylic Acid (<b>2c</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>2a</b> was used, and compound <b>2c</b> was obtained in yield of 84%. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 13.51 (s, 1H), 9.09 (s, 1H), 8.66 (dd, <i>J</i> = 6.1, 0.8 Hz, 1H), 8.19 (t, <i>J</i> = 7.8 Hz, 1H), 8.16 (dd, <i>J</i> = 8.5, 1.6 Hz, 1H), 8.01 (d, <i>J</i> = 8.5 Hz, 1H), 7.59 (dd, <i>J</i> = 8.5, 6.1 Hz, 1H). HRMS (ESI<sup>â</sup>) <i>m</i>/<i>z</i> 188.0347 [M â H]<sup>â</sup> (calcd for C<sub>10</sub>H<sub>6</sub>NO<sub>3</sub><sup>â</sup>: 188.0342).</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 1-Oxy-quinoline-7-carboxylic Acid 2,3,5,6-Tetrafluoro-phenyl Ester (<b>3c</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>3a</b> was used, and compound <b>3c</b> was obtained in yield of 77%. <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 9.32 (s, 1H), 8.75 (d, <i>J</i> = 6.0 Hz, 1H), 8.36 (t, <i>J</i> = 7.4 Hz, 1H), 8.34 (dd, <i>J</i> = 8.6, 1.6 Hz, 1H), 8.10 (d, <i>J</i> = 8.5 Hz, 1H), 8.05 (ddd, <i>J</i> = 18.3, 9.2, 5.4 Hz, 1H), 7.71 (dd, <i>J</i> = 8.5, 6.1 Hz, 1H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 338.0431 [M + H]<sup>+</sup> (calcd for C<sub>16</sub>H<sub>8</sub>F<sub>4</sub>NO<sub>3</sub><sup>+</sup>: 338.0435).</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> [7-(2,3,5,6-Tetrafluoro-phenoxycarbonyl)-quinolin-2-yl]-trimethylammonium Trifluoroacetate Salt (<b>4c</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>4a</b> was used, and compound <b>4c</b> (a mixture with Me<sub>3</sub>NÂ·TFA) was obtained in corrected yield of 37% according to <sup>1</sup>H NMR. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) Î´ 9.01 (d, <i>J</i> = 1.2 Hz, 1H), 8.81 (d, <i>J</i> = 9.0 Hz, 1H), 8.72 (d, <i>J</i> = 8.9 Hz, 1H), 8.44 (dd, <i>J</i> = 8.5, 1.6 Hz, 1H), 8.16 (d, <i>J</i> = 8.6 Hz, 1H), 7.10 (ddd, <i>J</i> = 9.9, 7.1, 2.8 Hz, 1H), 3.97 (s, 9H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 379.1061 [M]<sup>+</sup> (calcd for C<sub>19</sub>H<sub>15</sub>F<sub>4</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup>: 379.1064).</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (7-{5-[3-(1,3-Bis-<i>tert</i>-butoxycarbonyl-propyl)-ureido]-5-<i>tert</i>-butoxycarbonyl-pentylcarbamoyl}-quinolin-2-yl)-trimethylammonium Trifluoroacetate Salt (<b>5c</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>5a</b> was used, and compound <b>5c</b> was obtained in yield of 80%. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 8.91 (d, <i>J</i> = 6.9 Hz, 2H), 8.60 (s, 1H), 8.34 (d, <i>J</i> = 9.0 Hz, 1H), 8.34 (d, <i>J</i> = 9.0 Hz, 1H), 8.26 (d, <i>J</i> = 8.6 Hz, 1H), 6.33â6.28 (m, 2H), 4.06â3.96 (m, 2H), 3.71 (s, 9H), 3.09 (s, 3H), 2.27â2.19 (m, 2H), 1.91â1.82 (m, 1H), 1.69â1.37 (m, 6H), 1.41â1.37 (m, 27H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 700.4268 [M]<sup>+</sup> (calcd for C<sub>37</sub>H<sub>58</sub>N<sub>5</sub>O<sub>8</sub><sup>+</sup>: 700.4280).</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 2-(3-{1-<i>tert</i>-Butoxycarbonyl-5-[(2-fluoro-quinoline-7-carbonyl)-amino]-pentyl}-ureido)-pentanedioic Acid Di-<i>tert</i>-butyl Ester (<b>6c</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>6a</b> was used, and compound <b>6c</b> was obtained in yield of 70%. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) Î´ 8.46 (s, 1H), 8.28 (t, <i>J</i> = 8.3 Hz, 1H), 8.08 (dd, <i>J</i> = 8.4, 1.2 Hz, 1H), 7.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.17 (s, 1H), 7.14 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 5.21 (b, 2H), 4.39â4.30 (m, 2H), 3.59â3.54 (m, 1H), 3.49â3.43 (m, 1H), 2.41â2.29 (m, 2H), 1.88â1.63 (m, 8H), 1.46 (s, 9H), 1.43 (s, 9H), 1.34 (s, 9H). HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 661.3597 [M + H]<sup>+</sup> (calcd for C<sub>34</sub>H<sub>50</sub>FN<sub>4</sub>O<sub>8</sub><sup>+</sup>: 661.3607).</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (7-{5-Carboxy-5-[3-(1,3-dicarboxy-propyl)-ureido]-pentylcarbamoyl}-quinolin-2-yl)-trimethylammonium Trifluoroacetate Salt (<b>7c</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>7a</b> was used, and compound <b>7c</b> was obtained in yield of 80% (before RP-HPLC purfication). The recovery rate of RP-HPLC purfication was 73%, and retention time was 13.6 min. <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 12.46 (s, 3H), 8.93 (dd, <i>J</i> = 15.4, 7.2 Hz, 2H), 8.61 (s, 1H), 8.35 (dd, <i>J</i> = 9.0, 1.2 Hz, 1H), 8.26 (d, <i>J</i> = 8.5 Hz, 1H), 8.22 (d, <i>J</i> = 8.6 Hz, 1H), 6.36 (dd, <i>J</i> = 7.7, 3.7 Hz, 2H), 4.09 (ddd, <i>J</i> = 15.2, 13.1, 8.3 Hz, 2H), 3.72 (s, 9H), 3.34â3.31 (m, 2H), 2.30â2.19 (m, 2H), 1.96â1.88 (m, 1H), 1.76â1.67 (m, 2H), 1.63â1.54 (m, 3H), 1.42â1.33 (m, 2H). <sup>13</sup>C NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 174.58, 174.19, 173.76, 164.95, 157.35, 156.11, 143.96, 141.92, 137.28, 129.11, 128.27, 127.48, 127.24, 113.86, 54.49, 52.14, 51.74, 31.76, 29.9, 28.69, 27.56, 22.76, 20.78. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> 532.2408 [M]<sup>+</sup> (calcd for C<sub>25</sub>H<sub>34</sub>N<sub>5</sub>O<sub>8</sub><sup>+</sup>: 532.2402).</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2-(3-{1-Carboxy-5-[(2-fluoro-quinoline-7-carbonyl)-amino]-pentyl}-ureido)-pentanedioic Acid (<b>8c</b>)</h3><div class="NLM_p last">The same procedure described above to prepare compound <b>8a</b> was used, and compound <b>8c</b> was obtained in yield of 86% (before RP-HPLC purfication using a mobile phase of 25/75 acetonitrile/water containing 0.1% TFA at 4 mL/min). The recovery rate of RP-HPLC purfication was 74%, and retention time was 8.9 min. <sup>1</sup>H NMR (600 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ 12.41 (s, 2H), 8.77 (s, 1H), 8.65 (t, <i>J</i> = 8.4 Hz, 1H), 8.37 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 1H), 8.03 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 6.32 (t, <i>J</i> = 8.1 Hz, 2H), 4.09 (td, <i>J</i> = 12.9, 7.7 Hz, 2H), 3.35â3.27 (m, 2H), 2.31â2.18 (m, 2H), 1.92 (q, <i>J</i> = 13.5 Hz, 1H), 1.76â1.67 (m, 2H), 1.63â1.54 (m, 3H), 1.43â1.32 (m, 2H). <sup>13</sup>C NMR (151 MHz, CD<sub>3</sub>OD) Î´ 175.11, 174.51, 167.96, 162.74, 161.13, 158.83, 144.99 (d, <i>J</i> = 16.5 Hz), 142.64 (d, <i>J</i> = 10.1 Hz), 136.78, 128.55, 128.14, 126.31, 124.45, 111.26 (d, <i>J</i> = 42.1 Hz), 52.64, 52.19, 39.65, 31.93, 29.76, 28.61, 27.54, 22.71. <sup>19</sup>F NMR (565 MHz, (CD<sub>3</sub>)<sub>2</sub>SO) Î´ â60.79 (d, <i>J</i> = 11.6 Hz), â73.80. HRMS (ESI<sup>â</sup>) <i>m</i>/<i>z</i> 491.1585 [M â H]<sup>â</sup> (calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>4</sub>O<sub>8</sub><sup>â</sup>: 491.1584).</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Radiosynthesis of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b></h3><div class="NLM_p last">The automatic syntheses of radiotracers were performed with a homemade synthesis module (PET-MF-2 V-IT-I) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">Figure S1</a>). Sep-Pak Light QMA was activated via a successive pass through 5 mL of 75 mM tetrabutylammonium bicarbonate aqueous solution and 5 mL of high purity water. The [<sup>18</sup>F]fluoride ion produced by cyclotron was retained on the activated QMA column and eluted into the reaction vessel by 1 mL of TBAB solution (contain 6.8 mg TBAB, 0.7 mL acetonitrile, and 0.3 mL water). The solvent was heated at 115 Â°C and blew with nitrogen at a velocity of 100 mL/min. When the liquid was invisible, the heating temperature was reduced to 85 Â°C and maintained for 2 min to afford an anhydrous reaction system. A solution of 0.3â0.5 mg of precursors (<b>7a</b>, <b>7b</b>, and <b>7c</b>) in 0.5 mL of anhydrous DMF was added to the vessel, and the reaction solution was heated to 50 Â°C for 5 min. Then 5 mL of solution used for HPLC separation was added to the vessel, and the crude mixture was loaded onto a semipreparative HPLC column (Alltech Chrom BDS-C18, 5 Î¼m, 10 Ã 150 mm) for purification using the isocratic elution of aqueous-ethanol solution containing 0.2% phosphoric acid at 6 mL/min. The product was collected as monitored by online continuous UV (254 nm) and radioactivity detectors. The final formulation was then passed through a sterile filter into a sterile vial, followed by neutralization with sodium bicarbonate and dilution with 0.9% sodium chloride. The [<sup>18</sup>F]PyL was prepared according to the reported procedures.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Quality Control Procedures of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b></h3><div class="NLM_p last">Tests of quality control were carried out before release to further research. A visual inspection of the product was observed under bright light behind a lead glass. The pH of the product was detected by applying a small amount of injection to pH indicator sticks. Radioactivity was measured using a dose calibrator and radionuclidic identity was performed by calculating the half-life of <sup>18</sup>F. Radiochemical identity was confirmed using analytical HPLC by comparing the retention time of <sup>18</sup>F-labeled tracer to that of the nonradioactive <sup>19</sup>F-labeled reference standard (two mobile phase systems were used). Radiochemical purity was determined with the same chromatographic system. The molar activity of the final injection was determined by HPLC via a UV calibration curve. The in vitro stability of injection was confirmed by radiochemical purity, analyzing 6 h after the formation of the product at room temperature. Residual organic solvents were measured by a gas chromatograph (GC 7890, Techcomp (Shang Hai) Ltd.). The absence of residual phase transfer catalyst TBAB was confirmed by a semiquantitative color spot test. The bacterial endotoxin content of the injection was detected using the Limulus amebocyte lysate (LAL) method in a Portable Test System (PTS) Kinetic Reader (Charles Rivers Laboratories).</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Determination of Log <i>D</i><sub>pHÂ 7.4</sub> Value</h3><div class="NLM_p last">Log <i>D</i><sub>pHÂ 7.4</sub> values of these tracers were measured using the shake flask method. The purified [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, or [<sup>18</sup>F]<b>8c</b> (10 Î¼L, 370 kBq) was dropped into a centrifuge tube containing the mixture of 3.0 mL of potassium phosphate buffer (PBS, 0.05 M, pH = 7.4) and 3.0 mL of 1-octanol. The tube was vigorously vortexed for 3 min at room temperature and centrifuged at 5000 rpm for 5 min. Then 0.5 mL of the 1-octanol (upper layer) and 10 Î¼L of the PBS (lower layer) were collected in the respective tube. The activity of the two solutions was detected in an automatic Î³-counter (Wallac 2480 Wizard, MA). The lipid/water partition coefficient was calculated and expressed as log <i>D</i><sub>pHÂ 7.4</sub> = log[(counts in 1-octanol)/(counts in PBS)]. The measurement was carried out in triplicate and repeated three times.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Cell Lines and Animal Models</h3><div class="NLM_p">LNCaP cells were a generous gift from Yang, X. and Duan, X.J. (Peking University First Hospital). Two human PCa cell lines were purchased from the Stem Cell Bank, Chinese Academy of Science: 22Rv1 (PSMA+) and PC-3 (PSMAâ). LNCaP (PSMA+) and 22Rv1 cell lines were cultured in RPMI 1640 medium (Gibco, USA), supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco) and 1% (v/v) antibiotics (Gibco), while the PC-3 cell line was maintained in F12k medium supplemented with 10% FBS and 1% antibiotics at conditions of 37 Â°C with 5% CO<sub>2</sub>.</div><div class="NLM_p last">Healthy male ICR mice (6â7 weeks of age, 20 Â± 2 g) and BALB/c nude mice (5â6 weeks, 18 Â± 2g) were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). PSMA+ 22Rv1 cells (2 Ã 10<sup>6</sup> per mouse) were implanted subcutaneously into the forelimb skin of BALB/c nude mice. After 4â5 weeks, the tumor size reached about 0.6â1.0 cm in diameter, and the tumor-bearing mice were used for micro-PET imaging study. PSMAâ PC-3 tumor-bearing mice were used as a negative control group. Two male Cynomolgus monkeys (5 years of age, 4â5 kg) were used for PET scan. All animal experiments were carried out in strict compliance with the Guide for Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Beijing Normal University.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> NAALADase Assay</h3><div class="NLM_p last">The mixture of lysates of LNCaP cell extracts (25 Î¼L), 8 Î¼M of <i>N</i>-acetylaspartylglutamate (12.5 Î¼L), and <sup>19</sup>F-labeled reference standard (12.5 Î¼L, 0.01 nmol/L â 1 Î¼mol/L) were incubated at 37 Â°C for 2 h to form glutamate. The glutamate levels were determined by the commercial Amplex Red Glutamic Acid/Glutamate Oxidase Assay Kit. 50 Î¼L of working solution was added to the mixture with released glutamate and cultured at 37 Â°C for additional 1 h. Fluorescence intensity was detected by a fluorescence microplate reader (excitation at 530 nm and emission at 590 nm). Semilog plots were used to show the doseâresponse inhibition curves. The assays were performed in triplicate in a single analytical batch. The inhibition constant (<i>K</i><sub>i</sub> value) of the <sup>19</sup>F-labeled reference was calculated according to the ChengâPrusoff equation (<i>K</i><sub>i</sub> = IC<sub>50</sub>/(1 + S/km)).</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> In Vitro Cell Uptake Assay</h3><div class="NLM_p last">LNCaP and PC-3 cell lines in 24-well plates (2 Ã 10<sup>5</sup> cells/well) were incubated at 37 Â°C/5% CO<sub>2</sub> overnight, respectively. The medium was removed, and each well was washed by 0.5 mL of fresh RPMI 1640 medium supplemented with 0.5% bovine serum albumin 1 h before the assays. Each well of plates was added with the <sup>18</sup>F-labeled tracers (74 KBq, 10 Î¼L in saline). After 60 min incubation at 37 Â°C/5% CO<sub>2</sub>, the medium was removed, and each well was washed twice with 500 Î¼L of cold PBS. The cells were lysed with NaOH (1 M) and were individually collected into the EP tubes. The radioactivity counts were measured by automatic Î³-counter (Wallac 1470 Wizard, PerkinElmer, MA). A blocking experiment was performed by co-incubating cells with the <sup>18</sup>F-labeled tracers in the presence of 2 Î¼mol/well PSMA inhibitor 2-(phosphonomethyl)pentanoic acid (2-PMPA, Medchemexpress LLC, USA). The result was expressed as IA%/10<sup>5</sup> cells (<i>n</i> = 3).</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Ex Vivo Biodistribution Studies in Normal Male ICR Mice</h3><div class="NLM_p last">A saline solution of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, or [<sup>18</sup>F]<b>8c</b> (185 kBq, 0.1 mL, <1% ethanol) was intravenously injected into mice (five groups, <i>n</i> = 5 in each group) via the tail vein. The mice were decapitated at 2, 15, 30, and 60 min after injection. Samples of blood, whole brain, heart, liver, spleen, lungs, kidneys, pancreas, muscle, bone (femur), stomach, and small intestine were harvested, weighed, and counted in an automatic Î³-counter. All radioactivity measurements were decay corrected. The percentage of injected dose per gram of wet tissue (% ID/g) was calculated by a comparison of the tissue counts to suitably diluted aliquots of the injected radiotracer as counting standards. The data were expressed as mean Â± SD.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Î¼PET Studies of Tumor-Bearing Mice</h3><div class="NLM_p last">Injection of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, or [<sup>18</sup>F]PyL (5.55 MBq, 0.1 mL, <1% ethanol) was administered intravenously via tail into 22Rv1 tumor-bearing mouse. At 60 min postinjection, these mice were anesthetized by isoflurane inhalation, and the static Î¼PET/CT data were acquired (1-bed position, 10 min emission/bed) (Super Nova PET/CT, PINGSENG Healthcare Inc. China). Blocking study was performed by co-injection of the radiotracers with 2-PMPA (2 mg/kg). Î¼PET images of radiotracers in PC-3 tumor-bearing mice were acquired for comparison. Two-tailed Student <i>t</i> test as the statistical analysis was performed.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Imaging Protocol for PET Studies of Monkey</h3><div class="NLM_p last">Two male monkeys of similar age and weight were used for PET scans on a PET/CT system (uMI550 PET/CT, United imaging, China) to evaluate the pharmacokinetic characteristics of these radiotracers in primates. Monkeys were anesthetized by intramuscularly injection sodium pentobarbital (15 mg/kg) and were fixed on a plastic mold on the scanning Table 20 min before scanning. Each PET/CT acquisition was initiated by a transmission CT scan (120 kV, 110 mA). The first three-dimensional PET examination was acquired immediately while the probe (74â111 MBq, 0.5 mL of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, or [<sup>18</sup>F]PyL in saline) was injected intravenously into the forearm of the monkey. A single PET scan covering the head and the torso contained four 1 min/bed positions. The table was reset to the initial scanning position immediately after the completed PET scan, and the subsequent PET scan was performed. A total of 14 sequential PET scans were acquired, which took about 60â65 min. Reconstruction of PET images using OSEM algorithm (ordered-subsets expectation maximization algorithm) was performed with 21 subsets, 3 iterations, a matrix size of 192 Ã 192, a full width at half-maximum of 3.0 mm. Attenuation correction of PET reconstruction was based on the CT data.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> PET Imaging Procedure of Human Studies</h3><div class="NLM_p last">All human studies were approved by the ethics committee of Chinese PLA general hospital and have signed informed consent by the volunteers (approval of no. S2019-271-01). An uMI550 PET/CT (United imaging, China) or a Biograph 64 TruePoint PET/CT (Siemens) was used for human study. According to the results of preclinical study, due to the poorer PSMA binding affinity of [<sup>18</sup>F]<b>8a</b> compared to [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b>, only [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]<b>8c</b> were selected for preliminary human study to determine the distribution and pharmacokinetics of these two tracers in vivo. For human study, one static three-dimensional PET scan was acquired at 60â80 min postadministration of 4.44 MBq/kg of [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, or [<sup>18</sup>F]PyL, at 2 min/bed position for 6 bed positions to cover the base of the skull to mid thighs. The PET reconstruction parameters for human were the same as that for the monkey. In total, six patients with local or metastatic PCa confirmed by further pathological investigation were included in this study to evaluate characteristics of the human distribution between the two novel tracers and [<sup>18</sup>F]PyL. The Gleason score was calculated based on the results of biopsy or prostatectomy.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00117" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31347" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31347" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">In addition, the is also included. The Supporting Information is available free of charge on the ACS Publications Web site. The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00117?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00117</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Details of schematic diagram of the radiosynthesis, quality control data, semipreparative and analytical HPLC tracers, MA determination of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b>, ex vivo and in vivo biodistribution of the rodents, PET/CT imaging of the patients, spectral data (<sup>1</sup>H NMR, <sup>13</sup>C NMR, HPLC, HRMS, and <sup>18</sup>F NMR) data of novel compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings file (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf">jm1c00117_si_001.pdf (3.68 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_002.csv">jm1c00117_si_002.csv (0.36 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00117" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shulin Yao</span> - <span class="hlFld-Affiliation affiliation">Department
of Nuclear Medicine, Chinese PLA General
Hospital, Beijing 100853, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c4bda5abb7acb1a8adaaf7f4f584f5f2f7eaa7aba9"><span class="__cf_email__" data-cfemail="8ef7efe1fde6fbe2e7e0bdbebfcebfb8bda0ede1e3">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinming Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Nuclear Medicine, Chinese PLA General
Hospital, Beijing 100853, China</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#156f7d747b727f78262524552423263b767a78"><span class="__cf_email__" data-cfemail="52283a333c35383f616263126364617c313d3f">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mengchao Cui</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Radiopharmaceuticals, Ministry of Education, College
of Chemistry, Beijing Normal University, Beijing 100875, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Center
for Advanced Materials Research, Advanced Institute of Natural Sciences, Beijing Normal University at Zhuhai, Zhuhai 519087, China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3488-7864" title="Orcid link">http://orcid.org/0000-0002-3488-7864</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8cefe1efcceee2f9a2e9e8f9a2efe2"><span class="__cf_email__" data-cfemail="fd9e909ebd9f9388d3989988d39e93">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaojun Zhang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Radiopharmaceuticals, Ministry of Education, College
of Chemistry, Beijing Normal University, Beijing 100875, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Nuclear Medicine, Chinese PLA General
Hospital, Beijing 100853, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yitian Wu</span> - <span class="hlFld-Affiliation affiliation">Department
of Nuclear Medicine, Chinese PLA General
Hospital, Beijing 100853, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi Zeng</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Radiopharmaceuticals, Ministry of Education, College
of Chemistry, Beijing Normal University, Beijing 100875, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianxin Xie</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Radiopharmaceuticals, Ministry of Education, College
of Chemistry, Beijing Normal University, Beijing 100875, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M. Cui and X. Zhang conceived and designed the experiments. X. Zhang, Y. Wu, Q. Zeng, T. Xie, and S. Yao performed the experiments. M. Cui and X. Zhang analyzed the data. M. Cui, J. Zhang, and S. Yao contributed reagents, materials, and analysis tools. X. Zhang, Q. Zeng, and M. Cui wrote the paper.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by the National Natural Science Foundation of China (nos. U1967221 and 22022601) and the National Key Research and Development Program of China (2016YFC0103908). We thank Prof. Xing Yang and Dr. Xiaojiang Duan (Department of Nuclear Medicine, Peking University First Hospital) for providing of the LNCaP cells, the 22Rv1 tumor-bearing mice, and technical assistance.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PSMA</td><td class="NLM_def"><p class="first last">prostate-specific membrane antigen</p></td></tr><tr><td class="NLM_term">PCa</td><td class="NLM_def"><p class="first last">prostate cancer</p></td></tr><tr><td class="NLM_term">CT</td><td class="NLM_def"><p class="first last">computed tomography</p></td></tr><tr><td class="NLM_term">MRI</td><td class="NLM_def"><p class="first last">magnetic resonance imaging</p></td></tr><tr><td class="NLM_term">SPECT</td><td class="NLM_def"><p class="first last">single photon emission computed tomography</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">RCP</td><td class="NLM_def"><p class="first last">radiochemical purity</p></td></tr><tr><td class="NLM_term">RCY</td><td class="NLM_def"><p class="first last">radiochemical yield</p></td></tr><tr><td class="NLM_term">MA</td><td class="NLM_def"><p class="first last">molar activity</p></td></tr><tr><td class="NLM_term">MIP</td><td class="NLM_def"><p class="first last">maximum intensity projection</p></td></tr><tr><td class="NLM_term">SUV<sub>mean</sub></td><td class="NLM_def"><p class="first last">mean of the standardized uptake value based on body weight</p></td></tr><tr><td class="NLM_term">SUV<sub>max</sub></td><td class="NLM_def"><p class="first last">max of the standardized uptake value based on body weight</p></td></tr><tr><td class="NLM_term">TACs</td><td class="NLM_def"><p class="first last">time-activity curves</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">prostate-specific antigen</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-pressure liquid chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2021</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">7</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.3322/caac.21654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.3322%2Fcaac.21654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=33433946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BB3svptVKhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2021&pages=7-33&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=H.+E.+Fuchsauthor=A.+Jemal&title=Cancer+statistics%2C+2021&doi=10.3322%2Fcaac.21654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Statistics, 2021</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Fuchs Hannah E; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence.  Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data (through 2018) were collected by the National Center for Health Statistics.  In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States.  After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment.  This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted.  Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018.  The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall.  This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC).  For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%.  Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_jHscXVnJh1WTCLT8lX9SfW6udTcc2eYVxWb5g0wLvrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3svptVKhuw%253D%253D&md5=c65743e74b28b6c7dd1f912745f3edf1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21654%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DFuchs%26aufirst%3DH.%2BE.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202021%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2021%26volume%3D71%26spage%3D7%26epage%3D33%26doi%3D10.3322%2Fcaac.21654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶der, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugosson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roobol, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tammela, T. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lujan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¤Ã¤ttÃ¤nen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilja, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>384</i></span>,  <span class="NLM_fpage">2027</span>â <span class="NLM_lpage">2035</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(14)60525-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2FS0140-6736%2814%2960525-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=25108889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FgtlKrsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=2027-2035&author=F.+H.+Schr%C3%B6derauthor=J.+Hugossonauthor=M.+J.+Roobolauthor=T.+L.+J.+Tammelaauthor=M.+Zappaauthor=V.+Nelenauthor=M.+Kwiatkowskiauthor=M.+Lujanauthor=L.+M%C3%A4%C3%A4tt%C3%A4nenauthor=H.+Lilja&title=Screening+and+prostate+cancer+mortality%3A+results+of+the+European+Randomised+Study+of+Screening+for+Prostate+Cancer+%28ERSPC%29+at+13+years+of+follow-up&doi=10.1016%2FS0140-6736%2814%2960525-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up</span></div><div class="casAuthors">Schroder Fritz H; Hugosson Jonas; Roobol Monique J; Bangma Chris H; Tammela Teuvo L J; Zappa Marco; Puliti Donella; Nelen Vera; Kwiatkowski Maciej; Lujan Marcos; Maattanen Liisa; Lilja Hans; Denis Louis J; Recker Franz; Paez Alvaro; Carlsson Sigrid; Villers Arnauld; Rebillard Xavier; Hakama Matti; Stenman Ulf-Hakan; Kujala Paula; Taari Kimmo; Aus Gunnar; Huber Andreas; van der Kwast Theo H; van Schaik Ron H N; de Koning Harry J; Moss Sue M; Auvinen Anssi</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">9959</span>),
    <span class="NLM_cas:pages">2027-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis.  We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.  METHODS:  ERSPC is a multicentre, randomised trial with a predefined centralised database, analysis plan, and core age group (55-69 years), which assesses prostate-specific antigen (PSA) testing in eight European countries.  Eligible men aged 50-74 years were identified from population registries and randomly assigned by computer generated random numbers to screening or no intervention (control).  Investigators were masked to group allocation.  The primary outcome was prostate cancer mortality in the core age group.  Analysis was by intention to treat.  We did a secondary analysis that corrected for selection bias due to non-participation.  Only incidence and no mortality data at 9 years' follow-up are reported for the French centres.  This study is registered with Current Controlled Trials, number ISRCTN49127736.  FINDINGS:  With data truncated at 13 years of follow-up, 7408 prostate cancer cases were diagnosed in the intervention group and 6107 cases in the control group.  The rate ratio of prostate cancer incidence between the intervention and control groups was 1Â·91 (95% CI 1Â·83-1Â·99) after 9 years (1Â·64 [1Â·58-1Â·69] including France), 1Â·66 (1Â·60-1Â·73) after 11 years, and 1Â·57 (1Â·51-1Â·62) after 13 years.  The rate ratio of prostate cancer mortality was 0Â·85 (0Â·70-1Â·03) after 9 years, 0Â·78 (0Â·66-0Â·91) after 11 years, and 0Â·79 (0Â·69-0Â·91) at 13 years.  The absolute risk reduction of death from prostate cancer at 13 years was 0Â·11 per 1000 person-years or 1Â·28 per 1000 men randomised, which is equivalent to one prostate cancer death averted per 781 (95% CI 490-1929) men invited for screening or one per 27 (17-66) additional prostate cancer detected.  After adjustment for non-participation, the rate ratio of prostate cancer mortality in men screened was 0Â·73 (95% CI 0Â·61-0Â·88).  INTERPRETATION:  In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.  Despite our findings, further quantification of harms and their reduction are still considered a prerequisite for the introduction of populated-based screening.  FUNDING:  Each centre had its own funding responsibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJzFJXEpPop1m8bhe6roZYfW6udTcc2eawHQ8Lpp_hGrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FgtlKrsg%253D%253D&md5=d093e9d7b678f69ee5b49996614a6f2b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960525-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960525-0%26sid%3Dliteratum%253Aachs%26aulast%3DSchr%25C3%25B6der%26aufirst%3DF.%2BH.%26aulast%3DHugosson%26aufirst%3DJ.%26aulast%3DRoobol%26aufirst%3DM.%2BJ.%26aulast%3DTammela%26aufirst%3DT.%2BL.%2BJ.%26aulast%3DZappa%26aufirst%3DM.%26aulast%3DNelen%26aufirst%3DV.%26aulast%3DKwiatkowski%26aufirst%3DM.%26aulast%3DLujan%26aufirst%3DM.%26aulast%3DM%25C3%25A4%25C3%25A4tt%25C3%25A4nen%26aufirst%3DL.%26aulast%3DLilja%26aufirst%3DH.%26atitle%3DScreening%2520and%2520prostate%2520cancer%2520mortality%253A%2520results%2520of%2520the%2520European%2520Randomised%2520Study%2520of%2520Screening%2520for%2520Prostate%2520Cancer%2520%2528ERSPC%2529%2520at%252013%2520years%2520of%2520follow-up%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D2027%26epage%3D2035%26doi%3D10.1016%2FS0140-6736%2814%2960525-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingrosso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scartoni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, R.</span></span> <span> </span><span class="NLM_article-title">Current therapeutic options in metastatic castration-resistant prostate cancer</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">303</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1053/j.seminoncol.2018.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1053%2Fj.seminoncol.2018.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30446166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFyhtbrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=303-315&author=G.+Ingrossoauthor=B.+Dettiauthor=D.+Scartoniauthor=A.+Lanciaauthor=I.+Giacomelliauthor=M.+Bakiauthor=G.+Cartaauthor=L.+Liviauthor=R.+Santoni&title=Current+therapeutic+options+in+metastatic+castration-resistant+prostate+cancer&doi=10.1053%2Fj.seminoncol.2018.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Current therapeutic options in metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">Ingrosso, Gianluca; Detti, Beatrice; Scartoni, Daniele; Lancia, Andrea; Giacomelli, Irene; Baki, Muhammed; Carta, Giulio; Livi, Lorenzo; Santoni, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">303-315</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The tumors of many patients with prostate cancer eventually become refractory to androgen deprivation therapy with progression to metastatic castration-resistant disease.  Significant advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have been made in recent years, and new treatment strategies have recently been made available.  The aim of this report was to schematically review all the approved pharmacol. treatment options for patients with mCRPC through 2018, analyzing the efficacy and possible side effects of each therapy to assist clinicians in reaching an appropriate treatment decision.  New biomarkers potentially of aid in the choice of treatment in this setting are also briefly reviewed.  We performed a literature search of clin. trials of new drugs and treatments for patients diagnosed with mCRPC published through 2018.  Two new hormonal drugs, abiraterone acetate and enzalutamide have been approved by FDA in 2011 and 2012, resp. for the treatment of patients with mCRPC and have undergone extensive testing.  While these treatments have shown a benefit in progression-free and overall survival, the appropriate sequencing must still be detd. so that treatment decisions can be made based on their specific clin. profile.  Cabazitaxel has been shown to be an efficient therapeutic option in a postdocetaxel setting, while its role in chemotherapy-naive patients must still be detd.  Sipuleucel-T and radium-223 have been studied in patients without visceral metastases and have achieved overall survival benefits with good safety profiles.  The feasibility and efficacy of combinations of new treatments with other known therapies such as chemotherapy are currently under investigation.  Drug development efforts continue to attempt to prolong survival and improve quality of life in the mCRPC setting, with several therapeutic options available.  Ongoing and future trials are needed to further assess the efficacy and safety of these new drugs and their interactions, along with the most appropriate sequencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEsw7qU5pASrVg90H21EOLACvtfcHk0lgdYwVaVhbs5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFyhtbrI&md5=48487455dba4742b9120a1e0ca05e376</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2018.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2018.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DIngrosso%26aufirst%3DG.%26aulast%3DDetti%26aufirst%3DB.%26aulast%3DScartoni%26aufirst%3DD.%26aulast%3DLancia%26aufirst%3DA.%26aulast%3DGiacomelli%26aufirst%3DI.%26aulast%3DBaki%26aufirst%3DM.%26aulast%3DCarta%26aufirst%3DG.%26aulast%3DLivi%26aufirst%3DL.%26aulast%3DSantoni%26aufirst%3DR.%26atitle%3DCurrent%2520therapeutic%2520options%2520in%2520metastatic%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2018%26volume%3D45%26spage%3D303%26epage%3D315%26doi%3D10.1053%2Fj.seminoncol.2018.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alpajaro, S. I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. P.</span></span> <span> </span><span class="NLM_article-title">Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies</span>. <i>Prostate Cancer Prostatic Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">16</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1038/s41391-018-0078-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1038%2Fs41391-018-0078-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30115959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ovFahsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2019&pages=16-23&author=S.+I.+R.+Alpajaroauthor=J.+A.+K.+Harrisauthor=C.+P.+Evans&title=Non-metastatic+castration+resistant+prostate+cancer%3A+a+review+of+current+and+emerging+medical+therapies&doi=10.1038%2Fs41391-018-0078-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies</span></div><div class="casAuthors">Alpajaro Sigfred Ian R; Evans Christopher P; Harris Jerad A K</div><div class="citationInfo"><span class="NLM_cas:title">Prostate cancer and prostatic diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-metastatic castration resistant prostate cancer (M0CRPC) is a heterogenous disease state affecting an estimated 100,000 men in the United States.  Development of more sensitive modalities for detection of metastasis has altered the landscape of advanced prostate cancer, but M0CRPC has remained a condition that previously lacked FDA-approved treatment.  The emerging data on new generation Androgen Receptor (AR) pathway inhibitors should address this gap in the management of such patients.  METHODS:  We reviewed and summarized the current literature for the definition, diagnosis and treatment of M0CRPC.  We highlight the results of recent Phase III trials that show significant impact on the outcomes of M0CRPC.  RESULTS:  Androgen deprivation therapy remains the foundation of therapy for M0CRPC.  Recently published Phase III trials provided data on improved progression free survival when ADT is augmented with newer AR pathway inhibitors.  The SPARTAN trial showed that metastasis-free survival (MFS) for patients treated with apalutamide plus ADT is 40.5 months compared to 16.2 months for patients who received standard ADT plus placebo, a 72% reduction in the risk of distant metastasis or death in apalutamide plus ADT compared to ADT plus placebo.  The PROSPER trial demonstrated that MFS for patients treated with enzalutamide plus ADT was 36.6 months compared to 14.7 months for patients who received standard ADT only indicating a 71% reduction in the risk of developing metastatic CRPC or death compared to ADT alone.  The ARAMIS trial on darolutamide, another AR pathway inhibitor, is also ongoing, and can potentially be another fitting option for M0CRPC.  CONCLUSION:  The recent Phase III trials SPARTAN and PROPSER demonstrate effective treatment options for the M0CRPC disease state that has historically lacked treatment from high level evidence.  In particular, an FDA-approved treatment, Apalutamide, can finally be offered for M0CRPC patients.  The newer AR pathway inhibitors should provide a basis for further investigation into treatments for M0CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTexkzFIUjqpIxhnOQkIHOxfW6udTcc2eawHQ8Lpp_hGrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ovFahsQ%253D%253D&md5=3e3d4f566bbdbaeadcf8a50b6ab5f58a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41391-018-0078-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41391-018-0078-1%26sid%3Dliteratum%253Aachs%26aulast%3DAlpajaro%26aufirst%3DS.%2BI.%2BR.%26aulast%3DHarris%26aufirst%3DJ.%2BA.%2BK.%26aulast%3DEvans%26aufirst%3DC.%2BP.%26atitle%3DNon-metastatic%2520castration%2520resistant%2520prostate%2520cancer%253A%2520a%2520review%2520of%2520current%2520and%2520emerging%2520medical%2520therapies%26jtitle%3DProstate%2520Cancer%2520Prostatic%2520Dis.%26date%3D2019%26volume%3D22%26spage%3D16%26epage%3D23%26doi%3D10.1038%2Fs41391-018-0078-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djulbegovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agoritsas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahm, P.</span></span> <span> </span><span class="NLM_article-title">Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis</span>. <i>Brit Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>362</i></span>, <span class="NLM_elocation-id">k3519</span> <span class="refDoi">Â DOI: 10.1136/bmj.k3519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1136%2Fbmj.k3519" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2018&author=D.+Ilicauthor=M.+Djulbegovicauthor=J.+H.+Jungauthor=E.+C.+Hwangauthor=Q.+Zhouauthor=A.+Clevesauthor=T.+Agoritsasauthor=P.+Dahm&title=Prostate+cancer+screening+with+prostate-specific+antigen+%28PSA%29+test%3A+a+systematic+review+and+meta-analysis&doi=10.1136%2Fbmj.k3519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1136%2Fbmj.k3519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.k3519%26sid%3Dliteratum%253Aachs%26aulast%3DIlic%26aufirst%3DD.%26aulast%3DDjulbegovic%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DJ.%2BH.%26aulast%3DHwang%26aufirst%3DE.%2BC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DCleves%26aufirst%3DA.%26aulast%3DAgoritsas%26aufirst%3DT.%26aulast%3DDahm%26aufirst%3DP.%26atitle%3DProstate%2520cancer%2520screening%2520with%2520prostate-specific%2520antigen%2520%2528PSA%2529%2520test%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DBrit%2520Med.%2520J.%26date%3D2018%26volume%3D362%26doi%3D10.1136%2Fbmj.k3519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjurlin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tammela, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etzioni, R.</span></span> <span> </span><span class="NLM_article-title">Overdiagnosis and overtreatment of prostate cancer</span>. <i>Eur. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1046</span>â <span class="NLM_lpage">1055</span>, <span class="refDoi">Â DOI: 10.1016/j.eururo.2013.12.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2Fj.eururo.2013.12.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=24439788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BC2czms1WmtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2014&pages=1046-1055&author=S.+Loebauthor=M.+A.+Bjurlinauthor=J.+Nicholsonauthor=T.+L.+Tammelaauthor=D.+F.+Pensonauthor=H.+B.+Carterauthor=P.+Carrollauthor=R.+Etzioni&title=Overdiagnosis+and+overtreatment+of+prostate+cancer&doi=10.1016%2Fj.eururo.2013.12.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Overdiagnosis and overtreatment of prostate cancer</span></div><div class="casAuthors">Loeb Stacy; Bjurlin Marc A; Nicholson Joseph; Tammela Teuvo L; Penson David F; Carter H Ballentine; Carroll Peter; Etzioni Ruth</div><div class="citationInfo"><span class="NLM_cas:title">European urology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1046-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Although prostate cancer (PCa) screening reduces the incidence of advanced disease and mortality, trade-offs include overdiagnosis and resultant overtreatment.  OBJECTIVE:  To review primary data on PCa overdiagnosis and overtreatment.  EVIDENCE ACQUISITION:  Electronic searches were conducted in Cochrane Central Register of Controlled Trials, PubMed, and Embase from inception to July 2013 for original articles on PCa overdiagnosis and overtreatment.  Supplemental articles were identified through hand searches.  EVIDENCE SYNTHESIS:  The lead-time and excess-incidence approaches are the main ways used to estimate overdiagnosis in epidemiological studies, with estimates varying widely.  The estimated number of PCa cases needed to be diagnosed to save a life has ranged from 48 down to 5 with increasing follow-up.  In clinical studies, generally lower rates of overdiagnosis have been reported based on the frequency of low-grade minimal tumors at radical prostatectomy (1.7-46.8%).  Autopsy studies have reported PCa in 18.5-38.5%, although not all are low grade or low volume.  Factors influencing overdiagnosis include the study population, screening protocol, and background incidence, limiting generalizability between settings.  Reported rates of overtreatment vary widely in the literature, although contemporary international studies suggest increasing use of conservative management.  CONCLUSIONS:  Epidemiological, clinical, and autopsy studies have been used to examine PCa overdiagnosis, with estimates ranging widely from 1.7% to 67%.  Correspondingly, estimates of overtreatment vary widely based on patient features and may be declining internationally.  Careful patient selection for screening and reducing overtreatment are important to preserve the benefits and reduce the downstream harms of prostate-specific antigen testing.  Because all of these estimates are extremely population and context specific, this must be considered when using these data to inform policy.  PATIENT SUMMARY:  Screening reduces spread and death from prostate cancer (PCa) but overdiagnoses some low-risk tumors that may not have caused harm.  Because treatment has potential side effects, it is critical that not all patients with PCa receive aggressive treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQe5o8OTQwsu8jl5L8hwNX0fW6udTcc2ebR-Z4yl2Uuvrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czms1WmtA%253D%253D&md5=4c0b1d4f1d6f5942ebf05e632350db7d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2013.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2013.12.062%26sid%3Dliteratum%253Aachs%26aulast%3DLoeb%26aufirst%3DS.%26aulast%3DBjurlin%26aufirst%3DM.%2BA.%26aulast%3DNicholson%26aufirst%3DJ.%26aulast%3DTammela%26aufirst%3DT.%2BL.%26aulast%3DPenson%26aufirst%3DD.%2BF.%26aulast%3DCarter%26aufirst%3DH.%2BB.%26aulast%3DCarroll%26aufirst%3DP.%26aulast%3DEtzioni%26aufirst%3DR.%26atitle%3DOverdiagnosis%2520and%2520overtreatment%2520of%2520prostate%2520cancer%26jtitle%3DEur.%2520Urol.%26date%3D2014%26volume%3D65%26spage%3D1046%26epage%3D1055%26doi%3D10.1016%2Fj.eururo.2013.12.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, C.</span></span> <span> </span><span class="NLM_article-title">Dynamic contrast-enhanced CT for prostate cancer: relationship between image noise, voxel size, and repeatability editorial comment</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">2157</span>â <span class="NLM_lpage">2158</span>, <span class="refDoi">Â DOI: 10.1016/j.juro.2011.02.2679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2Fj.juro.2011.02.2679" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2011&pages=2157-2158&author=C.+Siegel&title=Dynamic+contrast-enhanced+CT+for+prostate+cancer%3A+relationship+between+image+noise%2C+voxel+size%2C+and+repeatability+editorial+comment&doi=10.1016%2Fj.juro.2011.02.2679"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2011.02.2679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2011.02.2679%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DC.%26atitle%3DDynamic%2520contrast-enhanced%2520CT%2520for%2520prostate%2520cancer%253A%2520relationship%2520between%2520image%2520noise%252C%2520voxel%2520size%252C%2520and%2520repeatability%2520editorial%2520comment%26jtitle%3DJ.%2520Urol.%26date%3D2011%26volume%3D185%26spage%3D2157%26epage%3D2158%26doi%3D10.1016%2Fj.juro.2011.02.2679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapelon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RouviÃ¨re, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubernard, J. M.</span></span> <span> </span><span class="NLM_article-title">Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome</span>. <i>Eur. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">124</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1159/000049761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1159%2F000049761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=11528187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BD3MvosFKquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=124-129&author=A.+Geletauthor=J.+Y.+Chapelonauthor=R.+Bouvierauthor=O.+Rouvi%C3%A8reauthor=J.+M.+Dubernard&title=Transrectal+high+intensity+focused+ultrasound+for+the+treatment+of+localized+prostate+cancer%3A+factors+influencing+the+outcome&doi=10.1159%2F000049761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome</span></div><div class="casAuthors">Gelet A; Chapelon J Y; Bouvier R; Rouviere O; Lyonnet D; Dubernard J M</div><div class="citationInfo"><span class="NLM_cas:title">European urology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-9</span>
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    </div><div class="casAbstract">OBJECTIVES:  Efficacy evaluation of high intensity focused ultrasound (HIFU) treatment for localized prostate cancer and identification of the factors affecting the outcome.  PATIENTS AND METHODS:  102 patients with prostate cancer stage T1-T2 and noncandidates for radical prostatectomy have been treated with HIFU (Ablatherm, EDAP-Technomed).  The disease progression (failure) was strictly defined by any positive sample at control biopsies, whatever the prostate-specific antigen (PSA) level, or by 3 consecutive increases in PSA levels in case of negative biopsies.  RESULTS:  At inclusion, patients' baseline characteristics were (mean +/- standard deviation): age 70.8 (+/-6.13) years, PSA 8.38 (+/-4.8) ng/ml, prostate volume 33.3 (+/-16.71) cm3.  The population mean follow-up was 19 months (3-76 months).  The overall success rate was 66%.  Statistically significant variations of the overall success with a more favorable outcome were observed when (1) the initial PSA level was < or =10 ng/ml (73 vs. 50%, p = 0.02), (2) the Gleason score was < or =6 (81 vs. 46%, p<0.001) and (3) the pretreatment sextant biopsy evidenced 1-4 positive samples (68 vs. 40%, p = 0.01).  CONCLUSION:  Results observed after HIFU treatment in localized prostate cancer are now challenging those obtained after radiation therapy.  The success rate is influenced by disease-related prognostic factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbD-sJc3uxCk2yPDyEFiigfW6udTcc2ebR-Z4yl2Uuvrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvosFKquw%253D%253D&md5=aa51620db6eb6a119d786a4c4f431a19</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1159%2F000049761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000049761%26sid%3Dliteratum%253Aachs%26aulast%3DGelet%26aufirst%3DA.%26aulast%3DChapelon%26aufirst%3DJ.%2BY.%26aulast%3DBouvier%26aufirst%3DR.%26aulast%3DRouvi%25C3%25A8re%26aufirst%3DO.%26aulast%3DDubernard%26aufirst%3DJ.%2BM.%26atitle%3DTransrectal%2520high%2520intensity%2520focused%2520ultrasound%2520for%2520the%2520treatment%2520of%2520localized%2520prostate%2520cancer%253A%2520factors%2520influencing%2520the%2520outcome%26jtitle%3DEur.%2520Urol.%26date%3D2001%26volume%3D40%26spage%3D124%26epage%3D129%26doi%3D10.1159%2F000049761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Shater Bosaily, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collaco-Moraes, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">815</span>â <span class="NLM_lpage">822</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(16)32401-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2FS0140-6736%2816%2932401-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=28110982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BC1c7otV2lsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=815-822&author=H.+U.+Ahmedauthor=A.+El-Shater+Bosailyauthor=L.+C.+Brownauthor=R.+Gabeauthor=R.+Kaplanauthor=M.+K.+Parmarauthor=Y.+Collaco-Moraesauthor=K.+Wardauthor=R.+G.+Hindleyauthor=A.+Freeman&title=Diagnostic+accuracy+of+multi-parametric+MRI+and+TRUS+biopsy+in+prostate+cancer+%28PROMIS%29%3A+a+paired+validating+confirmatory+study&doi=10.1016%2FS0140-6736%2816%2932401-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study</span></div><div class="casAuthors">Ahmed Hashim U; El-Shater Bosaily Ahmed; Emberton Mark; Brown Louise C; Kaplan Richard; Parmar Mahesh K; Collaco-Moraes Yolanda; Ward Katie; Gabe Rhian; Hindley Richard G; Freeman Alex; Kirkham Alex P; Oldroyd Robert; Parker Chris</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10071</span>),
    <span class="NLM_cas:pages">815-822</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy).  TRUS-biopsy can cause side-effects including bleeding, pain, and infection.  Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy.  METHODS:  We did this multicentre, paired-cohort, confirmatory study to test diagnostic accuracy of MP-MRI and TRUS-biopsy against a reference test (template prostate mapping biopsy [TPM-biopsy]).  Men with prostate-specific antigen concentrations up to 15 ng/mL, with no previous biopsy, underwent 1Â·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy.  The conduct and reporting of each test was done blind to other test results.  Clinically significant cancer was defined as Gleason score â¥4 + 3 or a maximum cancer core length 6 mm or longer.  This study is registered on ClinicalTrials.gov, NCT01292291.  FINDINGS:  Between May 17, 2012, and November 9, 2015, we enrolled 740 men, 576 of whom underwent 1Â·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy.  On TPM-biopsy, 408 (71%) of 576 men had cancer with 230 (40%) of 576 patients clinically significant.  For clinically significant cancer, MP-MRI was more sensitive (93%, 95% CI 88-96%) than TRUS-biopsy (48%, 42-55%; p<0Â·0001) and less specific (41%, 36-46% for MP-MRI vs 96%, 94-98% for TRUS-biopsy; p<0Â·0001). 44 (5Â·9%) of 740 patients reported serious adverse events, including 8 cases of sepsis.  INTERPRETATION:  Using MP-MRI to triage men might allow 27% of patients avoid a primary biopsy and diagnosis of 5% fewer clinically insignificant cancers.  If subsequent TRUS-biopsies were directed by MP-MRI findings, up to 18% more cases of clinically significant cancer might be detected compared with the standard pathway of TRUS-biopsy for all.  MP-MRI, used as a triage test before first prostate biopsy, could reduce unnecessary biopsies by a quarter.  MP-MRI can also reduce over-diagnosis of clinically insignificant prostate cancer and improve detection of clinically significant cancer.  FUNDING:  PROMIS is funded by the UK Government Department of Health, National Institute of Health Research-Health Technology Assessment Programme, (Project number 09/22/67).  This project is also supported and partly funded by UCLH/UCL Biomedical Research Centre and The Royal Marsden and Institute for Cancer Research Biomedical Research Centre and is coordinated by the Medical Research Council Clinical Trials Unit (MRC CTU) at UCL.  It is sponsored by University College London (UCL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-6ZkcyQCrzOIHSmpohpd0fW6udTcc2eZxi5aVkFrb1bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7otV2lsQ%253D%253D&md5=07131cf926ec0c7ea8b131235b9876d5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2932401-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252932401-1%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DH.%2BU.%26aulast%3DEl-Shater%2BBosaily%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DL.%2BC.%26aulast%3DGabe%26aufirst%3DR.%26aulast%3DKaplan%26aufirst%3DR.%26aulast%3DParmar%26aufirst%3DM.%2BK.%26aulast%3DCollaco-Moraes%26aufirst%3DY.%26aulast%3DWard%26aufirst%3DK.%26aulast%3DHindley%26aufirst%3DR.%2BG.%26aulast%3DFreeman%26aufirst%3DA.%26atitle%3DDiagnostic%2520accuracy%2520of%2520multi-parametric%2520MRI%2520and%2520TRUS%2520biopsy%2520in%2520prostate%2520cancer%2520%2528PROMIS%2529%253A%2520a%2520paired%2520validating%2520confirmatory%2520study%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D815%26epage%3D822%26doi%3D10.1016%2FS0140-6736%2816%2932401-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evensapir, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lievshitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibovitch, I.</span></span> <span> </span><span class="NLM_article-title">The detection of bone metastases in patients with high-risk prostate cancer: <sup>99m</sup>Tc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, <sup>18</sup>F-fluoride PET, and <sup>18</sup>F-fluoride PET/CT</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">287</span>â <span class="NLM_lpage">297</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=16455635" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=287-297&author=E.+Evensapirauthor=U.+Metserauthor=E.+Mishaniauthor=G.+Lievshitzauthor=H.+Lermanauthor=I.+Leibovitch&title=The+detection+of+bone+metastases+in+patients+with+high-risk+prostate+cancer%3A+99mTc-MDP+Planar+bone+scintigraphy%2C+single-+and+multi-field-of-view+SPECT%2C+18F-fluoride+PET%2C+and+18F-fluoride+PET%2FCT"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEvensapir%26aufirst%3DE.%26aulast%3DMetser%26aufirst%3DU.%26aulast%3DMishani%26aufirst%3DE.%26aulast%3DLievshitz%26aufirst%3DG.%26aulast%3DLerman%26aufirst%3DH.%26aulast%3DLeibovitch%26aufirst%3DI.%26atitle%3DThe%2520detection%2520of%2520bone%2520metastases%2520in%2520patients%2520with%2520high-risk%2520prostate%2520cancer%253A%252099mTc-MDP%2520Planar%2520bone%2520scintigraphy%252C%2520single-%2520and%2520multi-field-of-view%2520SPECT%252C%252018F-fluoride%2520PET%252C%2520and%252018F-fluoride%2520PET%252FCT%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D287%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gschwend, J. E.</span></span> <span> </span><span class="NLM_article-title">Current use of PSMA-PET in prostate cancer management</span>. <i>Nat. Rev. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">226</span>â <span class="NLM_lpage">235</span>, <span class="refDoi">Â DOI: 10.1038/nrurol.2016.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1038%2Fnrurol.2016.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=26902337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFehsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=226-235&author=T.+Maurerauthor=M.+Eiberauthor=M.+Schwaigerauthor=J.+E.+Gschwend&title=Current+use+of+PSMA-PET+in+prostate+cancer+management&doi=10.1038%2Fnrurol.2016.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Current use of PSMA-PET in prostate cancer management</span></div><div class="casAuthors">Maurer, Tobias; Eiber, Matthias; Schwaiger, Markus; Gschwend, Juergen E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Urology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">226-235</span>CODEN:
                <span class="NLM_cas:coden">NRNADQ</span>;
        ISSN:<span class="NLM_cas:issn">1759-4812</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Currently, the findings of imaging procedures used for detection or staging of prostate cancer depend on morphol. of lymph nodes or bone metab. and do not always meet diagnostic needs.  Prostate-specific membrane antigen (PSMA), a transmembrane protein that has considerable overexpression on most prostate cancer cells, has gained increasing interest as a target mol. for imaging.  To date, several small compds. for labeling PSMA have been developed and are currently being investigated as imaging probes for PET with the 68Ga-labeled PSMA inhibitor Glu-NH-CO-NH-Lys(Ahx)-HBED-CC being the most widely studied agent. 68Ga-PSMA-PET imaging in combination with multiparametric MRI (mpMRI) might provide addnl. mol. information on cancer localization within the prostate.  In patients with primary prostate cancer of intermediate-risk to high-risk, PSMA-based imaging has been reported to improve detection of metastatic disease compared with CT or mpMRI, rendering addnl. cross-sectional imaging or bone scintigraphy unnecessary.  Furthermore, in patients with biochem. recurrent prostate cancer, use of 68Ga-PSMA-PET imaging has been shown to increase detection of metastatic sites, even at low serum PSA values, compared with conventional imaging or PET examn. with different tracers.  Thus, although current knowledge is still limited and derived mostly from retrospective series, PSMA-based imaging holds great promise to improve prostate cancer management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMr0cJOu5I3LVg90H21EOLACvtfcHk0ligVIAbKN8Lvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFehsrk%253D&md5=a1570f8a442cb5cb403cf799ff6ba1f0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrurol.2016.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrurol.2016.26%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DEiber%26aufirst%3DM.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DGschwend%26aufirst%3DJ.%2BE.%26atitle%3DCurrent%2520use%2520of%2520PSMA-PET%2520in%2520prostate%2520cancer%2520management%26jtitle%3DNat.%2520Rev.%2520Urol.%26date%3D2016%26volume%3D13%26spage%3D226%26epage%3D235%26doi%3D10.1038%2Fnrurol.2016.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, H.</span></span> <span> </span><span class="NLM_article-title">PET imaging of prostate cancer using carbon-11-choline</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">990</span>â <span class="NLM_lpage">995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=9627331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADyaK1cXktV2itrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=990-995&author=T.+Haraauthor=N.+Kosakaauthor=H.+Kishi&title=PET+imaging+of+prostate+cancer+using+carbon-11-choline"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging of prostate cancer using carbon-11-choline</span></div><div class="casAuthors">Hara, Toshihiko; Kosaka, Noboru; Kishi, Hiroichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">990-995</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">Prostate cancer is difficult to visualize using current techniques.  Recently, 31P magnetic resonance spectroscopy has revealed that the tumor, in general, is characterized by an increased uptake of choline into the cell to meet increased synthesis of phosphatidyl-choline, an important cell membrane phospholipid.  We succeeded in using 11C-choline to visualize prostate cancer and its local metastasis in PET.  PET was performed on 10 prostate cancer patients from the level of pelvis to the lower abdomen.  After transmission scanning, 370 MBq 11C-choline were injected i.v.  The emission scan was performed 5-15 min postinjection.  Finally, PET images were displayed so that each pixel was painted by a specified color representing the degree of the standardized uptake value (SUV).  The 11C-choline image was compared with the 18F-fluorodeoxyglucose (FDG) image obtained from the same patient.  Imaging of prostate cancer and its local metastasis was difficult when 18F-FDG was used because, within the pelvis, the areas of high uptake were concealed by the overwhelmingly abundant radioactivity in urine (in ureters and bladder).  By contrast, it was easy when 11C-choline was used because the urinary activity was negligible and tumor uptake was marked.  The radioactivity concn. of 11C-choline in prostate cancer and metastatic sites was at an SUV of more than three in most cases.  The SUV of 18F-FDG was considerably lower than that of 11C-choline.  Prostate cancer and its local metastasis were visualized clearly in PET using 11C-choline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3mwwmLWCVprVg90H21EOLACvtfcHk0ligVIAbKN8Lvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktV2itrg%253D&md5=8556569bbe8650e1792490774700e1e2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKosaka%26aufirst%3DN.%26aulast%3DKishi%26aufirst%3DH.%26atitle%3DPET%2520imaging%2520of%2520prostate%2520cancer%2520using%2520carbon-11-choline%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1998%26volume%3D39%26spage%3D990%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanamaru, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span> <span> </span><span class="NLM_article-title">C-11-acetate PET imaging of prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">181</span>â <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=11850482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFWjtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=181-186&author=N.+Oyamaauthor=H.+Akinoauthor=H.+Kanamaruauthor=N.+Sadatoauthor=K.+Okada&title=C-11-acetate+PET+imaging+of+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">11C-Acetate PET imaging of prostate cancer</span></div><div class="casAuthors">Oyama, Nobuyuki; Akino, Hironobu; Kanamaru, Hiroshi; Suzuki, Yuji; Muramoto, Satoshi; Yonekura, Yoshiharu; Sadato, Norihiro; Yamamoto, Kazutaka; Okada, Kenichiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-186</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">11C-Acetate can act as a probe of tissue metab. through entry into catabolic or anabolic metabolic pathways as mediated by acetyl-CoA.  The uptake of 11C-acetate in prostate cancer was investigated to det. whether this tracer has potential in tumor identification.  Methods: Twenty-two patients with prostate cancer underwent PET after i.v. administration of 740 MBq 11C-acetate.  Eighteen of the 22 patients were also investigated with 18F-FDG PET.  Standardized uptake values (SUVs) for each tumor were investigated for tracer activity at 10-20 min after 11C-acetate and 40-60 min after 18F-FDG administration.  Results: Adenocarcinoma of the prostate showed variable uptake of 11C-acetate, with SUVs ranging from 3.27 to 9.87.  In contrast, SUVs for 18F-FDG ranged from 1.97 to 6.34.  By visual inspection, 11C-acetate accumulation in primary prostate tumors was pos. in all patients, whereas 18F-FDG accumulation was pos. in only 15 of 18 patients.  11C-Acetate PET in a patient with lymph node metastasis showed high intrapelvic accumulation corresponding to metastatic sites.  Similarly, 2 patients with bone metastases were 11C-acetate avid.  Conclusion: 11C-Acetate shows marked uptake in prostate cancer and is more sensitive in detection of prostate cancer than is 18F-FDG PET.  11C-Acetate represents a new tracer for detection of prostate cancer with PET, measuring radiopharmaceutical uptake pathways that are different from those measured by 18F-FDG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGmm55fhswoLVg90H21EOLACvtfcHk0ljZmmZbKdg95A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFWjtro%253D&md5=fe1f32ff68c230f628ab867d50833624</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOyama%26aufirst%3DN.%26aulast%3DAkino%26aufirst%3DH.%26aulast%3DKanamaru%26aufirst%3DH.%26aulast%3DSadato%26aufirst%3DN.%26aulast%3DOkada%26aufirst%3DK.%26atitle%3DC-11-acetate%2520PET%2520imaging%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2002%26volume%3D43%26spage%3D181%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pultrone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunocilla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malizia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigatti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonti, C.</span></span> <span> </span><span class="NLM_article-title"><sup>18</sup>F-FACBC (anti1-amino-3-<sup>18</sup>F-fluorocyclobutane-1-carboxylic acid) versus <sup>11</sup>C-choline PET/CT in prostate cancer relapse: results of a prospective trial</span>. <i>Eur. J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-016-3329-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=1-10&author=C.+Nanniauthor=L.+Zanoniauthor=C.+Pultroneauthor=R.+Schiavinaauthor=E.+Brunocillaauthor=F.+Lodiauthor=C.+Maliziaauthor=M.+Ferrariauthor=P.+Rigattiauthor=C.+Fonti&title=18F-FACBC+%28anti1-amino-3-18F-fluorocyclobutane-1-carboxylic+acid%29+versus+11C-choline+PET%2FCT+in+prostate+cancer+relapse%3A+results+of+a+prospective+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3329-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3329-1%26sid%3Dliteratum%253Aachs%26aulast%3DNanni%26aufirst%3DC.%26aulast%3DZanoni%26aufirst%3DL.%26aulast%3DPultrone%26aufirst%3DC.%26aulast%3DSchiavina%26aufirst%3DR.%26aulast%3DBrunocilla%26aufirst%3DE.%26aulast%3DLodi%26aufirst%3DF.%26aulast%3DMalizia%26aufirst%3DC.%26aulast%3DFerrari%26aufirst%3DM.%26aulast%3DRigatti%26aufirst%3DP.%26aulast%3DFonti%26aufirst%3DC.%26atitle%3D18F-FACBC%2520%2528anti1-amino-3-18F-fluorocyclobutane-1-carboxylic%2520acid%2529%2520versus%252011C-choline%2520PET%252FCT%2520in%2520prostate%2520cancer%2520relapse%253A%2520results%2520of%2520a%2520prospective%2520trial%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%26date%3D2016%26volume%3D43%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mannweiler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amersdorfer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trajanoski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehes, G.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis</span>. <i>Pathol. Oncol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">172</span>, <span class="refDoi">Â DOI: 10.1007/s12253-008-9104-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs12253-008-9104-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=18802790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvV2hurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=167-172&author=S.+Mannweilerauthor=P.+Amersdorferauthor=S.+Trajanoskiauthor=J.+A.+Terrettauthor=D.+Kingauthor=G.+Mehes&title=Heterogeneity+of+prostate-specific+membrane+antigen+%28PSMA%29+expression+in+prostate+carcinoma+with+distant+metastasis&doi=10.1007%2Fs12253-008-9104-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis</span></div><div class="casAuthors">Mannweiler, Sebastian; Amersdorfer, Peter; Trajanoski, Slave; Terrett, Jonathan A.; King, David; Mehes, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-172</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas.  As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest.  In this study we addressed the cellular distribution and heterogeneity of PSMA expression.  Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated.  Immunohistochem. was used to det. the cellular localization, staining intensity and pos. cell fraction which were related to tumor type and growth pattern.  We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern.  A significant no. of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the neg. range (<10% pos. tumor cells).  A direct correlation between histol. parameters and PSMA expression could not be demonstrated.  Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8D8BwOk-pgrVg90H21EOLACvtfcHk0ljZmmZbKdg95A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvV2hurg%253D&md5=c949aa0c134031ea07d5c9d0fc5e013b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs12253-008-9104-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-008-9104-2%26sid%3Dliteratum%253Aachs%26aulast%3DMannweiler%26aufirst%3DS.%26aulast%3DAmersdorfer%26aufirst%3DP.%26aulast%3DTrajanoski%26aufirst%3DS.%26aulast%3DTerrett%26aufirst%3DJ.%2BA.%26aulast%3DKing%26aufirst%3DD.%26aulast%3DMehes%26aufirst%3DG.%26atitle%3DHeterogeneity%2520of%2520prostate-specific%2520membrane%2520antigen%2520%2528PSMA%2529%2520expression%2520in%2520prostate%2520carcinoma%2520with%2520distant%2520metastasis%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2009%26volume%3D15%26spage%3D167%26epage%3D172%26doi%3D10.1007%2Fs12253-008-9104-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span> <span> </span><span class="NLM_article-title">PET imaging in prostate cancer: focus on prostate-specific membrane antigen</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">951</span>â <span class="NLM_lpage">962</span>, <span class="refDoi">Â DOI: 10.2174/1568026611313080008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2174%2F1568026611313080008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=23590171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslKhtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=951-962&author=R.+C.+Measeauthor=C.+A.+Fossauthor=M.+G.+Pomper&title=PET+imaging+in+prostate+cancer%3A+focus+on+prostate-specific+membrane+antigen&doi=10.2174%2F1568026611313080008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging in prostate cancer: focus on prostate-specific membrane antigen</span></div><div class="casAuthors">Mease, Ronnie C.; Foss, Catherine A.; Pomper, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">951-962</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Prostate cancer (PCa) is the second leading cause of cancer-related death in American men.  Positron emission tomog./computed tomog. (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease, detection of metastatic lesions and, ultimately, for predicting the aggressiveness of disease.  Prostate-specific membrane antigen (PSMA) is a well-characterized imaging biomarker of PCa.  Because PSMA levels are directly related to androgen independence, metastasis and progression, PSMA could prove an important target for the development of new radiopharmaceuticals for PET.  Preclin. data for new PSMA-based radiotracers are discussed and include new 89Zr- and 64Cu-labeled anti-PSMA antibodies and antibody fragments, 64Cu-labeled aptamers, and 11C-, 18F-, 68Ga-, 64Cu-, and 86Y-labeled low mol. wt. inhibitors of PSMA.  Several of these agents, namely 68Ga- HBED-CC conjugate 15, 18F-DCFBC 8, and BAY1075553 are particularly promising, each having detected sites of PCa in initial clin. studies.  These early clin. results suggest that PET/CT using PSMA-targeted agents, esp. with compds. of low mol. wt., will make valuable contributions to the management of PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojEOMftFlIjbVg90H21EOLACvtfcHk0ljZmmZbKdg95A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslKhtb0%253D&md5=e49d20dfdfbb41921517c501ca5182e2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F1568026611313080008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313080008%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DFoss%26aufirst%3DC.%2BA.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26atitle%3DPET%2520imaging%2520in%2520prostate%2520cancer%253A%2520focus%2520on%2520prostate-specific%2520membrane%2520antigen%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D951%26epage%3D962%26doi%3D10.2174%2F1568026611313080008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesche, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettschau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gromov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶hnke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¶nning, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegele-Hartung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DÃ¶hr, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinkelborg, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of BAY 1075553, a novel <sup>18</sup>F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">101</span>, <span class="refDoi">Â DOI: 10.1007/s00259-013-2527-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-013-2527-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=23955632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlShtrvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=89-101&author=R.+Lescheauthor=G.+Kettschauauthor=A.+V.+Gromovauthor=N.+B%C3%B6hnkeauthor=S.+Borkowskiauthor=U.+M%C3%B6nningauthor=C.+Hegele-Hartungauthor=O.+D%C3%B6hrauthor=L.+M.+Dinkelborgauthor=K.+Graham&title=Preclinical+evaluation+of+BAY+1075553%2C+a+novel+18F-labelled+inhibitor+of+prostate-specific+membrane+antigen+for+PET+imaging+of+prostate+cancer&doi=10.1007%2Fs00259-013-2527-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer</span></div><div class="casAuthors">Lesche, Ralf; Kettschau, Georg; Gromov, Alexey V.; Boehnke, Niels; Borkowski, Sandra; Moenning, Ursula; Hegele-Hartung, Christa; Doehr, Olaf; Dinkelborg, Ludger M.; Graham, Keith</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-101</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed in prostate cancer and is therefore being explored as a biomarker for diagnosing and staging of the disease.  Here we report preclin. data on BAY 1075553 (a 9:1 mixt. of (2S,4S)- and (2R,4S)-2-[18F]fluoro-4-phosphonomethyl-pentanedioic acid), a novel 18F-labeled small mol. inhibitor of PSMA enzymic activity, which can be efficiently synthesized from a direct radiolabelling precursor.  Methods: The 18F-radiolabeled stereoisomers of 2-[18F]fluoro-4-(phosphonomethyl)-pentanedioic acid were synthesized from their resp. isomerically pure precursors di-Me 2-{[bis(benzyloxy)phosphoryl]methyl}-4-(tosyloxy)pentanedioate.  In vivo positron emission tomog. (PET) imaging and biodistribution studies were conducted in mice bearing LNCaP, 22Rv1 and PC-3 tumors.  Pharmacokinetic parameters and dosimetry ests. were calcd. based on biodistribution studies in rodents.  For non-clin. safety assessment (safety pharmacol., toxicol.) to support a single-dose human microdose study, off-target effects in vitro, effects on vital organ functions (cardiovascular in dogs, nervous system in rats), mutagenicity screens and an extended single-dose study in rats were conducted with the non-radioactive racemic analog of BAY 1075553.  Results: BAY 1075553 showed high tumor accumulation specific to PSMA-pos. tumor-bearing mice and was superior to other stereoisomers tested.  Fast clearance of BAY 1075553 resulted overall in low background signals in other organs except for high uptake into kidney and bladder which was mainly caused by renal elimination of BAY 1075553.  A modest uptake into bone was obsd. which decreased over time indicating organ-specific uptake as opposed to defluorination of BAY 1075553 in vivo.  Biodistribution studies found highest organ doses for kidneys and the urinary bladder wall resulting in a projected ED (ED) in humans of 0.0219 mSv/MBq.  Non-clin. safety studies did not show off-target activity, effects on vital organs function or dose-dependent adverse effects.  Conclusion: BAY 1075553 was identified as a promising PET tracer for PSMA-pos. prostate tumors in preclin. studies.  BAY 1075553 can be produced using a robust, direct radiosynthesis procedure.  Pharmacokinetic, toxicol. and safety pharmacol. studies support the application of BAY 1075553 in a first-in-man microdose study with single i.v. administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYHP7jzbqlk7Vg90H21EOLACvtfcHk0lipskHOM5zAgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlShtrvI&md5=b01ac516103645481e22102a87373bc6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs00259-013-2527-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-013-2527-3%26sid%3Dliteratum%253Aachs%26aulast%3DLesche%26aufirst%3DR.%26aulast%3DKettschau%26aufirst%3DG.%26aulast%3DGromov%26aufirst%3DA.%2BV.%26aulast%3DB%25C3%25B6hnke%26aufirst%3DN.%26aulast%3DBorkowski%26aufirst%3DS.%26aulast%3DM%25C3%25B6nning%26aufirst%3DU.%26aulast%3DHegele-Hartung%26aufirst%3DC.%26aulast%3DD%25C3%25B6hr%26aufirst%3DO.%26aulast%3DDinkelborg%26aufirst%3DL.%2BM.%26aulast%3DGraham%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520BAY%25201075553%252C%2520a%2520novel%252018F-labelled%2520inhibitor%2520of%2520prostate-specific%2520membrane%2520antigen%2520for%2520PET%2520imaging%2520of%2520prostate%2520cancer%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2014%26volume%3D41%26spage%3D89%26epage%3D101%26doi%3D10.1007%2Fs00259-013-2527-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behr, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanBrocklin, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flavell, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blecha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jivan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simko, J. P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase I study of CTT1057, an F-18-labeled imaging agent with phosphoramidate core targeting prostate-specific membrane antigen in prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">910</span>â <span class="NLM_lpage">916</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.220715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.118.220715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30464040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsleisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=910-916&author=S.+C.+Behrauthor=R.+Aggarwalauthor=H.+F.+VanBrocklinauthor=R.+R.+Flavellauthor=K.+Gaoauthor=E.+J.+Smallauthor=J.+Blechaauthor=S.+Jivanauthor=T.+A.+Hopeauthor=J.+P.+Simko&title=Phase+I+study+of+CTT1057%2C+an+F-18-labeled+imaging+agent+with+phosphoramidate+core+targeting+prostate-specific+membrane+antigen+in+prostate+cancer&doi=10.2967%2Fjnumed.118.220715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of CTT1057, an 18F-labeled imaging agent with phosphoramidate core targeting prostate-specific membrane antigen in prostate cancer</span></div><div class="casAuthors">Behr, Spencer C.; Aggarwal, Rahul; Van Brocklin, Henry F.; Flavell, Robert R.; Gao, Kenneth; Small, Eric J.; Blecha, Joseph; Jivan, Salma; Hope, Thomas A.; Simko, Jeffry P.; Kurhanewicz, John; Noworolski, Susan M.; Korn, Natalie J.; Santos, Romelyn De Los; Cooperberg, Matthew R.; Carroll, Peter R.; Nguyen, Hao G.; Greene, Kirsten L.; Langton-Webster, Beatrice; Berkman, Clifford E.; Seo, Youngho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">910-916</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Unlike most other PSMA agents with a urea backbone, CTT1057 is based on a phosphoramidate scaffold that irreversibly binds to PSMA.  We conducted a first-in-humans phase I study of CTT1057 in patients with localized and metastatic prostate cancer.  Methods: Two patient cohorts were recruited.  Cohort A patients had biopsy-proven localized prostate cancer preceding radical prostatectomy, and cohort B patients had metastatic castration-resistant prostate cancer.  Cohort A patients were imaged at multiple time points after i.v. injection with 362 Â± 8 MBq of CTT1057 to evaluate the kinetics of CTT1057 and est. radiation dose profiles.  Mean organ-absorbed doses and EDs were calcd.  CTT1057 uptake in the prostate gland and regional lymph nodes was correlated with pathol., PSMA staining, and the results of conventional imaging.  In cohort B, patients were imaged 60-120 min after injection of CTT1057.  PET images were assessed for overall image quality, and areas of abnormal uptake were contrasted with conventional imaging.  Results: In cohort A (n = 5), the av. total ED was 0.023 mSv/MBq.  The kidneys exhibited the highest absorbed dose, 0.067 mGy/MBq.  The absorbed dose of the salivary glands was 0.015 mGy/MBq.  For cohort B (n = 15), CTT1057 PET detected 97 metastatic lesions, and 44 of 56 bone metastases detected on CTT1057 PET (78.5%) were also detectable on bone scanning.  Eight of 32 lymph nodes pos. on CTT1057 PET (25%) were enlarged by size criteria on CT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtVFC8Q1FLHbVg90H21EOLACvtfcHk0lipskHOM5zAgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsleisg%253D%253D&md5=bd32d2271de6e601bf8f019668ade1ee</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.220715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.220715%26sid%3Dliteratum%253Aachs%26aulast%3DBehr%26aufirst%3DS.%2BC.%26aulast%3DAggarwal%26aufirst%3DR.%26aulast%3DVanBrocklin%26aufirst%3DH.%2BF.%26aulast%3DFlavell%26aufirst%3DR.%2BR.%26aulast%3DGao%26aufirst%3DK.%26aulast%3DSmall%26aufirst%3DE.%2BJ.%26aulast%3DBlecha%26aufirst%3DJ.%26aulast%3DJivan%26aufirst%3DS.%26aulast%3DHope%26aufirst%3DT.%2BA.%26aulast%3DSimko%26aufirst%3DJ.%2BP.%26atitle%3DPhase%2520I%2520study%2520of%2520CTT1057%252C%2520an%2520F-18-labeled%2520imaging%2520agent%2520with%2520phosphoramidate%2520core%2520targeting%2520prostate-specific%2520membrane%2520antigen%2520in%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D910%26epage%3D916%26doi%3D10.2967%2Fjnumed.118.220715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gage, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthamizhchelvan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey-Kwanisai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgouros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Biodistribution, tumor detection, and radiation dosimetry of <sup>18</sup>F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1883</span>â <span class="NLM_lpage">1891</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.112.104661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.112.104661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=23203246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=1883-1891&author=S.+Y.+Choauthor=K.+L.+Gageauthor=R.+C.+Measeauthor=S.+Senthamizhchelvanauthor=D.+P.+Holtauthor=A.+Jeffrey-Kwanisaiauthor=C.+J.+Endresauthor=R.+F.+Dannalsauthor=G.+Sgourosauthor=M.+Lodge&title=Biodistribution%2C+tumor+detection%2C+and+radiation+dosimetry+of+18F-DCFBC%2C+a+low-molecular-weight+inhibitor+of+prostate-specific+membrane+antigen%2C+in+patients+with+metastatic+prostate+cancer&doi=10.2967%2Fjnumed.112.104661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer</span></div><div class="casAuthors">Cho, Steve Y.; Gage, Kenneth L.; Mease, Ronnie C.; Senthamizhchelvan, Srinivasan; Holt, Daniel P.; Jeffrey-Kwanisai, Akimosa; Endres, Christopher J.; Dannals, Robert F.; Sgouros, George; Lodge, Martin; Eisenberger, Mario A.; Rodiguez, Ronald; Carducci, Michael A.; Rojas, Camilo; Slusher, Barbara S.; Kozikowski, Alan P.; Pomper, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1883-1891</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate cancer (PCa) cells, particularly in androgen-independent, advanced, and metastatic disease.  Previously, we demonstrated that N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-18F-fluorobenzyl-L-cysteine (18F-DCFBC) could image an exptl. model of PSMA-pos. PCa using PET.  Here, we describe the initial clin. experience and radiation dosimetry of 18F-DCFBC in men with metastatic PCa.  Methods: Five patients with radio-logic evidence of metastatic PCa were studied after the i.v. administration of 370 MBq (10 mCi) of 18F-DCFBC.  Serial PET was performed until 2 h after administration.  Time-activity curves were generated for selected normal tissues and metastatic foci.  Radiation dose ests. were calcd. using OLINDA/EXM 1.1.  Results: Most vascular organs demonstrated a slow decrease in radioactivity concn. over time consistent with clearance from the blood pool, with primarily urinary radiotracer excretion.  Thirty-two PET-pos. suspected metastatic sites were identified, with 21 concordant on both PET and conventional imaging for abnormal findings compatible with metastatic disease.  Of the 11 PET-pos. sites not identified on conventional imaging, most were within the bone and could be considered suggestive for the detection of early bone metastases, although further validation is needed.  The highest mean absorbed dose per unit administered radioactivity (Î¼Gy/MBq) was in the bladder wall (32.4), and the resultant ED was 19.9 Â± 1.34 (Î¼Sv/MBq mean Â± SD).  Conclusion: Although further studies are needed for validation, our findings demonstrate the potential of 18F-DCFBC as a new positron-emitting imaging agent for the detection of metastatic PCa.  This study also provides dose ests. for 18F-DCFBC that are comparable to those of other PET radiopharmaceuticals such as 18F-FDG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDmNxmCAVauLVg90H21EOLACvtfcHk0lh1gs2HPZVuKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKrtA%253D%253D&md5=2e2e1f33dc78d2de4bed9f69d3f2cb21</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.112.104661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.112.104661%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DGage%26aufirst%3DK.%2BL.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DSenthamizhchelvan%26aufirst%3DS.%26aulast%3DHolt%26aufirst%3DD.%2BP.%26aulast%3DJeffrey-Kwanisai%26aufirst%3DA.%26aulast%3DEndres%26aufirst%3DC.%2BJ.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DSgouros%26aufirst%3DG.%26aulast%3DLodge%26aufirst%3DM.%26atitle%3DBiodistribution%252C%2520tumor%2520detection%252C%2520and%2520radiation%2520dosimetry%2520of%252018F-DCFBC%252C%2520a%2520low-molecular-weight%2520inhibitor%2520of%2520prostate-specific%2520membrane%2520antigen%252C%2520in%2520patients%2520with%2520metastatic%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2012%26volume%3D53%26spage%3D1883%26epage%3D1891%26doi%3D10.2967%2Fjnumed.112.104661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szajek, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesewetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Single low-dose injection of evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3213</span>â <span class="NLM_lpage">3221</span>, <span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.8b00556</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00556" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVylsrvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=3213-3221&author=Z.+Wangauthor=R.+Tianauthor=G.+Niuauthor=Y.+Maauthor=L.+Langauthor=L.+P.+Szajekauthor=D.+Kiesewetterauthor=O.+Jacobsonauthor=X.+Chen&title=Single+low-dose+injection+of+evans+blue+modified+PSMA-617+radioligand+therapy+eliminates+prostate-specific+membrane+antigen+positive+tumors&doi=10.1021%2Facs.bioconjchem.8b00556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors</span></div><div class="casAuthors">Wang, Zhantong; Tian, Rui; Niu, Gang; Ma, Ying; Lang, Lixin; Szajek, Lawrence P.; Kiesewetter, Dale O.; Jacobson, Orit; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3213-3221</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide.  Prostate-specific membrane antigen (PSMA) is a surface mol. specifically expressed by prostate tumors that has been shown to be a valid target for internal radionuclide therapy in both preclin. and clin. settings.  The most common radiotherapeutic agent is the small mol. 177Lu-PSMA-617, which is under clin. evaluation in multiple countries.  Nevertheless, its efficacy in causing tumor regression is still suboptimal, even when administered in several cycles per patient, perhaps due to poor pharmacokinetics (PK), which limits uptake by the tumor cells.  We postulated that the addn. of the Evans blue (EB) moiety to PSMA-617 would improve the PK by extending circulation half-life, which would increase tumor uptake and improve radiotherapeutic efficacy.  PSMA-617 was modified by conjugation of a 2-thiol acetate group onto the primary amine and thereafter reacted with a maleimide functional group of an EB deriv., to give EB-PSMA-617.  The PK and radiotherapeutic efficacy of 90Y- or 177Lu-EB-PSMA-617 was compared to the clin. used radiopharmaceutical 90Y- or 177Lu- PSMA-617 in PC3-PIP tumor-bearing mice.  EB-PSMA-617 retained binding to serum albumin as well as a high internalization rate by tumor cells.  Upon injection, metal-labeled EB-PSMA-617 demonstrated an extended blood half-life compared to PSMA-617 and, thereby, prolonged the time window for binding to PSMA.  The improved PK of EB-PSMA-617 resulted in significantly higher accumulation in PSMA+ tumors and highly effective radiotherapeutic efficacy.  Remarkably, a single dose of 1.85 MBq of 90Y- or 177Lu-EB-PSMA-617 was sufficient to eradicate established PMSA+ tumors in mice.  No significant body wt. loss was obsd., suggesting little to no gross toxicity.  The construct described here, EB-PSMA-617, may improve the radiotherapeutic efficacy for patients with PSMA-pos. tumors by reducing both the amt. of activity needed for therapy as well as the frequency of administration, as compared to PSMA-617.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIct9lbcQfrVg90H21EOLACvtfcHk0lh1gs2HPZVuKw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVylsrvO&md5=66a04f13d479e0fc7c4d7097ce148d31</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00556%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLang%26aufirst%3DL.%26aulast%3DSzajek%26aufirst%3DL.%2BP.%26aulast%3DKiesewetter%26aufirst%3DD.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DSingle%2520low-dose%2520injection%2520of%2520evans%2520blue%2520modified%2520PSMA-617%2520radioligand%2520therapy%2520eliminates%2520prostate-specific%2520membrane%2520antigen%2520positive%2520tumors%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D3213%26epage%3D3221%26doi%3D10.1021%2Facs.bioconjchem.8b00556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of <sup>68</sup>Ga-PSMA-BCH for prostate cancer imaging</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">933</span>â <span class="NLM_lpage">937</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2019.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2Fj.bmcl.2019.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30745258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivFyis74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=933-937&author=T.+Liuauthor=C.+Liuauthor=F.+Liuauthor=X.+Xuauthor=X.+Guoauthor=L.+Xiaauthor=H.+Zhuauthor=Z.+Yang&title=Synthesis+and+preclinical+evaluation+of+68Ga-PSMA-BCH+for+prostate+cancer+imaging&doi=10.1016%2Fj.bmcl.2019.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preclinical evaluation of 68Ga-PSMA-BCH for prostate cancer imaging</span></div><div class="casAuthors">Liu, Teli; Liu, Chen; Liu, Fei; Xu, Xiaoxia; Guo, Xiaoyi; Xia, Lei; Zhu, Hua; Yang, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">933-937</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prostate specific membrane antigen (PSMA) is a promising target for the diagnosis and therapy of prostate cancer.  In this report, a NOTA-conjugated precursor, NOTA-PSMA (also named PSMA-BCH), was synthesized by peptide synthesizer with the chem. purity over 95%. 68Ga-PSMA-BCH was obtained by radiolabeling NOTA-PSMA with 68GaCl3 with >99% radiochem. purity and 59-74 GBq/Î¼mol specific activity.  In vitro and in vivo study of 68Ga-PSMA-BCH showed high stability, high uptake in PSMA-expressing cells and tumor, fast clearance and low non-target uptake. 22Rv1 tumors were clearly obsd. in micro-PET images of and showed good retention.  Compared with 68Ga-PSMA-617, 68Ga-PSMA-BCH showed comparable tumor uptake and tumor-background ratios.  Indicating 68Ga-PSMA-BCH is a promising candidate for prostate cancer imaging and worthy of further clin. investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH7CclsNgDLbVg90H21EOLACvtfcHk0ljLdmC_DR11qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivFyis74%253D&md5=e5efe28c3f7dd34f0e1c579afca225b7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%252068Ga-PSMA-BCH%2520for%2520prostate%2520cancer%2520imaging%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D933%26epage%3D937%26doi%3D10.1016%2Fj.bmcl.2019.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wust, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, W.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhut, M.</span></span> <span> </span><span class="NLM_article-title"><sup>68</sup>Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">688</span>â <span class="NLM_lpage">697</span>, <span class="refDoi">Â DOI: 10.1021/bc200279b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc200279b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVCmtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=688-697&author=M.+Ederauthor=M.+Schaferauthor=U.+Bauder-Wustauthor=W.-E.+Hullauthor=C.+Wanglerauthor=W.+Mierauthor=U.+Haberkornauthor=M.+Eisenhut&title=68Ga-complex+lipophilicity+and+the+targeting+property+of+a+urea-based+PSMA+inhibitor+for+PET+imaging&doi=10.1021%2Fbc200279b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging</span></div><div class="casAuthors">Eder, Matthias; Schaefer, Martin; Bauder-Wuest, Ulrike; Hull, William-Edmund; Waengler, Carmen; Mier, Walter; Haberkorn, Uwe; Eisenhut, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">688-697</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Urea-based inhibitors of the prostate-specific membrane antigen (PSMA) represent low-mol.-wt. pepidomimetics showing the ability to image PSMA-expressing prostate tumors.  The highly efficient, acyclic Ga(III) chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'- diacetic acid (HBED-CC) was introduced as a lipophilic side chain into the hydrophilic pharmacophore Glu-NH-CO-NH-Lys which was found favorable to interact with the PSMA "active binding site".  This report describes the syntheses, in vitro binding analyses, and biodistribution data of the radiogallium labeled PSMA inhibitor Glu-NH-CO-NH-Lys(Ahx)-HBED-CC in comparison to the corresponding DOTA conjugate.  The binding properties were analyzed using competitive cell binding and enzyme-based assays followed by internalization expts.  Compared to the DOTA-conjugate, the HBED-CC deriv. showed reduced unspecific binding and considerable higher specific internalization in LNCaP cells.  The 68Ga complex of the HBED-CC ligand exhibited higher specificity for PSMA expressing tumor cells resulting in improved in vivo properties. 68Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC showed fast blood and organ clearances, low liver accumulation, and high specific uptake in PSMA expressing organs and tumor.  It could be demonstrated that the PET-imaging property of a urea-based PSMA inhibitor could significantly be improved with HBED-CC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9XoCnl_RguLVg90H21EOLACvtfcHk0ljLdmC_DR11qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVCmtLo%253D&md5=4bb4cbba9f510ed2561b87a44bafa00a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fbc200279b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc200279b%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DM.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DBauder-Wust%26aufirst%3DU.%26aulast%3DHull%26aufirst%3DW.-E.%26aulast%3DWangler%26aufirst%3DC.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DEisenhut%26aufirst%3DM.%26atitle%3D68Ga-complex%2520lipophilicity%2520and%2520the%2520targeting%2520property%2520of%2520a%2520urea-based%2520PSMA%2520inhibitor%2520for%2520PET%2520imaging%26jtitle%3DBioconjugate%2520Chem.%26date%3D2012%26volume%3D23%26spage%3D688%26epage%3D697%26doi%3D10.1021%2Fbc200279b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwenck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rempp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reischl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenzl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfannenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Fougere, C.</span></span> <span> </span><span class="NLM_article-title">Comparison of Ga-68-labelled PSMA-11 and C-11-choline in the detection of prostate cancer metastases by PET/CT</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">92</span>â <span class="NLM_lpage">101</span>, <span class="refDoi">Â DOI: 10.1007/s00259-016-3490-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-016-3490-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27557844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSqu73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=92-101&author=J.+Schwenckauthor=H.+Remppauthor=G.+Reischlauthor=S.+Kruckauthor=A.+Stenzlauthor=K.+Nikolaouauthor=C.+Pfannenbergauthor=C.+La+Fougere&title=Comparison+of+Ga-68-labelled+PSMA-11+and+C-11-choline+in+the+detection+of+prostate+cancer+metastases+by+PET%2FCT&doi=10.1007%2Fs00259-016-3490-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT</span></div><div class="casAuthors">Schwenck, Johannes; Rempp, Hansjoerg; Reischl, Gerald; Kruck, Stephan; Stenzl, Arnulf; Nikolaou, Konstantin; Pfannenberg, Christina; La Fougere, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">92-101</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Our aim was to compare the PSMA ligand 68Ga-PSMA-11 with 11C-choline in patients with primary and recurrent prostate cancer.  123 patients underwent a whole-body PET/CT examn. using 68Ga-PSMA-11 and 11C-choline.  Out of these, 103 suffered from a confirmed biochem. relapse after prostatectomy and/or radiotherapy (mean PSA level of 4.5 ng/mL), while 20 patients underwent primary staging.  In 67 patients with biochem. relapse, we detected 458 lymph nodes suspicious for metastasis.  PET using 68Ga-PSMA-11 showed a significantly higher uptake and detection rate than 11C-choline PET.  Also 68Ga-PSMA-11 PET identified significantly more patients with suspicious lymph nodes as well as affected lymph nodes regions esp. at low PSA levels.  Nevertheless, we detected also 29 suspicious lymph nodes and 8 bone lesions, which were only pos. as per 11C-choline PET.  These findings led to crucial differences in the TNM classification and the identification of oligometastatic patients.  In the patients who underwent initial staging, all primary tumors showed uptake of both tracers.  Although significantly more suspicious lymph nodes and bone lesions were identified, only 2 patients presented with bone lesions only detected by 68Ga-PSMA-11 PET.  Thus, PET using 68Ga-PSMA-11 showed a higher detection rate than 11C-choline PET for lymph nodes as well as bone lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBT7N63fNU77Vg90H21EOLACvtfcHk0ljLdmC_DR11qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSqu73K&md5=f7c71caaf7fd09b7f04c8f0f27ac4afd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3490-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3490-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchwenck%26aufirst%3DJ.%26aulast%3DRempp%26aufirst%3DH.%26aulast%3DReischl%26aufirst%3DG.%26aulast%3DKruck%26aufirst%3DS.%26aulast%3DStenzl%26aufirst%3DA.%26aulast%3DNikolaou%26aufirst%3DK.%26aulast%3DPfannenberg%26aufirst%3DC.%26aulast%3DLa%2BFougere%26aufirst%3DC.%26atitle%3DComparison%2520of%2520Ga-68-labelled%2520PSMA-11%2520and%2520C-11-choline%2520in%2520the%2520detection%2520of%2520prostate%2520cancer%2520metastases%2520by%2520PET%252FCT%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2017%26volume%3D44%26spage%3D92%26epage%3D101%26doi%3D10.1007%2Fs00259-016-3490-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullambhatla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmagadda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthamizhchelvan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgouros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span> <span> </span><span class="NLM_article-title">2-(3-{1-Carboxy-5-[(6-[<sup>18</sup>F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [<sup>18</sup>F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7645</span>â <span class="NLM_lpage">7653</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-11-1357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1158%2F1078-0432.CCR-11-1357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=22042970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1CqtrnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7645-7653&author=Y.+Chenauthor=M.+Pullambhatlaauthor=C.+A.+Fossauthor=Y.+Byunauthor=S.+Nimmagaddaauthor=S.+Senthamizhchelvanauthor=G.+Sgourosauthor=R.+C.+Measeauthor=M.+G.+Pomper&title=2-%283-%7B1-Carboxy-5-%5B%286-%5B18F%5Dfluoro-pyridine-3-carbonyl%29-amino%5D-pentyl%7D-ureido%29-pentanedioic+acid%2C+%5B18F%5DDCFPyL%2C+a+PSMA-based+PET+imaging+agent+for+prostate+cancer&doi=10.1158%2F1078-0432.CCR-11-1357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer</span></div><div class="casAuthors">Chen, Ying; Pullambhatla, Mrudula; Foss, Catherine A.; Byun, Youngjoo; Nimmagadda, Sridhar; Senthamizhchelvan, Srinivasan; Sgouros, George; Mease, Ronnie C.; Pomper, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7645-7653</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: We have synthesized and evaluated in vivo 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, as a potential imaging agent for the prostate-specific membrane antigen (PSMA).  PSMA is upregulated in prostate cancer epithelia and in the neovasculature of most solid tumors.  Exptl. Design: [18F]DCFPyL was synthesized in two steps from the p-methoxybenzyl (PMB) protected lys-C(O)-glu urea precursor using 6-[18F]fluoronicotinic acid tetrafluorophenyl ester ([18F]F-Py-TFP) for introduction of 18F.  Radiochem. synthesis was followed by biodistribution and imaging with PET in immunocompromised mice using isogenic PSMA PC3 PIP and PSMA- PC3 flu xenograft models.  Human radiation dosimetry ests. were calcd. using OLINDA/EXM 1.0.  RESULTS: DCFPyL displays a Ki value of 1.1 Â± 0.1 nmol/L for PSMA. [18F]DCFPyL was produced in radiochem. yields of 36%-53% (decay cor.) and specific radioactivities of 340-480 Ci/mmol (12.6-17.8 GBq/Î¼mol, n = 3).  In an immunocompromised mouse model [18F]DCFPyL clearly delineated PSMA+ PC3 PIP prostate tumor xenografts on imaging with PET.  At 2 h postinjection, 39.4 Â± 5.4 percent injected dose per g of tissue (%ID/g) was evident within the PSMA+ PC3 PIP tumor, with a ratio of 358:1 of uptake within PSMA+ PC3 PIP to PSMA- PC3 flu tumor placed in the opposite flank.  At or after 1 h postinjection, minimal nontarget tissue uptake of [18F]DCFPyL was obsd.  The bladder wall is the dose-limiting organ.  CONCLUSIONS: These data suggest [18F]DCFPyL as a viable, new positron-emitting imaging agent for PSMA-expressing tissues.  Clin Cancer Res; 17(24); 7645-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKmkSg8g44f7Vg90H21EOLACvtfcHk0ljqASmBVukNjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1CqtrnM&md5=dca0465b3b65f7b553a622e40a0c7463</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1357%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPullambhatla%26aufirst%3DM.%26aulast%3DFoss%26aufirst%3DC.%2BA.%26aulast%3DByun%26aufirst%3DY.%26aulast%3DNimmagadda%26aufirst%3DS.%26aulast%3DSenthamizhchelvan%26aufirst%3DS.%26aulast%3DSgouros%26aufirst%3DG.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26atitle%3D2-%25283-%257B1-Carboxy-5-%255B%25286-%255B18F%255Dfluoro-pyridine-3-carbonyl%2529-amino%255D-pentyl%257D-ureido%2529-pentanedioic%2520acid%252C%2520%255B18F%255DDCFPyL%252C%2520a%2520PSMA-based%2520PET%2520imaging%2520agent%2520for%2520prostate%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7645%26epage%3D7653%26doi%3D10.1158%2F1078-0432.CCR-11-1357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macura, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackford, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">PSMA-based [<sup>18</sup>F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer</span>. <i>Mol. Imaging. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">411</span>â <span class="NLM_lpage">419</span>, <span class="refDoi">Â DOI: 10.1007/s11307-016-0957-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs11307-016-0957-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27080322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Smu73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=411-419&author=S.+P.+Roweauthor=K.+J.+Macuraauthor=E.+Menaauthor=A.+L.+Blackfordauthor=R.+Nadalauthor=E.+S.+Antonarakisauthor=M.+Eisenbergerauthor=M.+Carducciauthor=H.+Fanauthor=R.+F.+Dannals&title=PSMA-based+%5B18F%5DDCFPyL+PET%2FCT+is+superior+to+conventional+imaging+for+lesion+detection+in+patients+with+metastatic+prostate+cancer&doi=10.1007%2Fs11307-016-0957-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer</span></div><div class="casAuthors">Rowe, Steven P.; Macura, Katarzyna J.; Mena, Esther; Blackford, Amanda L.; Nadal, Rosa; Antonarakis, Emmanuel S.; Eisenberger, Mario; Carducci, Michael; Fan, Hong; Dannals, Robert F.; Chen, Ying; Mease, Ronnie C.; Szabo, Zsolt; Pomper, Martin G.; Cho, Steve Y.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging and Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">MIBOCZ</span>;
        ISSN:<span class="NLM_cas:issn">1860-2002</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Current std. of care conventional imaging modalities (CIM) such as X-ray computed tomog. (CT) and bone scan can be limited for detection of metastatic prostate cancer and therefore improved imaging methods are an unmet clin. need.  We evaluated the utility of a novel second-generation low mol. wt. radiofluorinated prostate-specific membrane antigen (PSMA)-targeted positron emission tomog. (PET) radiotracer, [18F]DCFPyL, in patients with metastatic prostate cancer.  Procedures: Nine patients with suspected prostate cancer recurrence, eight with CIM evidence of metastatic prostate cancer and one with biochem. recurrence, were imaged with [18F]DCFPyL PET/CT.  Eight of the patients had contemporaneous CIM for comparison.  A lesion-by-lesion comparison of the detection of suspected sites of metastatic prostate cancer was carried out between PET and CIM.  Statistical anal. for estd. proportions of inter-modality agreement for detection of metastatic disease was calcd. accounting for intra-patient correlation using general estg. equation (GEE) intercept-only regression models.  Results: One hundred thirty-nine sites of PET pos. [18F]DCFPyL uptake (138 definite, 1 equivocal) for metastatic disease were detected in the eight patients with available comparison CIM.  By contrast, only 45 lesions were identified on CIM (30 definite, 15 equivocal).  When lesions were neg. or equivocal on CIM, it was estd. that a large portion of these lesions or 0.72 (95 % confidence interval (CI) 0.55-0.84) would be pos. on [18F]DCFPyL PET.  Conversely, of those lesions neg. or equivocal on [18F]DCFPyL PET, it was estd. that only a very small proportion or 0.03 (95 % CI 0.01-0.07) would be pos. on CIM.  Delayed 2-h-post-injection time point PET yielded higher tumor radiotracer uptake and higher tumor-to-background ratios than an earlier 1-h-post-injection time point.  Conclusions: A novel PSMA-targeted PET radiotracer, [18F]DCFPyL, was able to a large no. of suspected sites of prostate cancer, many of which were occult or equivocal by CIM.  This study provides strong preliminary evidence for the use of this second-generation PSMA-targeted PET radiotracer for detection of metastatic prostate cancer and lends further support for the importance of PSMA-targeted PET imaging in prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraR0lm561p3bVg90H21EOLACvtfcHk0ljqASmBVukNjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Smu73F&md5=460d955374fb33764986218b117dd5aa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11307-016-0957-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-016-0957-6%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DS.%2BP.%26aulast%3DMacura%26aufirst%3DK.%2BJ.%26aulast%3DMena%26aufirst%3DE.%26aulast%3DBlackford%26aufirst%3DA.%2BL.%26aulast%3DNadal%26aufirst%3DR.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DEisenberger%26aufirst%3DM.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DPSMA-based%2520%255B18F%255DDCFPyL%2520PET%252FCT%2520is%2520superior%2520to%2520conventional%2520imaging%2520for%2520lesion%2520detection%2520in%2520patients%2520with%2520metastatic%2520prostate%2520cancer%26jtitle%3DMol.%2520Imaging.%2520Biol.%26date%3D2016%26volume%3D18%26spage%3D411%26epage%3D419%26doi%3D10.1007%2Fs11307-016-0957-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wust, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of F-18-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">425</span>â <span class="NLM_lpage">431</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.116.181768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.116.181768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27789722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVSis7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=425-431&author=J.+Cardinaleauthor=M.+Schaferauthor=M.+Benesovaauthor=U.+Bauder-Wustauthor=K.+Leottaauthor=M.+Ederauthor=O.+C.+Neelsauthor=U.+Haberkornauthor=F.+L.+Gieselauthor=K.+Kopka&title=Preclinical+evaluation+of+F-18-PSMA-1007%2C+a+new+prostate-specific+membrane+antigen+ligand+for+prostate+cancer+imaging&doi=10.2967%2Fjnumed.116.181768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging</span></div><div class="casAuthors">Cardinale, Jens; Schaefer, Martin; Benesova, Martina; Bauder-Wuest, Ulrike; Leotta, Karin; Eder, Matthias; Neels, Oliver C.; Haberkorn, Uwe; Giesel, Frederik L.; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced.  Some of them have had a high clin. impact on the treatment of patients with prostate cancer.  However, the no. of 18F-labeled tracers addressing PSMA is still limited.  Therefore, we aimed to develop a radiofluorinated mol. resembling the structure of therapeutic PSMA-617.  Methods: The nonradioactive ref. compd. PSMA-1007 and the precursor were produced by solid-phase chem.  The radioligand 18F-PSMA-1007 was produced by a 2-step procedure with the prosthetic group 6-18F-fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester.  The binding affinity of the ligand for PSMA and its internalization properties were evaluated in vitro with PSMA-pos. LNCaP (lymph node carcinoma of the prostate) cells.  Further, organ distribution studies were performed with mice bearing LNCaP and PC-3 (prostate cancer cell line; PSMA-neg.) tumors.  Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performed.  Results: The identified ligand had a binding affinity of 6.7 Â± 1.7 nM for PSMA and an exceptionally high internalization ratio (67% Â± 13%) in vitro.  In organ distribution studies, high and specific tumor uptake (8.0 Â± 2.4 percentage injected dose per g) in LNCaP tumor-bearing mice was obsd.  In the small-animal PET expts., LNCaP tumors were clearly visualized.  Conclusion: The radiofluorinated PSMA ligand showed promising characteristics in its preclin. evaluation, and the feasibility of prostate cancer imaging was demonstrated by small-animal PET studies.  Therefore, we recommend clin. transfer of the radioligand 18F-PSMA-1007 for use as a diagnostic PET tracer in prestaging and monitoring of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_sOlj_VlMF7Vg90H21EOLACvtfcHk0ljqASmBVukNjg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVSis7o%253D&md5=168905fe2ee07195a189d26e9ac6be2b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.116.181768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.116.181768%26sid%3Dliteratum%253Aachs%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DBenesova%26aufirst%3DM.%26aulast%3DBauder-Wust%26aufirst%3DU.%26aulast%3DLeotta%26aufirst%3DK.%26aulast%3DEder%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DKopka%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520F-18-PSMA-1007%252C%2520a%2520new%2520prostate-specific%2520membrane%2520antigen%2520ligand%2520for%2520prostate%2520cancer%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D425%26epage%3D431%26doi%3D10.2967%2Fjnumed.116.181768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span> <span> </span><span class="NLM_article-title"><sup>18</sup>F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1929</span>â <span class="NLM_lpage">1930</span>, <span class="refDoi">Â DOI: 10.1007/s00259-016-3447-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-016-3447-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27342416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOitrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=1929-1930&author=F.+L.+Gieselauthor=J.+Cardinaleauthor=M.+Schaferauthor=O.+Neelsauthor=M.+Benesovaauthor=W.+Mierauthor=U.+Haberkornauthor=K.+Kopkaauthor=C.+Kratochwil&title=18F-Labelled+PSMA-1007+shows+similarity+in+structure%2C+biodistribution+and+tumour+uptake+to+the+theragnostic+compound+PSMA-617&doi=10.1007%2Fs00259-016-3447-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617</span></div><div class="casAuthors">Giesel, Frederik L.; Cardinale, Jens; Schaefer, Martin; Neels, Oliver; Benesova, Martina; Mier, Walter; Haberkorn, Uwe; Kopka, Klaus; Kratochwil, Clemens</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1929-1930</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The article showed 18F-labeled PSMA-1007 similarity in structure, biodistribution and tumor uptake to the theragnostic compd. PSMA-617 in metastatic castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcT8t2_DPvz7Vg90H21EOLACvtfcHk0lizUjE2-a6h5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOitrrP&md5=5208ade7e966d07f20fb63b211b0d11c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3447-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3447-9%26sid%3Dliteratum%253Aachs%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%26aulast%3DBenesova%26aufirst%3DM.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DKratochwil%26aufirst%3DC.%26atitle%3D18F-Labelled%2520PSMA-1007%2520shows%2520similarity%2520in%2520structure%252C%2520biodistribution%2520and%2520tumour%2520uptake%2520to%2520the%2520theragnostic%2520compound%2520PSMA-617%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2016%26volume%3D43%26spage%3D1929%26epage%3D1930%26doi%3D10.1007%2Fs00259-016-3447-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bene Ova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshar-Oromieh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with <sup>177</sup>Lu-labeled PSMA-617</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1170</span>â <span class="NLM_lpage">1176</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.115.171397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.115.171397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=26985056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaktb%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=1170-1176&author=C.+Kratochwilauthor=F.+L.+Gieselauthor=M.+Stefanovaauthor=M.+Bene+Ovaauthor=M.+Bronzelauthor=A.+Afshar-Oromiehauthor=W.+Mierauthor=M.+Ederauthor=K.+Kopkaauthor=U.+Haberkorn&title=PSMA-targeted+radionuclide+therapy+of+metastatic+castration-resistant+prostate+cancer+with+177Lu-labeled+PSMA-617&doi=10.2967%2Fjnumed.115.171397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617</span></div><div class="casAuthors">Kratochwil, Clemens; Giesel, Frederik L.; Stefanova, Melsa; Benesova, Martina; Bronzel, Marcus; Afshar-Oromieh, Ali; Mier, Walter; Eder, Matthias; Kopka, Klaus; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1170-1176</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC).  Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it an excellent choice for therapeutic application.  We retrospectively report our experience with 177Lu-PSMA-617-targeted radionuclide therapy in a case series of mCRPC patients resistant to other treatments.  Patients with PSMA-pos. tumor phenotypes were selected by mol. imaging.  Thirty patients received 1-3 cycles of 177Lu-PSMA-617.  During therapy, pharmacokinetics and radiation dosimetry were evaluated.  Blood cell count was checked every 2 wk after the first and every 4 wk after succeeding cycles.  Prostate-specific antigen (PSA) was detd. every 4 wk.  Radiol. restaging was performed after 3 cycles.  Twenty-one of 30 patients had a PSA response; in 13 of 30 the PSA decreased more than 50%.  After 3 cycles, 8 of 11 patients achieved a sustained PSA response (>50%) for over 24 wk, which also correlated with radiol. response (decreased lesion no. and size).  Normally, acute hematotoxicity was mild.  Diffuse bone marrow involvement was a risk factor for higher grade myelosuppression but could be identified by PSMA imaging in advance.  Xerostomia, nausea, and fatigue occurred sporadically (<10%).  Clearance of non-tumor-bound tracer was predominantly renal and widely completed by 48 h.  Safety dosimetry revealed kidney doses of approx. 0.75 Gy/GBq, red marrow doses of 0.03 Gy/GBq, and salivary gland doses of 1.4 Gy/GBq, irresp. of tumor burden and consistent on subsequent cycles.  Mean tumor-absorbed dose ranged from 6 to 22 Gy/GBq during cycle 1.  177Lu-PSMA-617 is a promising new option for therapy of mCRPC and deserves more attention in larger prospective trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8RfEV6P8Rm7Vg90H21EOLACvtfcHk0lizUjE2-a6h5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaktb%252FM&md5=1b4edc5c0930f12ae7ab41ab81c2349a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.115.171397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.115.171397%26sid%3Dliteratum%253Aachs%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DStefanova%26aufirst%3DM.%26aulast%3DBene%2BOva%26aufirst%3DM.%26aulast%3DBronzel%26aufirst%3DM.%26aulast%3DAfshar-Oromieh%26aufirst%3DA.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DEder%26aufirst%3DM.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DPSMA-targeted%2520radionuclide%2520therapy%2520of%2520metastatic%2520castration-resistant%2520prostate%2520cancer%2520with%2520177Lu-labeled%2520PSMA-617%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2016%26volume%3D57%26spage%3D1170%26epage%3D1176%26doi%3D10.2967%2Fjnumed.115.171397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Afshar-Oromieh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetzheim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesova, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1697</span>â <span class="NLM_lpage">1705</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.115.161299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.115.161299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=26294298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFGmtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=1697-1705&author=A.+Afshar-Oromiehauthor=H.+Hetzheimauthor=C.+Kratochwilauthor=M.+Benesova&title=The+theranostic+PSMA+ligand+PSMA-617+in+the+diagnosis+of+prostate+cancer+by+PET%2FCT%3A+biodistribution+in+humans%2C+radiation+dosimetry%2C+and+first+evaluation+of+tumor+lesions&doi=10.2967%2Fjnumed.115.161299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions</span></div><div class="casAuthors">Afshar-Oromieh, Ali; Hetzheim, Henrik; Kratochwil, Clemens; Benesova, Martina; Eder, Matthias; Neels, Oliver C.; Eisenhut, Michael; Kuebler, Wolfgang; Holland-Letz, Tim; Giesel, Frederik L.; Mier, Walter; Kopka, Klaus; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1697-1705</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">PET imaging with the prostate-specific membrane antigen (PSMA)-targeted radioligand 68Ga-PSMA-11 is regarded as a significant step forward in the diagnosis of prostate cancer (PCa).  More recently, a PSMA ligand was developed that can be labeled with 68Ga, 111In, 177Lu, and 90Y.  This ligand, named PSMA-617, therefore enables both diagnosis and therapy of PCa.  The aims of this evaluation were to clin. investigate the distribution of 68Ga-PSMA-617 in normal tissues and in PCa lesions as well as to evaluate the radiation exposure by the radioligand in PET imaging.  Nineteen patients, most of them with recurrent PCa, were referred for 68Ga-PSMA-617 PET/CT.  The quant. assessment of tracer uptake of several organs and of 53 representative tumor lesions was performed in 15 patients at 1 and 3 h after injection.  In 4 addnl. patients, the same procedure was conducted at 5 min, 1 h, 2 h, 3 h, 4 h, and 5 h after injection.  On the basis of the data for these 4 patients (mean injected dose, 231 MBq), the radiation exposure of a 68Ga-PSMA-617 PET/CT was identified.  Intense tracer uptake was obsd. in the kidneys and salivary glands.  In 14 of 19 patients (73.7%), at least 1 lesion suspected of being a tumor was detected at 3 h after injection.  Of 53 representative tumor lesions selected at 3 h after injection, 47 lesions were visible at 1 h after injection.  The mean tumor-to-background ratio for max. standardized uptake value was 20.4 Â± 17.3 (range, 2.3-84.0) at 1 h after injection and 38.2 Â± 38.6 (range, 3.6-154.3) at 3 h after injection.  The av. radiation exposure (ED) was approx. 0.021 mSv/MBq.  Within healthy organs, the kidneys and salivary glands showed the highest 68Ga-PSMA-617 uptake.  The radiation exposure was relatively low. 68Ga-PSMA-617 shows PCa lesions with high contrast.  Images obtained between 2 and 3 h after injection seem to be the best option with regard to radiotracer uptake and tumor contrast.  Later images can help to clarify unclear lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFcW87h_AWsLVg90H21EOLACvtfcHk0lizUjE2-a6h5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFGmtLw%253D&md5=0cbba73002ae27bcb6add228aff05fcd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.115.161299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.115.161299%26sid%3Dliteratum%253Aachs%26aulast%3DAfshar-Oromieh%26aufirst%3DA.%26aulast%3DHetzheim%26aufirst%3DH.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DBenesova%26aufirst%3DM.%26atitle%3DThe%2520theranostic%2520PSMA%2520ligand%2520PSMA-617%2520in%2520the%2520diagnosis%2520of%2520prostate%2520cancer%2520by%2520PET%252FCT%253A%2520biodistribution%2520in%2520humans%252C%2520radiation%2520dosimetry%252C%2520and%2520first%2520evaluation%2520of%2520tumor%2520lesions%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26spage%3D1697%26epage%3D1705%26doi%3D10.2967%2Fjnumed.115.161299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calais, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czernin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendler, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elashoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickols, N. G.</span></span> <span> </span><span class="NLM_article-title">Randomized phase III trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">TPS136</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2019.37.7_suppl.TPS136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1200%2FJCO.2019.37.7_suppl.TPS136" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=TPS136&author=J.+Calaisauthor=J.+Czerninauthor=W.+P.+Fendlerauthor=D.+Elashoffauthor=N.+G.+Nickols&title=Randomized+phase+III+trial+of+68Ga-PSMA-11+PET%2FCT+molecular+imaging+for+prostate+cancer+salvage+radiotherapy+planning+%5BPSMA-SRT%5D&doi=10.1200%2FJCO.2019.37.7_suppl.TPS136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.7_suppl.TPS136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.7_suppl.TPS136%26sid%3Dliteratum%253Aachs%26aulast%3DCalais%26aufirst%3DJ.%26aulast%3DCzernin%26aufirst%3DJ.%26aulast%3DFendler%26aufirst%3DW.%2BP.%26aulast%3DElashoff%26aufirst%3DD.%26aulast%3DNickols%26aufirst%3DN.%2BG.%26atitle%3DRandomized%2520phase%2520III%2520trial%2520of%252068Ga-PSMA-11%2520PET%252FCT%2520molecular%2520imaging%2520for%2520prostate%2520cancer%2520salvage%2520radiotherapy%2520planning%2520%255BPSMA-SRT%255D%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3DTPS136%26doi%3D10.1200%2FJCO.2019.37.7_suppl.TPS136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kesch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span> <span> </span><span class="NLM_article-title"><sup>68</sup>Ga or <sup>18</sup>F for prostate cancer imaging?</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">687</span>â <span class="NLM_lpage">688</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.117.190157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.117.190157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=28408526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslalsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=687-688&author=C.+Keschauthor=C.+Kratochwilauthor=W.+Mierauthor=K.+Kopkaauthor=F.+L.+Giesel&title=68Ga+or+18F+for+prostate+cancer+imaging%3F&doi=10.2967%2Fjnumed.117.190157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">(68)Ga or (18)F for Prostate Cancer Imaging?</span></div><div class="casAuthors">Kesch Claudia; Kratochwil Clemens; Mier Walter; Giesel Frederik L; Kopka Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">687-688</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTan9bSbQzZvjEC-75aqa5AfW6udTcc2eZwuvXYGMUBXrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslalsA%253D%253D&md5=9dcd47e46a010cd9415926d3babda381</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.117.190157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.117.190157%26sid%3Dliteratum%253Aachs%26aulast%3DKesch%26aufirst%3DC.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26atitle%3D68Ga%2520or%252018F%2520for%2520prostate%2520cancer%2520imaging%253F%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D687%26epage%3D688%26doi%3D10.2967%2Fjnumed.117.190157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyneke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkon, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathekge, M.</span></span> <span> </span><span class="NLM_article-title">Intraindividual comparison of F-18-PSMA-1007 and F-18-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1076</span>â <span class="NLM_lpage">1080</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.117.204669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.117.204669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=29269569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1CgtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1076-1080&author=F.+L.+Gieselauthor=L.+Willauthor=I.+Lawalauthor=T.+Lenganaauthor=C.+Kratochwilauthor=M.+Vorsterauthor=O.+Neelsauthor=F.+Reynekeauthor=U.+Haberkonauthor=K.+Kopkaauthor=M.+Sathekge&title=Intraindividual+comparison+of+F-18-PSMA-1007+and+F-18-DCFPyL+PET%2FCT+in+the+prospective+evaluation+of+patients+with+newly+diagnosed+prostate+carcinoma%3A+a+pilot+study&doi=10.2967%2Fjnumed.117.204669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study</span></div><div class="casAuthors">Giesel, Frederik L.; Will, Leon; Lawal, Ismaheel; Lengana, Thabo; Kratochwil, Clemens; Vorster, Mariza; Neels, Oliver; Reyneke, Florette; Haberkon, Uwe; Kopka, Klaus; Sathekge, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1076-1080</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The introduction of 18F-labeled prostate-specific membrane antigen (PSMA)-targeted PET/CT tracers, first 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) and more recently 18F-PSMA-1007 (((3S,10S,14S)-1-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-18F-fluoronicotinamido)butanamido)butanamido)methyl)phenyl)-3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid)), have demonstrated promising results for the diagnostic workup of prostate cancer.  This clin. study presents an intraindividual comparison to evaluate tracer-specific characteristics of 18F-DCFPyL vs. 18F-PSMA-1007.  Twelve prostate cancer patients, drug-naive or before surgery, received similar activities of about 250 MBq of 18F-DCFPyL and 18F-PSMA-1007 48 h apart and were imaged 2 h after injection on the same PET/CT scanner using the same reconstruction algorithm.  Normal-organ biodistribution and tumor uptake were quantified using SUVmax.  PSMA-pos. lesions were detected in 12 of 12 prostate cancer patients.  Both tracers, 18F-DCFPyL and 18F-PSMA-1007, detected the same lesions.  No statistical significance could be obsd. when comparing the SUVmax of 18F-DCFPyL and 18F-PSMA-1007 for local tumor, lymph node metastases, and bone metastases.  With regard to normal organs, 18F-DCFPyL had statistically significant higher uptake in kidneys, urinary bladder, and lacrimal gland.  Vice versa, significantly higher uptake of 18F-PSMA-1007 in muscle, submandibular and sublingual gland, spleen, pancreas, liver, and gallbladder was obsd.  Excellent imaging quality was achieved with both 18F-DCFPyL and 18F-PSMA-1007, resulting in identical clin. findings for the evaluated routine situations.  Nonurinary excretion of 18F-PSMA-1007 might present some advantage with regard to delineation of local recurrence or pelvic lymph node metastasis in selected patients; the lower hepatic background might favor 18F-DCFPyL in late stages, when rare cases of liver metastases can occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9sOieiddqnLVg90H21EOLACvtfcHk0lhok9h0O0KRCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1CgtLg%253D&md5=2f7ef3becefb959785c7e05c63ebdefc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.117.204669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.117.204669%26sid%3Dliteratum%253Aachs%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DWill%26aufirst%3DL.%26aulast%3DLawal%26aufirst%3DI.%26aulast%3DLengana%26aufirst%3DT.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DVorster%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%26aulast%3DReyneke%26aufirst%3DF.%26aulast%3DHaberkon%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DSathekge%26aufirst%3DM.%26atitle%3DIntraindividual%2520comparison%2520of%2520F-18-PSMA-1007%2520and%2520F-18-DCFPyL%2520PET%252FCT%2520in%2520the%2520prospective%2520evaluation%2520of%2520patients%2520with%2520newly%2520diagnosed%2520prostate%2520carcinoma%253A%2520a%2520pilot%2520study%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D1076%26epage%3D1080%26doi%3D10.2967%2Fjnumed.117.204669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhnert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockter, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Comparison of [<sup>18</sup>F]DCFPyL and [<sup>68</sup>Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer</span>. <i>Mol. Imaging. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">575</span>â <span class="NLM_lpage">584</span>, <span class="refDoi">Â DOI: 10.1007/s11307-015-0866-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs11307-015-0866-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=26013479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SmurnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=575-584&author=M.+Dietleinauthor=C.+Kobeauthor=G.+Kuhnertauthor=S.+Stockter&title=Comparison+of+%5B18F%5DDCFPyL+and+%5B68Ga%5DGa-PSMA-HBED-CC+for+PSMA-PET+imaging+in+patients+with+relapsed+prostate+cancer&doi=10.1007%2Fs11307-015-0866-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer</span></div><div class="casAuthors">Dietlein, Markus; Kobe, Carsten; Kuhnert, Georg; Stockter, Simone; Fischer, Thomas; Schomaecker, Klaus; Schmidt, Matthias; Dietlein, Felix; Zlatopolskiy, Boris D.; Krapf, Philipp; Richarz, Raphael; Neubauer, Stephan; Drzezga, Alexander; Neumaier, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging and Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">575-584</span>CODEN:
                <span class="NLM_cas:coden">MIBOCZ</span>;
        ISSN:<span class="NLM_cas:issn">1860-2002</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [68Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer.  However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, prodn. amt., and image resoln. [18F]DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomog. (PET) imaging that has been recently introduced.  In the current study, we aimed to compare [68Ga]Ga-PSMA-HBED-CC and [18F]DCFPyL for clin. use in biochem. relapsed prostate cancer.  Procedures: In 14 selected patients with PSA relapse of prostate cancer, [18F]DCFPyL PET/X-ray computed tomog. (CT) was performed in addn. to [68Ga]Ga-PSMA-HBED-CC PET/CT.  A systematic comparison was carried out between results obtained with both tracers with regard to the no. of detected PSMA-pos. lesions, the standardized uptake value (SUV)max and the lesion to background ratios.  Results: All suspicious lesions identified by [68Ga]Ga-PSMA-HBED-CC were also detected with [18F]DCFPyL.  In three patients, addnl. lesions were obsd. using [18F]DCFPyL PET/CT.  The mean SUVmax in the concordant [18F]DCFPyL PSMA-pos. lesions was significantly higher as compared to [68Ga]Ga-PSMA-HBED-CC (14.5 vs. 12.2, p = 0.028, n = 15).  The mean tumor to background ratios (n = 15) were significantly higher for [18F]DCFPyL compared to [68Ga]Ga-PSMA-HBED-CC using kidney, spleen, or parotid as ref. organs (p = 0.006, p = 0.002, p = 0.008), but no significant differences were found using the liver (p = 0.167) or the mediastinum (p = 0.363) as ref. organs.  Conclusion: [18F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. [18F]DCFPyL represents a highly promising alternative to [68Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7xf95U58dALVg90H21EOLACvtfcHk0lhok9h0O0KRCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SmurnP&md5=2995fc5d9b75be5f2c6e7b32d7d06b6b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs11307-015-0866-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-015-0866-0%26sid%3Dliteratum%253Aachs%26aulast%3DDietlein%26aufirst%3DM.%26aulast%3DKobe%26aufirst%3DC.%26aulast%3DKuhnert%26aufirst%3DG.%26aulast%3DStockter%26aufirst%3DS.%26atitle%3DComparison%2520of%2520%255B18F%255DDCFPyL%2520and%2520%255B68Ga%255DGa-PSMA-HBED-CC%2520for%2520PSMA-PET%2520imaging%2520in%2520patients%2520with%2520relapsed%2520prostate%2520cancer%26jtitle%3DMol.%2520Imaging.%2520Biol.%26date%3D2015%26volume%3D17%26spage%3D575%26epage%3D584%26doi%3D10.1007%2Fs11307-015-0866-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahbar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weckesser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadzadehfar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogemann, M.</span></span> <span> </span><span class="NLM_article-title">Advantage of F-18-PSMA-1007 over Ga-68-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1076</span>â <span class="NLM_lpage">1077</span>, <span class="refDoi">Â DOI: 10.1007/s00259-018-3952-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-018-3952-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=29445927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1Sju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1076-1077&author=K.+Rahbarauthor=M.+Weckesserauthor=H.+Ahmadzadehfarauthor=M.+Schafersauthor=L.+Steggerauthor=M.+Bogemann&title=Advantage+of+F-18-PSMA-1007+over+Ga-68-PSMA-11+PET+imaging+for+differentiation+of+local+recurrence+vs.+urinary+tracer+excretion&doi=10.1007%2Fs00259-018-3952-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion</span></div><div class="casAuthors">Rahbar, Kambiz; Weckesser, Matthias; Ahmadzadehfar, Hojjat; Schaefers, Michael; Stegger, Lars; Boegemann, Martin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1076-1077</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review discussing the advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.  The images of a 74-yr-old prostate cancer patient after radical prostatectomy (Gleason score 9) with biochem. recurrence (PSA: 2.1 ng/dL) was presented.  18F-PSMA-1007 seemed to be superior to 68Ga-PSMA-11 in cases of biochem. recurrence and unclear lesions close to the ureter or urinary bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAO915awAnqrVg90H21EOLACvtfcHk0liSiGH4HXEdpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1Sju78%253D&md5=c773329f88fac1c8936c7b26c87db98f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs00259-018-3952-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-018-3952-0%26sid%3Dliteratum%253Aachs%26aulast%3DRahbar%26aufirst%3DK.%26aulast%3DWeckesser%26aufirst%3DM.%26aulast%3DAhmadzadehfar%26aufirst%3DH.%26aulast%3DSchafers%26aufirst%3DM.%26aulast%3DStegger%26aufirst%3DL.%26aulast%3DBogemann%26aufirst%3DM.%26atitle%3DAdvantage%2520of%2520F-18-PSMA-1007%2520over%2520Ga-68-PSMA-11%2520PET%2520imaging%2520for%2520differentiation%2520of%2520local%2520recurrence%2520vs.%2520urinary%2520tracer%2520excretion%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2018%26volume%3D45%26spage%3D1076%26epage%3D1077%26doi%3D10.1007%2Fs00259-018-3952-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wurzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Carlo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H.-J.</span></span> <span> </span><span class="NLM_article-title">Radiohybrid ligands: a novel tracer concept exemplified by <sup>18</sup>F- or <sup>68</sup>Ga-labeled rhPSMA inhibitors</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">735</span>â <span class="NLM_lpage">742</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.119.234922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.119.234922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=31862804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOisL7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=735-742&author=A.+Wurzerauthor=D.+Di+Carloauthor=A.+Schmidtauthor=R.+Beckauthor=M.+Eiberauthor=M.+Schwaigerauthor=H.-J.+Wester&title=Radiohybrid+ligands%3A+a+novel+tracer+concept+exemplified+by+18F-+or+68Ga-labeled+rhPSMA+inhibitors&doi=10.2967%2Fjnumed.119.234922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors</span></div><div class="casAuthors">Wurzer, Alexander; Di Carlo, Daniel; Schmidt, Alexander; Beck, Roswitha; Eiber, Matthias; Schwaiger, Markus; Wester, Hans-Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">735-743</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">When we critically assess the reason for the current dominance of 68Ga-labeled peptides and peptide-like ligands in radiopharmacy and nuclear medicine, we have to conclude that the major advantage of such radiopharmaceuticals is the apparent lack of suitable 18F-labeling technologies with proven clin. relevance.  To prep. and to subsequently perform a clin. proof-of-concept study on the general suitability of silicon-fluoride-acceptor (SiFA)-conjugated radiopharmaceuticals, we developed inhibitors of the prostate-specific membrane antigen (PSMA) that are labeled by isotopic exchange (IE).  To compensate for the pronounced lipophilicity of the SiFA unit, we used metal chelates, conjugated in close proximity to SiFA.  Six different radiohybrid PSMA ligands (rhPSMA ligands) were evaluated and compared with the commonly used 18F-PSMA inhibitors 18F-DCFPyL and 18F-PSMA-1007.  All inhibitors were synthesized by solid-phase peptide synthesis.  Human serum albumin binding was measured by affinity high-performance liq. chromatog., whereas the lipophilicity of each tracer was detd. by the n-octanol/buffer method.  In vitro studies (IC50, internalization) were performed on LNCaP cells.  Biodistribution studies were conducted on LNCaP tumor-bearing male CB-17 SCID mice.  On the lab. scale (starting activities, 0.2-9.0 GBq), labeling of 18F-rhPSMA-5 to -10 by IE was completed in , <20 min (radiochem. yields, 58% Â±9%; radiochem. purity, >97%) with molar activities of 12-60 GBq/Î¼mol.  All rhPSMAs showed low nanomolar affinity and high internalization by PSMA-expressing cells when compared with the ref. radiopharmaceuticals, medium-to-low lipophilicity, and high human serum albumin binding.  Biodistribution studies in LNCaP tumor- bearing mice revealed high tumor uptake, sufficiently fast clearance kinetics from blood, low hepatobiliary excretion, fast renal excretion, and very low uptake of 18F- activity in bone.  The novel 18F-rhPSMA radiopharmaceuticals developed under the radiohybrid concept show equal or better targeting characteristics than the established 18F-PSMA tracers 18F-DCFPyL and 18F-PSMA- 1007.  The unparalleled simplicity of prodn., the possibility to produce the identical 68Ga-labeled 19F-68Ga-rhPSMA tracers, and the possibility to extend this concept to true theranostic radiohybrid radiopharmaceuticals, such as F-Lu-rhPSMA, are unique features of these radiopharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFshUQeZMd2bVg90H21EOLACvtfcHk0liSiGH4HXEdpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOisL7E&md5=f06ff865b42826703ce21818e2510fc8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.234922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.234922%26sid%3Dliteratum%253Aachs%26aulast%3DWurzer%26aufirst%3DA.%26aulast%3DDi%2BCarlo%26aufirst%3DD.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DBeck%26aufirst%3DR.%26aulast%3DEiber%26aufirst%3DM.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DWester%26aufirst%3DH.-J.%26atitle%3DRadiohybrid%2520ligands%253A%2520a%2520novel%2520tracer%2520concept%2520exemplified%2520by%252018F-%2520or%252068Ga-labeled%2520rhPSMA%2520inhibitors%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D735%26epage%3D742%26doi%3D10.2967%2Fjnumed.119.234922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroenke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulbrich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jooss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, W.</span></span> <span> </span><span class="NLM_article-title">F-18-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">696</span>â <span class="NLM_lpage">701</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.119.234914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.119.234914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=31836682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOis7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=696-701&author=M.+Eiberauthor=M.+Kroenkeauthor=A.+Wurzerauthor=L.+Ulbrichauthor=L.+Joossauthor=T.+Maurerauthor=T.+Hornauthor=K.+Schillerauthor=T.+Langbeinauthor=G.+Buschnerauthor=H.+J.+Westerauthor=W.+Weber&title=F-18-rhPSMA-7+PET+for+the+detection+of+biochemical+recurrence+of+prostate+cancer+after+radical+prostatectomy&doi=10.2967%2Fjnumed.119.234914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A 18F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy</span></div><div class="casAuthors">Eiber, Matthias; Kroenke, Markus; Wurzer, Alexander; Ulbrich, Lena; Jooss, Lena; Maurer, Tobias; Horn, Thomas; Schiller, Kilian; Langbein, Thomas; Buschner, Gabriel; Wester, Hans-Juergen; Weber, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">696-702</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">18F-labeled prostate-specific membrane antigen (PSMA) PET tracers are increasingly used in preference to 68Ga-PSMA-11 for restaging biochem. recurrence (BCR) of prostate cancer.  They are assocd. with longer half-lives, larger-scale prodn., and lower positron range than their 68Ga-labeled counterparts.  Here, we describe the efficacy of an 18F-labeled radiohybrid PSMA, rhPSMA-7, a novel theranostic PSMA-targeting agent for imaging BCR of prostate cancer.  Datasets from 261 consecutive patients with noncastrate BCR after radical prostatectomy who underwent 18F-rhPSMA-7 PET/CT at our institution between June 2017 and March 2018 were reviewed retrospectively.  All lesions suspected of being recurrent prostate cancer were recorded.  The detection rate for sites of presumed recurrence was correlated with patients' prostate-specific antigen (PSA) level, primary Gleason score, and prior therapy (androgen deprivation therapy and external-beam radiation therapy).  The 261 patients had a median PSA level of 0.96 ng/mL (range, 0.01 -400 ng/mL).  The median injected activity of 18F-rhPSMA-7 was 336 MBq, with a median uptake time of 76 min.  In total, 211 patients (81%) showed pathol. findings on 18F-rhPSMA-7 PET/CT.  The detection rates were 71% (42/59), 86% (44/51), 86% (42/49), and 95% (76/80) at PSA levels of 0.2 to <0.5 ng/mL, 0.5 to <1 ng/mL, 1 to <2 ng/mL, and â¥2 ng/mL, resp.  In 32% patients (7/22) with a PSA of less than 0.2 ng/mL, suggestive lesions were present.  18FrhPSMA-7 PET/CT revealed local recurrence in 43% of patients (113).  Lymph node metastases were present in the pelvis in 42% of patients (110), in the retroperitoneum in 17% (45), and in a supradiaphragmatic location in 8.0% (21).  Bone and visceral metastases were detected in 21% (54) and 3.8% (10), resp.  Detection efficacy was not influenced by prior external-beam radiation therapy (79.1% vs. 82.1%, P = 5 0.55), androgen deprivation therapy within the 6 mo preceding imaging (80.6% vs. 80.9%, P = 5 0.54), or primary Gleason score (77.9% for â¤7 vs. 82.6% for â¥8, P = 5 0.38).  18F-rhPSMA-7 PET/CT offers high detection rates in early BCR after radical prostatectomy, esp. among patients with low PSA values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUI_hOGyZ9XbVg90H21EOLACvtfcHk0liSiGH4HXEdpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOis7fN&md5=897bece05e2df0d94fc8342eb183529f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.234914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.234914%26sid%3Dliteratum%253Aachs%26aulast%3DEiber%26aufirst%3DM.%26aulast%3DKroenke%26aufirst%3DM.%26aulast%3DWurzer%26aufirst%3DA.%26aulast%3DUlbrich%26aufirst%3DL.%26aulast%3DJooss%26aufirst%3DL.%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DHorn%26aufirst%3DT.%26aulast%3DSchiller%26aufirst%3DK.%26aulast%3DLangbein%26aufirst%3DT.%26aulast%3DBuschner%26aufirst%3DG.%26aulast%3DWester%26aufirst%3DH.%2BJ.%26aulast%3DWeber%26aufirst%3DW.%26atitle%3DF-18-rhPSMA-7%2520PET%2520for%2520the%2520detection%2520of%2520biochemical%2520recurrence%2520of%2520prostate%2520cancer%2520after%2520radical%2520prostatectomy%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D696%26epage%3D701%26doi%3D10.2967%2Fjnumed.119.234914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roscher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerlings, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Development of PSMA-1007-related series of <sup>18</sup>F-labeled Glu-ureido type PSMA inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10897</span>â <span class="NLM_lpage">10907</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01479</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01479" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs12rtrnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10897-10907&author=J.+Cardinaleauthor=M.+Roscherauthor=M.+Schaeferauthor=M.+Geerlings&title=Development+of+PSMA-1007-related+series+of+18F-labeled+Glu-ureido+type+PSMA+inhibitors&doi=10.1021%2Facs.jmedchem.9b01479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors</span></div><div class="casAuthors">Cardinale, Jens; Roscher, Mareike; Schaefer, Martin; Geerlings, Max; Benesova, Martina; Bauder-Wuest, Ulrike; Remde, Yvonne; Eder, Matthias; Novakova, Zora; Motlova, Lucia; Barinka, Cyril; Giesel, Frederik L.; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10897-10907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In recent years, a no. of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer.  In the present work, we report on the synthesis and preclin. evaluation of a series of 18F-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617.  By applying modifications to the linker structure, insight into the structure-activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution.  Selected compds. were co-crystd. with the PSMA protein and analyzed by X-rays with mixed results.  Among these, PSMA-1007 (compd. 5) showed the best interaction with the PSMA protein.  The resp. radiotracer [18F]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8EfOyscxlC7Vg90H21EOLACvtfcHk0lhNCkvW2Jftyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs12rtrnM&md5=a9b0a2087eec7d108d74f916930c0c97</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01479%26sid%3Dliteratum%253Aachs%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DRoscher%26aufirst%3DM.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DGeerlings%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520PSMA-1007-related%2520series%2520of%252018F-labeled%2520Glu-ureido%2520type%2520PSMA%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10897%26epage%3D10907%26doi%3D10.1021%2Facs.jmedchem.9b01479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benesova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wust, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klika, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span> <span> </span><span class="NLM_article-title">Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1761</span>â <span class="NLM_lpage">1775</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01210</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01210" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGmur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1761-1775&author=M.+Benesovaauthor=U.+Bauder-Wustauthor=M.+Schaferauthor=K.+D.+Klikaauthor=W.+Mierauthor=U.+Haberkornauthor=K.+Kopkaauthor=M.+Eder&title=Linker+modification+strategies+to+control+the+prostate-specific+membrane+antigen+%28PSMA%29-targeting+and+pharmacokinetic+properties+of+DOTA-conjugated+PSMA+inhibitors&doi=10.1021%2Facs.jmedchem.5b01210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors</span></div><div class="casAuthors">Benesova, Martina; Bauder-Wuest, Ulrike; Schaefer, Martin; Klika, Karel D.; Mier, Walter; Haberkorn, Uwe; Kopka, Klaus; Eder, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1761-1775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since prostate-specific membrane antigen (PSMA) is up-regulated in nearly all stages of prostate cancer (PCa), PSMA can be considered as a viable diagnostic biomarker and treatment target in PCa.  This project is focused on the development and evaluation of a series of compds. directed against PSMA.  The modifications to the linker are designed to improve the binding potential and pharmacokinetics for theranostic application.  In addn., the results help to further elucidate the structure-activity relationships (SAR) of the resulting PSMA inhibitors.  Both in vitro and in vivo expts. of 18 synthesized PSMA inhibitor variants showed that systematic chem. modification of the linker has a significant impact on the tumor-targeting and pharmacokinetic properties.  This approach can lead to an improved management of patients suffering from recurrent prostate cancer by the use of one radiolabeling precursor, which can be radiolabeled either with 68Ga for diagnosis or with 177Lu or 225Ac for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq0IyrD7bU0LVg90H21EOLACvtfcHk0lhNCkvW2Jftyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGmur8%253D&md5=437f339a55b519c54206942e5b51161c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01210%26sid%3Dliteratum%253Aachs%26aulast%3DBenesova%26aufirst%3DM.%26aulast%3DBauder-Wust%26aufirst%3DU.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DKlika%26aufirst%3DK.%2BD.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DEder%26aufirst%3DM.%26atitle%3DLinker%2520modification%2520strategies%2520to%2520control%2520the%2520prostate-specific%2520membrane%2520antigen%2520%2528PSMA%2529-targeting%2520and%2520pharmacokinetic%2520properties%2520of%2520DOTA-conjugated%2520PSMA%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1761%26epage%3D1775%26doi%3D10.1021%2Facs.jmedchem.5b01210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [<sup>18</sup>F]DCFPyL</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">439</span>â <span class="NLM_lpage">450</span>, <span class="refDoi">Â DOI: 10.1002/jlcr.3430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1002%2Fjlcr.3430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27470935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GisL7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=439-450&author=H.+T.+Ravertauthor=D.+P.+Holtauthor=Y.+Chenauthor=R.+C.+Measeauthor=H.+Fanauthor=M.+G.+Pomperauthor=R.+F.+Dannals&title=An+improved+synthesis+of+the+radiolabeled+prostate-specific+membrane+antigen+inhibitor%2C+%5B18F%5DDCFPyL&doi=10.1002%2Fjlcr.3430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL</span></div><div class="casAuthors">Ravert, Hayden T.; Holt, Daniel P.; Chen, Ying; Mease, Ronnie C.; Fan, Hong; Pomper, Martin G.; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">439-450</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The radiosynthesis of [18F]DCFPyL I on 2 distinct automated platforms with full regulatory compliant quality control specifications is described.  The radiotracer synthesis was performed on a custom-made radiofluorination module and the Sofie Biosciences ELIXYS.  The radiofluorination module synthesis was accomplished in an av. of 66 min from end of bombardment with an av. specific activity at end of synthesis (EOS) of 4.4 TBq/Î¼mol (120 Ci/Î¼mol) and an av. radiochem. yield of 30.9% at EOS.  The ELIXYS synthesis was completed in an av. of 87 min with an av. specific activity of 2.2 TBq/Î¼mol (59.3 Ci/Î¼mol) and an av. radiochem. yield of 19% at EOS.  Both synthesis modules produced large millicurie quantities of [18F]DCFPyL while conforming to all std. US Pharmacopeia Chapter <823> acceptance testing criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB-H3Bt9yVULVg90H21EOLACvtfcHk0lhNCkvW2Jftyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GisL7O&md5=2976699f47c43e015181805c1620089c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3430%26sid%3Dliteratum%253Aachs%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DHolt%26aufirst%3DD.%2BP.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DAn%2520improved%2520synthesis%2520of%2520the%2520radiolabeled%2520prostate-specific%2520membrane%2520antigen%2520inhibitor%252C%2520%255B18F%255DDCFPyL%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2016%26volume%3D59%26spage%3D439%26epage%3D450%26doi%3D10.1002%2Fjlcr.3430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span> <i>Chinese Pharmacopoeia</i>, <span class="NLM_edition">2020</span> ed.; <span class="NLM_publisher-name">Chinese Pharmacopoeia Commission, Ministry
of Health</span>: <span class="NLM_publisher-loc">People's Republic
of China</span>, <span class="NLM_year">2020</span>; Vol.  <span class="NLM_volume">II</span>, Part 2.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chinese+Pharmacopoeia%2C+2020+ed.%3B+Chinese+Pharmacopoeia+Commission%2C+Ministry%0Aof+Health%3A+People%27s+Republic%0Aof+China%2C+2020%3B+Vol.+II%2C+Part+2."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DChinese%2520Pharmacopoeia%26pub%3DChinese%2520Pharmacopoeia%2520Commission%252C%2520Ministry%250Aof%2520Health%26date%3D2020%26volume%3DII" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saperstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantel, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gage, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iagaru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stambler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, B.</span></span> <span> </span><span class="NLM_article-title">Impact of PSMA-targeted imaging with <sup>18</sup>F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">5501</span>â <span class="NLM_lpage">5501</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2020.38.15_suppl.5501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1200%2FJCO.2020.38.15_suppl.5501" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=5501-5501&author=M.+J.+Morrisauthor=P.+R.+Carrollauthor=L.+Sapersteinauthor=F.+Pouliotauthor=D.+Josephsonauthor=J.+Y.+C.+Wongauthor=A.+R.+Pantelauthor=S.+Y.+Choauthor=K.+Gageauthor=M.+Piertauthor=A.+Iagaruauthor=J.+H.+Pollardauthor=V.+Wongauthor=J.+D.+Jensenauthor=N.+Stamblerauthor=M.+A.+Gorinauthor=B.+Siegel&title=Impact+of+PSMA-targeted+imaging+with+18F-DCFPyL-PET%2FCT+on+clinical+management+of+patients+%28pts%29+with+biochemically+recurrent+%28BCR%29+prostate+cancer+%28PCa%29%3A+Results+from+a+phase+III%2C+prospective%2C+multicenter+study+%28CONDOR%29&doi=10.1200%2FJCO.2020.38.15_suppl.5501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.5501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.5501%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DM.%2BJ.%26aulast%3DCarroll%26aufirst%3DP.%2BR.%26aulast%3DSaperstein%26aufirst%3DL.%26aulast%3DPouliot%26aufirst%3DF.%26aulast%3DJosephson%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DJ.%2BY.%2BC.%26aulast%3DPantel%26aufirst%3DA.%2BR.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DGage%26aufirst%3DK.%26aulast%3DPiert%26aufirst%3DM.%26aulast%3DIagaru%26aufirst%3DA.%26aulast%3DPollard%26aufirst%3DJ.%2BH.%26aulast%3DWong%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DJ.%2BD.%26aulast%3DStambler%26aufirst%3DN.%26aulast%3DGorin%26aufirst%3DM.%2BA.%26aulast%3DSiegel%26aufirst%3DB.%26atitle%3DImpact%2520of%2520PSMA-targeted%2520imaging%2520with%252018F-DCFPyL-PET%252FCT%2520on%2520clinical%2520management%2520of%2520patients%2520%2528pts%2529%2520with%2520biochemically%2520recurrent%2520%2528BCR%2529%2520prostate%2520cancer%2520%2528PCa%2529%253A%2520Results%2520from%2520a%2520phase%2520III%252C%2520prospective%252C%2520multicenter%2520study%2520%2528CONDOR%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D5501%26epage%3D5501%26doi%3D10.1200%2FJCO.2020.38.15_suppl.5501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schottelius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of novel <sup>18</sup>F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with <sup>18</sup>F-DCFPyl and <sup>18</sup>F-PSMA-1007</span>. <i>Eur. J. Nucl. Med. Mol. Imaging. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi">Â DOI: 10.1186/s13550-018-0382-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1186%2Fs13550-018-0382-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=30&author=S.+Robuauthor=A.+Schmidtauthor=M.+Eiberauthor=M.+Schotteliusauthor=T.+Guntherauthor=B.+H.+Yousefiauthor=M.+Schwaigerauthor=H.+J.+Wester&title=Synthesis+and+preclinical+evaluation+of+novel+18F-labeled+Glu-urea-Glu-based+PSMA+inhibitors+for+prostate+cancer+imaging%3A+a+comparison+with+18F-DCFPyl+and+18F-PSMA-1007&doi=10.1186%2Fs13550-018-0382-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2Fs13550-018-0382-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13550-018-0382-8%26sid%3Dliteratum%253Aachs%26aulast%3DRobu%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DEiber%26aufirst%3DM.%26aulast%3DSchottelius%26aufirst%3DM.%26aulast%3DGunther%26aufirst%3DT.%26aulast%3DYousefi%26aufirst%3DB.%2BH.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DWester%26aufirst%3DH.%2BJ.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520novel%252018F-labeled%2520Glu-urea-Glu-based%2520PSMA%2520inhibitors%2520for%2520prostate%2520cancer%2520imaging%253A%2520a%2520comparison%2520with%252018F-DCFPyl%2520and%252018F-PSMA-1007%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging.%2520Res.%26date%3D2018%26volume%3D8%26spage%3D30%26doi%3D10.1186%2Fs13550-018-0382-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zlatopolskiy, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endepols, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guliyev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urusova, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richarz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drzezga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumaier, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of <sup>18</sup>F-JK-PSMA-7, a PET Probe for the detection of small PSMA-positive lesions</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">817</span>â <span class="NLM_lpage">823</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.218495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.118.218495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30389823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpslaksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=817-823&author=B.+D.+Zlatopolskiyauthor=H.+Endepolsauthor=P.+Krapfauthor=M.+Guliyevauthor=E.+A.+Urusovaauthor=R.+Richarzauthor=M.+Hohbergauthor=M.+Dietleinauthor=A.+Drzezgaauthor=B.+Neumaier&title=Discovery+of+18F-JK-PSMA-7%2C+a+PET+Probe+for+the+detection+of+small+PSMA-positive+lesions&doi=10.2967%2Fjnumed.118.218495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 18F-JK-PSMA-7, a PET probe for the detection of small PSMA-positive lesions</span></div><div class="casAuthors">Zlatopolskiy, Boris D.; Endepols, Heike; Krapf, Philipp; Guliyev, Mehrab; Urusova, Elizaveta A.; Richarz, Raphael; Hohberg, Melanie; Dietlein, Markus; Drzezga, Alexander; Neumaier, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">817-823</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The aim of this study was the development of highly selective and specific PSMA probes with enhanced imaging properties, in comparison with 18FDCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11.  Methods: Eight novel 18F-labeled PSMA ligands were prepd.  Their cellular uptake in PSMA-pos. LNCaP C4-2 and PSMA-neg. PC-3 cells was compared with that of 18F-DCFPyL.  The most promising candidates were addnl. evaluated by small-animal PET in healthy rats using PSMA-pos. peripheral ganglia as a model for small PCa lesions.  PET images of the ligand with the best outcome, 18F-JKPSMA- 7, were compared with those of 18F-DCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11 with respect to key image-quality parameters for the time frame 60-120 min.  Results: Compared with 18F-DCFPyL, 18FJK- PSMA-7 demonstrated increased PSMA-specific cellular uptake.  Although target-to-background ratios of 18F-DCFPyL and 18F-PSMA- 1007 were comparable, this parameter was higher for 18F-JK-PSMA- 7 and lower for 68Ga-PSMA-11.  Image acutance was significantly higher for 18F-JK-PSMA-7 and 18F-PSMA-1007 than for 18F-DCFPyL and 68Ga-PSMA-11.  Conclusion: 18F-JK-PSMA-7 is a promising candidate for high-quality visualization of small PSMApos. lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqde4Vvp9QQrbVg90H21EOLACvtfcHk0lgGxI5veGEbEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpslaksg%253D%253D&md5=344fee789fd142980a6a4810e573e17e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.218495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.218495%26sid%3Dliteratum%253Aachs%26aulast%3DZlatopolskiy%26aufirst%3DB.%2BD.%26aulast%3DEndepols%26aufirst%3DH.%26aulast%3DKrapf%26aufirst%3DP.%26aulast%3DGuliyev%26aufirst%3DM.%26aulast%3DUrusova%26aufirst%3DE.%2BA.%26aulast%3DRicharz%26aufirst%3DR.%26aulast%3DHohberg%26aufirst%3DM.%26aulast%3DDietlein%26aufirst%3DM.%26aulast%3DDrzezga%26aufirst%3DA.%26aulast%3DNeumaier%26aufirst%3DB.%26atitle%3DDiscovery%2520of%252018F-JK-PSMA-7%252C%2520a%2520PET%2520Probe%2520for%2520the%2520detection%2520of%2520small%2520PSMA-positive%2520lesions%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D817%26epage%3D823%26doi%3D10.2967%2Fjnumed.118.218495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatopolskiy, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endepols, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tager, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidenreich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumaier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drzezga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, M.</span></span> <span> </span><span class="NLM_article-title">Intraindividual comparison of <sup>18</sup>F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">729</span>â <span class="NLM_lpage">734</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.119.234898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.119.234898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=31628219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOisLzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=729-734&author=F.+Dietleinauthor=C.+Kobeauthor=M.+Hohbergauthor=B.+D.+Zlatopolskiyauthor=P.+Krapfauthor=H.+Endepolsauthor=P.+Tagerauthor=J.+Hammesauthor=A.+Heidenreichauthor=T.+Persigehlauthor=B.+Neumaierauthor=A.+Drzezgaauthor=M.+Dietlein&title=Intraindividual+comparison+of+18F-PSMA-1007+with+renally+excreted+PSMA+ligands+for+PSMA+PET+imaging+in+patients+with+relapsed+prostate+cancer&doi=10.2967%2Fjnumed.119.234898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer</span></div><div class="casAuthors">Dietlein, Felix; Kobe, Carsten; Hohberg, Melanie; Zlatopolskiy, Boris D.; Krapf, Philipp; Endepols, Heike; Taeger, Philipp; Hammes, Jochen; Heidenreich, Axel; Persigehl, Thorsten; Neumaier, Bernd; Drzezga, Alexander; Dietlein, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">729-735</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">18F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver.  We benchmarked the performance of 18F-PSMA-1007 against 3 renally excreted PSMA tracers.  Among 668 patients, we selected 27 in whom PET/CT results obtained with 68Ga-PSMA-11, 18F-DCFPyL (2-(3-(1-carboxy-5- [(6-18F]fluoro-pyridine-3-carbonyl)-amino-pentyl)-ureido)-pentanedioic acid), or 18F-JK-PSMA-7 (JK, Juelich-Koeln) were interpreted as equivocal or neg. or as oligometastatic disease (PET-1).  Within 3 wk, a second PET scan with 18F-PSMA-1007 was performed (PET-2).  The confidence in the interpretation of PSMA-pos. locoregional findings was scored on a 5-point scale, first in routine diagnostics (reader 1) and then by an independent second evaluation (reader 2).  Discordant PSMA-pos. skeletal findings were examd. by contrast-enhanced MRI.  For both readers, 18F-PSMA-1007 facilitated the interpretability of 27 locoregional lesions.  In PET-2, the clin. readout led to a significantly lower no. of equivocal locoregional lesions (P = 0.024), and reader 2 reported a significantly higher rate of suspected lesions that were falsely interpreted as probably benign in PET-1 (P = 0.023).  Exclusively in PET-2, we obsd. a total of 15 PSMA-pos. spots in the bone marrow of 6 patients (22%).  None of the 15 discordant spots had a morphol. correlate on the corresponding CT scan or on the subsequent MRI scan.  Thus, 18F-PSMA-1007 exhibits a significantly higher rate of unspecific medullary spots (P = 0.0006).  18F-PSMA-1007 may increase confidence in interpreting small locoregional lesions adjacent to the urinary tract but may decrease the interpretability of skeletal lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYs4GfFaySOLVg90H21EOLACvtfcHk0ljZtxToT5Q4QA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOisLzM&md5=5c2a252dabb347101316e394cba3fb34</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.234898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.234898%26sid%3Dliteratum%253Aachs%26aulast%3DDietlein%26aufirst%3DF.%26aulast%3DKobe%26aufirst%3DC.%26aulast%3DHohberg%26aufirst%3DM.%26aulast%3DZlatopolskiy%26aufirst%3DB.%2BD.%26aulast%3DKrapf%26aufirst%3DP.%26aulast%3DEndepols%26aufirst%3DH.%26aulast%3DTager%26aufirst%3DP.%26aulast%3DHammes%26aufirst%3DJ.%26aulast%3DHeidenreich%26aufirst%3DA.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DNeumaier%26aufirst%3DB.%26aulast%3DDrzezga%26aufirst%3DA.%26aulast%3DDietlein%26aufirst%3DM.%26atitle%3DIntraindividual%2520comparison%2520of%252018F-PSMA-1007%2520with%2520renally%2520excreted%2520PSMA%2520ligands%2520for%2520PSMA%2520PET%2520imaging%2520in%2520patients%2520with%2520relapsed%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D729%26epage%3D734%26doi%3D10.2967%2Fjnumed.119.234898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadaschik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radtke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinsensia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehnert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duensing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span> <span> </span><span class="NLM_article-title">F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">678</span>â <span class="NLM_lpage">688</span>, <span class="refDoi">Â DOI: 10.1007/s00259-016-3573-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-016-3573-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27889802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2msLvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=678-688&author=F.+L.+Gieselauthor=B.+Hadaschikauthor=J.+Cardinaleauthor=J.+Radtkeauthor=M.+Vinsensiaauthor=W.+Lehnertauthor=C.+Keschauthor=Y.+Tolstovauthor=S.+Singerauthor=N.+Grabeauthor=S.+Duensingauthor=M.+Schaferauthor=O.+C.+Neelsauthor=W.+Mierauthor=U.+Haberkornauthor=K.+Kopkaauthor=C.+Kratochwil&title=F-18+labelled+PSMA-1007%3A+biodistribution%2C+radiation+dosimetry+and+histopathological+validation+of+tumor+lesions+in+prostate+cancer+patients&doi=10.1007%2Fs00259-016-3573-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients</span></div><div class="casAuthors">Giesel, Frederik L.; Hadaschik, B.; Cardinale, J.; Radtke, J.; Vinsensia, M.; Lehnert, W.; Kesch, C.; Tolstov, Y.; Singer, S.; Grabe, N.; Duensing, S.; Schaefer, M.; Neels, O. C.; Mier, W.; Haberkorn, U.; Kopka, K.; Kratochwil, C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-688</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomog. (PET) tracer 68Ga-PSMA-11 shows great promise in the detection of prostate cancer.  However, 68Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of 18F-labeled analogs.  18F-PSMA-1007 was selected among several 18F-PSMA-ligand candidate compds. because it demonstrated high labeling yields, outstanding tumor uptake and fast, non-urinary background clearance.  Here, we describe the properties of 18F-PSMA-1007 in human volunteers and patients.  Radiation dosimetry of 18F-PSMA-1007 was detd. in three healthy volunteers who underwent whole-body PET-scans and concomitant blood and urine sampling.  Following this, ten patients with high-risk prostate cancer underwent 18F-PSMA-1007 PET/CT (1 h and 3 h p.i.) and normal organ biodistribution and tumor uptakes were examd.  Eight patients underwent prostatectomy with extended pelvic lymphadenectomy.  Uptake in intra-prostatic lesions and lymph node metastases were correlated with final histopathol., including PSMA immunostaining.  With an ED of approx. 4.4-5.5 mSv per 200-250 MBq examn., 18F-PSMA-1007 behaves similar to other PSMA-PET agents as well as to other 18F-labeled PET-tracers.  In comparison to other PSMA-targeting PET-tracers, 18F-PSMA-1007 has reduced urinary clearance enabling excellent assessment of the prostate.  Similar to 18F-DCFPyL and with slightly slower clearance kinetics than PSMA-11, favorable tumor-to-background ratios are obsd. 2-3 h after injection.  In eight patients, diagnostic findings were successfully validated by histopathol. 18F-PSMA-1007 PET/CT detected 18 of 19 lymph node metastases in the pelvis, including nodes as small as 1 mm in diam.  18F-PSMA-1007 performs at least comparably to 68Ga-PSMA-11, but its longer half-life combined with its superior energy characteristics and non-urinary excretion overcomes some practical limitations of 68Ga-labeled PSMA-targeted tracers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Yj0npCi6-LVg90H21EOLACvtfcHk0ljZtxToT5Q4QA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2msLvM&md5=86df221aea3e7c3e1c83ac39289b3b30</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3573-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3573-4%26sid%3Dliteratum%253Aachs%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DHadaschik%26aufirst%3DB.%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DRadtke%26aufirst%3DJ.%26aulast%3DVinsensia%26aufirst%3DM.%26aulast%3DLehnert%26aufirst%3DW.%26aulast%3DKesch%26aufirst%3DC.%26aulast%3DTolstov%26aufirst%3DY.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGrabe%26aufirst%3DN.%26aulast%3DDuensing%26aufirst%3DS.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DKratochwil%26aufirst%3DC.%26atitle%3DF-18%2520labelled%2520PSMA-1007%253A%2520biodistribution%252C%2520radiation%2520dosimetry%2520and%2520histopathological%2520validation%2520of%2520tumor%2520lesions%2520in%2520prostate%2520cancer%2520patients%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2017%26volume%3D44%26spage%3D678%26epage%3D688%26doi%3D10.1007%2Fs00259-016-3573-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoye, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horchler, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attardo, G.</span></span> <span> </span><span class="NLM_article-title">Facile route to 2-fluoropyridines via 2-pyridyltrialkylammonium salts prepared from pyridine N-oxides and application to <sup>18</sup>F-labeling</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3726</span>â <span class="NLM_lpage">3729</span>, <span class="refDoi">Â DOI: 10.1021/acs.orglett.5b01703</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.5b01703" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2ltrbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=3726-3729&author=H.+Xiongauthor=A.+T.+Hoyeauthor=K.-H.+Fanauthor=X.+Liauthor=J.+Clemensauthor=C.+L.+Horchlerauthor=N.+C.+Limauthor=G.+Attardo&title=Facile+route+to+2-fluoropyridines+via+2-pyridyltrialkylammonium+salts+prepared+from+pyridine+N-oxides+and+application+to+18F-labeling&doi=10.1021%2Facs.orglett.5b01703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Route to 2-Fluoropyridines via 2-Pyridyltrialkylammonium Salts Prepared from Pyridine N-Oxides and Application to 18F-Labeling</span></div><div class="casAuthors">Xiong, Hui; Hoye, Adam T.; Fan, Kuo-Hsien; Li, Ximin; Clemens, Jennifer; Horchler, Carey L.; Lim, Nathaniel C.; Attardo, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3726-3729</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among known precursors for 2-[18F]fluoropyridines, pyridyltrialkylammonium salts have shown excellent reactivity; however, their broader utility has been limited because synthetic methods for their prepn. suffer from poor functional group compatibility.  In this paper, we demonstrate the regioselective conversion of readily available pyridine N-oxides into 2-pyridyltrialkylammonium salts under mild and metal-free conditions.  These isolable intermediates serve as effective precursors to structurally diverse 2-fluoropyridines, including mols. relevant to PET imaging.  In addn. to providing access to nonradioactive analogs, this method has been successfully applied to 18F-labeling in the radiosynthesis of [18F]AV-1451 ([18F]T807), a PET tracer currently under development for imaging tau.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVTE6KPqgCdLVg90H21EOLACvtfcHk0ljZtxToT5Q4QA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2ltrbM&md5=ee36c30d7305c50722e912ad257cd90e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.5b01703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.5b01703%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DHoye%26aufirst%3DA.%2BT.%26aulast%3DFan%26aufirst%3DK.-H.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DClemens%26aufirst%3DJ.%26aulast%3DHorchler%26aufirst%3DC.%2BL.%26aulast%3DLim%26aufirst%3DN.%2BC.%26aulast%3DAttardo%26aufirst%3DG.%26atitle%3DFacile%2520route%2520to%25202-fluoropyridines%2520via%25202-pyridyltrialkylammonium%2520salts%2520prepared%2520from%2520pyridine%2520N-oxides%2520and%2520application%2520to%252018F-labeling%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26spage%3D3726%26epage%3D3729%26doi%3D10.1021%2Facs.orglett.5b01703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remde, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hienzsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerges, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepping, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span> <span> </span><span class="NLM_article-title">Procedures for the GMP-compliant production and quality control of [F-18]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">77</span>, <span class="refDoi">Â DOI: 10.3390/ph10040077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.3390%2Fph10040077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFelsLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=77&author=J.+Cardinaleauthor=R.+Martinauthor=Y.+Remdeauthor=M.+Schaferauthor=A.+Hienzschauthor=S.+Hubnerauthor=A.+M.+Zergesauthor=H.+Marxauthor=R.+Hesseauthor=K.+Weberauthor=R.+Smitsauthor=A.+Hoeppingauthor=M.+Mullerauthor=O.+C.+Neelsauthor=K.+Kopka&title=Procedures+for+the+GMP-compliant+production+and+quality+control+of+%5BF-18%5DPSMA-1007%3A+a+next+generation+radiofluorinated+tracer+for+the+detection+of+prostate+cancer&doi=10.3390%2Fph10040077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Procedures for the GMP-compliant production and quality control of [18F]PSMA-1007: A next generation radiofluorinated tracer for the detection</span></div><div class="casAuthors">Cardinale, Jens; Martin, Rene; Remde, Yvonne; Schaefer, Martin; Hienzsch, Antje; Huebner, Sandra; Zerges, Anna-Maria; Marx, Heike; Hesse, Ronny; Weber, Klaus; Smits, Rene; Hoepping, Alexander; Mueller, Marco; Neels, Oliver C.; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">77/1-77/18</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for the PET-imaging of prostate cancer.  In this connection, we recently developed the fluorine-18-labeled PSMA-ligand [18F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC.  Since radiosynthesis so far has been suffering from rather poor yields, novel procedures for the automated radiosyntheses of [18F]PSMA-1007 have been developed.  We herein report on both the two-step and the novel one-step procedures, which have been performed on different commonly-used radiosynthesisers.  Using the novel one-step procedure, the [18F]PSMA-1007 was produced in good radiochem. yields ranging from 25 to 80% and synthesis times of less than 55 min.  Furthermore, upscaling to product activities up to 50 GBq per batch was successfully conducted.  All batches passed quality control according to European Pharmacopoeia stds.  Therefore, we were able to disclose a new, simple and, at the same time, high yielding prodn. pathway for the next generation PSMA radioligand [18F]PSMA-1007.  Actually, it turned out that the radiosynthesis is as easily realized as the well-known [18F]FDG synthesis and, thus, transferable to all currently-available radiosynthesisers.  Using the new procedures, the clin. daily routine can be sustainably supported inhouse even in larger hospitals by a single prodn. batch.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc_vc2WuIrebVg90H21EOLACvtfcHk0lgkBsiRuF7T3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFelsLjE&md5=fc4151e4f367befd82b179776608f2dc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3390%2Fph10040077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph10040077%26sid%3Dliteratum%253Aachs%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DRemde%26aufirst%3DY.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DHienzsch%26aufirst%3DA.%26aulast%3DHubner%26aufirst%3DS.%26aulast%3DZerges%26aufirst%3DA.%2BM.%26aulast%3DMarx%26aufirst%3DH.%26aulast%3DHesse%26aufirst%3DR.%26aulast%3DWeber%26aufirst%3DK.%26aulast%3DSmits%26aufirst%3DR.%26aulast%3DHoepping%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DKopka%26aufirst%3DK.%26atitle%3DProcedures%2520for%2520the%2520GMP-compliant%2520production%2520and%2520quality%2520control%2520of%2520%255BF-18%255DPSMA-1007%253A%2520a%2520next%2520generation%2520radiofluorinated%2520tracer%2520for%2520the%2520detection%2520of%2520prostate%2520cancer%26jtitle%3DPharmaceuticals%26date%3D2017%26volume%3D10%26spage%3D77%26doi%3D10.3390%2Fph10040077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dornan, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juneau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delouya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva, J. N.</span></span> <span> </span><span class="NLM_article-title">Simplified and robust one-step radiosynthesis of [F-18]DCFPyL via direct radiofluorination and cartridge-based purification</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">757</span>â <span class="NLM_lpage">763</span>, <span class="refDoi">Â DOI: 10.1002/jlcr.3632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1002%2Fjlcr.3632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSgsrjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=757-763&author=M.+H.+Dornanauthor=J.+M.+Simardauthor=A.+Leblondauthor=D.+Juneauauthor=G.+Delouyaauthor=F.+Saadauthor=C.+Menardauthor=J.+N.+DaSilva&title=Simplified+and+robust+one-step+radiosynthesis+of+%5BF-18%5DDCFPyL+via+direct+radiofluorination+and+cartridge-based+purification&doi=10.1002%2Fjlcr.3632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Simplified and robust one-step radiosynthesis of [18F]DCFPyL via direct radiofluorination and cartridge-based purification</span></div><div class="casAuthors">Dornan, Mark H.; Simard, Jose-Mathieu; Leblond, Antoine; Juneau, Daniel; Delouya, Guila; Saad, Fred; Menard, Cynthia; Da Silva, Jean N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">757-763</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The efficient prodn. of [18FF]DCFPyL (I) using single-step direct radiofluorination, without use of carboxylic acid-protecting groups was described.  Radiolabeling reaction optimization studies revealed an inverse correlation between the amt. of precursor used and the radiochem. yield.  This simplified approach enabled automated prepn. of I within 28 min using HPLC purifn. (26% Â± 6%, at EOS, n = 4), which was then scaled up for large-batch prodn. to generate 1.46 Â± 0.23 Ci of I at EOS (n = 7) in high molar activity (37 933 Â± 4158 mCi/Î¼mol, 1403 Â± 153 GBq/Î¼mol, at EOS, n = 7).  Further, this work enabled the development of I prodn. in 21 min using an easy cartridge-based purifn. (25% Â± 9% radiochem. yield, at EOS, n = 3).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCzW6H17jPobVg90H21EOLACvtfcHk0lgkBsiRuF7T3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSgsrjE&md5=3c3bb6ff7677356ab044a0cd7207d865</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3632%26sid%3Dliteratum%253Aachs%26aulast%3DDornan%26aufirst%3DM.%2BH.%26aulast%3DSimard%26aufirst%3DJ.%2BM.%26aulast%3DLeblond%26aufirst%3DA.%26aulast%3DJuneau%26aufirst%3DD.%26aulast%3DDelouya%26aufirst%3DG.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DMenard%26aufirst%3DC.%26aulast%3DDaSilva%26aufirst%3DJ.%2BN.%26atitle%3DSimplified%2520and%2520robust%2520one-step%2520radiosynthesis%2520of%2520%255BF-18%255DDCFPyL%2520via%2520direct%2520radiofluorination%2520and%2520cartridge-based%2520purification%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2018%26volume%3D61%26spage%3D757%26epage%3D763%26doi%3D10.1002%2Fjlcr.3632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murelli, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocleaza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubkowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, D. A.</span></span> <span> </span><span class="NLM_article-title">A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">12711</span>â <span class="NLM_lpage">12716</span>, <span class="refDoi">Â DOI: 10.1021/ja104591m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja104591m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=12711-12716&author=A.+X.+Zhangauthor=R.+P.+Murelliauthor=C.+Barinkaauthor=J.+Michelauthor=A.+Cocleazaauthor=W.+L.+Jorgensenauthor=J.+Lubkowskiauthor=D.+A.+Spiegel&title=A+remote+arene-binding+site+on+prostate+specific+membrane+antigen+revealed+by+antibody-recruiting+small+molecules&doi=10.1021%2Fja104591m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules</span></div><div class="casAuthors">Zhang, Andrew X.; Murelli, Ryan P.; Barinka, Cyril; Michel, Julien; Cocleaza, Alexandra; Jorgensen, William L.; Lubkowski, Jacek; Spiegel, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12711-12716</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate specific membrane antigen (PSMA) is a membrane-bound glutamate carboxypeptidase overexpressed in many forms of prostate cancer.  Our lab. has recently disclosed a class of small mols., called ARM-Ps (antibody-recruiting mol. targeting prostate cancer) that are capable of enhancing antibody-mediated immune recognition of prostate cancer cells.  Interestingly, during the course of these studies, we found ARM-Ps to exhibit extraordinarily high potencies toward PSMA, compared to previously reported inhibitors.  Here, we report in-depth biochem., crystallog., and computational investigations which elucidate the origin of the obsd. affinity enhancement.  These studies reveal a previously unreported arene-binding site on PSMA, which we believe participates in an arom. stacking interaction with ARMs.  Although this site is composed of only a few amino acid residues, it drastically enhances small mol. binding affinity.  These results provide crit. insights into the design of PSMA-targeted small mols. for prostate cancer diagnosis and treatment; more broadly, the presence of similar arene-binding sites throughout the proteome could prove widely enabling in the optimization of small mol.-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjRo6U6PlHcbVg90H21EOLACvtfcHk0lgkBsiRuF7T3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbvP&md5=286b5454ee036028cbac3ff6a5b7579d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fja104591m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja104591m%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DA.%2BX.%26aulast%3DMurelli%26aufirst%3DR.%2BP.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DMichel%26aufirst%3DJ.%26aulast%3DCocleaza%26aufirst%3DA.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DLubkowski%26aufirst%3DJ.%26aulast%3DSpiegel%26aufirst%3DD.%2BA.%26atitle%3DA%2520remote%2520arene-binding%2520site%2520on%2520prostate%2520specific%2520membrane%2520antigen%2520revealed%2520by%2520antibody-recruiting%2520small%2520molecules%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D12711%26epage%3D12716%26doi%3D10.1021%2Fja104591m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Visschere, P. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Standaert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futterer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeirs, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panebianco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadaschik, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecouvet, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannarini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanti, S.</span></span> <span> </span><span class="NLM_article-title">A systematic review on the role of imaging in early recurrent prostate cancer</span>. <i>Eur. Urol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">47</span>â <span class="NLM_lpage">76</span>, <span class="refDoi">Â DOI: 10.1016/j.euo.2018.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2Fj.euo.2018.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30929846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BB3cbpvFGrtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=47-76&author=P.+J.+L.+De%0AVisschereauthor=C.+Standaertauthor=J.+J.+Futtererauthor=G.+M.+Villeirsauthor=V.+Panebiancoauthor=J.+Walzauthor=T.+Maurerauthor=B.+A.+Hadaschikauthor=F.+E.+Lecouvetauthor=G.+Giannariniauthor=S.+Fanti&title=A+systematic+review+on+the+role+of+imaging+in+early+recurrent+prostate+cancer&doi=10.1016%2Fj.euo.2018.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer</span></div><div class="casAuthors">De Visschere Pieter J L; Standaert Chloe; Villeirs Geert M; Futterer Jurgen J; Panebianco Valeria; Walz Jochen; Maurer Tobias; Hadaschik Boris A; Lecouvet Frederic E; Giannarini Gianluca; Fanti Stefano</div><div class="citationInfo"><span class="NLM_cas:title">European urology oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-76</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a first sign of relapse, but imaging is needed to determine the localization of the recurrence, which may be local, in lymph nodes, and/or metastatic.  With the increasing success rate of earlier salvage therapy, the diagnosis has become pertinent when the recurrent PSA level is still very low.  OBJECTIVE:  To systematically review the literature on the role of the existing imaging techniques in patients with early recurrent prostate cancer.  EVIDENCE ACQUISITION:  A systematic literature search across the MEDLINE and EMBASE databases was conducted in February 2018, searching for original studies reporting on imaging in a (sub)group of patients with recurrent PSA levels not higher than 5ng/ml.  This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.  The methodological quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.  EVIDENCE SYNTHESIS:  A total of 98 studies were included in this systematic review, reporting on the role of transrectal ultrasonography (TRUS), computed tomography (CT), bone scintigraphy (BS), single-photon emission CT, multiparametric magnetic resonance imaging (mpMRI), whole-body MRI (wbMRI), and positron emission tomography (PET)-CT/MRI using 18F fluoro-deoxy-glucose, 11C choline, 18F (fluoro)(methyl)choline, 11C acetate, 18F FACBC (fluciclovine) and prostate-specific membrane antigen (PSMA)-based tracers.  CT and BS were not sufficiently sensitive in the early recurrence setting.  For the detection of local recurrence, TRUS or mpMRI can be used; however, at the lowest PSA levels, few data were available, only after radical prostatectomy, showing a wide range of positivity.  TRUS or mpMRI need to be combined with (PET)-CT to assess distant disease, but new techniques such as wbMRI, PET-MRI, or PET-CT allow for an all-in-one approach.  At recurrent PSA levels <0.5ng/ml, detection rates up to 31.3% were reported using (11)C choline PET-CT and up to 65.0% using (68)Ga PSMA-11 PET-CT.  At recurrent PSA levels <0.2ng/ml, detection rates of (68)Ga PSMA-11 PET-CT ranged from 11.3% to as high as 58.3%.  CONCLUSIONS:  Detection rates of different imaging techniques depend on the PSA level at the time of imaging.  Recent advanced imaging techniques may detect the localization of the recurrence, even when the PSA levels are still very low.  PATIENT SUMMARY:  In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a sign of recurrence of the disease.  Advanced imaging techniques may demonstrate the localization of the recurrence, even when the PSA levels are still very low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbC3QWfaAoKYNpW7w2tapOfW6udTcc2eYQApKg1IySj7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbpvFGrtg%253D%253D&md5=e5d4952c71334529eba57c71184bfd9d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.euo.2018.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euo.2018.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVisschere%26aufirst%3DP.%2BJ.%2BL.%26aulast%3DStandaert%26aufirst%3DC.%26aulast%3DFutterer%26aufirst%3DJ.%2BJ.%26aulast%3DVilleirs%26aufirst%3DG.%2BM.%26aulast%3DPanebianco%26aufirst%3DV.%26aulast%3DWalz%26aufirst%3DJ.%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DHadaschik%26aufirst%3DB.%2BA.%26aulast%3DLecouvet%26aufirst%3DF.%2BE.%26aulast%3DGiannarini%26aufirst%3DG.%26aulast%3DFanti%26aufirst%3DS.%26atitle%3DA%2520systematic%2520review%2520on%2520the%2520role%2520of%2520imaging%2520in%2520early%2520recurrent%2520prostate%2520cancer%26jtitle%3DEur.%2520Urol.%2520Oncol.%26date%3D2019%26volume%3D2%26spage%3D47%26epage%3D76%26doi%3D10.1016%2Fj.euo.2018.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rauscher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gafita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span> <span> </span><span class="NLM_article-title">Matched-Pair Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">51</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.119.229187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.119.229187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=31253741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSktbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=51-57&author=I.+Rauscherauthor=M.+Kronkeauthor=M.+Konigauthor=A.+Gafitaauthor=T.+Maurerauthor=T.+Hornauthor=K.+Schillerauthor=W.+Weberauthor=M.+Eiber&title=Matched-Pair+Comparison+of+68Ga-PSMA-11+PET%2FCT+and+18F-PSMA-1007+PET%2FCT%3A+frequency+of+pitfalls+and+detection+efficacy+in+biochemical+recurrence+after+radical+prostatectomy&doi=10.2967%2Fjnumed.119.229187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy</span></div><div class="casAuthors">Rauscher, Isabel; Kroenke, Markus; Koenig, Michael; Gafita, Andrei; Maurer, Tobias; Horn, Thomas; Schiller, Kilian; Weber, Wolfgang; Eiber, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-58</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">18F-labeled prostate-specific membrane antigen (PSMA)-ligand PET has several principal advantages over 68Ga-PSMA-11.  The purpose of this retrospective study was to evaluate the frequency of non-tumor-related uptake and the detection efficacy comparing 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT in recurrent prostate cancer (PC) patients.  Methods: The study included 102 patients with biochem. recurrent PC after radical prostatectomy undergoing 18F-PSMA-1007 PET/CT imaging.  On the basis of various clin. variables, patients with corresponding 68Ga-PSMA-11 PET/CT scans were matched.  All PET/CT scans (n = 204) were reviewed by 1 nuclear medicine physician.  First, all PET-pos. lesions were noted.  Then, lesions suspected of being recurrent PC were differentiated from lesions attributed to a benign origin on the basis of known pitfalls and information from CT.  For each region, the SUVmax of the lesion with the highest PSMA-ligand uptake was noted.  Detection rates were detd., and SUVmax was compared sep. for 68Ga-PSMA-11 and 18F-PSMA-1007.  Results: In total, 18F-PSMA-1007 PET and 68Ga-PSMA-11 PET revealed 369 and 178 PSMA-ligand-pos. lesions, resp. 18F-PSMA-1007 PET revealed approx. 5 times more lesions attributed to a benign origin than did 68Ga-PSMA-11 PET (245 vs. 52 lesions, resp.).  The benign lesions most frequently obsd. were ganglia, unspecific lymph node, and bone lesions, at a rate of 43%, 31%, and 24% for 18F-PSMA-1007 PET and 29%, 42%, and 27% for 68Ga-PSMA-11 PET, resp.  The SUVmax of lesions attributed to a benign origin was significantly higher (P < 0.0001) for 18F-PSMA-1007 PET.  Further, a similar no. of lesions was attributed to recurrent PC (124/369 for 18F-PSMA-1007 PET and 126/178 for 68Ga-PSMA-11 PET).  Conclusion: The no. of lesions with increased PSMA-ligand uptake attributed to a benign origin is considerably higher for 18F-PSMA-1007 PET than for 68Ga-PSMA-11 PET.  This finding indicates the need for sophisticated reader training emphasizing known pitfalls and reporting within the clin. context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh763SMqPZV7Vg90H21EOLACvtfcHk0ljtUdUQxG8_Cg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSktbnN&md5=4aebc27b4a47b082f0d4428e64a55d5f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.229187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.229187%26sid%3Dliteratum%253Aachs%26aulast%3DRauscher%26aufirst%3DI.%26aulast%3DKronke%26aufirst%3DM.%26aulast%3DKonig%26aufirst%3DM.%26aulast%3DGafita%26aufirst%3DA.%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DHorn%26aufirst%3DT.%26aulast%3DSchiller%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DW.%26aulast%3DEiber%26aufirst%3DM.%26atitle%3DMatched-Pair%2520Comparison%2520of%252068Ga-PSMA-11%2520PET%252FCT%2520and%252018F-PSMA-1007%2520PET%252FCT%253A%2520frequency%2520of%2520pitfalls%2520and%2520detection%2520efficacy%2520in%2520biochemical%2520recurrence%2520after%2520radical%2520prostatectomy%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D51%26epage%3D57%26doi%3D10.2967%2Fjnumed.119.229187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panagiotidis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannoula, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatzipavlidou, V.</span></span> <span> </span><span class="NLM_article-title">Rib fractures mimicking bone metastases in <sup>18</sup>F-PSMA-1007 PET/CT for prostate cancer</span>. <i>Clin. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">E46</span>â <span class="NLM_lpage">E48</span>, <span class="refDoi">Â DOI: 10.1097/RLU.0000000000002354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1097%2FRLU.0000000000002354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30371591" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=E46-E48&author=E.+Panagiotidisauthor=A.+Paschaliauthor=E.+Giannoulaauthor=V.+Chatzipavlidou&title=Rib+fractures+mimicking+bone+metastases+in+18F-PSMA-1007+PET%2FCT+for+prostate+cancer&doi=10.1097%2FRLU.0000000000002354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1097%2FRLU.0000000000002354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FRLU.0000000000002354%26sid%3Dliteratum%253Aachs%26aulast%3DPanagiotidis%26aufirst%3DE.%26aulast%3DPaschali%26aufirst%3DA.%26aulast%3DGiannoula%26aufirst%3DE.%26aulast%3DChatzipavlidou%26aufirst%3DV.%26atitle%3DRib%2520fractures%2520mimicking%2520bone%2520metastases%2520in%252018F-PSMA-1007%2520PET%252FCT%2520for%2520prostate%2520cancer%26jtitle%3DClin.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D44%26spage%3DE46%26epage%3DE48%26doi%3D10.1097%2FRLU.0000000000002354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of reported tracers for the detection of PCa and the newly designed quinoline-based PSMA tracers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Quinoline-Based PSMA Inhibitors<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) <i>m</i>-CPBA, CH<sub>2</sub>Cl<sub>2</sub>, RT; (b) NaOH, THF, EtOH, RT; (c) 2,3,5,6-tetrafluorophenol, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT; (d) NMe<sub>3</sub> (2M in THF), TFAA, CH<sub>2</sub>Cl<sub>2</sub>, RT; (e) H-Lys-O<i>t</i>Bu-ureido-Glu(O<i>t</i>Bu)<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N,RT; (f) TBAF (1M in THF), MeCN, 60 Â°C; (g) TFA, CH<sub>2</sub>Cl<sub>2</sub>, RT; (h) [<sup>18</sup>F]Bu<sub>4</sub>NF/Bu<sub>4</sub>NHCO<sub>3</sub>, DMF, 50 Â°C.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Integration diagram of analytical HPLC radioactive traces of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL using two different mobile phases. (A) Mobile phase of 25/75 ethanol/water containing 0.2% H<sub>3</sub>PO<sub>4</sub> at 1 mL/min. (B) Mobile phase of 20/80 acetonitrile/water containing 0.1% TFA at 1 mL/min.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cell uptake of the radio tracers in LNCaP and PC-3 cell line; blocked with 2 Î¼mol/well of 2-PMPA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Uptake values for ex vivo tissues of [<sup>18</sup>F]<b>8a</b> (A), [<sup>18</sup>F]<b>8b</b> (B), and [<sup>18</sup>F]<b>8c</b> (C) in normal male ICR mice (6â7 weeks, 20 Â± 2 g, male, <i>n</i> = 5). Error bars indicate SD values.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Uptake values of tumors for [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyLat 1 h postinjection in tumor-bearing mice (BALB/c nude mice, aged 9â11 weeks with the 22Rv1 tumors reached diameter of 0.6â1.0 cm, <i>n</i> = 4; BALB/c nude mice aged 11â13 weeks with the PC-3 tumors reached diameter of 1.0â1.5 cm, <i>n</i> = 4) based on the micro-PET studies. For all tracers, uptake in 22Rv1 tumors was significantly blocked by 2-PMPA. PC-3 tumors showed a significantly lower uptake than 22Rv1 tumors. Error bars indicate SD values. Significant differences between [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL presented at top of bars: *<i>P</i> < 0.05, NS = not significant, and SUV<sub>mean</sub> = mean of the standardized uptake value based on body weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MIP images of 22Rv1 tumor-bearing mice injected [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL without (top row) or with (second row) 2-PMPA (2 mg/kg) inhibition and PC-3 tumor-bearing mice (bottom row) at 1 h postinjection. The 22Rv1 tumors are under the left shoulders (white solid arrow), whereas the PC-3 tumors are under the bilateral shoulders (yellow solid arrow).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Selected sequential PET MIP images from the same monkey injected with [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL. Four 1 min/bed positions covered from the vertex to midthighs of monkeys were acquired for each PET scan. A total of 14 sequences were collected from the injection of tracers to the end of scanning (1 h).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Timeâactivity curves of the selected monkey tissues after injection of [<sup>18</sup>F]PyL (A), [<sup>18</sup>F]<b>8a</b> (B), [<sup>18</sup>F]<b>8b</b> (C), and [<sup>18</sup>F]<b>8c</b> (D). Values are expressed as SUV<sub>mean</sub> Â± SD, <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Direct comparison of timeâactivity curves of liver (A), kidneys (B), bladder (C), salivary glands (D), and spleen (E) in monkeys after injection of tracers. Upake values of liver, kidneys, salivary glands, and spleen are expressed as SUV<sub>mean</sub> Â± SD. Uptake values of bladder are expressed as MBq<sub>mean</sub> Â± SD; uptake (MBq) = average concentration (Bq/mL) Ã bladder volume (mL) Ã 10<sup>â6</sup>, <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Comparison of [<sup>18</sup>F]<b>8b</b> and [<sup>18</sup>F]PyL in a 64-year-old patient with a rising PSA level of 0.933 ng/mL. Both tracers revealed the lesion (red arrow) of the right prostate gland. (A) MIP image injected with [<sup>18</sup>F]<b>8b</b>. (B) MIP image of the patient injected with [<sup>18</sup>F]PyL. (C) Image of low-dose CT. (D) Fused axial PET/CT image of the patient injected with [<sup>18</sup>F]<b>8b</b>. (E) Fused axial PET/CT image of the patient injected with [<sup>18</sup>F]PyL.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Comparison of [<sup>18</sup>F]<b>8c</b> and [<sup>18</sup>F]PyL in a 73-year-old patient with a Gleason pattern of 4 + 5 and a PSA level of 61.6 ng/mL. MIP image of the patient injected with [<sup>18</sup>F]<b>8c</b> (A) and [<sup>18</sup>F]PyL (B). Image of low-dose CT (C and F). Fused axial PET/CT image of the patient injected with [<sup>18</sup>F]<b>8c</b>, which clearly depicts the diffuse prostatic carcinoma in situ and the lymph node (red arrow) adjacent to the pelvic wall (D) and the lymph node (blue arrow) adjacent external iliac vessels (G). Fused axial PET/CT image of the patient injected with [<sup>18</sup>F]PyL (E and H).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/medium/jm1c00117_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Comparison of mean SUV<sub>max</sub> of [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL for normal organs in patients at 1 h postinjection (<i>n</i> = 3). Significant differences between [<sup>18</sup>F]<b>8b</b>, [<sup>18</sup>F]<b>8c</b>, and [<sup>18</sup>F]PyL presented at the top of bars: *<i>P</i> < 0.05; SUV<sub>max</sub> = maximum of the standardized uptake value based on body weight.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00117/20210331/images/large/jm1c00117_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00117&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i59">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2021</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">7</span>â <span class="NLM_lpage">33</span>, <span class="refDoi">Â DOI: 10.3322/caac.21654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.3322%2Fcaac.21654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=33433946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BB3svptVKhuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2021&pages=7-33&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=H.+E.+Fuchsauthor=A.+Jemal&title=Cancer+statistics%2C+2021&doi=10.3322%2Fcaac.21654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Statistics, 2021</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Fuchs Hannah E; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence.  Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries.  Mortality data (through 2018) were collected by the National Center for Health Statistics.  In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States.  After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment.  This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted.  Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018.  The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall.  This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC).  For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%.  Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_jHscXVnJh1WTCLT8lX9SfW6udTcc2eakOdyvvPwr_Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3svptVKhuw%253D%253D&md5=c65743e74b28b6c7dd1f912745f3edf1</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21654%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DFuchs%26aufirst%3DH.%2BE.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202021%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2021%26volume%3D71%26spage%3D7%26epage%3D33%26doi%3D10.3322%2Fcaac.21654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">SchrÃ¶der, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hugosson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roobol, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tammela, T. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lujan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¤Ã¤ttÃ¤nen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lilja, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>384</i></span>,  <span class="NLM_fpage">2027</span>â <span class="NLM_lpage">2035</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(14)60525-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2FS0140-6736%2814%2960525-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=25108889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FgtlKrsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2014&pages=2027-2035&author=F.+H.+Schr%C3%B6derauthor=J.+Hugossonauthor=M.+J.+Roobolauthor=T.+L.+J.+Tammelaauthor=M.+Zappaauthor=V.+Nelenauthor=M.+Kwiatkowskiauthor=M.+Lujanauthor=L.+M%C3%A4%C3%A4tt%C3%A4nenauthor=H.+Lilja&title=Screening+and+prostate+cancer+mortality%3A+results+of+the+European+Randomised+Study+of+Screening+for+Prostate+Cancer+%28ERSPC%29+at+13+years+of+follow-up&doi=10.1016%2FS0140-6736%2814%2960525-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up</span></div><div class="casAuthors">Schroder Fritz H; Hugosson Jonas; Roobol Monique J; Bangma Chris H; Tammela Teuvo L J; Zappa Marco; Puliti Donella; Nelen Vera; Kwiatkowski Maciej; Lujan Marcos; Maattanen Liisa; Lilja Hans; Denis Louis J; Recker Franz; Paez Alvaro; Carlsson Sigrid; Villers Arnauld; Rebillard Xavier; Hakama Matti; Stenman Ulf-Hakan; Kujala Paula; Taari Kimmo; Aus Gunnar; Huber Andreas; van der Kwast Theo H; van Schaik Ron H N; de Koning Harry J; Moss Sue M; Auvinen Anssi</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue">9959</span>),
    <span class="NLM_cas:pages">2027-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The European Randomised study of Screening for Prostate Cancer (ERSPC) has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis.  We provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years.  METHODS:  ERSPC is a multicentre, randomised trial with a predefined centralised database, analysis plan, and core age group (55-69 years), which assesses prostate-specific antigen (PSA) testing in eight European countries.  Eligible men aged 50-74 years were identified from population registries and randomly assigned by computer generated random numbers to screening or no intervention (control).  Investigators were masked to group allocation.  The primary outcome was prostate cancer mortality in the core age group.  Analysis was by intention to treat.  We did a secondary analysis that corrected for selection bias due to non-participation.  Only incidence and no mortality data at 9 years' follow-up are reported for the French centres.  This study is registered with Current Controlled Trials, number ISRCTN49127736.  FINDINGS:  With data truncated at 13 years of follow-up, 7408 prostate cancer cases were diagnosed in the intervention group and 6107 cases in the control group.  The rate ratio of prostate cancer incidence between the intervention and control groups was 1Â·91 (95% CI 1Â·83-1Â·99) after 9 years (1Â·64 [1Â·58-1Â·69] including France), 1Â·66 (1Â·60-1Â·73) after 11 years, and 1Â·57 (1Â·51-1Â·62) after 13 years.  The rate ratio of prostate cancer mortality was 0Â·85 (0Â·70-1Â·03) after 9 years, 0Â·78 (0Â·66-0Â·91) after 11 years, and 0Â·79 (0Â·69-0Â·91) at 13 years.  The absolute risk reduction of death from prostate cancer at 13 years was 0Â·11 per 1000 person-years or 1Â·28 per 1000 men randomised, which is equivalent to one prostate cancer death averted per 781 (95% CI 490-1929) men invited for screening or one per 27 (17-66) additional prostate cancer detected.  After adjustment for non-participation, the rate ratio of prostate cancer mortality in men screened was 0Â·73 (95% CI 0Â·61-0Â·88).  INTERPRETATION:  In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.  Despite our findings, further quantification of harms and their reduction are still considered a prerequisite for the introduction of populated-based screening.  FUNDING:  Each centre had its own funding responsibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJzFJXEpPop1m8bhe6roZYfW6udTcc2eZZX5ta7gvA7Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FgtlKrsg%253D%253D&md5=d093e9d7b678f69ee5b49996614a6f2b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960525-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960525-0%26sid%3Dliteratum%253Aachs%26aulast%3DSchr%25C3%25B6der%26aufirst%3DF.%2BH.%26aulast%3DHugosson%26aufirst%3DJ.%26aulast%3DRoobol%26aufirst%3DM.%2BJ.%26aulast%3DTammela%26aufirst%3DT.%2BL.%2BJ.%26aulast%3DZappa%26aufirst%3DM.%26aulast%3DNelen%26aufirst%3DV.%26aulast%3DKwiatkowski%26aufirst%3DM.%26aulast%3DLujan%26aufirst%3DM.%26aulast%3DM%25C3%25A4%25C3%25A4tt%25C3%25A4nen%26aufirst%3DL.%26aulast%3DLilja%26aufirst%3DH.%26atitle%3DScreening%2520and%2520prostate%2520cancer%2520mortality%253A%2520results%2520of%2520the%2520European%2520Randomised%2520Study%2520of%2520Screening%2520for%2520Prostate%2520Cancer%2520%2528ERSPC%2529%2520at%252013%2520years%2520of%2520follow-up%26jtitle%3DLancet%26date%3D2014%26volume%3D384%26spage%3D2027%26epage%3D2035%26doi%3D10.1016%2FS0140-6736%2814%2960525-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingrosso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scartoni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, R.</span></span> <span> </span><span class="NLM_article-title">Current therapeutic options in metastatic castration-resistant prostate cancer</span>. <i>Semin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">303</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1053/j.seminoncol.2018.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1053%2Fj.seminoncol.2018.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30446166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFyhtbrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=303-315&author=G.+Ingrossoauthor=B.+Dettiauthor=D.+Scartoniauthor=A.+Lanciaauthor=I.+Giacomelliauthor=M.+Bakiauthor=G.+Cartaauthor=L.+Liviauthor=R.+Santoni&title=Current+therapeutic+options+in+metastatic+castration-resistant+prostate+cancer&doi=10.1053%2Fj.seminoncol.2018.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Current therapeutic options in metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">Ingrosso, Gianluca; Detti, Beatrice; Scartoni, Daniele; Lancia, Andrea; Giacomelli, Irene; Baki, Muhammed; Carta, Giulio; Livi, Lorenzo; Santoni, Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">303-315</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The tumors of many patients with prostate cancer eventually become refractory to androgen deprivation therapy with progression to metastatic castration-resistant disease.  Significant advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have been made in recent years, and new treatment strategies have recently been made available.  The aim of this report was to schematically review all the approved pharmacol. treatment options for patients with mCRPC through 2018, analyzing the efficacy and possible side effects of each therapy to assist clinicians in reaching an appropriate treatment decision.  New biomarkers potentially of aid in the choice of treatment in this setting are also briefly reviewed.  We performed a literature search of clin. trials of new drugs and treatments for patients diagnosed with mCRPC published through 2018.  Two new hormonal drugs, abiraterone acetate and enzalutamide have been approved by FDA in 2011 and 2012, resp. for the treatment of patients with mCRPC and have undergone extensive testing.  While these treatments have shown a benefit in progression-free and overall survival, the appropriate sequencing must still be detd. so that treatment decisions can be made based on their specific clin. profile.  Cabazitaxel has been shown to be an efficient therapeutic option in a postdocetaxel setting, while its role in chemotherapy-naive patients must still be detd.  Sipuleucel-T and radium-223 have been studied in patients without visceral metastases and have achieved overall survival benefits with good safety profiles.  The feasibility and efficacy of combinations of new treatments with other known therapies such as chemotherapy are currently under investigation.  Drug development efforts continue to attempt to prolong survival and improve quality of life in the mCRPC setting, with several therapeutic options available.  Ongoing and future trials are needed to further assess the efficacy and safety of these new drugs and their interactions, along with the most appropriate sequencing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEsw7qU5pASrVg90H21EOLACvtfcHk0ljrEaX727ouNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFyhtbrI&md5=48487455dba4742b9120a1e0ca05e376</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2018.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2018.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DIngrosso%26aufirst%3DG.%26aulast%3DDetti%26aufirst%3DB.%26aulast%3DScartoni%26aufirst%3DD.%26aulast%3DLancia%26aufirst%3DA.%26aulast%3DGiacomelli%26aufirst%3DI.%26aulast%3DBaki%26aufirst%3DM.%26aulast%3DCarta%26aufirst%3DG.%26aulast%3DLivi%26aufirst%3DL.%26aulast%3DSantoni%26aufirst%3DR.%26atitle%3DCurrent%2520therapeutic%2520options%2520in%2520metastatic%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2018%26volume%3D45%26spage%3D303%26epage%3D315%26doi%3D10.1053%2Fj.seminoncol.2018.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alpajaro, S. I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. P.</span></span> <span> </span><span class="NLM_article-title">Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies</span>. <i>Prostate Cancer Prostatic Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">16</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1038/s41391-018-0078-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1038%2Fs41391-018-0078-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30115959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ovFahsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2019&pages=16-23&author=S.+I.+R.+Alpajaroauthor=J.+A.+K.+Harrisauthor=C.+P.+Evans&title=Non-metastatic+castration+resistant+prostate+cancer%3A+a+review+of+current+and+emerging+medical+therapies&doi=10.1038%2Fs41391-018-0078-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies</span></div><div class="casAuthors">Alpajaro Sigfred Ian R; Evans Christopher P; Harris Jerad A K</div><div class="citationInfo"><span class="NLM_cas:title">Prostate cancer and prostatic diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-metastatic castration resistant prostate cancer (M0CRPC) is a heterogenous disease state affecting an estimated 100,000 men in the United States.  Development of more sensitive modalities for detection of metastasis has altered the landscape of advanced prostate cancer, but M0CRPC has remained a condition that previously lacked FDA-approved treatment.  The emerging data on new generation Androgen Receptor (AR) pathway inhibitors should address this gap in the management of such patients.  METHODS:  We reviewed and summarized the current literature for the definition, diagnosis and treatment of M0CRPC.  We highlight the results of recent Phase III trials that show significant impact on the outcomes of M0CRPC.  RESULTS:  Androgen deprivation therapy remains the foundation of therapy for M0CRPC.  Recently published Phase III trials provided data on improved progression free survival when ADT is augmented with newer AR pathway inhibitors.  The SPARTAN trial showed that metastasis-free survival (MFS) for patients treated with apalutamide plus ADT is 40.5 months compared to 16.2 months for patients who received standard ADT plus placebo, a 72% reduction in the risk of distant metastasis or death in apalutamide plus ADT compared to ADT plus placebo.  The PROSPER trial demonstrated that MFS for patients treated with enzalutamide plus ADT was 36.6 months compared to 14.7 months for patients who received standard ADT only indicating a 71% reduction in the risk of developing metastatic CRPC or death compared to ADT alone.  The ARAMIS trial on darolutamide, another AR pathway inhibitor, is also ongoing, and can potentially be another fitting option for M0CRPC.  CONCLUSION:  The recent Phase III trials SPARTAN and PROPSER demonstrate effective treatment options for the M0CRPC disease state that has historically lacked treatment from high level evidence.  In particular, an FDA-approved treatment, Apalutamide, can finally be offered for M0CRPC patients.  The newer AR pathway inhibitors should provide a basis for further investigation into treatments for M0CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTexkzFIUjqpIxhnOQkIHOxfW6udTcc2ebBp1ZZU3IDj7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ovFahsQ%253D%253D&md5=3e3d4f566bbdbaeadcf8a50b6ab5f58a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41391-018-0078-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41391-018-0078-1%26sid%3Dliteratum%253Aachs%26aulast%3DAlpajaro%26aufirst%3DS.%2BI.%2BR.%26aulast%3DHarris%26aufirst%3DJ.%2BA.%2BK.%26aulast%3DEvans%26aufirst%3DC.%2BP.%26atitle%3DNon-metastatic%2520castration%2520resistant%2520prostate%2520cancer%253A%2520a%2520review%2520of%2520current%2520and%2520emerging%2520medical%2520therapies%26jtitle%3DProstate%2520Cancer%2520Prostatic%2520Dis.%26date%3D2019%26volume%3D22%26spage%3D16%26epage%3D23%26doi%3D10.1038%2Fs41391-018-0078-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ilic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djulbegovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agoritsas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahm, P.</span></span> <span> </span><span class="NLM_article-title">Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis</span>. <i>Brit Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>362</i></span>, <span class="NLM_elocation-id">k3519</span> <span class="refDoi">Â DOI: 10.1136/bmj.k3519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1136%2Fbmj.k3519" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2018&author=D.+Ilicauthor=M.+Djulbegovicauthor=J.+H.+Jungauthor=E.+C.+Hwangauthor=Q.+Zhouauthor=A.+Clevesauthor=T.+Agoritsasauthor=P.+Dahm&title=Prostate+cancer+screening+with+prostate-specific+antigen+%28PSA%29+test%3A+a+systematic+review+and+meta-analysis&doi=10.1136%2Fbmj.k3519"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1136%2Fbmj.k3519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.k3519%26sid%3Dliteratum%253Aachs%26aulast%3DIlic%26aufirst%3DD.%26aulast%3DDjulbegovic%26aufirst%3DM.%26aulast%3DJung%26aufirst%3DJ.%2BH.%26aulast%3DHwang%26aufirst%3DE.%2BC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DCleves%26aufirst%3DA.%26aulast%3DAgoritsas%26aufirst%3DT.%26aulast%3DDahm%26aufirst%3DP.%26atitle%3DProstate%2520cancer%2520screening%2520with%2520prostate-specific%2520antigen%2520%2528PSA%2529%2520test%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DBrit%2520Med.%2520J.%26date%3D2018%26volume%3D362%26doi%3D10.1136%2Fbmj.k3519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loeb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjurlin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tammela, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penson, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etzioni, R.</span></span> <span> </span><span class="NLM_article-title">Overdiagnosis and overtreatment of prostate cancer</span>. <i>Eur. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1046</span>â <span class="NLM_lpage">1055</span>, <span class="refDoi">Â DOI: 10.1016/j.eururo.2013.12.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2Fj.eururo.2013.12.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=24439788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BC2czms1WmtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2014&pages=1046-1055&author=S.+Loebauthor=M.+A.+Bjurlinauthor=J.+Nicholsonauthor=T.+L.+Tammelaauthor=D.+F.+Pensonauthor=H.+B.+Carterauthor=P.+Carrollauthor=R.+Etzioni&title=Overdiagnosis+and+overtreatment+of+prostate+cancer&doi=10.1016%2Fj.eururo.2013.12.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Overdiagnosis and overtreatment of prostate cancer</span></div><div class="casAuthors">Loeb Stacy; Bjurlin Marc A; Nicholson Joseph; Tammela Teuvo L; Penson David F; Carter H Ballentine; Carroll Peter; Etzioni Ruth</div><div class="citationInfo"><span class="NLM_cas:title">European urology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1046-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Although prostate cancer (PCa) screening reduces the incidence of advanced disease and mortality, trade-offs include overdiagnosis and resultant overtreatment.  OBJECTIVE:  To review primary data on PCa overdiagnosis and overtreatment.  EVIDENCE ACQUISITION:  Electronic searches were conducted in Cochrane Central Register of Controlled Trials, PubMed, and Embase from inception to July 2013 for original articles on PCa overdiagnosis and overtreatment.  Supplemental articles were identified through hand searches.  EVIDENCE SYNTHESIS:  The lead-time and excess-incidence approaches are the main ways used to estimate overdiagnosis in epidemiological studies, with estimates varying widely.  The estimated number of PCa cases needed to be diagnosed to save a life has ranged from 48 down to 5 with increasing follow-up.  In clinical studies, generally lower rates of overdiagnosis have been reported based on the frequency of low-grade minimal tumors at radical prostatectomy (1.7-46.8%).  Autopsy studies have reported PCa in 18.5-38.5%, although not all are low grade or low volume.  Factors influencing overdiagnosis include the study population, screening protocol, and background incidence, limiting generalizability between settings.  Reported rates of overtreatment vary widely in the literature, although contemporary international studies suggest increasing use of conservative management.  CONCLUSIONS:  Epidemiological, clinical, and autopsy studies have been used to examine PCa overdiagnosis, with estimates ranging widely from 1.7% to 67%.  Correspondingly, estimates of overtreatment vary widely based on patient features and may be declining internationally.  Careful patient selection for screening and reducing overtreatment are important to preserve the benefits and reduce the downstream harms of prostate-specific antigen testing.  Because all of these estimates are extremely population and context specific, this must be considered when using these data to inform policy.  PATIENT SUMMARY:  Screening reduces spread and death from prostate cancer (PCa) but overdiagnoses some low-risk tumors that may not have caused harm.  Because treatment has potential side effects, it is critical that not all patients with PCa receive aggressive treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQe5o8OTQwsu8jl5L8hwNX0fW6udTcc2eaoSXh3z4H5_Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czms1WmtA%253D%253D&md5=4c0b1d4f1d6f5942ebf05e632350db7d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2013.12.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2013.12.062%26sid%3Dliteratum%253Aachs%26aulast%3DLoeb%26aufirst%3DS.%26aulast%3DBjurlin%26aufirst%3DM.%2BA.%26aulast%3DNicholson%26aufirst%3DJ.%26aulast%3DTammela%26aufirst%3DT.%2BL.%26aulast%3DPenson%26aufirst%3DD.%2BF.%26aulast%3DCarter%26aufirst%3DH.%2BB.%26aulast%3DCarroll%26aufirst%3DP.%26aulast%3DEtzioni%26aufirst%3DR.%26atitle%3DOverdiagnosis%2520and%2520overtreatment%2520of%2520prostate%2520cancer%26jtitle%3DEur.%2520Urol.%26date%3D2014%26volume%3D65%26spage%3D1046%26epage%3D1055%26doi%3D10.1016%2Fj.eururo.2013.12.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, C.</span></span> <span> </span><span class="NLM_article-title">Dynamic contrast-enhanced CT for prostate cancer: relationship between image noise, voxel size, and repeatability editorial comment</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">2157</span>â <span class="NLM_lpage">2158</span>, <span class="refDoi">Â DOI: 10.1016/j.juro.2011.02.2679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2Fj.juro.2011.02.2679" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2011&pages=2157-2158&author=C.+Siegel&title=Dynamic+contrast-enhanced+CT+for+prostate+cancer%3A+relationship+between+image+noise%2C+voxel+size%2C+and+repeatability+editorial+comment&doi=10.1016%2Fj.juro.2011.02.2679"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2011.02.2679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2011.02.2679%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DC.%26atitle%3DDynamic%2520contrast-enhanced%2520CT%2520for%2520prostate%2520cancer%253A%2520relationship%2520between%2520image%2520noise%252C%2520voxel%2520size%252C%2520and%2520repeatability%2520editorial%2520comment%26jtitle%3DJ.%2520Urol.%26date%3D2011%26volume%3D185%26spage%3D2157%26epage%3D2158%26doi%3D10.1016%2Fj.juro.2011.02.2679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapelon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RouviÃ¨re, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubernard, J. M.</span></span> <span> </span><span class="NLM_article-title">Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome</span>. <i>Eur. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">124</span>â <span class="NLM_lpage">129</span>, <span class="refDoi">Â DOI: 10.1159/000049761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1159%2F000049761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=11528187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BD3MvosFKquw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=124-129&author=A.+Geletauthor=J.+Y.+Chapelonauthor=R.+Bouvierauthor=O.+Rouvi%C3%A8reauthor=J.+M.+Dubernard&title=Transrectal+high+intensity+focused+ultrasound+for+the+treatment+of+localized+prostate+cancer%3A+factors+influencing+the+outcome&doi=10.1159%2F000049761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome</span></div><div class="casAuthors">Gelet A; Chapelon J Y; Bouvier R; Rouviere O; Lyonnet D; Dubernard J M</div><div class="citationInfo"><span class="NLM_cas:title">European urology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">124-9</span>
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    </div><div class="casAbstract">OBJECTIVES:  Efficacy evaluation of high intensity focused ultrasound (HIFU) treatment for localized prostate cancer and identification of the factors affecting the outcome.  PATIENTS AND METHODS:  102 patients with prostate cancer stage T1-T2 and noncandidates for radical prostatectomy have been treated with HIFU (Ablatherm, EDAP-Technomed).  The disease progression (failure) was strictly defined by any positive sample at control biopsies, whatever the prostate-specific antigen (PSA) level, or by 3 consecutive increases in PSA levels in case of negative biopsies.  RESULTS:  At inclusion, patients' baseline characteristics were (mean +/- standard deviation): age 70.8 (+/-6.13) years, PSA 8.38 (+/-4.8) ng/ml, prostate volume 33.3 (+/-16.71) cm3.  The population mean follow-up was 19 months (3-76 months).  The overall success rate was 66%.  Statistically significant variations of the overall success with a more favorable outcome were observed when (1) the initial PSA level was < or =10 ng/ml (73 vs. 50%, p = 0.02), (2) the Gleason score was < or =6 (81 vs. 46%, p<0.001) and (3) the pretreatment sextant biopsy evidenced 1-4 positive samples (68 vs. 40%, p = 0.01).  CONCLUSION:  Results observed after HIFU treatment in localized prostate cancer are now challenging those obtained after radiation therapy.  The success rate is influenced by disease-related prognostic factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQbD-sJc3uxCk2yPDyEFiigfW6udTcc2eaoSXh3z4H5_Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MvosFKquw%253D%253D&md5=aa51620db6eb6a119d786a4c4f431a19</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1159%2F000049761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000049761%26sid%3Dliteratum%253Aachs%26aulast%3DGelet%26aufirst%3DA.%26aulast%3DChapelon%26aufirst%3DJ.%2BY.%26aulast%3DBouvier%26aufirst%3DR.%26aulast%3DRouvi%25C3%25A8re%26aufirst%3DO.%26aulast%3DDubernard%26aufirst%3DJ.%2BM.%26atitle%3DTransrectal%2520high%2520intensity%2520focused%2520ultrasound%2520for%2520the%2520treatment%2520of%2520localized%2520prostate%2520cancer%253A%2520factors%2520influencing%2520the%2520outcome%26jtitle%3DEur.%2520Urol.%26date%3D2001%26volume%3D40%26spage%3D124%26epage%3D129%26doi%3D10.1159%2F000049761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, H. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Shater Bosaily, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collaco-Moraes, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">815</span>â <span class="NLM_lpage">822</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(16)32401-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2FS0140-6736%2816%2932401-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=28110982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BC1c7otV2lsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=815-822&author=H.+U.+Ahmedauthor=A.+El-Shater+Bosailyauthor=L.+C.+Brownauthor=R.+Gabeauthor=R.+Kaplanauthor=M.+K.+Parmarauthor=Y.+Collaco-Moraesauthor=K.+Wardauthor=R.+G.+Hindleyauthor=A.+Freeman&title=Diagnostic+accuracy+of+multi-parametric+MRI+and+TRUS+biopsy+in+prostate+cancer+%28PROMIS%29%3A+a+paired+validating+confirmatory+study&doi=10.1016%2FS0140-6736%2816%2932401-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study</span></div><div class="casAuthors">Ahmed Hashim U; El-Shater Bosaily Ahmed; Emberton Mark; Brown Louise C; Kaplan Richard; Parmar Mahesh K; Collaco-Moraes Yolanda; Ward Katie; Gabe Rhian; Hindley Richard G; Freeman Alex; Kirkham Alex P; Oldroyd Robert; Parker Chris</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10071</span>),
    <span class="NLM_cas:pages">815-822</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy).  TRUS-biopsy can cause side-effects including bleeding, pain, and infection.  Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy.  METHODS:  We did this multicentre, paired-cohort, confirmatory study to test diagnostic accuracy of MP-MRI and TRUS-biopsy against a reference test (template prostate mapping biopsy [TPM-biopsy]).  Men with prostate-specific antigen concentrations up to 15 ng/mL, with no previous biopsy, underwent 1Â·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy.  The conduct and reporting of each test was done blind to other test results.  Clinically significant cancer was defined as Gleason score â¥4 + 3 or a maximum cancer core length 6 mm or longer.  This study is registered on ClinicalTrials.gov, NCT01292291.  FINDINGS:  Between May 17, 2012, and November 9, 2015, we enrolled 740 men, 576 of whom underwent 1Â·5 Tesla MP-MRI followed by both TRUS-biopsy and TPM-biopsy.  On TPM-biopsy, 408 (71%) of 576 men had cancer with 230 (40%) of 576 patients clinically significant.  For clinically significant cancer, MP-MRI was more sensitive (93%, 95% CI 88-96%) than TRUS-biopsy (48%, 42-55%; p<0Â·0001) and less specific (41%, 36-46% for MP-MRI vs 96%, 94-98% for TRUS-biopsy; p<0Â·0001). 44 (5Â·9%) of 740 patients reported serious adverse events, including 8 cases of sepsis.  INTERPRETATION:  Using MP-MRI to triage men might allow 27% of patients avoid a primary biopsy and diagnosis of 5% fewer clinically insignificant cancers.  If subsequent TRUS-biopsies were directed by MP-MRI findings, up to 18% more cases of clinically significant cancer might be detected compared with the standard pathway of TRUS-biopsy for all.  MP-MRI, used as a triage test before first prostate biopsy, could reduce unnecessary biopsies by a quarter.  MP-MRI can also reduce over-diagnosis of clinically insignificant prostate cancer and improve detection of clinically significant cancer.  FUNDING:  PROMIS is funded by the UK Government Department of Health, National Institute of Health Research-Health Technology Assessment Programme, (Project number 09/22/67).  This project is also supported and partly funded by UCLH/UCL Biomedical Research Centre and The Royal Marsden and Institute for Cancer Research Biomedical Research Centre and is coordinated by the Medical Research Council Clinical Trials Unit (MRC CTU) at UCL.  It is sponsored by University College London (UCL).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-6ZkcyQCrzOIHSmpohpd0fW6udTcc2eZtK7xmdjjH7rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7otV2lsQ%253D%253D&md5=07131cf926ec0c7ea8b131235b9876d5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2932401-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252932401-1%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed%26aufirst%3DH.%2BU.%26aulast%3DEl-Shater%2BBosaily%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DL.%2BC.%26aulast%3DGabe%26aufirst%3DR.%26aulast%3DKaplan%26aufirst%3DR.%26aulast%3DParmar%26aufirst%3DM.%2BK.%26aulast%3DCollaco-Moraes%26aufirst%3DY.%26aulast%3DWard%26aufirst%3DK.%26aulast%3DHindley%26aufirst%3DR.%2BG.%26aulast%3DFreeman%26aufirst%3DA.%26atitle%3DDiagnostic%2520accuracy%2520of%2520multi-parametric%2520MRI%2520and%2520TRUS%2520biopsy%2520in%2520prostate%2520cancer%2520%2528PROMIS%2529%253A%2520a%2520paired%2520validating%2520confirmatory%2520study%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D815%26epage%3D822%26doi%3D10.1016%2FS0140-6736%2816%2932401-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evensapir, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lievshitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibovitch, I.</span></span> <span> </span><span class="NLM_article-title">The detection of bone metastases in patients with high-risk prostate cancer: <sup>99m</sup>Tc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, <sup>18</sup>F-fluoride PET, and <sup>18</sup>F-fluoride PET/CT</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">287</span>â <span class="NLM_lpage">297</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=16455635" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=287-297&author=E.+Evensapirauthor=U.+Metserauthor=E.+Mishaniauthor=G.+Lievshitzauthor=H.+Lermanauthor=I.+Leibovitch&title=The+detection+of+bone+metastases+in+patients+with+high-risk+prostate+cancer%3A+99mTc-MDP+Planar+bone+scintigraphy%2C+single-+and+multi-field-of-view+SPECT%2C+18F-fluoride+PET%2C+and+18F-fluoride+PET%2FCT"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEvensapir%26aufirst%3DE.%26aulast%3DMetser%26aufirst%3DU.%26aulast%3DMishani%26aufirst%3DE.%26aulast%3DLievshitz%26aufirst%3DG.%26aulast%3DLerman%26aufirst%3DH.%26aulast%3DLeibovitch%26aufirst%3DI.%26atitle%3DThe%2520detection%2520of%2520bone%2520metastases%2520in%2520patients%2520with%2520high-risk%2520prostate%2520cancer%253A%252099mTc-MDP%2520Planar%2520bone%2520scintigraphy%252C%2520single-%2520and%2520multi-field-of-view%2520SPECT%252C%252018F-fluoride%2520PET%252C%2520and%252018F-fluoride%2520PET%252FCT%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2006%26volume%3D47%26spage%3D287%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gschwend, J. E.</span></span> <span> </span><span class="NLM_article-title">Current use of PSMA-PET in prostate cancer management</span>. <i>Nat. Rev. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">226</span>â <span class="NLM_lpage">235</span>, <span class="refDoi">Â DOI: 10.1038/nrurol.2016.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1038%2Fnrurol.2016.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=26902337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFehsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=226-235&author=T.+Maurerauthor=M.+Eiberauthor=M.+Schwaigerauthor=J.+E.+Gschwend&title=Current+use+of+PSMA-PET+in+prostate+cancer+management&doi=10.1038%2Fnrurol.2016.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Current use of PSMA-PET in prostate cancer management</span></div><div class="casAuthors">Maurer, Tobias; Eiber, Matthias; Schwaiger, Markus; Gschwend, Juergen E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Urology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">226-235</span>CODEN:
                <span class="NLM_cas:coden">NRNADQ</span>;
        ISSN:<span class="NLM_cas:issn">1759-4812</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Currently, the findings of imaging procedures used for detection or staging of prostate cancer depend on morphol. of lymph nodes or bone metab. and do not always meet diagnostic needs.  Prostate-specific membrane antigen (PSMA), a transmembrane protein that has considerable overexpression on most prostate cancer cells, has gained increasing interest as a target mol. for imaging.  To date, several small compds. for labeling PSMA have been developed and are currently being investigated as imaging probes for PET with the 68Ga-labeled PSMA inhibitor Glu-NH-CO-NH-Lys(Ahx)-HBED-CC being the most widely studied agent. 68Ga-PSMA-PET imaging in combination with multiparametric MRI (mpMRI) might provide addnl. mol. information on cancer localization within the prostate.  In patients with primary prostate cancer of intermediate-risk to high-risk, PSMA-based imaging has been reported to improve detection of metastatic disease compared with CT or mpMRI, rendering addnl. cross-sectional imaging or bone scintigraphy unnecessary.  Furthermore, in patients with biochem. recurrent prostate cancer, use of 68Ga-PSMA-PET imaging has been shown to increase detection of metastatic sites, even at low serum PSA values, compared with conventional imaging or PET examn. with different tracers.  Thus, although current knowledge is still limited and derived mostly from retrospective series, PSMA-based imaging holds great promise to improve prostate cancer management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMr0cJOu5I3LVg90H21EOLACvtfcHk0lhozuOiDgg0cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFehsrk%253D&md5=a1570f8a442cb5cb403cf799ff6ba1f0</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrurol.2016.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrurol.2016.26%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DEiber%26aufirst%3DM.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DGschwend%26aufirst%3DJ.%2BE.%26atitle%3DCurrent%2520use%2520of%2520PSMA-PET%2520in%2520prostate%2520cancer%2520management%26jtitle%3DNat.%2520Rev.%2520Urol.%26date%3D2016%26volume%3D13%26spage%3D226%26epage%3D235%26doi%3D10.1038%2Fnrurol.2016.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, H.</span></span> <span> </span><span class="NLM_article-title">PET imaging of prostate cancer using carbon-11-choline</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">990</span>â <span class="NLM_lpage">995</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=9627331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADyaK1cXktV2itrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1998&pages=990-995&author=T.+Haraauthor=N.+Kosakaauthor=H.+Kishi&title=PET+imaging+of+prostate+cancer+using+carbon-11-choline"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging of prostate cancer using carbon-11-choline</span></div><div class="casAuthors">Hara, Toshihiko; Kosaka, Noboru; Kishi, Hiroichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">990-995</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">Prostate cancer is difficult to visualize using current techniques.  Recently, 31P magnetic resonance spectroscopy has revealed that the tumor, in general, is characterized by an increased uptake of choline into the cell to meet increased synthesis of phosphatidyl-choline, an important cell membrane phospholipid.  We succeeded in using 11C-choline to visualize prostate cancer and its local metastasis in PET.  PET was performed on 10 prostate cancer patients from the level of pelvis to the lower abdomen.  After transmission scanning, 370 MBq 11C-choline were injected i.v.  The emission scan was performed 5-15 min postinjection.  Finally, PET images were displayed so that each pixel was painted by a specified color representing the degree of the standardized uptake value (SUV).  The 11C-choline image was compared with the 18F-fluorodeoxyglucose (FDG) image obtained from the same patient.  Imaging of prostate cancer and its local metastasis was difficult when 18F-FDG was used because, within the pelvis, the areas of high uptake were concealed by the overwhelmingly abundant radioactivity in urine (in ureters and bladder).  By contrast, it was easy when 11C-choline was used because the urinary activity was negligible and tumor uptake was marked.  The radioactivity concn. of 11C-choline in prostate cancer and metastatic sites was at an SUV of more than three in most cases.  The SUV of 18F-FDG was considerably lower than that of 11C-choline.  Prostate cancer and its local metastasis were visualized clearly in PET using 11C-choline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3mwwmLWCVprVg90H21EOLACvtfcHk0lhozuOiDgg0cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktV2itrg%253D&md5=8556569bbe8650e1792490774700e1e2</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DT.%26aulast%3DKosaka%26aufirst%3DN.%26aulast%3DKishi%26aufirst%3DH.%26atitle%3DPET%2520imaging%2520of%2520prostate%2520cancer%2520using%2520carbon-11-choline%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D1998%26volume%3D39%26spage%3D990%26epage%3D995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanamaru, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, K.</span></span> <span> </span><span class="NLM_article-title">C-11-acetate PET imaging of prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">181</span>â <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=11850482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFWjtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=181-186&author=N.+Oyamaauthor=H.+Akinoauthor=H.+Kanamaruauthor=N.+Sadatoauthor=K.+Okada&title=C-11-acetate+PET+imaging+of+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">11C-Acetate PET imaging of prostate cancer</span></div><div class="casAuthors">Oyama, Nobuyuki; Akino, Hironobu; Kanamaru, Hiroshi; Suzuki, Yuji; Muramoto, Satoshi; Yonekura, Yoshiharu; Sadato, Norihiro; Yamamoto, Kazutaka; Okada, Kenichiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-186</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine</span>)
        </div><div class="casAbstract">11C-Acetate can act as a probe of tissue metab. through entry into catabolic or anabolic metabolic pathways as mediated by acetyl-CoA.  The uptake of 11C-acetate in prostate cancer was investigated to det. whether this tracer has potential in tumor identification.  Methods: Twenty-two patients with prostate cancer underwent PET after i.v. administration of 740 MBq 11C-acetate.  Eighteen of the 22 patients were also investigated with 18F-FDG PET.  Standardized uptake values (SUVs) for each tumor were investigated for tracer activity at 10-20 min after 11C-acetate and 40-60 min after 18F-FDG administration.  Results: Adenocarcinoma of the prostate showed variable uptake of 11C-acetate, with SUVs ranging from 3.27 to 9.87.  In contrast, SUVs for 18F-FDG ranged from 1.97 to 6.34.  By visual inspection, 11C-acetate accumulation in primary prostate tumors was pos. in all patients, whereas 18F-FDG accumulation was pos. in only 15 of 18 patients.  11C-Acetate PET in a patient with lymph node metastasis showed high intrapelvic accumulation corresponding to metastatic sites.  Similarly, 2 patients with bone metastases were 11C-acetate avid.  Conclusion: 11C-Acetate shows marked uptake in prostate cancer and is more sensitive in detection of prostate cancer than is 18F-FDG PET.  11C-Acetate represents a new tracer for detection of prostate cancer with PET, measuring radiopharmaceutical uptake pathways that are different from those measured by 18F-FDG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGmm55fhswoLVg90H21EOLACvtfcHk0lhozuOiDgg0cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFWjtro%253D&md5=fe1f32ff68c230f628ab867d50833624</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOyama%26aufirst%3DN.%26aulast%3DAkino%26aufirst%3DH.%26aulast%3DKanamaru%26aufirst%3DH.%26aulast%3DSadato%26aufirst%3DN.%26aulast%3DOkada%26aufirst%3DK.%26atitle%3DC-11-acetate%2520PET%2520imaging%2520of%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2002%26volume%3D43%26spage%3D181%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pultrone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunocilla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malizia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigatti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonti, C.</span></span> <span> </span><span class="NLM_article-title"><sup>18</sup>F-FACBC (anti1-amino-3-<sup>18</sup>F-fluorocyclobutane-1-carboxylic acid) versus <sup>11</sup>C-choline PET/CT in prostate cancer relapse: results of a prospective trial</span>. <i>Eur. J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-016-3329-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=1-10&author=C.+Nanniauthor=L.+Zanoniauthor=C.+Pultroneauthor=R.+Schiavinaauthor=E.+Brunocillaauthor=F.+Lodiauthor=C.+Maliziaauthor=M.+Ferrariauthor=P.+Rigattiauthor=C.+Fonti&title=18F-FACBC+%28anti1-amino-3-18F-fluorocyclobutane-1-carboxylic+acid%29+versus+11C-choline+PET%2FCT+in+prostate+cancer+relapse%3A+results+of+a+prospective+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3329-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3329-1%26sid%3Dliteratum%253Aachs%26aulast%3DNanni%26aufirst%3DC.%26aulast%3DZanoni%26aufirst%3DL.%26aulast%3DPultrone%26aufirst%3DC.%26aulast%3DSchiavina%26aufirst%3DR.%26aulast%3DBrunocilla%26aufirst%3DE.%26aulast%3DLodi%26aufirst%3DF.%26aulast%3DMalizia%26aufirst%3DC.%26aulast%3DFerrari%26aufirst%3DM.%26aulast%3DRigatti%26aufirst%3DP.%26aulast%3DFonti%26aufirst%3DC.%26atitle%3D18F-FACBC%2520%2528anti1-amino-3-18F-fluorocyclobutane-1-carboxylic%2520acid%2529%2520versus%252011C-choline%2520PET%252FCT%2520in%2520prostate%2520cancer%2520relapse%253A%2520results%2520of%2520a%2520prospective%2520trial%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%26date%3D2016%26volume%3D43%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mannweiler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amersdorfer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trajanoski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehes, G.</span></span> <span> </span><span class="NLM_article-title">Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis</span>. <i>Pathol. Oncol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">167</span>â <span class="NLM_lpage">172</span>, <span class="refDoi">Â DOI: 10.1007/s12253-008-9104-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs12253-008-9104-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=18802790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvV2hurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=167-172&author=S.+Mannweilerauthor=P.+Amersdorferauthor=S.+Trajanoskiauthor=J.+A.+Terrettauthor=D.+Kingauthor=G.+Mehes&title=Heterogeneity+of+prostate-specific+membrane+antigen+%28PSMA%29+expression+in+prostate+carcinoma+with+distant+metastasis&doi=10.1007%2Fs12253-008-9104-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis</span></div><div class="casAuthors">Mannweiler, Sebastian; Amersdorfer, Peter; Trajanoski, Slave; Terrett, Jonathan A.; King, David; Mehes, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-172</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas.  As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest.  In this study we addressed the cellular distribution and heterogeneity of PSMA expression.  Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated.  Immunohistochem. was used to det. the cellular localization, staining intensity and pos. cell fraction which were related to tumor type and growth pattern.  We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern.  A significant no. of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the neg. range (<10% pos. tumor cells).  A direct correlation between histol. parameters and PSMA expression could not be demonstrated.  Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8D8BwOk-pgrVg90H21EOLACvtfcHk0liq-HYgzJZIDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvV2hurg%253D&md5=c949aa0c134031ea07d5c9d0fc5e013b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs12253-008-9104-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-008-9104-2%26sid%3Dliteratum%253Aachs%26aulast%3DMannweiler%26aufirst%3DS.%26aulast%3DAmersdorfer%26aufirst%3DP.%26aulast%3DTrajanoski%26aufirst%3DS.%26aulast%3DTerrett%26aufirst%3DJ.%2BA.%26aulast%3DKing%26aufirst%3DD.%26aulast%3DMehes%26aufirst%3DG.%26atitle%3DHeterogeneity%2520of%2520prostate-specific%2520membrane%2520antigen%2520%2528PSMA%2529%2520expression%2520in%2520prostate%2520carcinoma%2520with%2520distant%2520metastasis%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2009%26volume%3D15%26spage%3D167%26epage%3D172%26doi%3D10.1007%2Fs12253-008-9104-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span> <span> </span><span class="NLM_article-title">PET imaging in prostate cancer: focus on prostate-specific membrane antigen</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">951</span>â <span class="NLM_lpage">962</span>, <span class="refDoi">Â DOI: 10.2174/1568026611313080008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2174%2F1568026611313080008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=23590171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslKhtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=951-962&author=R.+C.+Measeauthor=C.+A.+Fossauthor=M.+G.+Pomper&title=PET+imaging+in+prostate+cancer%3A+focus+on+prostate-specific+membrane+antigen&doi=10.2174%2F1568026611313080008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">PET imaging in prostate cancer: focus on prostate-specific membrane antigen</span></div><div class="casAuthors">Mease, Ronnie C.; Foss, Catherine A.; Pomper, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">951-962</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Prostate cancer (PCa) is the second leading cause of cancer-related death in American men.  Positron emission tomog./computed tomog. (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease, detection of metastatic lesions and, ultimately, for predicting the aggressiveness of disease.  Prostate-specific membrane antigen (PSMA) is a well-characterized imaging biomarker of PCa.  Because PSMA levels are directly related to androgen independence, metastasis and progression, PSMA could prove an important target for the development of new radiopharmaceuticals for PET.  Preclin. data for new PSMA-based radiotracers are discussed and include new 89Zr- and 64Cu-labeled anti-PSMA antibodies and antibody fragments, 64Cu-labeled aptamers, and 11C-, 18F-, 68Ga-, 64Cu-, and 86Y-labeled low mol. wt. inhibitors of PSMA.  Several of these agents, namely 68Ga- HBED-CC conjugate 15, 18F-DCFBC 8, and BAY1075553 are particularly promising, each having detected sites of PCa in initial clin. studies.  These early clin. results suggest that PET/CT using PSMA-targeted agents, esp. with compds. of low mol. wt., will make valuable contributions to the management of PCa.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojEOMftFlIjbVg90H21EOLACvtfcHk0liq-HYgzJZIDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslKhtb0%253D&md5=e49d20dfdfbb41921517c501ca5182e2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F1568026611313080008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313080008%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DFoss%26aufirst%3DC.%2BA.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26atitle%3DPET%2520imaging%2520in%2520prostate%2520cancer%253A%2520focus%2520on%2520prostate-specific%2520membrane%2520antigen%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D951%26epage%3D962%26doi%3D10.2174%2F1568026611313080008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesche, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettschau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gromov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶hnke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¶nning, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegele-Hartung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DÃ¶hr, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinkelborg, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of BAY 1075553, a novel <sup>18</sup>F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">101</span>, <span class="refDoi">Â DOI: 10.1007/s00259-013-2527-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-013-2527-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=23955632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlShtrvI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=89-101&author=R.+Lescheauthor=G.+Kettschauauthor=A.+V.+Gromovauthor=N.+B%C3%B6hnkeauthor=S.+Borkowskiauthor=U.+M%C3%B6nningauthor=C.+Hegele-Hartungauthor=O.+D%C3%B6hrauthor=L.+M.+Dinkelborgauthor=K.+Graham&title=Preclinical+evaluation+of+BAY+1075553%2C+a+novel+18F-labelled+inhibitor+of+prostate-specific+membrane+antigen+for+PET+imaging+of+prostate+cancer&doi=10.1007%2Fs00259-013-2527-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of BAY 1075553, a novel 18F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer</span></div><div class="casAuthors">Lesche, Ralf; Kettschau, Georg; Gromov, Alexey V.; Boehnke, Niels; Borkowski, Sandra; Moenning, Ursula; Hegele-Hartung, Christa; Doehr, Olaf; Dinkelborg, Ludger M.; Graham, Keith</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-101</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed in prostate cancer and is therefore being explored as a biomarker for diagnosing and staging of the disease.  Here we report preclin. data on BAY 1075553 (a 9:1 mixt. of (2S,4S)- and (2R,4S)-2-[18F]fluoro-4-phosphonomethyl-pentanedioic acid), a novel 18F-labeled small mol. inhibitor of PSMA enzymic activity, which can be efficiently synthesized from a direct radiolabelling precursor.  Methods: The 18F-radiolabeled stereoisomers of 2-[18F]fluoro-4-(phosphonomethyl)-pentanedioic acid were synthesized from their resp. isomerically pure precursors di-Me 2-{[bis(benzyloxy)phosphoryl]methyl}-4-(tosyloxy)pentanedioate.  In vivo positron emission tomog. (PET) imaging and biodistribution studies were conducted in mice bearing LNCaP, 22Rv1 and PC-3 tumors.  Pharmacokinetic parameters and dosimetry ests. were calcd. based on biodistribution studies in rodents.  For non-clin. safety assessment (safety pharmacol., toxicol.) to support a single-dose human microdose study, off-target effects in vitro, effects on vital organ functions (cardiovascular in dogs, nervous system in rats), mutagenicity screens and an extended single-dose study in rats were conducted with the non-radioactive racemic analog of BAY 1075553.  Results: BAY 1075553 showed high tumor accumulation specific to PSMA-pos. tumor-bearing mice and was superior to other stereoisomers tested.  Fast clearance of BAY 1075553 resulted overall in low background signals in other organs except for high uptake into kidney and bladder which was mainly caused by renal elimination of BAY 1075553.  A modest uptake into bone was obsd. which decreased over time indicating organ-specific uptake as opposed to defluorination of BAY 1075553 in vivo.  Biodistribution studies found highest organ doses for kidneys and the urinary bladder wall resulting in a projected ED (ED) in humans of 0.0219 mSv/MBq.  Non-clin. safety studies did not show off-target activity, effects on vital organs function or dose-dependent adverse effects.  Conclusion: BAY 1075553 was identified as a promising PET tracer for PSMA-pos. prostate tumors in preclin. studies.  BAY 1075553 can be produced using a robust, direct radiosynthesis procedure.  Pharmacokinetic, toxicol. and safety pharmacol. studies support the application of BAY 1075553 in a first-in-man microdose study with single i.v. administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYHP7jzbqlk7Vg90H21EOLACvtfcHk0liq-HYgzJZIDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlShtrvI&md5=b01ac516103645481e22102a87373bc6</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2Fs00259-013-2527-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-013-2527-3%26sid%3Dliteratum%253Aachs%26aulast%3DLesche%26aufirst%3DR.%26aulast%3DKettschau%26aufirst%3DG.%26aulast%3DGromov%26aufirst%3DA.%2BV.%26aulast%3DB%25C3%25B6hnke%26aufirst%3DN.%26aulast%3DBorkowski%26aufirst%3DS.%26aulast%3DM%25C3%25B6nning%26aufirst%3DU.%26aulast%3DHegele-Hartung%26aufirst%3DC.%26aulast%3DD%25C3%25B6hr%26aufirst%3DO.%26aulast%3DDinkelborg%26aufirst%3DL.%2BM.%26aulast%3DGraham%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520BAY%25201075553%252C%2520a%2520novel%252018F-labelled%2520inhibitor%2520of%2520prostate-specific%2520membrane%2520antigen%2520for%2520PET%2520imaging%2520of%2520prostate%2520cancer%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2014%26volume%3D41%26spage%3D89%26epage%3D101%26doi%3D10.1007%2Fs00259-013-2527-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Behr, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanBrocklin, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flavell, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Small, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blecha, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jivan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hope, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simko, J. P.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase I study of CTT1057, an F-18-labeled imaging agent with phosphoramidate core targeting prostate-specific membrane antigen in prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">910</span>â <span class="NLM_lpage">916</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.220715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.118.220715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30464040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsleisg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=910-916&author=S.+C.+Behrauthor=R.+Aggarwalauthor=H.+F.+VanBrocklinauthor=R.+R.+Flavellauthor=K.+Gaoauthor=E.+J.+Smallauthor=J.+Blechaauthor=S.+Jivanauthor=T.+A.+Hopeauthor=J.+P.+Simko&title=Phase+I+study+of+CTT1057%2C+an+F-18-labeled+imaging+agent+with+phosphoramidate+core+targeting+prostate-specific+membrane+antigen+in+prostate+cancer&doi=10.2967%2Fjnumed.118.220715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of CTT1057, an 18F-labeled imaging agent with phosphoramidate core targeting prostate-specific membrane antigen in prostate cancer</span></div><div class="casAuthors">Behr, Spencer C.; Aggarwal, Rahul; Van Brocklin, Henry F.; Flavell, Robert R.; Gao, Kenneth; Small, Eric J.; Blecha, Joseph; Jivan, Salma; Hope, Thomas A.; Simko, Jeffry P.; Kurhanewicz, John; Noworolski, Susan M.; Korn, Natalie J.; Santos, Romelyn De Los; Cooperberg, Matthew R.; Carroll, Peter R.; Nguyen, Hao G.; Greene, Kirsten L.; Langton-Webster, Beatrice; Berkman, Clifford E.; Seo, Youngho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">910-916</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Unlike most other PSMA agents with a urea backbone, CTT1057 is based on a phosphoramidate scaffold that irreversibly binds to PSMA.  We conducted a first-in-humans phase I study of CTT1057 in patients with localized and metastatic prostate cancer.  Methods: Two patient cohorts were recruited.  Cohort A patients had biopsy-proven localized prostate cancer preceding radical prostatectomy, and cohort B patients had metastatic castration-resistant prostate cancer.  Cohort A patients were imaged at multiple time points after i.v. injection with 362 Â± 8 MBq of CTT1057 to evaluate the kinetics of CTT1057 and est. radiation dose profiles.  Mean organ-absorbed doses and EDs were calcd.  CTT1057 uptake in the prostate gland and regional lymph nodes was correlated with pathol., PSMA staining, and the results of conventional imaging.  In cohort B, patients were imaged 60-120 min after injection of CTT1057.  PET images were assessed for overall image quality, and areas of abnormal uptake were contrasted with conventional imaging.  Results: In cohort A (n = 5), the av. total ED was 0.023 mSv/MBq.  The kidneys exhibited the highest absorbed dose, 0.067 mGy/MBq.  The absorbed dose of the salivary glands was 0.015 mGy/MBq.  For cohort B (n = 15), CTT1057 PET detected 97 metastatic lesions, and 44 of 56 bone metastases detected on CTT1057 PET (78.5%) were also detectable on bone scanning.  Eight of 32 lymph nodes pos. on CTT1057 PET (25%) were enlarged by size criteria on CT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtVFC8Q1FLHbVg90H21EOLACvtfcHk0ljuDLMNvFSp6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsleisg%253D%253D&md5=bd32d2271de6e601bf8f019668ade1ee</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.220715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.220715%26sid%3Dliteratum%253Aachs%26aulast%3DBehr%26aufirst%3DS.%2BC.%26aulast%3DAggarwal%26aufirst%3DR.%26aulast%3DVanBrocklin%26aufirst%3DH.%2BF.%26aulast%3DFlavell%26aufirst%3DR.%2BR.%26aulast%3DGao%26aufirst%3DK.%26aulast%3DSmall%26aufirst%3DE.%2BJ.%26aulast%3DBlecha%26aufirst%3DJ.%26aulast%3DJivan%26aufirst%3DS.%26aulast%3DHope%26aufirst%3DT.%2BA.%26aulast%3DSimko%26aufirst%3DJ.%2BP.%26atitle%3DPhase%2520I%2520study%2520of%2520CTT1057%252C%2520an%2520F-18-labeled%2520imaging%2520agent%2520with%2520phosphoramidate%2520core%2520targeting%2520prostate-specific%2520membrane%2520antigen%2520in%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D910%26epage%3D916%26doi%3D10.2967%2Fjnumed.118.220715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gage, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthamizhchelvan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffrey-Kwanisai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgouros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Biodistribution, tumor detection, and radiation dosimetry of <sup>18</sup>F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1883</span>â <span class="NLM_lpage">1891</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.112.104661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.112.104661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=23203246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFKrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=1883-1891&author=S.+Y.+Choauthor=K.+L.+Gageauthor=R.+C.+Measeauthor=S.+Senthamizhchelvanauthor=D.+P.+Holtauthor=A.+Jeffrey-Kwanisaiauthor=C.+J.+Endresauthor=R.+F.+Dannalsauthor=G.+Sgourosauthor=M.+Lodge&title=Biodistribution%2C+tumor+detection%2C+and+radiation+dosimetry+of+18F-DCFBC%2C+a+low-molecular-weight+inhibitor+of+prostate-specific+membrane+antigen%2C+in+patients+with+metastatic+prostate+cancer&doi=10.2967%2Fjnumed.112.104661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer</span></div><div class="casAuthors">Cho, Steve Y.; Gage, Kenneth L.; Mease, Ronnie C.; Senthamizhchelvan, Srinivasan; Holt, Daniel P.; Jeffrey-Kwanisai, Akimosa; Endres, Christopher J.; Dannals, Robert F.; Sgouros, George; Lodge, Martin; Eisenberger, Mario A.; Rodiguez, Ronald; Carducci, Michael A.; Rojas, Camilo; Slusher, Barbara S.; Kozikowski, Alan P.; Pomper, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1883-1891</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate cancer (PCa) cells, particularly in androgen-independent, advanced, and metastatic disease.  Previously, we demonstrated that N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-18F-fluorobenzyl-L-cysteine (18F-DCFBC) could image an exptl. model of PSMA-pos. PCa using PET.  Here, we describe the initial clin. experience and radiation dosimetry of 18F-DCFBC in men with metastatic PCa.  Methods: Five patients with radio-logic evidence of metastatic PCa were studied after the i.v. administration of 370 MBq (10 mCi) of 18F-DCFBC.  Serial PET was performed until 2 h after administration.  Time-activity curves were generated for selected normal tissues and metastatic foci.  Radiation dose ests. were calcd. using OLINDA/EXM 1.1.  Results: Most vascular organs demonstrated a slow decrease in radioactivity concn. over time consistent with clearance from the blood pool, with primarily urinary radiotracer excretion.  Thirty-two PET-pos. suspected metastatic sites were identified, with 21 concordant on both PET and conventional imaging for abnormal findings compatible with metastatic disease.  Of the 11 PET-pos. sites not identified on conventional imaging, most were within the bone and could be considered suggestive for the detection of early bone metastases, although further validation is needed.  The highest mean absorbed dose per unit administered radioactivity (Î¼Gy/MBq) was in the bladder wall (32.4), and the resultant ED was 19.9 Â± 1.34 (Î¼Sv/MBq mean Â± SD).  Conclusion: Although further studies are needed for validation, our findings demonstrate the potential of 18F-DCFBC as a new positron-emitting imaging agent for the detection of metastatic PCa.  This study also provides dose ests. for 18F-DCFBC that are comparable to those of other PET radiopharmaceuticals such as 18F-FDG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDmNxmCAVauLVg90H21EOLACvtfcHk0ljuDLMNvFSp6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFKrtA%253D%253D&md5=2e2e1f33dc78d2de4bed9f69d3f2cb21</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.112.104661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.112.104661%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DGage%26aufirst%3DK.%2BL.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DSenthamizhchelvan%26aufirst%3DS.%26aulast%3DHolt%26aufirst%3DD.%2BP.%26aulast%3DJeffrey-Kwanisai%26aufirst%3DA.%26aulast%3DEndres%26aufirst%3DC.%2BJ.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26aulast%3DSgouros%26aufirst%3DG.%26aulast%3DLodge%26aufirst%3DM.%26atitle%3DBiodistribution%252C%2520tumor%2520detection%252C%2520and%2520radiation%2520dosimetry%2520of%252018F-DCFBC%252C%2520a%2520low-molecular-weight%2520inhibitor%2520of%2520prostate-specific%2520membrane%2520antigen%252C%2520in%2520patients%2520with%2520metastatic%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2012%26volume%3D53%26spage%3D1883%26epage%3D1891%26doi%3D10.2967%2Fjnumed.112.104661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szajek, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesewetter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Single low-dose injection of evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3213</span>â <span class="NLM_lpage">3221</span>, <span class="refDoi">Â DOI: 10.1021/acs.bioconjchem.8b00556</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00556" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVylsrvO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=3213-3221&author=Z.+Wangauthor=R.+Tianauthor=G.+Niuauthor=Y.+Maauthor=L.+Langauthor=L.+P.+Szajekauthor=D.+Kiesewetterauthor=O.+Jacobsonauthor=X.+Chen&title=Single+low-dose+injection+of+evans+blue+modified+PSMA-617+radioligand+therapy+eliminates+prostate-specific+membrane+antigen+positive+tumors&doi=10.1021%2Facs.bioconjchem.8b00556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors</span></div><div class="casAuthors">Wang, Zhantong; Tian, Rui; Niu, Gang; Ma, Ying; Lang, Lixin; Szajek, Lawrence P.; Kiesewetter, Dale O.; Jacobson, Orit; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3213-3221</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide.  Prostate-specific membrane antigen (PSMA) is a surface mol. specifically expressed by prostate tumors that has been shown to be a valid target for internal radionuclide therapy in both preclin. and clin. settings.  The most common radiotherapeutic agent is the small mol. 177Lu-PSMA-617, which is under clin. evaluation in multiple countries.  Nevertheless, its efficacy in causing tumor regression is still suboptimal, even when administered in several cycles per patient, perhaps due to poor pharmacokinetics (PK), which limits uptake by the tumor cells.  We postulated that the addn. of the Evans blue (EB) moiety to PSMA-617 would improve the PK by extending circulation half-life, which would increase tumor uptake and improve radiotherapeutic efficacy.  PSMA-617 was modified by conjugation of a 2-thiol acetate group onto the primary amine and thereafter reacted with a maleimide functional group of an EB deriv., to give EB-PSMA-617.  The PK and radiotherapeutic efficacy of 90Y- or 177Lu-EB-PSMA-617 was compared to the clin. used radiopharmaceutical 90Y- or 177Lu- PSMA-617 in PC3-PIP tumor-bearing mice.  EB-PSMA-617 retained binding to serum albumin as well as a high internalization rate by tumor cells.  Upon injection, metal-labeled EB-PSMA-617 demonstrated an extended blood half-life compared to PSMA-617 and, thereby, prolonged the time window for binding to PSMA.  The improved PK of EB-PSMA-617 resulted in significantly higher accumulation in PSMA+ tumors and highly effective radiotherapeutic efficacy.  Remarkably, a single dose of 1.85 MBq of 90Y- or 177Lu-EB-PSMA-617 was sufficient to eradicate established PMSA+ tumors in mice.  No significant body wt. loss was obsd., suggesting little to no gross toxicity.  The construct described here, EB-PSMA-617, may improve the radiotherapeutic efficacy for patients with PSMA-pos. tumors by reducing both the amt. of activity needed for therapy as well as the frequency of administration, as compared to PSMA-617.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIct9lbcQfrVg90H21EOLACvtfcHk0liV6MOeZdN9gQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVylsrvO&md5=66a04f13d479e0fc7c4d7097ce148d31</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00556%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLang%26aufirst%3DL.%26aulast%3DSzajek%26aufirst%3DL.%2BP.%26aulast%3DKiesewetter%26aufirst%3DD.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DSingle%2520low-dose%2520injection%2520of%2520evans%2520blue%2520modified%2520PSMA-617%2520radioligand%2520therapy%2520eliminates%2520prostate-specific%2520membrane%2520antigen%2520positive%2520tumors%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D3213%26epage%3D3221%26doi%3D10.1021%2Facs.bioconjchem.8b00556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of <sup>68</sup>Ga-PSMA-BCH for prostate cancer imaging</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">933</span>â <span class="NLM_lpage">937</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2019.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2Fj.bmcl.2019.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30745258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivFyis74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=933-937&author=T.+Liuauthor=C.+Liuauthor=F.+Liuauthor=X.+Xuauthor=X.+Guoauthor=L.+Xiaauthor=H.+Zhuauthor=Z.+Yang&title=Synthesis+and+preclinical+evaluation+of+68Ga-PSMA-BCH+for+prostate+cancer+imaging&doi=10.1016%2Fj.bmcl.2019.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and preclinical evaluation of 68Ga-PSMA-BCH for prostate cancer imaging</span></div><div class="casAuthors">Liu, Teli; Liu, Chen; Liu, Fei; Xu, Xiaoxia; Guo, Xiaoyi; Xia, Lei; Zhu, Hua; Yang, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">933-937</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prostate specific membrane antigen (PSMA) is a promising target for the diagnosis and therapy of prostate cancer.  In this report, a NOTA-conjugated precursor, NOTA-PSMA (also named PSMA-BCH), was synthesized by peptide synthesizer with the chem. purity over 95%. 68Ga-PSMA-BCH was obtained by radiolabeling NOTA-PSMA with 68GaCl3 with >99% radiochem. purity and 59-74 GBq/Î¼mol specific activity.  In vitro and in vivo study of 68Ga-PSMA-BCH showed high stability, high uptake in PSMA-expressing cells and tumor, fast clearance and low non-target uptake. 22Rv1 tumors were clearly obsd. in micro-PET images of and showed good retention.  Compared with 68Ga-PSMA-617, 68Ga-PSMA-BCH showed comparable tumor uptake and tumor-background ratios.  Indicating 68Ga-PSMA-BCH is a promising candidate for prostate cancer imaging and worthy of further clin. investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH7CclsNgDLbVg90H21EOLACvtfcHk0liV6MOeZdN9gQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivFyis74%253D&md5=e5efe28c3f7dd34f0e1c579afca225b7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%252068Ga-PSMA-BCH%2520for%2520prostate%2520cancer%2520imaging%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D933%26epage%3D937%26doi%3D10.1016%2Fj.bmcl.2019.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wust, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, W.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wangler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenhut, M.</span></span> <span> </span><span class="NLM_article-title"><sup>68</sup>Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">688</span>â <span class="NLM_lpage">697</span>, <span class="refDoi">Â DOI: 10.1021/bc200279b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc200279b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVCmtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=688-697&author=M.+Ederauthor=M.+Schaferauthor=U.+Bauder-Wustauthor=W.-E.+Hullauthor=C.+Wanglerauthor=W.+Mierauthor=U.+Haberkornauthor=M.+Eisenhut&title=68Ga-complex+lipophilicity+and+the+targeting+property+of+a+urea-based+PSMA+inhibitor+for+PET+imaging&doi=10.1021%2Fbc200279b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging</span></div><div class="casAuthors">Eder, Matthias; Schaefer, Martin; Bauder-Wuest, Ulrike; Hull, William-Edmund; Waengler, Carmen; Mier, Walter; Haberkorn, Uwe; Eisenhut, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">688-697</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Urea-based inhibitors of the prostate-specific membrane antigen (PSMA) represent low-mol.-wt. pepidomimetics showing the ability to image PSMA-expressing prostate tumors.  The highly efficient, acyclic Ga(III) chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'- diacetic acid (HBED-CC) was introduced as a lipophilic side chain into the hydrophilic pharmacophore Glu-NH-CO-NH-Lys which was found favorable to interact with the PSMA "active binding site".  This report describes the syntheses, in vitro binding analyses, and biodistribution data of the radiogallium labeled PSMA inhibitor Glu-NH-CO-NH-Lys(Ahx)-HBED-CC in comparison to the corresponding DOTA conjugate.  The binding properties were analyzed using competitive cell binding and enzyme-based assays followed by internalization expts.  Compared to the DOTA-conjugate, the HBED-CC deriv. showed reduced unspecific binding and considerable higher specific internalization in LNCaP cells.  The 68Ga complex of the HBED-CC ligand exhibited higher specificity for PSMA expressing tumor cells resulting in improved in vivo properties. 68Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC showed fast blood and organ clearances, low liver accumulation, and high specific uptake in PSMA expressing organs and tumor.  It could be demonstrated that the PET-imaging property of a urea-based PSMA inhibitor could significantly be improved with HBED-CC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9XoCnl_RguLVg90H21EOLACvtfcHk0ljbzz4fijmpxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVCmtLo%253D&md5=4bb4cbba9f510ed2561b87a44bafa00a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fbc200279b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc200279b%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DM.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DBauder-Wust%26aufirst%3DU.%26aulast%3DHull%26aufirst%3DW.-E.%26aulast%3DWangler%26aufirst%3DC.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DEisenhut%26aufirst%3DM.%26atitle%3D68Ga-complex%2520lipophilicity%2520and%2520the%2520targeting%2520property%2520of%2520a%2520urea-based%2520PSMA%2520inhibitor%2520for%2520PET%2520imaging%26jtitle%3DBioconjugate%2520Chem.%26date%3D2012%26volume%3D23%26spage%3D688%26epage%3D697%26doi%3D10.1021%2Fbc200279b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwenck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rempp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reischl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenzl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfannenberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Fougere, C.</span></span> <span> </span><span class="NLM_article-title">Comparison of Ga-68-labelled PSMA-11 and C-11-choline in the detection of prostate cancer metastases by PET/CT</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">92</span>â <span class="NLM_lpage">101</span>, <span class="refDoi">Â DOI: 10.1007/s00259-016-3490-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-016-3490-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27557844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVSqu73K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=92-101&author=J.+Schwenckauthor=H.+Remppauthor=G.+Reischlauthor=S.+Kruckauthor=A.+Stenzlauthor=K.+Nikolaouauthor=C.+Pfannenbergauthor=C.+La+Fougere&title=Comparison+of+Ga-68-labelled+PSMA-11+and+C-11-choline+in+the+detection+of+prostate+cancer+metastases+by+PET%2FCT&doi=10.1007%2Fs00259-016-3490-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT</span></div><div class="casAuthors">Schwenck, Johannes; Rempp, Hansjoerg; Reischl, Gerald; Kruck, Stephan; Stenzl, Arnulf; Nikolaou, Konstantin; Pfannenberg, Christina; La Fougere, Christian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">92-101</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Our aim was to compare the PSMA ligand 68Ga-PSMA-11 with 11C-choline in patients with primary and recurrent prostate cancer.  123 patients underwent a whole-body PET/CT examn. using 68Ga-PSMA-11 and 11C-choline.  Out of these, 103 suffered from a confirmed biochem. relapse after prostatectomy and/or radiotherapy (mean PSA level of 4.5 ng/mL), while 20 patients underwent primary staging.  In 67 patients with biochem. relapse, we detected 458 lymph nodes suspicious for metastasis.  PET using 68Ga-PSMA-11 showed a significantly higher uptake and detection rate than 11C-choline PET.  Also 68Ga-PSMA-11 PET identified significantly more patients with suspicious lymph nodes as well as affected lymph nodes regions esp. at low PSA levels.  Nevertheless, we detected also 29 suspicious lymph nodes and 8 bone lesions, which were only pos. as per 11C-choline PET.  These findings led to crucial differences in the TNM classification and the identification of oligometastatic patients.  In the patients who underwent initial staging, all primary tumors showed uptake of both tracers.  Although significantly more suspicious lymph nodes and bone lesions were identified, only 2 patients presented with bone lesions only detected by 68Ga-PSMA-11 PET.  Thus, PET using 68Ga-PSMA-11 showed a higher detection rate than 11C-choline PET for lymph nodes as well as bone lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBT7N63fNU77Vg90H21EOLACvtfcHk0ljbzz4fijmpxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVSqu73K&md5=f7c71caaf7fd09b7f04c8f0f27ac4afd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3490-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3490-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchwenck%26aufirst%3DJ.%26aulast%3DRempp%26aufirst%3DH.%26aulast%3DReischl%26aufirst%3DG.%26aulast%3DKruck%26aufirst%3DS.%26aulast%3DStenzl%26aufirst%3DA.%26aulast%3DNikolaou%26aufirst%3DK.%26aulast%3DPfannenberg%26aufirst%3DC.%26aulast%3DLa%2BFougere%26aufirst%3DC.%26atitle%3DComparison%2520of%2520Ga-68-labelled%2520PSMA-11%2520and%2520C-11-choline%2520in%2520the%2520detection%2520of%2520prostate%2520cancer%2520metastases%2520by%2520PET%252FCT%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2017%26volume%3D44%26spage%3D92%26epage%3D101%26doi%3D10.1007%2Fs00259-016-3490-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullambhatla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmagadda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthamizhchelvan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sgouros, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span> <span> </span><span class="NLM_article-title">2-(3-{1-Carboxy-5-[(6-[<sup>18</sup>F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [<sup>18</sup>F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7645</span>â <span class="NLM_lpage">7653</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-11-1357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1158%2F1078-0432.CCR-11-1357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=22042970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1CqtrnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7645-7653&author=Y.+Chenauthor=M.+Pullambhatlaauthor=C.+A.+Fossauthor=Y.+Byunauthor=S.+Nimmagaddaauthor=S.+Senthamizhchelvanauthor=G.+Sgourosauthor=R.+C.+Measeauthor=M.+G.+Pomper&title=2-%283-%7B1-Carboxy-5-%5B%286-%5B18F%5Dfluoro-pyridine-3-carbonyl%29-amino%5D-pentyl%7D-ureido%29-pentanedioic+acid%2C+%5B18F%5DDCFPyL%2C+a+PSMA-based+PET+imaging+agent+for+prostate+cancer&doi=10.1158%2F1078-0432.CCR-11-1357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer</span></div><div class="casAuthors">Chen, Ying; Pullambhatla, Mrudula; Foss, Catherine A.; Byun, Youngjoo; Nimmagadda, Sridhar; Senthamizhchelvan, Srinivasan; Sgouros, George; Mease, Ronnie C.; Pomper, Martin G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7645-7653</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: We have synthesized and evaluated in vivo 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, as a potential imaging agent for the prostate-specific membrane antigen (PSMA).  PSMA is upregulated in prostate cancer epithelia and in the neovasculature of most solid tumors.  Exptl. Design: [18F]DCFPyL was synthesized in two steps from the p-methoxybenzyl (PMB) protected lys-C(O)-glu urea precursor using 6-[18F]fluoronicotinic acid tetrafluorophenyl ester ([18F]F-Py-TFP) for introduction of 18F.  Radiochem. synthesis was followed by biodistribution and imaging with PET in immunocompromised mice using isogenic PSMA PC3 PIP and PSMA- PC3 flu xenograft models.  Human radiation dosimetry ests. were calcd. using OLINDA/EXM 1.0.  RESULTS: DCFPyL displays a Ki value of 1.1 Â± 0.1 nmol/L for PSMA. [18F]DCFPyL was produced in radiochem. yields of 36%-53% (decay cor.) and specific radioactivities of 340-480 Ci/mmol (12.6-17.8 GBq/Î¼mol, n = 3).  In an immunocompromised mouse model [18F]DCFPyL clearly delineated PSMA+ PC3 PIP prostate tumor xenografts on imaging with PET.  At 2 h postinjection, 39.4 Â± 5.4 percent injected dose per g of tissue (%ID/g) was evident within the PSMA+ PC3 PIP tumor, with a ratio of 358:1 of uptake within PSMA+ PC3 PIP to PSMA- PC3 flu tumor placed in the opposite flank.  At or after 1 h postinjection, minimal nontarget tissue uptake of [18F]DCFPyL was obsd.  The bladder wall is the dose-limiting organ.  CONCLUSIONS: These data suggest [18F]DCFPyL as a viable, new positron-emitting imaging agent for PSMA-expressing tissues.  Clin Cancer Res; 17(24); 7645-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKmkSg8g44f7Vg90H21EOLACvtfcHk0ljbzz4fijmpxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1CqtrnM&md5=dca0465b3b65f7b553a622e40a0c7463</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1357%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPullambhatla%26aufirst%3DM.%26aulast%3DFoss%26aufirst%3DC.%2BA.%26aulast%3DByun%26aufirst%3DY.%26aulast%3DNimmagadda%26aufirst%3DS.%26aulast%3DSenthamizhchelvan%26aufirst%3DS.%26aulast%3DSgouros%26aufirst%3DG.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26atitle%3D2-%25283-%257B1-Carboxy-5-%255B%25286-%255B18F%255Dfluoro-pyridine-3-carbonyl%2529-amino%255D-pentyl%257D-ureido%2529-pentanedioic%2520acid%252C%2520%255B18F%255DDCFPyL%252C%2520a%2520PSMA-based%2520PET%2520imaging%2520agent%2520for%2520prostate%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7645%26epage%3D7653%26doi%3D10.1158%2F1078-0432.CCR-11-1357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macura, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackford, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carducci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">PSMA-based [<sup>18</sup>F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer</span>. <i>Mol. Imaging. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">411</span>â <span class="NLM_lpage">419</span>, <span class="refDoi">Â DOI: 10.1007/s11307-016-0957-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs11307-016-0957-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27080322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Smu73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=411-419&author=S.+P.+Roweauthor=K.+J.+Macuraauthor=E.+Menaauthor=A.+L.+Blackfordauthor=R.+Nadalauthor=E.+S.+Antonarakisauthor=M.+Eisenbergerauthor=M.+Carducciauthor=H.+Fanauthor=R.+F.+Dannals&title=PSMA-based+%5B18F%5DDCFPyL+PET%2FCT+is+superior+to+conventional+imaging+for+lesion+detection+in+patients+with+metastatic+prostate+cancer&doi=10.1007%2Fs11307-016-0957-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer</span></div><div class="casAuthors">Rowe, Steven P.; Macura, Katarzyna J.; Mena, Esther; Blackford, Amanda L.; Nadal, Rosa; Antonarakis, Emmanuel S.; Eisenberger, Mario; Carducci, Michael; Fan, Hong; Dannals, Robert F.; Chen, Ying; Mease, Ronnie C.; Szabo, Zsolt; Pomper, Martin G.; Cho, Steve Y.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging and Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">411-419</span>CODEN:
                <span class="NLM_cas:coden">MIBOCZ</span>;
        ISSN:<span class="NLM_cas:issn">1860-2002</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Current std. of care conventional imaging modalities (CIM) such as X-ray computed tomog. (CT) and bone scan can be limited for detection of metastatic prostate cancer and therefore improved imaging methods are an unmet clin. need.  We evaluated the utility of a novel second-generation low mol. wt. radiofluorinated prostate-specific membrane antigen (PSMA)-targeted positron emission tomog. (PET) radiotracer, [18F]DCFPyL, in patients with metastatic prostate cancer.  Procedures: Nine patients with suspected prostate cancer recurrence, eight with CIM evidence of metastatic prostate cancer and one with biochem. recurrence, were imaged with [18F]DCFPyL PET/CT.  Eight of the patients had contemporaneous CIM for comparison.  A lesion-by-lesion comparison of the detection of suspected sites of metastatic prostate cancer was carried out between PET and CIM.  Statistical anal. for estd. proportions of inter-modality agreement for detection of metastatic disease was calcd. accounting for intra-patient correlation using general estg. equation (GEE) intercept-only regression models.  Results: One hundred thirty-nine sites of PET pos. [18F]DCFPyL uptake (138 definite, 1 equivocal) for metastatic disease were detected in the eight patients with available comparison CIM.  By contrast, only 45 lesions were identified on CIM (30 definite, 15 equivocal).  When lesions were neg. or equivocal on CIM, it was estd. that a large portion of these lesions or 0.72 (95 % confidence interval (CI) 0.55-0.84) would be pos. on [18F]DCFPyL PET.  Conversely, of those lesions neg. or equivocal on [18F]DCFPyL PET, it was estd. that only a very small proportion or 0.03 (95 % CI 0.01-0.07) would be pos. on CIM.  Delayed 2-h-post-injection time point PET yielded higher tumor radiotracer uptake and higher tumor-to-background ratios than an earlier 1-h-post-injection time point.  Conclusions: A novel PSMA-targeted PET radiotracer, [18F]DCFPyL, was able to a large no. of suspected sites of prostate cancer, many of which were occult or equivocal by CIM.  This study provides strong preliminary evidence for the use of this second-generation PSMA-targeted PET radiotracer for detection of metastatic prostate cancer and lends further support for the importance of PSMA-targeted PET imaging in prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraR0lm561p3bVg90H21EOLACvtfcHk0lgjVLs1XlfQow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Smu73F&md5=460d955374fb33764986218b117dd5aa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs11307-016-0957-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-016-0957-6%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DS.%2BP.%26aulast%3DMacura%26aufirst%3DK.%2BJ.%26aulast%3DMena%26aufirst%3DE.%26aulast%3DBlackford%26aufirst%3DA.%2BL.%26aulast%3DNadal%26aufirst%3DR.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DEisenberger%26aufirst%3DM.%26aulast%3DCarducci%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DPSMA-based%2520%255B18F%255DDCFPyL%2520PET%252FCT%2520is%2520superior%2520to%2520conventional%2520imaging%2520for%2520lesion%2520detection%2520in%2520patients%2520with%2520metastatic%2520prostate%2520cancer%26jtitle%3DMol.%2520Imaging.%2520Biol.%26date%3D2016%26volume%3D18%26spage%3D411%26epage%3D419%26doi%3D10.1007%2Fs11307-016-0957-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wust, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leotta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of F-18-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">425</span>â <span class="NLM_lpage">431</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.116.181768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.116.181768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27789722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVSis7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=425-431&author=J.+Cardinaleauthor=M.+Schaferauthor=M.+Benesovaauthor=U.+Bauder-Wustauthor=K.+Leottaauthor=M.+Ederauthor=O.+C.+Neelsauthor=U.+Haberkornauthor=F.+L.+Gieselauthor=K.+Kopka&title=Preclinical+evaluation+of+F-18-PSMA-1007%2C+a+new+prostate-specific+membrane+antigen+ligand+for+prostate+cancer+imaging&doi=10.2967%2Fjnumed.116.181768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging</span></div><div class="casAuthors">Cardinale, Jens; Schaefer, Martin; Benesova, Martina; Bauder-Wuest, Ulrike; Leotta, Karin; Eder, Matthias; Neels, Oliver C.; Haberkorn, Uwe; Giesel, Frederik L.; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced.  Some of them have had a high clin. impact on the treatment of patients with prostate cancer.  However, the no. of 18F-labeled tracers addressing PSMA is still limited.  Therefore, we aimed to develop a radiofluorinated mol. resembling the structure of therapeutic PSMA-617.  Methods: The nonradioactive ref. compd. PSMA-1007 and the precursor were produced by solid-phase chem.  The radioligand 18F-PSMA-1007 was produced by a 2-step procedure with the prosthetic group 6-18F-fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester.  The binding affinity of the ligand for PSMA and its internalization properties were evaluated in vitro with PSMA-pos. LNCaP (lymph node carcinoma of the prostate) cells.  Further, organ distribution studies were performed with mice bearing LNCaP and PC-3 (prostate cancer cell line; PSMA-neg.) tumors.  Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performed.  Results: The identified ligand had a binding affinity of 6.7 Â± 1.7 nM for PSMA and an exceptionally high internalization ratio (67% Â± 13%) in vitro.  In organ distribution studies, high and specific tumor uptake (8.0 Â± 2.4 percentage injected dose per g) in LNCaP tumor-bearing mice was obsd.  In the small-animal PET expts., LNCaP tumors were clearly visualized.  Conclusion: The radiofluorinated PSMA ligand showed promising characteristics in its preclin. evaluation, and the feasibility of prostate cancer imaging was demonstrated by small-animal PET studies.  Therefore, we recommend clin. transfer of the radioligand 18F-PSMA-1007 for use as a diagnostic PET tracer in prestaging and monitoring of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_sOlj_VlMF7Vg90H21EOLACvtfcHk0lgjVLs1XlfQow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVSis7o%253D&md5=168905fe2ee07195a189d26e9ac6be2b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.116.181768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.116.181768%26sid%3Dliteratum%253Aachs%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DBenesova%26aufirst%3DM.%26aulast%3DBauder-Wust%26aufirst%3DU.%26aulast%3DLeotta%26aufirst%3DK.%26aulast%3DEder%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DKopka%26aufirst%3DK.%26atitle%3DPreclinical%2520evaluation%2520of%2520F-18-PSMA-1007%252C%2520a%2520new%2520prostate-specific%2520membrane%2520antigen%2520ligand%2520for%2520prostate%2520cancer%2520imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D425%26epage%3D431%26doi%3D10.2967%2Fjnumed.116.181768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span> <span> </span><span class="NLM_article-title"><sup>18</sup>F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1929</span>â <span class="NLM_lpage">1930</span>, <span class="refDoi">Â DOI: 10.1007/s00259-016-3447-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-016-3447-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27342416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVOitrrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=1929-1930&author=F.+L.+Gieselauthor=J.+Cardinaleauthor=M.+Schaferauthor=O.+Neelsauthor=M.+Benesovaauthor=W.+Mierauthor=U.+Haberkornauthor=K.+Kopkaauthor=C.+Kratochwil&title=18F-Labelled+PSMA-1007+shows+similarity+in+structure%2C+biodistribution+and+tumour+uptake+to+the+theragnostic+compound+PSMA-617&doi=10.1007%2Fs00259-016-3447-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617</span></div><div class="casAuthors">Giesel, Frederik L.; Cardinale, Jens; Schaefer, Martin; Neels, Oliver; Benesova, Martina; Mier, Walter; Haberkorn, Uwe; Kopka, Klaus; Kratochwil, Clemens</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1929-1930</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The article showed 18F-labeled PSMA-1007 similarity in structure, biodistribution and tumor uptake to the theragnostic compd. PSMA-617 in metastatic castration-resistant prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcT8t2_DPvz7Vg90H21EOLACvtfcHk0liHabmTcrqJng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVOitrrP&md5=5208ade7e966d07f20fb63b211b0d11c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3447-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3447-9%26sid%3Dliteratum%253Aachs%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%26aulast%3DBenesova%26aufirst%3DM.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DKratochwil%26aufirst%3DC.%26atitle%3D18F-Labelled%2520PSMA-1007%2520shows%2520similarity%2520in%2520structure%252C%2520biodistribution%2520and%2520tumour%2520uptake%2520to%2520the%2520theragnostic%2520compound%2520PSMA-617%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2016%26volume%3D43%26spage%3D1929%26epage%3D1930%26doi%3D10.1007%2Fs00259-016-3447-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bene Ova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshar-Oromieh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span> <span> </span><span class="NLM_article-title">PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with <sup>177</sup>Lu-labeled PSMA-617</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1170</span>â <span class="NLM_lpage">1176</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.115.171397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.115.171397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=26985056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslaktb%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=1170-1176&author=C.+Kratochwilauthor=F.+L.+Gieselauthor=M.+Stefanovaauthor=M.+Bene+Ovaauthor=M.+Bronzelauthor=A.+Afshar-Oromiehauthor=W.+Mierauthor=M.+Ederauthor=K.+Kopkaauthor=U.+Haberkorn&title=PSMA-targeted+radionuclide+therapy+of+metastatic+castration-resistant+prostate+cancer+with+177Lu-labeled+PSMA-617&doi=10.2967%2Fjnumed.115.171397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617</span></div><div class="casAuthors">Kratochwil, Clemens; Giesel, Frederik L.; Stefanova, Melsa; Benesova, Martina; Bronzel, Marcus; Afshar-Oromieh, Ali; Mier, Walter; Eder, Matthias; Kopka, Klaus; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1170-1176</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC).  Besides high affinity and long tumor retention, the DOTA-conjugated ligand PSMA-617 has low kidney uptake, making it an excellent choice for therapeutic application.  We retrospectively report our experience with 177Lu-PSMA-617-targeted radionuclide therapy in a case series of mCRPC patients resistant to other treatments.  Patients with PSMA-pos. tumor phenotypes were selected by mol. imaging.  Thirty patients received 1-3 cycles of 177Lu-PSMA-617.  During therapy, pharmacokinetics and radiation dosimetry were evaluated.  Blood cell count was checked every 2 wk after the first and every 4 wk after succeeding cycles.  Prostate-specific antigen (PSA) was detd. every 4 wk.  Radiol. restaging was performed after 3 cycles.  Twenty-one of 30 patients had a PSA response; in 13 of 30 the PSA decreased more than 50%.  After 3 cycles, 8 of 11 patients achieved a sustained PSA response (>50%) for over 24 wk, which also correlated with radiol. response (decreased lesion no. and size).  Normally, acute hematotoxicity was mild.  Diffuse bone marrow involvement was a risk factor for higher grade myelosuppression but could be identified by PSMA imaging in advance.  Xerostomia, nausea, and fatigue occurred sporadically (<10%).  Clearance of non-tumor-bound tracer was predominantly renal and widely completed by 48 h.  Safety dosimetry revealed kidney doses of approx. 0.75 Gy/GBq, red marrow doses of 0.03 Gy/GBq, and salivary gland doses of 1.4 Gy/GBq, irresp. of tumor burden and consistent on subsequent cycles.  Mean tumor-absorbed dose ranged from 6 to 22 Gy/GBq during cycle 1.  177Lu-PSMA-617 is a promising new option for therapy of mCRPC and deserves more attention in larger prospective trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8RfEV6P8Rm7Vg90H21EOLACvtfcHk0liHabmTcrqJng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslaktb%252FM&md5=1b4edc5c0930f12ae7ab41ab81c2349a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.115.171397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.115.171397%26sid%3Dliteratum%253Aachs%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DStefanova%26aufirst%3DM.%26aulast%3DBene%2BOva%26aufirst%3DM.%26aulast%3DBronzel%26aufirst%3DM.%26aulast%3DAfshar-Oromieh%26aufirst%3DA.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DEder%26aufirst%3DM.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DHaberkorn%26aufirst%3DU.%26atitle%3DPSMA-targeted%2520radionuclide%2520therapy%2520of%2520metastatic%2520castration-resistant%2520prostate%2520cancer%2520with%2520177Lu-labeled%2520PSMA-617%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2016%26volume%3D57%26spage%3D1170%26epage%3D1176%26doi%3D10.2967%2Fjnumed.115.171397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Afshar-Oromieh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hetzheim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benesova, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1697</span>â <span class="NLM_lpage">1705</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.115.161299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.115.161299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=26294298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFGmtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=1697-1705&author=A.+Afshar-Oromiehauthor=H.+Hetzheimauthor=C.+Kratochwilauthor=M.+Benesova&title=The+theranostic+PSMA+ligand+PSMA-617+in+the+diagnosis+of+prostate+cancer+by+PET%2FCT%3A+biodistribution+in+humans%2C+radiation+dosimetry%2C+and+first+evaluation+of+tumor+lesions&doi=10.2967%2Fjnumed.115.161299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions</span></div><div class="casAuthors">Afshar-Oromieh, Ali; Hetzheim, Henrik; Kratochwil, Clemens; Benesova, Martina; Eder, Matthias; Neels, Oliver C.; Eisenhut, Michael; Kuebler, Wolfgang; Holland-Letz, Tim; Giesel, Frederik L.; Mier, Walter; Kopka, Klaus; Haberkorn, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1697-1705</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">PET imaging with the prostate-specific membrane antigen (PSMA)-targeted radioligand 68Ga-PSMA-11 is regarded as a significant step forward in the diagnosis of prostate cancer (PCa).  More recently, a PSMA ligand was developed that can be labeled with 68Ga, 111In, 177Lu, and 90Y.  This ligand, named PSMA-617, therefore enables both diagnosis and therapy of PCa.  The aims of this evaluation were to clin. investigate the distribution of 68Ga-PSMA-617 in normal tissues and in PCa lesions as well as to evaluate the radiation exposure by the radioligand in PET imaging.  Nineteen patients, most of them with recurrent PCa, were referred for 68Ga-PSMA-617 PET/CT.  The quant. assessment of tracer uptake of several organs and of 53 representative tumor lesions was performed in 15 patients at 1 and 3 h after injection.  In 4 addnl. patients, the same procedure was conducted at 5 min, 1 h, 2 h, 3 h, 4 h, and 5 h after injection.  On the basis of the data for these 4 patients (mean injected dose, 231 MBq), the radiation exposure of a 68Ga-PSMA-617 PET/CT was identified.  Intense tracer uptake was obsd. in the kidneys and salivary glands.  In 14 of 19 patients (73.7%), at least 1 lesion suspected of being a tumor was detected at 3 h after injection.  Of 53 representative tumor lesions selected at 3 h after injection, 47 lesions were visible at 1 h after injection.  The mean tumor-to-background ratio for max. standardized uptake value was 20.4 Â± 17.3 (range, 2.3-84.0) at 1 h after injection and 38.2 Â± 38.6 (range, 3.6-154.3) at 3 h after injection.  The av. radiation exposure (ED) was approx. 0.021 mSv/MBq.  Within healthy organs, the kidneys and salivary glands showed the highest 68Ga-PSMA-617 uptake.  The radiation exposure was relatively low. 68Ga-PSMA-617 shows PCa lesions with high contrast.  Images obtained between 2 and 3 h after injection seem to be the best option with regard to radiotracer uptake and tumor contrast.  Later images can help to clarify unclear lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFcW87h_AWsLVg90H21EOLACvtfcHk0liHabmTcrqJng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFGmtLw%253D&md5=0cbba73002ae27bcb6add228aff05fcd</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.115.161299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.115.161299%26sid%3Dliteratum%253Aachs%26aulast%3DAfshar-Oromieh%26aufirst%3DA.%26aulast%3DHetzheim%26aufirst%3DH.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DBenesova%26aufirst%3DM.%26atitle%3DThe%2520theranostic%2520PSMA%2520ligand%2520PSMA-617%2520in%2520the%2520diagnosis%2520of%2520prostate%2520cancer%2520by%2520PET%252FCT%253A%2520biodistribution%2520in%2520humans%252C%2520radiation%2520dosimetry%252C%2520and%2520first%2520evaluation%2520of%2520tumor%2520lesions%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2015%26volume%3D56%26spage%3D1697%26epage%3D1705%26doi%3D10.2967%2Fjnumed.115.161299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Calais, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czernin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendler, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elashoff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickols, N. G.</span></span> <span> </span><span class="NLM_article-title">Randomized phase III trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">TPS136</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2019.37.7_suppl.TPS136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1200%2FJCO.2019.37.7_suppl.TPS136" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=TPS136&author=J.+Calaisauthor=J.+Czerninauthor=W.+P.+Fendlerauthor=D.+Elashoffauthor=N.+G.+Nickols&title=Randomized+phase+III+trial+of+68Ga-PSMA-11+PET%2FCT+molecular+imaging+for+prostate+cancer+salvage+radiotherapy+planning+%5BPSMA-SRT%5D&doi=10.1200%2FJCO.2019.37.7_suppl.TPS136"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.7_suppl.TPS136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.7_suppl.TPS136%26sid%3Dliteratum%253Aachs%26aulast%3DCalais%26aufirst%3DJ.%26aulast%3DCzernin%26aufirst%3DJ.%26aulast%3DFendler%26aufirst%3DW.%2BP.%26aulast%3DElashoff%26aufirst%3DD.%26aulast%3DNickols%26aufirst%3DN.%2BG.%26atitle%3DRandomized%2520phase%2520III%2520trial%2520of%252068Ga-PSMA-11%2520PET%252FCT%2520molecular%2520imaging%2520for%2520prostate%2520cancer%2520salvage%2520radiotherapy%2520planning%2520%255BPSMA-SRT%255D%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3DTPS136%26doi%3D10.1200%2FJCO.2019.37.7_suppl.TPS136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kesch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span> <span> </span><span class="NLM_article-title"><sup>68</sup>Ga or <sup>18</sup>F for prostate cancer imaging?</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">687</span>â <span class="NLM_lpage">688</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.117.190157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.117.190157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=28408526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BC1cvnslalsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=687-688&author=C.+Keschauthor=C.+Kratochwilauthor=W.+Mierauthor=K.+Kopkaauthor=F.+L.+Giesel&title=68Ga+or+18F+for+prostate+cancer+imaging%3F&doi=10.2967%2Fjnumed.117.190157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">(68)Ga or (18)F for Prostate Cancer Imaging?</span></div><div class="casAuthors">Kesch Claudia; Kratochwil Clemens; Mier Walter; Giesel Frederik L; Kopka Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">687-688</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTan9bSbQzZvjEC-75aqa5AfW6udTcc2eYKsHR7RnSwxLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvnslalsA%253D%253D&md5=9dcd47e46a010cd9415926d3babda381</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.117.190157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.117.190157%26sid%3Dliteratum%253Aachs%26aulast%3DKesch%26aufirst%3DC.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26atitle%3D68Ga%2520or%252018F%2520for%2520prostate%2520cancer%2520imaging%253F%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D687%26epage%3D688%26doi%3D10.2967%2Fjnumed.117.190157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengana, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyneke, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkon, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathekge, M.</span></span> <span> </span><span class="NLM_article-title">Intraindividual comparison of F-18-PSMA-1007 and F-18-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1076</span>â <span class="NLM_lpage">1080</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.117.204669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.117.204669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=29269569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1CgtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1076-1080&author=F.+L.+Gieselauthor=L.+Willauthor=I.+Lawalauthor=T.+Lenganaauthor=C.+Kratochwilauthor=M.+Vorsterauthor=O.+Neelsauthor=F.+Reynekeauthor=U.+Haberkonauthor=K.+Kopkaauthor=M.+Sathekge&title=Intraindividual+comparison+of+F-18-PSMA-1007+and+F-18-DCFPyL+PET%2FCT+in+the+prospective+evaluation+of+patients+with+newly+diagnosed+prostate+carcinoma%3A+a+pilot+study&doi=10.2967%2Fjnumed.117.204669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study</span></div><div class="casAuthors">Giesel, Frederik L.; Will, Leon; Lawal, Ismaheel; Lengana, Thabo; Kratochwil, Clemens; Vorster, Mariza; Neels, Oliver; Reyneke, Florette; Haberkon, Uwe; Kopka, Klaus; Sathekge, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1076-1080</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The introduction of 18F-labeled prostate-specific membrane antigen (PSMA)-targeted PET/CT tracers, first 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) and more recently 18F-PSMA-1007 (((3S,10S,14S)-1-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-18F-fluoronicotinamido)butanamido)butanamido)methyl)phenyl)-3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid)), have demonstrated promising results for the diagnostic workup of prostate cancer.  This clin. study presents an intraindividual comparison to evaluate tracer-specific characteristics of 18F-DCFPyL vs. 18F-PSMA-1007.  Twelve prostate cancer patients, drug-naive or before surgery, received similar activities of about 250 MBq of 18F-DCFPyL and 18F-PSMA-1007 48 h apart and were imaged 2 h after injection on the same PET/CT scanner using the same reconstruction algorithm.  Normal-organ biodistribution and tumor uptake were quantified using SUVmax.  PSMA-pos. lesions were detected in 12 of 12 prostate cancer patients.  Both tracers, 18F-DCFPyL and 18F-PSMA-1007, detected the same lesions.  No statistical significance could be obsd. when comparing the SUVmax of 18F-DCFPyL and 18F-PSMA-1007 for local tumor, lymph node metastases, and bone metastases.  With regard to normal organs, 18F-DCFPyL had statistically significant higher uptake in kidneys, urinary bladder, and lacrimal gland.  Vice versa, significantly higher uptake of 18F-PSMA-1007 in muscle, submandibular and sublingual gland, spleen, pancreas, liver, and gallbladder was obsd.  Excellent imaging quality was achieved with both 18F-DCFPyL and 18F-PSMA-1007, resulting in identical clin. findings for the evaluated routine situations.  Nonurinary excretion of 18F-PSMA-1007 might present some advantage with regard to delineation of local recurrence or pelvic lymph node metastasis in selected patients; the lower hepatic background might favor 18F-DCFPyL in late stages, when rare cases of liver metastases can occur.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9sOieiddqnLVg90H21EOLACvtfcHk0ljxc7hEHiSeHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1CgtLg%253D&md5=2f7ef3becefb959785c7e05c63ebdefc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.117.204669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.117.204669%26sid%3Dliteratum%253Aachs%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DWill%26aufirst%3DL.%26aulast%3DLawal%26aufirst%3DI.%26aulast%3DLengana%26aufirst%3DT.%26aulast%3DKratochwil%26aufirst%3DC.%26aulast%3DVorster%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%26aulast%3DReyneke%26aufirst%3DF.%26aulast%3DHaberkon%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DSathekge%26aufirst%3DM.%26atitle%3DIntraindividual%2520comparison%2520of%2520F-18-PSMA-1007%2520and%2520F-18-DCFPyL%2520PET%252FCT%2520in%2520the%2520prospective%2520evaluation%2520of%2520patients%2520with%2520newly%2520diagnosed%2520prostate%2520carcinoma%253A%2520a%2520pilot%2520study%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D1076%26epage%3D1080%26doi%3D10.2967%2Fjnumed.117.204669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhnert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockter, S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Comparison of [<sup>18</sup>F]DCFPyL and [<sup>68</sup>Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer</span>. <i>Mol. Imaging. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">575</span>â <span class="NLM_lpage">584</span>, <span class="refDoi">Â DOI: 10.1007/s11307-015-0866-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs11307-015-0866-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=26013479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SmurnP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=575-584&author=M.+Dietleinauthor=C.+Kobeauthor=G.+Kuhnertauthor=S.+Stockter&title=Comparison+of+%5B18F%5DDCFPyL+and+%5B68Ga%5DGa-PSMA-HBED-CC+for+PSMA-PET+imaging+in+patients+with+relapsed+prostate+cancer&doi=10.1007%2Fs11307-015-0866-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer</span></div><div class="casAuthors">Dietlein, Markus; Kobe, Carsten; Kuhnert, Georg; Stockter, Simone; Fischer, Thomas; Schomaecker, Klaus; Schmidt, Matthias; Dietlein, Felix; Zlatopolskiy, Boris D.; Krapf, Philipp; Richarz, Raphael; Neubauer, Stephan; Drzezga, Alexander; Neumaier, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging and Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">575-584</span>CODEN:
                <span class="NLM_cas:coden">MIBOCZ</span>;
        ISSN:<span class="NLM_cas:issn">1860-2002</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific membrane antigen (PSMA) such as the [68Ga]Ga-PSMA-HBED-CC have already demonstrated high potential for the detection of recurrent prostate cancer.  However, compared to Ga-68, a labeling with fluorine-18 (F-18) would offer advantages with respect to availability, prodn. amt., and image resoln. [18F]DCFPyL is a promising F-18-labeled candidate for PSMA-positron emission tomog. (PET) imaging that has been recently introduced.  In the current study, we aimed to compare [68Ga]Ga-PSMA-HBED-CC and [18F]DCFPyL for clin. use in biochem. relapsed prostate cancer.  Procedures: In 14 selected patients with PSA relapse of prostate cancer, [18F]DCFPyL PET/X-ray computed tomog. (CT) was performed in addn. to [68Ga]Ga-PSMA-HBED-CC PET/CT.  A systematic comparison was carried out between results obtained with both tracers with regard to the no. of detected PSMA-pos. lesions, the standardized uptake value (SUV)max and the lesion to background ratios.  Results: All suspicious lesions identified by [68Ga]Ga-PSMA-HBED-CC were also detected with [18F]DCFPyL.  In three patients, addnl. lesions were obsd. using [18F]DCFPyL PET/CT.  The mean SUVmax in the concordant [18F]DCFPyL PSMA-pos. lesions was significantly higher as compared to [68Ga]Ga-PSMA-HBED-CC (14.5 vs. 12.2, p = 0.028, n = 15).  The mean tumor to background ratios (n = 15) were significantly higher for [18F]DCFPyL compared to [68Ga]Ga-PSMA-HBED-CC using kidney, spleen, or parotid as ref. organs (p = 0.006, p = 0.002, p = 0.008), but no significant differences were found using the liver (p = 0.167) or the mediastinum (p = 0.363) as ref. organs.  Conclusion: [18F]DCFPyL PET/CT provided a high image quality and visualized small prostate lesions with excellent sensitivity. [18F]DCFPyL represents a highly promising alternative to [68Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7xf95U58dALVg90H21EOLACvtfcHk0ljxc7hEHiSeHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SmurnP&md5=2995fc5d9b75be5f2c6e7b32d7d06b6b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs11307-015-0866-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11307-015-0866-0%26sid%3Dliteratum%253Aachs%26aulast%3DDietlein%26aufirst%3DM.%26aulast%3DKobe%26aufirst%3DC.%26aulast%3DKuhnert%26aufirst%3DG.%26aulast%3DStockter%26aufirst%3DS.%26atitle%3DComparison%2520of%2520%255B18F%255DDCFPyL%2520and%2520%255B68Ga%255DGa-PSMA-HBED-CC%2520for%2520PSMA-PET%2520imaging%2520in%2520patients%2520with%2520relapsed%2520prostate%2520cancer%26jtitle%3DMol.%2520Imaging.%2520Biol.%26date%3D2015%26volume%3D17%26spage%3D575%26epage%3D584%26doi%3D10.1007%2Fs11307-015-0866-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rahbar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weckesser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadzadehfar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegger, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogemann, M.</span></span> <span> </span><span class="NLM_article-title">Advantage of F-18-PSMA-1007 over Ga-68-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1076</span>â <span class="NLM_lpage">1077</span>, <span class="refDoi">Â DOI: 10.1007/s00259-018-3952-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-018-3952-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=29445927" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1Sju78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1076-1077&author=K.+Rahbarauthor=M.+Weckesserauthor=H.+Ahmadzadehfarauthor=M.+Schafersauthor=L.+Steggerauthor=M.+Bogemann&title=Advantage+of+F-18-PSMA-1007+over+Ga-68-PSMA-11+PET+imaging+for+differentiation+of+local+recurrence+vs.+urinary+tracer+excretion&doi=10.1007%2Fs00259-018-3952-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion</span></div><div class="casAuthors">Rahbar, Kambiz; Weckesser, Matthias; Ahmadzadehfar, Hojjat; Schaefers, Michael; Stegger, Lars; Boegemann, Martin</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1076-1077</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review discussing the advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion.  The images of a 74-yr-old prostate cancer patient after radical prostatectomy (Gleason score 9) with biochem. recurrence (PSA: 2.1 ng/dL) was presented.  18F-PSMA-1007 seemed to be superior to 68Ga-PSMA-11 in cases of biochem. recurrence and unclear lesions close to the ureter or urinary bladder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAO915awAnqrVg90H21EOLACvtfcHk0ljYn8ECDgm2sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1Sju78%253D&md5=c773329f88fac1c8936c7b26c87db98f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs00259-018-3952-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-018-3952-0%26sid%3Dliteratum%253Aachs%26aulast%3DRahbar%26aufirst%3DK.%26aulast%3DWeckesser%26aufirst%3DM.%26aulast%3DAhmadzadehfar%26aufirst%3DH.%26aulast%3DSchafers%26aufirst%3DM.%26aulast%3DStegger%26aufirst%3DL.%26aulast%3DBogemann%26aufirst%3DM.%26atitle%3DAdvantage%2520of%2520F-18-PSMA-1007%2520over%2520Ga-68-PSMA-11%2520PET%2520imaging%2520for%2520differentiation%2520of%2520local%2520recurrence%2520vs.%2520urinary%2520tracer%2520excretion%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2018%26volume%3D45%26spage%3D1076%26epage%3D1077%26doi%3D10.1007%2Fs00259-018-3952-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wurzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Carlo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H.-J.</span></span> <span> </span><span class="NLM_article-title">Radiohybrid ligands: a novel tracer concept exemplified by <sup>18</sup>F- or <sup>68</sup>Ga-labeled rhPSMA inhibitors</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">735</span>â <span class="NLM_lpage">742</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.119.234922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.119.234922" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=31862804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOisL7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=735-742&author=A.+Wurzerauthor=D.+Di+Carloauthor=A.+Schmidtauthor=R.+Beckauthor=M.+Eiberauthor=M.+Schwaigerauthor=H.-J.+Wester&title=Radiohybrid+ligands%3A+a+novel+tracer+concept+exemplified+by+18F-+or+68Ga-labeled+rhPSMA+inhibitors&doi=10.2967%2Fjnumed.119.234922"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors</span></div><div class="casAuthors">Wurzer, Alexander; Di Carlo, Daniel; Schmidt, Alexander; Beck, Roswitha; Eiber, Matthias; Schwaiger, Markus; Wester, Hans-Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">735-743</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">When we critically assess the reason for the current dominance of 68Ga-labeled peptides and peptide-like ligands in radiopharmacy and nuclear medicine, we have to conclude that the major advantage of such radiopharmaceuticals is the apparent lack of suitable 18F-labeling technologies with proven clin. relevance.  To prep. and to subsequently perform a clin. proof-of-concept study on the general suitability of silicon-fluoride-acceptor (SiFA)-conjugated radiopharmaceuticals, we developed inhibitors of the prostate-specific membrane antigen (PSMA) that are labeled by isotopic exchange (IE).  To compensate for the pronounced lipophilicity of the SiFA unit, we used metal chelates, conjugated in close proximity to SiFA.  Six different radiohybrid PSMA ligands (rhPSMA ligands) were evaluated and compared with the commonly used 18F-PSMA inhibitors 18F-DCFPyL and 18F-PSMA-1007.  All inhibitors were synthesized by solid-phase peptide synthesis.  Human serum albumin binding was measured by affinity high-performance liq. chromatog., whereas the lipophilicity of each tracer was detd. by the n-octanol/buffer method.  In vitro studies (IC50, internalization) were performed on LNCaP cells.  Biodistribution studies were conducted on LNCaP tumor-bearing male CB-17 SCID mice.  On the lab. scale (starting activities, 0.2-9.0 GBq), labeling of 18F-rhPSMA-5 to -10 by IE was completed in , <20 min (radiochem. yields, 58% Â±9%; radiochem. purity, >97%) with molar activities of 12-60 GBq/Î¼mol.  All rhPSMAs showed low nanomolar affinity and high internalization by PSMA-expressing cells when compared with the ref. radiopharmaceuticals, medium-to-low lipophilicity, and high human serum albumin binding.  Biodistribution studies in LNCaP tumor- bearing mice revealed high tumor uptake, sufficiently fast clearance kinetics from blood, low hepatobiliary excretion, fast renal excretion, and very low uptake of 18F- activity in bone.  The novel 18F-rhPSMA radiopharmaceuticals developed under the radiohybrid concept show equal or better targeting characteristics than the established 18F-PSMA tracers 18F-DCFPyL and 18F-PSMA- 1007.  The unparalleled simplicity of prodn., the possibility to produce the identical 68Ga-labeled 19F-68Ga-rhPSMA tracers, and the possibility to extend this concept to true theranostic radiohybrid radiopharmaceuticals, such as F-Lu-rhPSMA, are unique features of these radiopharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFshUQeZMd2bVg90H21EOLACvtfcHk0ljYn8ECDgm2sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOisL7E&md5=f06ff865b42826703ce21818e2510fc8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.234922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.234922%26sid%3Dliteratum%253Aachs%26aulast%3DWurzer%26aufirst%3DA.%26aulast%3DDi%2BCarlo%26aufirst%3DD.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DBeck%26aufirst%3DR.%26aulast%3DEiber%26aufirst%3DM.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DWester%26aufirst%3DH.-J.%26atitle%3DRadiohybrid%2520ligands%253A%2520a%2520novel%2520tracer%2520concept%2520exemplified%2520by%252018F-%2520or%252068Ga-labeled%2520rhPSMA%2520inhibitors%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D735%26epage%3D742%26doi%3D10.2967%2Fjnumed.119.234922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroenke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulbrich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jooss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, W.</span></span> <span> </span><span class="NLM_article-title">F-18-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">696</span>â <span class="NLM_lpage">701</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.119.234914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.119.234914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=31836682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOis7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=696-701&author=M.+Eiberauthor=M.+Kroenkeauthor=A.+Wurzerauthor=L.+Ulbrichauthor=L.+Joossauthor=T.+Maurerauthor=T.+Hornauthor=K.+Schillerauthor=T.+Langbeinauthor=G.+Buschnerauthor=H.+J.+Westerauthor=W.+Weber&title=F-18-rhPSMA-7+PET+for+the+detection+of+biochemical+recurrence+of+prostate+cancer+after+radical+prostatectomy&doi=10.2967%2Fjnumed.119.234914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A 18F-rhPSMA-7 PET for the detection of biochemical recurrence of prostate cancer after radical prostatectomy</span></div><div class="casAuthors">Eiber, Matthias; Kroenke, Markus; Wurzer, Alexander; Ulbrich, Lena; Jooss, Lena; Maurer, Tobias; Horn, Thomas; Schiller, Kilian; Langbein, Thomas; Buschner, Gabriel; Wester, Hans-Juergen; Weber, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">696-702</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">18F-labeled prostate-specific membrane antigen (PSMA) PET tracers are increasingly used in preference to 68Ga-PSMA-11 for restaging biochem. recurrence (BCR) of prostate cancer.  They are assocd. with longer half-lives, larger-scale prodn., and lower positron range than their 68Ga-labeled counterparts.  Here, we describe the efficacy of an 18F-labeled radiohybrid PSMA, rhPSMA-7, a novel theranostic PSMA-targeting agent for imaging BCR of prostate cancer.  Datasets from 261 consecutive patients with noncastrate BCR after radical prostatectomy who underwent 18F-rhPSMA-7 PET/CT at our institution between June 2017 and March 2018 were reviewed retrospectively.  All lesions suspected of being recurrent prostate cancer were recorded.  The detection rate for sites of presumed recurrence was correlated with patients' prostate-specific antigen (PSA) level, primary Gleason score, and prior therapy (androgen deprivation therapy and external-beam radiation therapy).  The 261 patients had a median PSA level of 0.96 ng/mL (range, 0.01 -400 ng/mL).  The median injected activity of 18F-rhPSMA-7 was 336 MBq, with a median uptake time of 76 min.  In total, 211 patients (81%) showed pathol. findings on 18F-rhPSMA-7 PET/CT.  The detection rates were 71% (42/59), 86% (44/51), 86% (42/49), and 95% (76/80) at PSA levels of 0.2 to <0.5 ng/mL, 0.5 to <1 ng/mL, 1 to <2 ng/mL, and â¥2 ng/mL, resp.  In 32% patients (7/22) with a PSA of less than 0.2 ng/mL, suggestive lesions were present.  18FrhPSMA-7 PET/CT revealed local recurrence in 43% of patients (113).  Lymph node metastases were present in the pelvis in 42% of patients (110), in the retroperitoneum in 17% (45), and in a supradiaphragmatic location in 8.0% (21).  Bone and visceral metastases were detected in 21% (54) and 3.8% (10), resp.  Detection efficacy was not influenced by prior external-beam radiation therapy (79.1% vs. 82.1%, P = 5 0.55), androgen deprivation therapy within the 6 mo preceding imaging (80.6% vs. 80.9%, P = 5 0.54), or primary Gleason score (77.9% for â¤7 vs. 82.6% for â¥8, P = 5 0.38).  18F-rhPSMA-7 PET/CT offers high detection rates in early BCR after radical prostatectomy, esp. among patients with low PSA values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUI_hOGyZ9XbVg90H21EOLACvtfcHk0ljYn8ECDgm2sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOis7fN&md5=897bece05e2df0d94fc8342eb183529f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.234914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.234914%26sid%3Dliteratum%253Aachs%26aulast%3DEiber%26aufirst%3DM.%26aulast%3DKroenke%26aufirst%3DM.%26aulast%3DWurzer%26aufirst%3DA.%26aulast%3DUlbrich%26aufirst%3DL.%26aulast%3DJooss%26aufirst%3DL.%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DHorn%26aufirst%3DT.%26aulast%3DSchiller%26aufirst%3DK.%26aulast%3DLangbein%26aufirst%3DT.%26aulast%3DBuschner%26aufirst%3DG.%26aulast%3DWester%26aufirst%3DH.%2BJ.%26aulast%3DWeber%26aufirst%3DW.%26atitle%3DF-18-rhPSMA-7%2520PET%2520for%2520the%2520detection%2520of%2520biochemical%2520recurrence%2520of%2520prostate%2520cancer%2520after%2520radical%2520prostatectomy%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D696%26epage%3D701%26doi%3D10.2967%2Fjnumed.119.234914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roscher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geerlings, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Development of PSMA-1007-related series of <sup>18</sup>F-labeled Glu-ureido type PSMA inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10897</span>â <span class="NLM_lpage">10907</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01479</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01479" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs12rtrnM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10897-10907&author=J.+Cardinaleauthor=M.+Roscherauthor=M.+Schaeferauthor=M.+Geerlings&title=Development+of+PSMA-1007-related+series+of+18F-labeled+Glu-ureido+type+PSMA+inhibitors&doi=10.1021%2Facs.jmedchem.9b01479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors</span></div><div class="casAuthors">Cardinale, Jens; Roscher, Mareike; Schaefer, Martin; Geerlings, Max; Benesova, Martina; Bauder-Wuest, Ulrike; Remde, Yvonne; Eder, Matthias; Novakova, Zora; Motlova, Lucia; Barinka, Cyril; Giesel, Frederik L.; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10897-10907</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In recent years, a no. of drugs targeting the prostate-specific membrane antigen (PSMA) have become important tools in the diagnosis and treatment of prostate cancer.  In the present work, we report on the synthesis and preclin. evaluation of a series of 18F-labeled PSMA ligands for diagnostic application based on the theragnostic ligand PSMA-617.  By applying modifications to the linker structure, insight into the structure-activity relationship could be gained, highlighting the importance of hydrophilicity and stereoselectivity on interaction with PSMA and hence the biodistribution.  Selected compds. were co-crystd. with the PSMA protein and analyzed by X-rays with mixed results.  Among these, PSMA-1007 (compd. 5) showed the best interaction with the PSMA protein.  The resp. radiotracer [18F]PSMA-1007 was translated into the clinic and is, in the meantime, subject of advanced clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8EfOyscxlC7Vg90H21EOLACvtfcHk0ljOoLPzYZnnsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs12rtrnM&md5=a9b0a2087eec7d108d74f916930c0c97</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01479%26sid%3Dliteratum%253Aachs%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DRoscher%26aufirst%3DM.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DGeerlings%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520PSMA-1007-related%2520series%2520of%252018F-labeled%2520Glu-ureido%2520type%2520PSMA%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10897%26epage%3D10907%26doi%3D10.1021%2Facs.jmedchem.9b01479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benesova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauder-Wust, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klika, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, M.</span></span> <span> </span><span class="NLM_article-title">Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1761</span>â <span class="NLM_lpage">1775</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01210</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01210" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGmur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1761-1775&author=M.+Benesovaauthor=U.+Bauder-Wustauthor=M.+Schaferauthor=K.+D.+Klikaauthor=W.+Mierauthor=U.+Haberkornauthor=K.+Kopkaauthor=M.+Eder&title=Linker+modification+strategies+to+control+the+prostate-specific+membrane+antigen+%28PSMA%29-targeting+and+pharmacokinetic+properties+of+DOTA-conjugated+PSMA+inhibitors&doi=10.1021%2Facs.jmedchem.5b01210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors</span></div><div class="casAuthors">Benesova, Martina; Bauder-Wuest, Ulrike; Schaefer, Martin; Klika, Karel D.; Mier, Walter; Haberkorn, Uwe; Kopka, Klaus; Eder, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1761-1775</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since prostate-specific membrane antigen (PSMA) is up-regulated in nearly all stages of prostate cancer (PCa), PSMA can be considered as a viable diagnostic biomarker and treatment target in PCa.  This project is focused on the development and evaluation of a series of compds. directed against PSMA.  The modifications to the linker are designed to improve the binding potential and pharmacokinetics for theranostic application.  In addn., the results help to further elucidate the structure-activity relationships (SAR) of the resulting PSMA inhibitors.  Both in vitro and in vivo expts. of 18 synthesized PSMA inhibitor variants showed that systematic chem. modification of the linker has a significant impact on the tumor-targeting and pharmacokinetic properties.  This approach can lead to an improved management of patients suffering from recurrent prostate cancer by the use of one radiolabeling precursor, which can be radiolabeled either with 68Ga for diagnosis or with 177Lu or 225Ac for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq0IyrD7bU0LVg90H21EOLACvtfcHk0ljOoLPzYZnnsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGmur8%253D&md5=437f339a55b519c54206942e5b51161c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01210%26sid%3Dliteratum%253Aachs%26aulast%3DBenesova%26aufirst%3DM.%26aulast%3DBauder-Wust%26aufirst%3DU.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DKlika%26aufirst%3DK.%2BD.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DEder%26aufirst%3DM.%26atitle%3DLinker%2520modification%2520strategies%2520to%2520control%2520the%2520prostate-specific%2520membrane%2520antigen%2520%2528PSMA%2529-targeting%2520and%2520pharmacokinetic%2520properties%2520of%2520DOTA-conjugated%2520PSMA%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1761%26epage%3D1775%26doi%3D10.1021%2Facs.jmedchem.5b01210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravert, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mease, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomper, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dannals, R. F.</span></span> <span> </span><span class="NLM_article-title">An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [<sup>18</sup>F]DCFPyL</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">439</span>â <span class="NLM_lpage">450</span>, <span class="refDoi">Â DOI: 10.1002/jlcr.3430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1002%2Fjlcr.3430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27470935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GisL7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=439-450&author=H.+T.+Ravertauthor=D.+P.+Holtauthor=Y.+Chenauthor=R.+C.+Measeauthor=H.+Fanauthor=M.+G.+Pomperauthor=R.+F.+Dannals&title=An+improved+synthesis+of+the+radiolabeled+prostate-specific+membrane+antigen+inhibitor%2C+%5B18F%5DDCFPyL&doi=10.1002%2Fjlcr.3430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL</span></div><div class="casAuthors">Ravert, Hayden T.; Holt, Daniel P.; Chen, Ying; Mease, Ronnie C.; Fan, Hong; Pomper, Martin G.; Dannals, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">439-450</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The radiosynthesis of [18F]DCFPyL I on 2 distinct automated platforms with full regulatory compliant quality control specifications is described.  The radiotracer synthesis was performed on a custom-made radiofluorination module and the Sofie Biosciences ELIXYS.  The radiofluorination module synthesis was accomplished in an av. of 66 min from end of bombardment with an av. specific activity at end of synthesis (EOS) of 4.4 TBq/Î¼mol (120 Ci/Î¼mol) and an av. radiochem. yield of 30.9% at EOS.  The ELIXYS synthesis was completed in an av. of 87 min with an av. specific activity of 2.2 TBq/Î¼mol (59.3 Ci/Î¼mol) and an av. radiochem. yield of 19% at EOS.  Both synthesis modules produced large millicurie quantities of [18F]DCFPyL while conforming to all std. US Pharmacopeia Chapter <823> acceptance testing criteria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB-H3Bt9yVULVg90H21EOLACvtfcHk0ljOoLPzYZnnsg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GisL7O&md5=2976699f47c43e015181805c1620089c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3430%26sid%3Dliteratum%253Aachs%26aulast%3DRavert%26aufirst%3DH.%2BT.%26aulast%3DHolt%26aufirst%3DD.%2BP.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DMease%26aufirst%3DR.%2BC.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DPomper%26aufirst%3DM.%2BG.%26aulast%3DDannals%26aufirst%3DR.%2BF.%26atitle%3DAn%2520improved%2520synthesis%2520of%2520the%2520radiolabeled%2520prostate-specific%2520membrane%2520antigen%2520inhibitor%252C%2520%255B18F%255DDCFPyL%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2016%26volume%3D59%26spage%3D439%26epage%3D450%26doi%3D10.1002%2Fjlcr.3430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span> <i>Chinese Pharmacopoeia</i>, <span class="NLM_edition">2020</span> ed.; <span class="NLM_publisher-name">Chinese Pharmacopoeia Commission, Ministry
of Health</span>: <span class="NLM_publisher-loc">People's Republic
of China</span>, <span class="NLM_year">2020</span>; Vol.  <span class="NLM_volume">II</span>, Part 2.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chinese+Pharmacopoeia%2C+2020+ed.%3B+Chinese+Pharmacopoeia+Commission%2C+Ministry%0Aof+Health%3A+People%27s+Republic%0Aof+China%2C+2020%3B+Vol.+II%2C+Part+2."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DChinese%2520Pharmacopoeia%26pub%3DChinese%2520Pharmacopoeia%2520Commission%252C%2520Ministry%250Aof%2520Health%26date%3D2020%26volume%3DII" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saperstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouliot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantel, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gage, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iagaru, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stambler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, B.</span></span> <span> </span><span class="NLM_article-title">Impact of PSMA-targeted imaging with <sup>18</sup>F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">5501</span>â <span class="NLM_lpage">5501</span>, <span class="refDoi">Â DOI: 10.1200/JCO.2020.38.15_suppl.5501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1200%2FJCO.2020.38.15_suppl.5501" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2020&pages=5501-5501&author=M.+J.+Morrisauthor=P.+R.+Carrollauthor=L.+Sapersteinauthor=F.+Pouliotauthor=D.+Josephsonauthor=J.+Y.+C.+Wongauthor=A.+R.+Pantelauthor=S.+Y.+Choauthor=K.+Gageauthor=M.+Piertauthor=A.+Iagaruauthor=J.+H.+Pollardauthor=V.+Wongauthor=J.+D.+Jensenauthor=N.+Stamblerauthor=M.+A.+Gorinauthor=B.+Siegel&title=Impact+of+PSMA-targeted+imaging+with+18F-DCFPyL-PET%2FCT+on+clinical+management+of+patients+%28pts%29+with+biochemically+recurrent+%28BCR%29+prostate+cancer+%28PCa%29%3A+Results+from+a+phase+III%2C+prospective%2C+multicenter+study+%28CONDOR%29&doi=10.1200%2FJCO.2020.38.15_suppl.5501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1200%2FJCO.2020.38.15_suppl.5501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2020.38.15_suppl.5501%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DM.%2BJ.%26aulast%3DCarroll%26aufirst%3DP.%2BR.%26aulast%3DSaperstein%26aufirst%3DL.%26aulast%3DPouliot%26aufirst%3DF.%26aulast%3DJosephson%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DJ.%2BY.%2BC.%26aulast%3DPantel%26aufirst%3DA.%2BR.%26aulast%3DCho%26aufirst%3DS.%2BY.%26aulast%3DGage%26aufirst%3DK.%26aulast%3DPiert%26aufirst%3DM.%26aulast%3DIagaru%26aufirst%3DA.%26aulast%3DPollard%26aufirst%3DJ.%2BH.%26aulast%3DWong%26aufirst%3DV.%26aulast%3DJensen%26aufirst%3DJ.%2BD.%26aulast%3DStambler%26aufirst%3DN.%26aulast%3DGorin%26aufirst%3DM.%2BA.%26aulast%3DSiegel%26aufirst%3DB.%26atitle%3DImpact%2520of%2520PSMA-targeted%2520imaging%2520with%252018F-DCFPyL-PET%252FCT%2520on%2520clinical%2520management%2520of%2520patients%2520%2528pts%2529%2520with%2520biochemically%2520recurrent%2520%2528BCR%2529%2520prostate%2520cancer%2520%2528PCa%2529%253A%2520Results%2520from%2520a%2520phase%2520III%252C%2520prospective%252C%2520multicenter%2520study%2520%2528CONDOR%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2020%26volume%3D38%26spage%3D5501%26epage%3D5501%26doi%3D10.1200%2FJCO.2020.38.15_suppl.5501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schottelius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and preclinical evaluation of novel <sup>18</sup>F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with <sup>18</sup>F-DCFPyl and <sup>18</sup>F-PSMA-1007</span>. <i>Eur. J. Nucl. Med. Mol. Imaging. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi">Â DOI: 10.1186/s13550-018-0382-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1186%2Fs13550-018-0382-8" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=30&author=S.+Robuauthor=A.+Schmidtauthor=M.+Eiberauthor=M.+Schotteliusauthor=T.+Guntherauthor=B.+H.+Yousefiauthor=M.+Schwaigerauthor=H.+J.+Wester&title=Synthesis+and+preclinical+evaluation+of+novel+18F-labeled+Glu-urea-Glu-based+PSMA+inhibitors+for+prostate+cancer+imaging%3A+a+comparison+with+18F-DCFPyl+and+18F-PSMA-1007&doi=10.1186%2Fs13550-018-0382-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2Fs13550-018-0382-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13550-018-0382-8%26sid%3Dliteratum%253Aachs%26aulast%3DRobu%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DEiber%26aufirst%3DM.%26aulast%3DSchottelius%26aufirst%3DM.%26aulast%3DGunther%26aufirst%3DT.%26aulast%3DYousefi%26aufirst%3DB.%2BH.%26aulast%3DSchwaiger%26aufirst%3DM.%26aulast%3DWester%26aufirst%3DH.%2BJ.%26atitle%3DSynthesis%2520and%2520preclinical%2520evaluation%2520of%2520novel%252018F-labeled%2520Glu-urea-Glu-based%2520PSMA%2520inhibitors%2520for%2520prostate%2520cancer%2520imaging%253A%2520a%2520comparison%2520with%252018F-DCFPyl%2520and%252018F-PSMA-1007%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging.%2520Res.%26date%3D2018%26volume%3D8%26spage%3D30%26doi%3D10.1186%2Fs13550-018-0382-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zlatopolskiy, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endepols, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guliyev, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urusova, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richarz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drzezga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumaier, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of <sup>18</sup>F-JK-PSMA-7, a PET Probe for the detection of small PSMA-positive lesions</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">817</span>â <span class="NLM_lpage">823</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.118.218495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.118.218495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30389823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpslaksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=817-823&author=B.+D.+Zlatopolskiyauthor=H.+Endepolsauthor=P.+Krapfauthor=M.+Guliyevauthor=E.+A.+Urusovaauthor=R.+Richarzauthor=M.+Hohbergauthor=M.+Dietleinauthor=A.+Drzezgaauthor=B.+Neumaier&title=Discovery+of+18F-JK-PSMA-7%2C+a+PET+Probe+for+the+detection+of+small+PSMA-positive+lesions&doi=10.2967%2Fjnumed.118.218495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 18F-JK-PSMA-7, a PET probe for the detection of small PSMA-positive lesions</span></div><div class="casAuthors">Zlatopolskiy, Boris D.; Endepols, Heike; Krapf, Philipp; Guliyev, Mehrab; Urusova, Elizaveta A.; Richarz, Raphael; Hohberg, Melanie; Dietlein, Markus; Drzezga, Alexander; Neumaier, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">817-823</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The aim of this study was the development of highly selective and specific PSMA probes with enhanced imaging properties, in comparison with 18FDCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11.  Methods: Eight novel 18F-labeled PSMA ligands were prepd.  Their cellular uptake in PSMA-pos. LNCaP C4-2 and PSMA-neg. PC-3 cells was compared with that of 18F-DCFPyL.  The most promising candidates were addnl. evaluated by small-animal PET in healthy rats using PSMA-pos. peripheral ganglia as a model for small PCa lesions.  PET images of the ligand with the best outcome, 18F-JKPSMA- 7, were compared with those of 18F-DCFPyL, 18F-PSMA-1007, and 68Ga-PSMA-11 with respect to key image-quality parameters for the time frame 60-120 min.  Results: Compared with 18F-DCFPyL, 18FJK- PSMA-7 demonstrated increased PSMA-specific cellular uptake.  Although target-to-background ratios of 18F-DCFPyL and 18F-PSMA- 1007 were comparable, this parameter was higher for 18F-JK-PSMA- 7 and lower for 68Ga-PSMA-11.  Image acutance was significantly higher for 18F-JK-PSMA-7 and 18F-PSMA-1007 than for 18F-DCFPyL and 68Ga-PSMA-11.  Conclusion: 18F-JK-PSMA-7 is a promising candidate for high-quality visualization of small PSMApos. lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqde4Vvp9QQrbVg90H21EOLACvtfcHk0ljiE96hS5vu1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpslaksg%253D%253D&md5=344fee789fd142980a6a4810e573e17e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.218495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.218495%26sid%3Dliteratum%253Aachs%26aulast%3DZlatopolskiy%26aufirst%3DB.%2BD.%26aulast%3DEndepols%26aufirst%3DH.%26aulast%3DKrapf%26aufirst%3DP.%26aulast%3DGuliyev%26aufirst%3DM.%26aulast%3DUrusova%26aufirst%3DE.%2BA.%26aulast%3DRicharz%26aufirst%3DR.%26aulast%3DHohberg%26aufirst%3DM.%26aulast%3DDietlein%26aufirst%3DM.%26aulast%3DDrzezga%26aufirst%3DA.%26aulast%3DNeumaier%26aufirst%3DB.%26atitle%3DDiscovery%2520of%252018F-JK-PSMA-7%252C%2520a%2520PET%2520Probe%2520for%2520the%2520detection%2520of%2520small%2520PSMA-positive%2520lesions%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D817%26epage%3D823%26doi%3D10.2967%2Fjnumed.118.218495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatopolskiy, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endepols, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tager, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidenreich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumaier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drzezga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietlein, M.</span></span> <span> </span><span class="NLM_article-title">Intraindividual comparison of <sup>18</sup>F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">729</span>â <span class="NLM_lpage">734</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.119.234898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.119.234898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=31628219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOisLzM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=729-734&author=F.+Dietleinauthor=C.+Kobeauthor=M.+Hohbergauthor=B.+D.+Zlatopolskiyauthor=P.+Krapfauthor=H.+Endepolsauthor=P.+Tagerauthor=J.+Hammesauthor=A.+Heidenreichauthor=T.+Persigehlauthor=B.+Neumaierauthor=A.+Drzezgaauthor=M.+Dietlein&title=Intraindividual+comparison+of+18F-PSMA-1007+with+renally+excreted+PSMA+ligands+for+PSMA+PET+imaging+in+patients+with+relapsed+prostate+cancer&doi=10.2967%2Fjnumed.119.234898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer</span></div><div class="casAuthors">Dietlein, Felix; Kobe, Carsten; Hohberg, Melanie; Zlatopolskiy, Boris D.; Krapf, Philipp; Endepols, Heike; Taeger, Philipp; Hammes, Jochen; Heidenreich, Axel; Persigehl, Thorsten; Neumaier, Bernd; Drzezga, Alexander; Dietlein, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">729-735</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">18F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver.  We benchmarked the performance of 18F-PSMA-1007 against 3 renally excreted PSMA tracers.  Among 668 patients, we selected 27 in whom PET/CT results obtained with 68Ga-PSMA-11, 18F-DCFPyL (2-(3-(1-carboxy-5- [(6-18F]fluoro-pyridine-3-carbonyl)-amino-pentyl)-ureido)-pentanedioic acid), or 18F-JK-PSMA-7 (JK, Juelich-Koeln) were interpreted as equivocal or neg. or as oligometastatic disease (PET-1).  Within 3 wk, a second PET scan with 18F-PSMA-1007 was performed (PET-2).  The confidence in the interpretation of PSMA-pos. locoregional findings was scored on a 5-point scale, first in routine diagnostics (reader 1) and then by an independent second evaluation (reader 2).  Discordant PSMA-pos. skeletal findings were examd. by contrast-enhanced MRI.  For both readers, 18F-PSMA-1007 facilitated the interpretability of 27 locoregional lesions.  In PET-2, the clin. readout led to a significantly lower no. of equivocal locoregional lesions (P = 0.024), and reader 2 reported a significantly higher rate of suspected lesions that were falsely interpreted as probably benign in PET-1 (P = 0.023).  Exclusively in PET-2, we obsd. a total of 15 PSMA-pos. spots in the bone marrow of 6 patients (22%).  None of the 15 discordant spots had a morphol. correlate on the corresponding CT scan or on the subsequent MRI scan.  Thus, 18F-PSMA-1007 exhibits a significantly higher rate of unspecific medullary spots (P = 0.0006).  18F-PSMA-1007 may increase confidence in interpreting small locoregional lesions adjacent to the urinary tract but may decrease the interpretability of skeletal lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYs4GfFaySOLVg90H21EOLACvtfcHk0ljiE96hS5vu1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOisLzM&md5=5c2a252dabb347101316e394cba3fb34</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.234898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.234898%26sid%3Dliteratum%253Aachs%26aulast%3DDietlein%26aufirst%3DF.%26aulast%3DKobe%26aufirst%3DC.%26aulast%3DHohberg%26aufirst%3DM.%26aulast%3DZlatopolskiy%26aufirst%3DB.%2BD.%26aulast%3DKrapf%26aufirst%3DP.%26aulast%3DEndepols%26aufirst%3DH.%26aulast%3DTager%26aufirst%3DP.%26aulast%3DHammes%26aufirst%3DJ.%26aulast%3DHeidenreich%26aufirst%3DA.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DNeumaier%26aufirst%3DB.%26aulast%3DDrzezga%26aufirst%3DA.%26aulast%3DDietlein%26aufirst%3DM.%26atitle%3DIntraindividual%2520comparison%2520of%252018F-PSMA-1007%2520with%2520renally%2520excreted%2520PSMA%2520ligands%2520for%2520PSMA%2520PET%2520imaging%2520in%2520patients%2520with%2520relapsed%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D729%26epage%3D734%26doi%3D10.2967%2Fjnumed.119.234898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giesel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadaschik, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radtke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinsensia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehnert, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolstov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duensing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberkorn, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kratochwil, C.</span></span> <span> </span><span class="NLM_article-title">F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">678</span>â <span class="NLM_lpage">688</span>, <span class="refDoi">Â DOI: 10.1007/s00259-016-3573-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1007%2Fs00259-016-3573-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=27889802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2msLvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=678-688&author=F.+L.+Gieselauthor=B.+Hadaschikauthor=J.+Cardinaleauthor=J.+Radtkeauthor=M.+Vinsensiaauthor=W.+Lehnertauthor=C.+Keschauthor=Y.+Tolstovauthor=S.+Singerauthor=N.+Grabeauthor=S.+Duensingauthor=M.+Schaferauthor=O.+C.+Neelsauthor=W.+Mierauthor=U.+Haberkornauthor=K.+Kopkaauthor=C.+Kratochwil&title=F-18+labelled+PSMA-1007%3A+biodistribution%2C+radiation+dosimetry+and+histopathological+validation+of+tumor+lesions+in+prostate+cancer+patients&doi=10.1007%2Fs00259-016-3573-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients</span></div><div class="casAuthors">Giesel, Frederik L.; Hadaschik, B.; Cardinale, J.; Radtke, J.; Vinsensia, M.; Lehnert, W.; Kesch, C.; Tolstov, Y.; Singer, S.; Grabe, N.; Duensing, S.; Schaefer, M.; Neels, O. C.; Mier, W.; Haberkorn, U.; Kopka, K.; Kratochwil, C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">678-688</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomog. (PET) tracer 68Ga-PSMA-11 shows great promise in the detection of prostate cancer.  However, 68Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of 18F-labeled analogs.  18F-PSMA-1007 was selected among several 18F-PSMA-ligand candidate compds. because it demonstrated high labeling yields, outstanding tumor uptake and fast, non-urinary background clearance.  Here, we describe the properties of 18F-PSMA-1007 in human volunteers and patients.  Radiation dosimetry of 18F-PSMA-1007 was detd. in three healthy volunteers who underwent whole-body PET-scans and concomitant blood and urine sampling.  Following this, ten patients with high-risk prostate cancer underwent 18F-PSMA-1007 PET/CT (1 h and 3 h p.i.) and normal organ biodistribution and tumor uptakes were examd.  Eight patients underwent prostatectomy with extended pelvic lymphadenectomy.  Uptake in intra-prostatic lesions and lymph node metastases were correlated with final histopathol., including PSMA immunostaining.  With an ED of approx. 4.4-5.5 mSv per 200-250 MBq examn., 18F-PSMA-1007 behaves similar to other PSMA-PET agents as well as to other 18F-labeled PET-tracers.  In comparison to other PSMA-targeting PET-tracers, 18F-PSMA-1007 has reduced urinary clearance enabling excellent assessment of the prostate.  Similar to 18F-DCFPyL and with slightly slower clearance kinetics than PSMA-11, favorable tumor-to-background ratios are obsd. 2-3 h after injection.  In eight patients, diagnostic findings were successfully validated by histopathol. 18F-PSMA-1007 PET/CT detected 18 of 19 lymph node metastases in the pelvis, including nodes as small as 1 mm in diam.  18F-PSMA-1007 performs at least comparably to 68Ga-PSMA-11, but its longer half-life combined with its superior energy characteristics and non-urinary excretion overcomes some practical limitations of 68Ga-labeled PSMA-targeted tracers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Yj0npCi6-LVg90H21EOLACvtfcHk0lhPIzVsO2PAFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2msLvM&md5=86df221aea3e7c3e1c83ac39289b3b30</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs00259-016-3573-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-016-3573-4%26sid%3Dliteratum%253Aachs%26aulast%3DGiesel%26aufirst%3DF.%2BL.%26aulast%3DHadaschik%26aufirst%3DB.%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DRadtke%26aufirst%3DJ.%26aulast%3DVinsensia%26aufirst%3DM.%26aulast%3DLehnert%26aufirst%3DW.%26aulast%3DKesch%26aufirst%3DC.%26aulast%3DTolstov%26aufirst%3DY.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGrabe%26aufirst%3DN.%26aulast%3DDuensing%26aufirst%3DS.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DKopka%26aufirst%3DK.%26aulast%3DKratochwil%26aufirst%3DC.%26atitle%3DF-18%2520labelled%2520PSMA-1007%253A%2520biodistribution%252C%2520radiation%2520dosimetry%2520and%2520histopathological%2520validation%2520of%2520tumor%2520lesions%2520in%2520prostate%2520cancer%2520patients%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2017%26volume%3D44%26spage%3D678%26epage%3D688%26doi%3D10.1007%2Fs00259-016-3573-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoye, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horchler, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attardo, G.</span></span> <span> </span><span class="NLM_article-title">Facile route to 2-fluoropyridines via 2-pyridyltrialkylammonium salts prepared from pyridine N-oxides and application to <sup>18</sup>F-labeling</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3726</span>â <span class="NLM_lpage">3729</span>, <span class="refDoi">Â DOI: 10.1021/acs.orglett.5b01703</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.5b01703" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2ltrbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=3726-3729&author=H.+Xiongauthor=A.+T.+Hoyeauthor=K.-H.+Fanauthor=X.+Liauthor=J.+Clemensauthor=C.+L.+Horchlerauthor=N.+C.+Limauthor=G.+Attardo&title=Facile+route+to+2-fluoropyridines+via+2-pyridyltrialkylammonium+salts+prepared+from+pyridine+N-oxides+and+application+to+18F-labeling&doi=10.1021%2Facs.orglett.5b01703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Route to 2-Fluoropyridines via 2-Pyridyltrialkylammonium Salts Prepared from Pyridine N-Oxides and Application to 18F-Labeling</span></div><div class="casAuthors">Xiong, Hui; Hoye, Adam T.; Fan, Kuo-Hsien; Li, Ximin; Clemens, Jennifer; Horchler, Carey L.; Lim, Nathaniel C.; Attardo, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3726-3729</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Among known precursors for 2-[18F]fluoropyridines, pyridyltrialkylammonium salts have shown excellent reactivity; however, their broader utility has been limited because synthetic methods for their prepn. suffer from poor functional group compatibility.  In this paper, we demonstrate the regioselective conversion of readily available pyridine N-oxides into 2-pyridyltrialkylammonium salts under mild and metal-free conditions.  These isolable intermediates serve as effective precursors to structurally diverse 2-fluoropyridines, including mols. relevant to PET imaging.  In addn. to providing access to nonradioactive analogs, this method has been successfully applied to 18F-labeling in the radiosynthesis of [18F]AV-1451 ([18F]T807), a PET tracer currently under development for imaging tau.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVTE6KPqgCdLVg90H21EOLACvtfcHk0lhPIzVsO2PAFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2ltrbM&md5=ee36c30d7305c50722e912ad257cd90e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.5b01703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.5b01703%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DHoye%26aufirst%3DA.%2BT.%26aulast%3DFan%26aufirst%3DK.-H.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DClemens%26aufirst%3DJ.%26aulast%3DHorchler%26aufirst%3DC.%2BL.%26aulast%3DLim%26aufirst%3DN.%2BC.%26aulast%3DAttardo%26aufirst%3DG.%26atitle%3DFacile%2520route%2520to%25202-fluoropyridines%2520via%25202-pyridyltrialkylammonium%2520salts%2520prepared%2520from%2520pyridine%2520N-oxides%2520and%2520application%2520to%252018F-labeling%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26spage%3D3726%26epage%3D3729%26doi%3D10.1021%2Facs.orglett.5b01703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remde, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hienzsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerges, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepping, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neels, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopka, K.</span></span> <span> </span><span class="NLM_article-title">Procedures for the GMP-compliant production and quality control of [F-18]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">77</span>, <span class="refDoi">Â DOI: 10.3390/ph10040077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.3390%2Fph10040077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFelsLjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=77&author=J.+Cardinaleauthor=R.+Martinauthor=Y.+Remdeauthor=M.+Schaferauthor=A.+Hienzschauthor=S.+Hubnerauthor=A.+M.+Zergesauthor=H.+Marxauthor=R.+Hesseauthor=K.+Weberauthor=R.+Smitsauthor=A.+Hoeppingauthor=M.+Mullerauthor=O.+C.+Neelsauthor=K.+Kopka&title=Procedures+for+the+GMP-compliant+production+and+quality+control+of+%5BF-18%5DPSMA-1007%3A+a+next+generation+radiofluorinated+tracer+for+the+detection+of+prostate+cancer&doi=10.3390%2Fph10040077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Procedures for the GMP-compliant production and quality control of [18F]PSMA-1007: A next generation radiofluorinated tracer for the detection</span></div><div class="casAuthors">Cardinale, Jens; Martin, Rene; Remde, Yvonne; Schaefer, Martin; Hienzsch, Antje; Huebner, Sandra; Zerges, Anna-Maria; Marx, Heike; Hesse, Ronny; Weber, Klaus; Smits, Rene; Hoepping, Alexander; Mueller, Marco; Neels, Oliver C.; Kopka, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceuticals</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">77/1-77/18</span>CODEN:
                <span class="NLM_cas:coden">PHARH2</span>;
        ISSN:<span class="NLM_cas:issn">1424-8247</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for the PET-imaging of prostate cancer.  In this connection, we recently developed the fluorine-18-labeled PSMA-ligand [18F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC.  Since radiosynthesis so far has been suffering from rather poor yields, novel procedures for the automated radiosyntheses of [18F]PSMA-1007 have been developed.  We herein report on both the two-step and the novel one-step procedures, which have been performed on different commonly-used radiosynthesisers.  Using the novel one-step procedure, the [18F]PSMA-1007 was produced in good radiochem. yields ranging from 25 to 80% and synthesis times of less than 55 min.  Furthermore, upscaling to product activities up to 50 GBq per batch was successfully conducted.  All batches passed quality control according to European Pharmacopoeia stds.  Therefore, we were able to disclose a new, simple and, at the same time, high yielding prodn. pathway for the next generation PSMA radioligand [18F]PSMA-1007.  Actually, it turned out that the radiosynthesis is as easily realized as the well-known [18F]FDG synthesis and, thus, transferable to all currently-available radiosynthesisers.  Using the new procedures, the clin. daily routine can be sustainably supported inhouse even in larger hospitals by a single prodn. batch.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc_vc2WuIrebVg90H21EOLACvtfcHk0lgU2d1zn6gs2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFelsLjE&md5=fc4151e4f367befd82b179776608f2dc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3390%2Fph10040077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph10040077%26sid%3Dliteratum%253Aachs%26aulast%3DCardinale%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DR.%26aulast%3DRemde%26aufirst%3DY.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DHienzsch%26aufirst%3DA.%26aulast%3DHubner%26aufirst%3DS.%26aulast%3DZerges%26aufirst%3DA.%2BM.%26aulast%3DMarx%26aufirst%3DH.%26aulast%3DHesse%26aufirst%3DR.%26aulast%3DWeber%26aufirst%3DK.%26aulast%3DSmits%26aufirst%3DR.%26aulast%3DHoepping%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DNeels%26aufirst%3DO.%2BC.%26aulast%3DKopka%26aufirst%3DK.%26atitle%3DProcedures%2520for%2520the%2520GMP-compliant%2520production%2520and%2520quality%2520control%2520of%2520%255BF-18%255DPSMA-1007%253A%2520a%2520next%2520generation%2520radiofluorinated%2520tracer%2520for%2520the%2520detection%2520of%2520prostate%2520cancer%26jtitle%3DPharmaceuticals%26date%3D2017%26volume%3D10%26spage%3D77%26doi%3D10.3390%2Fph10040077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dornan, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblond, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juneau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delouya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva, J. N.</span></span> <span> </span><span class="NLM_article-title">Simplified and robust one-step radiosynthesis of [F-18]DCFPyL via direct radiofluorination and cartridge-based purification</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">757</span>â <span class="NLM_lpage">763</span>, <span class="refDoi">Â DOI: 10.1002/jlcr.3632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1002%2Fjlcr.3632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSgsrjE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=757-763&author=M.+H.+Dornanauthor=J.+M.+Simardauthor=A.+Leblondauthor=D.+Juneauauthor=G.+Delouyaauthor=F.+Saadauthor=C.+Menardauthor=J.+N.+DaSilva&title=Simplified+and+robust+one-step+radiosynthesis+of+%5BF-18%5DDCFPyL+via+direct+radiofluorination+and+cartridge-based+purification&doi=10.1002%2Fjlcr.3632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Simplified and robust one-step radiosynthesis of [18F]DCFPyL via direct radiofluorination and cartridge-based purification</span></div><div class="casAuthors">Dornan, Mark H.; Simard, Jose-Mathieu; Leblond, Antoine; Juneau, Daniel; Delouya, Guila; Saad, Fred; Menard, Cynthia; Da Silva, Jean N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">757-763</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The efficient prodn. of [18FF]DCFPyL (I) using single-step direct radiofluorination, without use of carboxylic acid-protecting groups was described.  Radiolabeling reaction optimization studies revealed an inverse correlation between the amt. of precursor used and the radiochem. yield.  This simplified approach enabled automated prepn. of I within 28 min using HPLC purifn. (26% Â± 6%, at EOS, n = 4), which was then scaled up for large-batch prodn. to generate 1.46 Â± 0.23 Ci of I at EOS (n = 7) in high molar activity (37 933 Â± 4158 mCi/Î¼mol, 1403 Â± 153 GBq/Î¼mol, at EOS, n = 7).  Further, this work enabled the development of I prodn. in 21 min using an easy cartridge-based purifn. (25% Â± 9% radiochem. yield, at EOS, n = 3).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCzW6H17jPobVg90H21EOLACvtfcHk0lgU2d1zn6gs2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSgsrjE&md5=3c3bb6ff7677356ab044a0cd7207d865</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.3632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.3632%26sid%3Dliteratum%253Aachs%26aulast%3DDornan%26aufirst%3DM.%2BH.%26aulast%3DSimard%26aufirst%3DJ.%2BM.%26aulast%3DLeblond%26aufirst%3DA.%26aulast%3DJuneau%26aufirst%3DD.%26aulast%3DDelouya%26aufirst%3DG.%26aulast%3DSaad%26aufirst%3DF.%26aulast%3DMenard%26aufirst%3DC.%26aulast%3DDaSilva%26aufirst%3DJ.%2BN.%26atitle%3DSimplified%2520and%2520robust%2520one-step%2520radiosynthesis%2520of%2520%255BF-18%255DDCFPyL%2520via%2520direct%2520radiofluorination%2520and%2520cartridge-based%2520purification%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D2018%26volume%3D61%26spage%3D757%26epage%3D763%26doi%3D10.1002%2Fjlcr.3632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murelli, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocleaza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubkowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, D. A.</span></span> <span> </span><span class="NLM_article-title">A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">12711</span>â <span class="NLM_lpage">12716</span>, <span class="refDoi">Â DOI: 10.1021/ja104591m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja104591m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=12711-12716&author=A.+X.+Zhangauthor=R.+P.+Murelliauthor=C.+Barinkaauthor=J.+Michelauthor=A.+Cocleazaauthor=W.+L.+Jorgensenauthor=J.+Lubkowskiauthor=D.+A.+Spiegel&title=A+remote+arene-binding+site+on+prostate+specific+membrane+antigen+revealed+by+antibody-recruiting+small+molecules&doi=10.1021%2Fja104591m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules</span></div><div class="casAuthors">Zhang, Andrew X.; Murelli, Ryan P.; Barinka, Cyril; Michel, Julien; Cocleaza, Alexandra; Jorgensen, William L.; Lubkowski, Jacek; Spiegel, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12711-12716</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate specific membrane antigen (PSMA) is a membrane-bound glutamate carboxypeptidase overexpressed in many forms of prostate cancer.  Our lab. has recently disclosed a class of small mols., called ARM-Ps (antibody-recruiting mol. targeting prostate cancer) that are capable of enhancing antibody-mediated immune recognition of prostate cancer cells.  Interestingly, during the course of these studies, we found ARM-Ps to exhibit extraordinarily high potencies toward PSMA, compared to previously reported inhibitors.  Here, we report in-depth biochem., crystallog., and computational investigations which elucidate the origin of the obsd. affinity enhancement.  These studies reveal a previously unreported arene-binding site on PSMA, which we believe participates in an arom. stacking interaction with ARMs.  Although this site is composed of only a few amino acid residues, it drastically enhances small mol. binding affinity.  These results provide crit. insights into the design of PSMA-targeted small mols. for prostate cancer diagnosis and treatment; more broadly, the presence of similar arene-binding sites throughout the proteome could prove widely enabling in the optimization of small mol.-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjRo6U6PlHcbVg90H21EOLACvtfcHk0lgU2d1zn6gs2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGjtbvP&md5=286b5454ee036028cbac3ff6a5b7579d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fja104591m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja104591m%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DA.%2BX.%26aulast%3DMurelli%26aufirst%3DR.%2BP.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DMichel%26aufirst%3DJ.%26aulast%3DCocleaza%26aufirst%3DA.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26aulast%3DLubkowski%26aufirst%3DJ.%26aulast%3DSpiegel%26aufirst%3DD.%2BA.%26atitle%3DA%2520remote%2520arene-binding%2520site%2520on%2520prostate%2520specific%2520membrane%2520antigen%2520revealed%2520by%2520antibody-recruiting%2520small%2520molecules%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D12711%26epage%3D12716%26doi%3D10.1021%2Fja104591m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Visschere, P. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Standaert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futterer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villeirs, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panebianco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadaschik, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecouvet, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannarini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanti, S.</span></span> <span> </span><span class="NLM_article-title">A systematic review on the role of imaging in early recurrent prostate cancer</span>. <i>Eur. Urol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">47</span>â <span class="NLM_lpage">76</span>, <span class="refDoi">Â DOI: 10.1016/j.euo.2018.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1016%2Fj.euo.2018.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30929846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A280%3ADC%252BB3cbpvFGrtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=47-76&author=P.+J.+L.+De%0AVisschereauthor=C.+Standaertauthor=J.+J.+Futtererauthor=G.+M.+Villeirsauthor=V.+Panebiancoauthor=J.+Walzauthor=T.+Maurerauthor=B.+A.+Hadaschikauthor=F.+E.+Lecouvetauthor=G.+Giannariniauthor=S.+Fanti&title=A+systematic+review+on+the+role+of+imaging+in+early+recurrent+prostate+cancer&doi=10.1016%2Fj.euo.2018.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer</span></div><div class="casAuthors">De Visschere Pieter J L; Standaert Chloe; Villeirs Geert M; Futterer Jurgen J; Panebianco Valeria; Walz Jochen; Maurer Tobias; Hadaschik Boris A; Lecouvet Frederic E; Giannarini Gianluca; Fanti Stefano</div><div class="citationInfo"><span class="NLM_cas:title">European urology oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-76</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a first sign of relapse, but imaging is needed to determine the localization of the recurrence, which may be local, in lymph nodes, and/or metastatic.  With the increasing success rate of earlier salvage therapy, the diagnosis has become pertinent when the recurrent PSA level is still very low.  OBJECTIVE:  To systematically review the literature on the role of the existing imaging techniques in patients with early recurrent prostate cancer.  EVIDENCE ACQUISITION:  A systematic literature search across the MEDLINE and EMBASE databases was conducted in February 2018, searching for original studies reporting on imaging in a (sub)group of patients with recurrent PSA levels not higher than 5ng/ml.  This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.  The methodological quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool.  EVIDENCE SYNTHESIS:  A total of 98 studies were included in this systematic review, reporting on the role of transrectal ultrasonography (TRUS), computed tomography (CT), bone scintigraphy (BS), single-photon emission CT, multiparametric magnetic resonance imaging (mpMRI), whole-body MRI (wbMRI), and positron emission tomography (PET)-CT/MRI using 18F fluoro-deoxy-glucose, 11C choline, 18F (fluoro)(methyl)choline, 11C acetate, 18F FACBC (fluciclovine) and prostate-specific membrane antigen (PSMA)-based tracers.  CT and BS were not sufficiently sensitive in the early recurrence setting.  For the detection of local recurrence, TRUS or mpMRI can be used; however, at the lowest PSA levels, few data were available, only after radical prostatectomy, showing a wide range of positivity.  TRUS or mpMRI need to be combined with (PET)-CT to assess distant disease, but new techniques such as wbMRI, PET-MRI, or PET-CT allow for an all-in-one approach.  At recurrent PSA levels <0.5ng/ml, detection rates up to 31.3% were reported using (11)C choline PET-CT and up to 65.0% using (68)Ga PSMA-11 PET-CT.  At recurrent PSA levels <0.2ng/ml, detection rates of (68)Ga PSMA-11 PET-CT ranged from 11.3% to as high as 58.3%.  CONCLUSIONS:  Detection rates of different imaging techniques depend on the PSA level at the time of imaging.  Recent advanced imaging techniques may detect the localization of the recurrence, even when the PSA levels are still very low.  PATIENT SUMMARY:  In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a sign of recurrence of the disease.  Advanced imaging techniques may demonstrate the localization of the recurrence, even when the PSA levels are still very low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbC3QWfaAoKYNpW7w2tapOfW6udTcc2ebN7R_IMVS7Hrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbpvFGrtg%253D%253D&md5=e5d4952c71334529eba57c71184bfd9d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.euo.2018.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.euo.2018.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BVisschere%26aufirst%3DP.%2BJ.%2BL.%26aulast%3DStandaert%26aufirst%3DC.%26aulast%3DFutterer%26aufirst%3DJ.%2BJ.%26aulast%3DVilleirs%26aufirst%3DG.%2BM.%26aulast%3DPanebianco%26aufirst%3DV.%26aulast%3DWalz%26aufirst%3DJ.%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DHadaschik%26aufirst%3DB.%2BA.%26aulast%3DLecouvet%26aufirst%3DF.%2BE.%26aulast%3DGiannarini%26aufirst%3DG.%26aulast%3DFanti%26aufirst%3DS.%26atitle%3DA%2520systematic%2520review%2520on%2520the%2520role%2520of%2520imaging%2520in%2520early%2520recurrent%2520prostate%2520cancer%26jtitle%3DEur.%2520Urol.%2520Oncol.%26date%3D2019%26volume%3D2%26spage%3D47%26epage%3D76%26doi%3D10.1016%2Fj.euo.2018.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rauscher, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gafita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiber, M.</span></span> <span> </span><span class="NLM_article-title">Matched-Pair Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">51</span>â <span class="NLM_lpage">57</span>, <span class="refDoi">Â DOI: 10.2967/jnumed.119.229187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.2967%2Fjnumed.119.229187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=31253741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslSktbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=51-57&author=I.+Rauscherauthor=M.+Kronkeauthor=M.+Konigauthor=A.+Gafitaauthor=T.+Maurerauthor=T.+Hornauthor=K.+Schillerauthor=W.+Weberauthor=M.+Eiber&title=Matched-Pair+Comparison+of+68Ga-PSMA-11+PET%2FCT+and+18F-PSMA-1007+PET%2FCT%3A+frequency+of+pitfalls+and+detection+efficacy+in+biochemical+recurrence+after+radical+prostatectomy&doi=10.2967%2Fjnumed.119.229187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy</span></div><div class="casAuthors">Rauscher, Isabel; Kroenke, Markus; Koenig, Michael; Gafita, Andrei; Maurer, Tobias; Horn, Thomas; Schiller, Kilian; Weber, Wolfgang; Eiber, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-58</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">18F-labeled prostate-specific membrane antigen (PSMA)-ligand PET has several principal advantages over 68Ga-PSMA-11.  The purpose of this retrospective study was to evaluate the frequency of non-tumor-related uptake and the detection efficacy comparing 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT in recurrent prostate cancer (PC) patients.  Methods: The study included 102 patients with biochem. recurrent PC after radical prostatectomy undergoing 18F-PSMA-1007 PET/CT imaging.  On the basis of various clin. variables, patients with corresponding 68Ga-PSMA-11 PET/CT scans were matched.  All PET/CT scans (n = 204) were reviewed by 1 nuclear medicine physician.  First, all PET-pos. lesions were noted.  Then, lesions suspected of being recurrent PC were differentiated from lesions attributed to a benign origin on the basis of known pitfalls and information from CT.  For each region, the SUVmax of the lesion with the highest PSMA-ligand uptake was noted.  Detection rates were detd., and SUVmax was compared sep. for 68Ga-PSMA-11 and 18F-PSMA-1007.  Results: In total, 18F-PSMA-1007 PET and 68Ga-PSMA-11 PET revealed 369 and 178 PSMA-ligand-pos. lesions, resp. 18F-PSMA-1007 PET revealed approx. 5 times more lesions attributed to a benign origin than did 68Ga-PSMA-11 PET (245 vs. 52 lesions, resp.).  The benign lesions most frequently obsd. were ganglia, unspecific lymph node, and bone lesions, at a rate of 43%, 31%, and 24% for 18F-PSMA-1007 PET and 29%, 42%, and 27% for 68Ga-PSMA-11 PET, resp.  The SUVmax of lesions attributed to a benign origin was significantly higher (P < 0.0001) for 18F-PSMA-1007 PET.  Further, a similar no. of lesions was attributed to recurrent PC (124/369 for 18F-PSMA-1007 PET and 126/178 for 68Ga-PSMA-11 PET).  Conclusion: The no. of lesions with increased PSMA-ligand uptake attributed to a benign origin is considerably higher for 18F-PSMA-1007 PET than for 68Ga-PSMA-11 PET.  This finding indicates the need for sophisticated reader training emphasizing known pitfalls and reporting within the clin. context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh763SMqPZV7Vg90H21EOLACvtfcHk0lgKTHeukFqROA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslSktbnN&md5=4aebc27b4a47b082f0d4428e64a55d5f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.229187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.229187%26sid%3Dliteratum%253Aachs%26aulast%3DRauscher%26aufirst%3DI.%26aulast%3DKronke%26aufirst%3DM.%26aulast%3DKonig%26aufirst%3DM.%26aulast%3DGafita%26aufirst%3DA.%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DHorn%26aufirst%3DT.%26aulast%3DSchiller%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DW.%26aulast%3DEiber%26aufirst%3DM.%26atitle%3DMatched-Pair%2520Comparison%2520of%252068Ga-PSMA-11%2520PET%252FCT%2520and%252018F-PSMA-1007%2520PET%252FCT%253A%2520frequency%2520of%2520pitfalls%2520and%2520detection%2520efficacy%2520in%2520biochemical%2520recurrence%2520after%2520radical%2520prostatectomy%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D51%26epage%3D57%26doi%3D10.2967%2Fjnumed.119.229187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panagiotidis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannoula, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatzipavlidou, V.</span></span> <span> </span><span class="NLM_article-title">Rib fractures mimicking bone metastases in <sup>18</sup>F-PSMA-1007 PET/CT for prostate cancer</span>. <i>Clin. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">E46</span>â <span class="NLM_lpage">E48</span>, <span class="refDoi">Â DOI: 10.1097/RLU.0000000000002354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=10.1097%2FRLU.0000000000002354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;key=30371591" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=E46-E48&author=E.+Panagiotidisauthor=A.+Paschaliauthor=E.+Giannoulaauthor=V.+Chatzipavlidou&title=Rib+fractures+mimicking+bone+metastases+in+18F-PSMA-1007+PET%2FCT+for+prostate+cancer&doi=10.1097%2FRLU.0000000000002354"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1097%2FRLU.0000000000002354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FRLU.0000000000002354%26sid%3Dliteratum%253Aachs%26aulast%3DPanagiotidis%26aufirst%3DE.%26aulast%3DPaschali%26aufirst%3DA.%26aulast%3DGiannoula%26aufirst%3DE.%26aulast%3DChatzipavlidou%26aufirst%3DV.%26atitle%3DRib%2520fractures%2520mimicking%2520bone%2520metastases%2520in%252018F-PSMA-1007%2520PET%252FCT%2520for%2520prostate%2520cancer%26jtitle%3DClin.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D44%26spage%3DE46%26epage%3DE48%26doi%3D10.1097%2FRLU.0000000000002354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i55"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00117">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80530"></div></div></div></div></div><hr /></hr><p class="last">In addition, the is also included. The Supporting Information is available free of charge on the ACS Publications Web site. The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00117?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00117</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Details of schematic diagram of the radiosynthesis, quality control data, semipreparative and analytical HPLC tracers, MA determination of [<sup>18</sup>F]<b>8a</b>, [<sup>18</sup>F]<b>8b</b>, and [<sup>18</sup>F]<b>8c</b>, ex vivo and in vivo biodistribution of the rodents, PET/CT imaging of the patients, spectral data (<sup>1</sup>H NMR, <sup>13</sup>C NMR, HPLC, HRMS, and <sup>18</sup>F NMR) data of novel compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings file (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_001.pdf">jm1c00117_si_001.pdf (3.68 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00117/suppl_file/jm1c00117_si_002.csv">jm1c00117_si_002.csv (0.36 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00117&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00117%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00117" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                11MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994a0dcd5e2308","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
